



CHILDHOOD INITIATION OF CARDIOVASCULAR DISEASE: CURRENT EVIDENCE

Main Session

Chairperson(s): G.C. Schuler (Leipzig, DE); J.P.J. Halcox (Cardiff, GB)

08:30	Early life environmental exposures and cardiovascular disease. – D. Celermajer (Sydney, AU)	106
08:48	Childhood obesity: a precursor of cardiovascular disease? – P. Whincup (London, GB)	107
09:06	Cardiovascular risk assessment in childhood. – J.S.A. Viikari (Turku, FI)	108
09:24	Cardiovascular risk reduction in childhood: empirical evidence. – S. Erbs (Leipzig, DE)	109
09:42	Political strategies for cardiovascular health in children. – J.E. Deanfield (London, GB)	110

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)



XXL IS THE SIZE OF THE PROBLEM?

Clinical Seminar

Chairperson(s): I. Seljeflot (Oslo, NO); C. Torp-Pedersen (Hellerup, DK)

11:00	Genetics of obesity. – G. Fruhbeck (Pamplona, ES)	111
11:22	How to define and assess obesity, waist circumference and visceral fat. – R. Ross (Kingston, CA)	112
11:44	Weight and waist: risk factors for cardiovascular disease. – L. Van Gaal (Edegem-Antwerp, BE)	113
12:06	Therapeutic options for obesity in cardiovascular disease. – N. Finer (London, GB)	114



THE CHANGING PERILS OF THE PHYSICAL ENVIRONMENT

Symposium

Chairperson(s): E. Prescott (Copenhagen, DK); S. Sans Menendez (Barcelona, ES)

- | | | |
|-------|--|-----|
| 08:30 | Mercury rising: global warming, carbon and cardiovascular health.
– O. Faergeman (Aarhus, DK) | 115 |
| 08:52 | Cars, fumes and cardiovascular disease.
– M. Twickler (Amsterdam, NL) | 116 |
| 09:14 | Environmental tobacco smoke: insights from Scotland.
– J. Pell (Glasgow, GB) | 117 |
| 09:36 | Acute inflammatory episodes and the triggering of acute vascular events.
– A. Hingorani (London, GB) | 118 |

SUNDAY AM

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)



A WOMAN'S HEART

Symposium

Chairperson(s): T.M. Norekval (Bergen, NO); M.C. Deaton (Manchester, GB)

- | | | |
|-------|--|-----|
| 11:00 | Impact of classic lifestyle factors on cardiovascular mortality in women.
– D.M. Lombardo (Orange, US) | 119 |
| 11:22 | Have we cracked the 'gender barrier' in symptom recognition?
– B.G.A. Fridlund (Jonkoping, SE) | 120 |
| 11:44 | Hormonal replacement: for whom, when and for how long?
– J.C. Stevenson (London, GB) | 121 |
| 12:06 | Statins for women?
– D.E. Grobbee (Utrecht, NL) | 122 |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)



UNMET PSYCHOSOCIAL NEEDS IN HEART DISEASE

Abstracts

Chairperson(s): J. Martensson (Jonkoping, SE); J. Riley (London, GB)

- 08:30 **Family member interventions improve their knowledge of heart failure and supportive communication.** 123
 – S.B. Dunbar, P.C. Clark, R.A. Gary, F. Mccarty, M. Higgins, C.M. Reilly, D. Grossniklaus, J.M. Robinson, A.L. Smith (Atlanta, US)
- 08:45 **Exploring the boundaries of heart failure prevention: The Nurse-led Intervention for Less Chronic Heart Failure (NIL-CHF) study.** 124
 – S. Stewart, M.C. Carrington, G. Lee, G. Jennings (Melbourne, AU)
- 09:00 **Determinants of quality of life in cardioverter-defibrillator recipients: a nurse-led study.** 125
 – J.D. Kasprzak, M. Kaczmarek, M. Fiutowski, Z. Bednarkiewicz, T. Wcislo, M. Krzeminska-Pakula (Lodz, PL)
- 09:15 **Comparative prognostic value of the Kansas City cardiomyopathy and the Minnesota living with heart failure questionnaires in chronic heart failure.** 126
 – J.T. Parissis, D. Farmakis, M. Nikolaou, V. Bistola, D. Birmpa, S. Lagou, T. Katsoulas, D. Karatzas, G. Filippatos, D. Kremastinos (Athens, GR)
- 09:30 **A comparative study addressing health-related quality of life, symptoms of depression, perceived control and knowledge in patients with heart failure and their partners.** 127
 – S. Agren, L. Evangelista, A. Stromberg (Linkoping, SE; Los Angeles, US)
- 09:45 **Does telephone follow-up after discharge for acute myocardial infarction reduce anxiety and depression? A randomized controlled trial.** 128
 – T.A. Hanssen, J.E. Nordrehaug, G.E. Eide, I. Bjelland, B. Rokne (Bergen, NO)

SUNDAY AM

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)



MARKERS AND MAKERS OF CARDIOVASCULAR RISK

Abstracts

Chairperson(s): A. Catapano (Milan, IT); M. Acevedo (Santiago, CL)



- 11:00 **Is elevated resting heart rate an independent predictor of cardiovascular disease? A report from the National FINRISK Study.** 129
 – M.T. Cooney, E. Vartiainen, T. Laatikainen, A. Juolevi, A. Dudina, I.M. Graham (Dublin, IE; Helsinki, FI)
- 11:15 **Resting heart rate remains a risk factor for CardioVascular (CV) and non-CardioVascular (non-CV) mortality in healthy subjects after adjusting for inflammatory markers. The Copenhagen city heart study.** 130
 – M.T. Jensen, J.L. Marott, G.B. Jensen (Copenhagen, DK)
- 11:30 **Increased exercise capacity is associated with lower mortality risk in men 70 years and older.** 131
 – P. Kokkinos, J. Myers, C. Faselis, M. Dourmas, A. Pittaras, A. Manolis, J.P. Kokkinos, S. Singh, R. Fletcher (Washington and Palo Alto, US)
- 11:45 **Adipokines and coronary heart disease - results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.** 132
 – M. Karakas, A. Zierer, C. Herder, J. Baumert, C. Meisinger, W. Koenig, B. Thorand (Ulm, Neuherberg and Dusseldorf, DE)
- 12:00 **Respective contribution of carotid intima-media thickness and plaques to incident coronary heart disease in community-dwelling elderly. The three-city study.** 133
 – M. Plichart, M. Zureik, J. Garipey, J.F. Dartigues, X. Jouven, K. Ritchie, C. Tzourio, P. Ducimetiere, J.P. Empana (Paris, Bordeaux and Montpellier, FR)
- 12:15 **Uric acid: an underestimated cardiovascular risk factor.** 134
 – G. Levantesi, R.M. Marfisi, M.G. Franzosi, A.P. Maggioni, G.L. Nicolosi, C. Schweiger, M.G. Sillelta, L. Tavazzi, G. Tognoni, R. Marchioli (Santa Maria Imbaro, Milan, Florence, Pordenone, Passirana Di Rho and Cotignola, IT)

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

SALT AND ALDOSTERONE: 'LES LIAISONS DANGEREUSES' Clinical Seminar

Chairperson(s): F. Zannad (Dommartin-Les-Toul, FR); G. Kamensky (Bratislava, SK)

- | | | |
|-------|---|------------|
| 08:30 | Salt and the cardiovascular system - all clear?
– E. Ritz (Heidelberg, DE) | 135 |
| 08:52 | Aldosterone moving center stage in cardiovascular prevention.
– R. Schmieder (Erlangen, DE) | 136 |
| 09:14 | Salt and aldosterone: which is the villain?
– F. Jaisser (Paris, FR) | 137 |
| 09:36 | Salt restriction and/or aldosterone blockade: what are the options?
– T.M. MacDonald (Dundee, GB) | 138 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

MULTIMODALITY IMAGING IN HEART FAILURE Read with the Experts

Chairperson(s): U. Sechtem (Stuttgart, DE); F.E. Rademakers (Leuven, BE)

- | | | |
|-------|--|------------|
| 10:05 | Case 1.
– S. Prasad (London, GB) | 139 |
| 10:15 | Panel discussion.
– S. Prasad, T. Dill (London, GB; Bad Nauheim, DE) | 140 |
| 10:30 | Case 2.
– T. Dill (Bad Nauheim, DE) | 141 |
| 10:40 | Panel discussion.
– S. Prasad, T. Dill (London, GB; Bad Nauheim, DE) | 142 |



KEEPING BLOOD PRESSURE DOWN WHILE AGEING: WHAT WORKS? Clinical Seminar

Chairperson(s): A. Coca (Barcelona, ES); H.M. Mardikar (Nagpur, IN)

- | | | |
|-------|---|------------|
| 11:00 | Potassium, magnesium and/or calcium supplementation.
– F.H. Messerli (New York, US) | 143 |
| 11:22 | Wine? Beer? Some alcohol!
– G. Noll (Zurich, CH) | 144 |
| 11:44 | Fish oil.
– H. Dickinson (Newcastle, GB) | 145 |
| 12:06 | Low, moderate or high intensity exercise.
– R. Fagard (Leuven, BE) | 146 |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

STROKE: CURRENT CHALLENGES AND EMERGING THERAPIES

Abstracts

Chairperson(s): P. Poredos (Ljubljana, SI); V. Pyrgakis (Corinth, GR)

- 08:30 **Impact of incidentally discovered patent foramen ovale and its operative repair on long-term survival.** 147
 – S.A. Hart, D. Allen, A. Qureshi, G. Pettersson, R.A. Krasuski (Cleveland, US)
- 08:45 **Natriuretic peptide testing for long-term risk assessment following acute ischemic stroke.** 148
 – J.K. Jensen, J.L. Januzzi, D. Atar, S.R. Kristensen, H. Mickley (Odense and Aalborg, DK; Boston, US; Oslo, NO)
- 09:00 **Bleeding history and stroke subtypes, a cohort study of 105 043 patients reported to the Swedish Stroke Register (Riks-Stroke).** 149
 – S. Aasberg, K.M. Henriksson, B. Farahmand, A. Terent (Uppsala, Lund and Stockholm, SE)
- 09:15 **Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke.** 150
 – S.C. Inglis, J.D. Lewsey, P. Jhund, M. Gillies, P. Langhorne, M. Walters, A. Briggs, J. Chalmers, J.J.V. McMurray, K. Macintyre (Glasgow and Edinburgh, GB)
- 09:30 **Efficacy of tirofiban in reducing short-term and long-term neurologic deficit in patients with ischaemic stroke. A double-blind, randomized trial of intravenous tirofiban versus aspirin.** 151
 – G. Torgano, C. Mandelli, B. Zecca, A. Maestroni, P. Rossi, D. Manganaro, C. Casiraghi, M. Cazzaniga, V. Monzani (Milan, IT)
- 09:45 **Plasma homocysteine level predicts stroke recurrence and all-cause mortality.** 152
 – W. Zhang, K. Sun, J. Chen, D. Wang, Q. Qin, A. Ma, Y. Liao, R. Hui (Beijing, Wuhan City, Tianjin and Xi'an City, CN)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

PERIPHERAL ARTERIAL DISEASE: FROM PATHOPHYSIOLOGY TO PROGNOSIS

Abstracts

Chairperson(s): A. Balbarini (Pisa, IT); G. Parharidis (Thessaloniki, GR)

- 11:00 **The 9p21 locus and arterial stiffening in the general population: results from ASKLEPIOS.** 153
 – E. Rietzschel, I. Buysschaert, T. De Meyer, G. De Backer, S. Bekaert, D. De Bacquer, T.C. Gillebert, P. Segers, D. Lambrechts, M.L. De Buyzere (Ghent and Leuven, BE)
- 11:15 **Are levels of the complex between activated protein C and the protein C inhibitor useful for prediction of clinical events in patients with peripheral arterial disease?** 154
 – A. Gottsater, D. Blomstrand, T. Kolbel, B. Lindblad (Malmo, SE)
- 11:30 **Hemorheological profile in peripheral arterial disease patients.** 155
 – F. Sofi, F. Cesari, L. Mannini, G. Pratesi, R. Pulli, C. Pratesi, R. Abbate, G.F. Gensini (Florence, IT)
- 11:45 **Prognosis of atrial fibrillation in patients with peripheral arterial disease: data from the Reduction of Atherothrombosis for Continued Health (REACH) registry.** 156
 – T.A. Winkel, S.E. Hoeks, T. Limbourg, U. Zeymer, I. Baumgartner, D.L. Bhatt, P.G. Steg, S. Goto, D. Poldermans (Rotterdam, NL; Ludwigshafen am Rhein, DE; Berne, CH; Cleveland, US; Paris, FR; Kanagawa, JP)
- 12:00 **Impaired walking distance is a strong prognostic indicator on long-term outcome in both patients with impaired and normal ABI.** 157
 – I.I. De Liefde, S.E. Hoeks, Y.R.B.M. Van Gestel, J. Klein, J.J. Bax, H.J.M. Verhagen, R.T. Van Domburg, D. Poldermans (Rotterdam and Leiden, NL)
- 12:15 **Adiponectin predicts 5-year all cause in patients with symptomatic peripheral arterial disease: Results from the Linz Peripheral Arterial Disease (LIPAD) study.** 158
 – B. Dieplinger, A. Gegenhuber, W. Poelz, M. Haltmayer, T. Mueller (Linz and Bad Ischl, AT)

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

UNDER PRESSURE – TARGET ORGAN DAMAGE IN HYPERTENSION

Abstracts

Chairperson(s): M. Dorobantu (Bucharest, RO); G. Parati (Milan, IT)

- 08:30 **Is it necessary to perform echocardiography in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study?** 159
 – E. Gerdts, P.M. Okin, K. Wachtell, K. Boman, M.S. Nieminen, R.B. Devereux (Bergen, NO; New York, US; Copenhagen, DK; Skejfteaa, SE; Helsinki, FI)
- 08:45 **White-coat hypertension as a risk factor for developing left ventricular hypertrophy. The harvest study.** 160
 – L. Mos, P. Visentin, F. Dorigatti, M. Santonastaso, A. Bortolazzi, S. Cozzio, P. Bratti, F. Saladini, D. D'Este, P. Palatini (San Daniele Del Friuli, Padua, Vittorio Veneto, Rovigo, Trento and Mirano, IT)
- 09:00 **Regional myocardial performance in hypertensive heart disease.** 161
 – D. Foell, M. Markl, E. Schilli, F. Staehle, J. Hennig, C.H. Bode, B. Jung (Freiburg im Breisgau, DE)
- 09:15 **Penile vasculature: an organ target in essential hypertensive men.** 162
 – C. Vlachopoulos, N. Ioakeimidis, K. Rokkas, D. Terentes-Printzios, A. Bratsas, K. Baoui, P. Pietri, G. Lazaros, A. Askitis, C. Stefanadis (Athens, GR)
- 09:30 **Carotid intima-media thickness correlates closer with central than brachial pulse pressure.** 163
 – P. Jankowski, Y. Jin, K. Stolarz-Skrzypek, L. Thijs, W. Wojciechowska, T. Kuznetsova, T. Richart, T. Grodzicki, J.A. Staessen, K. Kawecka-Jaszcz (Krakow, PL; Leuven, BE)
- 09:45 **Excessive inotropic response during exercise as a marker of cardiovascular stiffening in newly diagnosed essential hypertension.** 164
 – D. Tsiachris, C. Tsioufis, D. Syrseloudis, D. Soulis, T. Papaioannou, A. Mazaraki, V. Tzamouri, I. Andrikou, I. Vlasseros, C. Stefanadis (Athens, GR)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

PROGNOSIS IN HYPERTENSION

Abstracts

Chairperson(s): S.E. Erdine (Istanbul, TR); P. Verdecchia (Perugia, IT)

- 11:00 **Exercise capacity status has a strong association with long term mortality risk in both young and older pre-hypertensive men.** 165
 – A. Pittaras, J. Myers, A.J. Manolis, M. Doulmas, M. Kallistratos, A. Giannakopoulos, C. Faselis, P. Narayan, S. Singh, P.F. Kokkinos (Athens, GR; Palo Alto and Washington Dc, US)
- 11:15 **Treated hypertensives with normal standard echocardiography at rest have marked left ventricular dysfunction on exercise.** 166
 – Y.T. Tan, E. Lee, F. Wenzelburger, G. Heatlie, M. Frenneaux, J.E. Sanderson (Birmingham and Stoke-On-Trent, GB)
- 11:30 **Impaired orthostatic response predicts mortality and coronary events in middle-aged individuals.** 167
 – A. Fedorowski, L. Stavenow, B. Hedblad, O. Melander (Malmo, SE)
- 11:45 **Relationship of morning blood pressure surge with cardiovascular events and total mortality in a general population.** 168
 – M. Bombelli, E. Toso, F. Ganz, D. Fodri, V. Galbiati, G. Seravalle, R. Facchetti, G. Grassi, R. Sega, G. Mancia (Monza, Milan and Vimercate, IT)
- 12:00 **Influence of blood pressure and blood pressure change on the risk of congestive heart failure in the elderly.** 169
 – D. Conen, C.U. Chae, J.M. Guralnik, R.J. Glynn (Basel, CH; Boston and Bethesda, US)
- 12:15 **Predictors of progression from prehypertension to hypertension in Japanese men.** 170
 – M. Odaira, H. Tomiyama, C. Matsumoto, M. Yoshida, J. Yamada, K. Shiina, A. Yamashina (Tokyo, JP)

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)



THE NEW 2009 ESC GUIDELINES

Chairperson(s): S. Smith (Chapel Hill, US); A. Vahanian (Paris, FR)
The Committee for Practice Guidelines

Symposium



- | | | |
|-------|---|-----|
| 08:30 | ESC Guidelines on the prevention, diagnosis and treatment of infective endocarditis. | 171 |
| | – G. Habib (Marseille, FR) | |
| 08:52 | ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. | 172 |
| | – N. Galie (Bologna, IT) | |
| 09:14 | ESC Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. | 173 |
| | – D. Poldermans (Rotterdam, NL) | |
| 09:36 | ESC Guidelines for the management of syncope. | 174 |
| | – A. Moya I Mitjans (Barcelona, ES) | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

HOT LINE I

Chairperson(s): R. Ferrari (Ferrara, IT); F.J. Pinto (Lisbon, PT)

Hot Line



- | | | |
|-------|---|-----|
| 11:00 | Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis. | 175 |
| | – G. Fowkes (Edinburgh, GB) | |
| 11:13 | Discussant. | 176 |
| | – C. Patrono (Rome, IT) | |
| 11:18 | A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial. | 177 |
| | – S.R. Mehta (Hamilton, CA) | |
| 11:31 | Discussant. | 178 |
| | – F. Van de Werf (Leuven, BE) | |
| 11:36 | Comparison of Ticagrelor, the first reversible oral P2Y₁₂ receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial. | 179 |
| | – L.C. Wallentin (Uppsala, SE) | |
| 11:49 | Discussant. | 180 |
| | – S.D. Kristensen (Aarhus, DK) | |
| 11:54 | A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke. RELY trial. | 181 |
| | – S.J. Connolly (Hamilton, CA) | |
| 12:07 | Discussant. | 182 |
| | – A.J. Camm (London, GB) | |
| 12:12 | Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes: Results of SEPIA-ACS1 TIMI 42. | 183 |
| | – M. Sabatine (Boston, US) | |
| 12:25 | Discussant. | 184 |
| | – H.D. White (Auckland, NZ) | |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

No session

S
U
N
D
A
Y
A
M

10:00–11:30

**TECHNICAL PRINCIPLES, CLINICAL
INDICATIONS AND ANALYSIS OF
CORONARY COMPUTED TOMOGRAPHY
ANGIOGRAPHY (LEVEL I)**

Hands-on Tutorial

Chairperson(s): J. Rixe (Bad Nauheim, DE)

Hands-on Tutorial organised by Siemens AG, Healthcare Sector

11:45–13:15

**CARDIOVASCULAR MAGNETIC
RESONANCE IN CORONARY ARTERY
DISEASE (LEVEL I)**

Hands-on Tutorial

Chairperson(s): G. von der Recke (Bonn, DE)

Hands-on Tutorial organised by Siemens AG, Healthcare Sector

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

No session

- 10:00–11:00 **REVASCULARISATION AND THE PATIENT WITH DIABETES: KEY ISSUES? PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION: IS IT DIFFERENT?** **Hands-on Tutorial**
Chairperson(s): A.A. Khattab (Berne, CH)
Hands-on Tutorial organised by Cordis, a Johnson & Johnson Company
- 11:00–12:30 **VASCULAR CLOSURE DEVICE WORKSHOP. INFORMATION AND PRACTICE ON THE DEPLOYMENT OF NEW CORDIS VASCULAR CLOSURE DEVICE** **Hands-on Tutorial**
Chairperson(s): To be announced
Hands-on Tutorial organised by Cordis, a Johnson & Johnson Company

**DRUG-ELUTING STENTS SAFETY – IS IT TIME TO
TURN THE PAGE ON BARCELONA 2006?**

Main Session

Chairperson(s): M. Tendera (Katowice, PL); A.H. Gershlick (Leicester, GB)

08:30	Did I repent? – E. Camenzind (Geneva, CH)	185
08:52	A critical analysis of randomised trials. – A. Kastrati (Munich, DE)	186
09:14	Latest data from registries. – S. James (Uppsala, SE)	187
09:36	Which recommendations can we give in 2009? – D. Holmes (Rochester, US)	188

SUNDAY
AM

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

**CHALLENGES IN CORONARY ARTERY
REVASCULARISATION IN DIABETIC PATIENTS**

Main Session

Chairperson(s): J.L. Pomar Moya-Prats (Barcelona, ES); J. Fajadet (Toulouse, FR)

11:00	Specificities of coronary disease in diabetic patients. – L. Ryden (Stockholm, SE)	189
11:22	Revascularisation: interventional perspective. – K.J. Beatt (London, GB)	190
11:44	Revascularisation: surgical perspective. – F. Oei (Rotterdam, NL)	191
12:06	Diabetic patients: more than just stents or grafts. – M. Roffi (Geneva, CH)	192

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

No session

- 10:00–12:30 **CARDIAC ANATOMY FOR INTERVENTIONAL CARDIOLOGISTS**
Chairperson(s): G. Thiene (Padua, IT); J.A. Cabrera (Madrid, ES)
Discussants from WG 17 and EAPCI
- 10:15 **Live-video demonstration.** **193**
– S.Y. Ho (London, GB)
- 11:15 **Hands-on specimen demonstration.** **194**

08:30–10:00

IMAGING THE RIGHT HEART. LIVE FROM MADRID

FOCUS Session

LIVE

Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); V. Fuster (New York, US)

Supported by **Siemens AG, Healthcare Sector** in the form of an unrestricted educational grant

Why is the assessment of right ventricular function important?	195
How can imaging help in the evaluation of right ventricular function. Role of MRI.	196
The isolated tricuspid valve disease: what can we do with those patients?	197
2D and 3D Echo of tricuspid and right ventricle.	198
Live case Interventionists in University Clinic San Carlos, Madrid.	199
– C. Fernandez-Gofin Loban, P. Marcos-Alberca Moreno (Madrid, ES)	
Panel.	200
– J.S. Russell Gibbs (London, GB), A. Torbicki (Warsaw, PL)	



10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

11:00–12:30

WHO WILL BENEFIT FROM CARDIAC RESYNCHRONISATION THERAPY? LIVE FROM LIEGE

FOCUS Session

LIVE

Chairperson(s): J.J. Bax (Leiden, NL); L.A. Piérard (Liège, BE)

Echo measurements of LV dyssynchrony.	201
MRI and CT: what can they offer?	202
AV and VV optimisation: how to do it?	203
AV and VV optimisation. LIVE.	204
Live case interventionist in University of Liège (C.H.U. du Sart Tilman).	205
– P. Lancellotti (Liège, BE)	
Panel.	206
– S. Lafitte (Pessac, FR), N. Van De Veire (Leiden, NL)	



12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

08:30–10:00

**ATRIAL FIBRILLATION: FACTS EVERYONE
NEEDS TO KNOW**

FOCUS Session

Chairperson(s): H.J.G.M. Crijns (Maastricht, NL); A.J. Camm (London, GB)

How lone is lone atrial fibrillation?	207
Balancing stroke and bleeding risk in an elderly atrial fibrillation patient.	208
A patient with atrial fibrillation and heart failure.	209
Facts you should know about antiarrhythmic therapy for atrial fibrillation.	210
Panel.	211
– S.H. Hohnloser (Frankfurt, DE), J.-Y. Le Heuzey (Paris, FR), G.Y.H. Lip (Birmingham, GB), I.C. Van Gelder (Groningen, NL)	



10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

11:00–12:30

**ACUTE CORONARY SYNDROME – DIFFICULT
TREATMENT DECISIONS**

FOCUS Session

Chairperson(s): S.D. Kristensen (Aarhus, DK); G.S. Filippatos (Athens, GR)

Acute anterior STEMI: transfer or lysis.	212
Timing of invasive therapy and appropriate medication in nonSTEMI.	213
Chronic anaemia, bleeding and renal failure in ACS.	214
Panel.	215
– J.-P. Bassand (Besançon, FR), T. Cuisset (Marseille, FR), A.W.J. Van 't Hof (Zwolle, NL)	



12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)



INDIVIDUALISED ANTIPLATELET THERAPY: EVIDENCE OR EMOTION BASED?

Symposium

Chairperson(s): D. Millicic (Zagreb, HR); S.D. Kristensen (Aarhus, DK)

- | | | |
|-------|--|-----|
| 08:30 | On-site platelet function testing: what are the options?
– J. Eikelboom (Hamilton, CA) | 216 |
| 08:52 | Mechanisms of the variable responses to antiplatelet drugs.
– C. Patrono (Rome, IT) | 217 |
| 09:14 | Antiplatelet therapy should be individualised.
– M. Gawaz (Tübingen, DE) | 218 |
| 09:36 | It is too soon to individualise antiplatelet therapy.
– P. Hjerdahl (Stockholm, SE) | 219 |

SUNDAY
AM

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

PLATELETS AND STENT THROMBOSIS

Symposium

Chairperson(s): F.W.A. Verheugt (Amsterdam, NL); N. Sinha (Lucknow, IN)

- | | | |
|-------|--|-----|
| 11:00 | Pathophysiology: early versus late stent thrombosis.
– R. Virmani (Gaithersburg, US) | 220 |
| 11:18 | Incidence: registries versus randomised trials.
– M.E. Pfisterer (Basel, CH) | 221 |
| 11:36 | Prevention: early and long-term platelet inhibition.
– L. Bonello (Marseille, FR) | 222 |
| 11:54 | Management and outcome of stent thrombosis.
– F. Burzotta (Rome, IT) | 223 |
| 12:12 | New devices, new drugs, new tests. Is the future as bright as we think?
– F.J. Neumann (Bad Krozingen, DE) | 224 |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

CARDIO-RENAL SYNDROME IN ACUTE HEART FAILURE **Symposium**

Chairperson(s): P. Ponikowski (Wroclaw, PL); M. Komajda (Paris, FR)

- | | | |
|-------|--|------------|
| 08:30 | Pathophysiology and prognosis. | 225 |
| | – A.A. Voors (Groningen, NL) | |
| 08:52 | Standard heart failure therapies and kidney function. | 226 |
| | – J.G.F. Cleland (Kingston upon Hull, GB) | |
| 09:14 | Overall management of fluid overload. | 227 |
| | – W.T. Abraham (Columbus, US) | |
| 09:36 | Emerging therapies for the management of the cardio-renal syndrome. | 228 |
| | – M. Metra (Brescia, IT) | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

REFRACTORY HEART FAILURE: CHALLENGES IN 2009 **Symposium**

Chairperson(s): R. De Caterina (Chieti, IT);
M. Gheorghiuade (Chicago, US)

 **Webcast**

- | | | |
|-------|---|------------|
| 11:00 | Defining and managing advanced heart failure. | 229 |
| | – A. Fucili (Ferrara, IT) | |
| 11:22 | Lessons from the INTERMACS registry. | 230 |
| | – K. Dickstein (Stavanger, NO) | |
| 11:44 | Surgical interventions and short-term devices. | 231 |
| | – A. Pitsis (Thessaloniki, GR) | |
| 12:06 | Long-term devices and the artificial heart. | 232 |
| | – S. Westaby (Oxford, GB) | |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

CARDIAC RESYNCHRONISATION THERAPY: EXPLORING NEW INDICATIONS

Abstracts

Chairperson(s): F. Macedo (Porto, PT); L. Mont (Barcelona, ES)

- 08:30 **Incidence and prognostic impact of spontaneous conversion to sinus rhythm in patients with permanent atrial fibrillation treated with cardiac resynchronization devices.** 233
 – C. Leclercq, M. Gasparini, A. Arshad, A. Rozier, G. Kamath, P. Galimbert, C. Daubert, C. Klersy, J.S. Steinberg (Rennes, FR; Milan, IT; New York, US)
- 08:45 **Why the patients with permanent atrial fibrillation indicated to CRT have worse prognosis comparing to the patients with sinus rhythm?** 234
 – M. Taborsky, P. Neuzil, E. Mandysova, E. Vait (Prague, CZ)
- 09:00 **Atrial fibrillation does not influence long-term response to cardiac resynchronization therapy.** 235
 – S. Buck, A.H. Maass, B.A. Schoonderwoord, D.J. Van Veldhuisen, I.C. Van Gelder (Groningen, NL)
- 09:15 **Expedited management of patients with acute atrial fibrillation and mild structural heart disease in the emergency department.** 236
 – A. Conti, B. Del Taglia, Y. Mariannini, C. Puggioni, B. Paladini, G. Pepe, S. Vanni, S. Magazzini, M. Zanobetti, S. Grifoni (Florence, IT)
- 09:30 **Relationship of QRS duration to reverse remodeling with CRT in mild heart failure over 2 years. Results from the European cohort of the REVERSE trial.** 237
 – M. Gold, C. Linde, I. Lozano, J.C. Daubert, W.T. Abraham (Charleston and Ohio, US; Stockholm, SZ; Madrid, ES; Rennes, FR)
- 09:45 **CRT in mild heart failure: Differences in outcomes between NYHA Class I and II patients over 24 month of CRT. Results from the European cohort of the REVERSE Trial.** 238
 – C. Linde, R. Leman, J.C. Daubert, W.T. Abraham, M.R. Gold (Stockholm, SE; Charleston and Ohio, US; Rennes, FR)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)



NEW INSIGHTS INTO THE MECHANISMS OF HEART FAILURE

Abstracts

Chairperson(s): S. Adamopoulos (Athens, GR); P. Ponikowski (Wroclaw, PL)

- 11:00 **Cachexia in cancer and heart failure development.** 239
 – J. Springer, A. Hartmann, S. Palus, A. Grzesiak, E. Kaschina, S. Von Haehling, J.M. Argiles, S.D. Anker (Berlin, DE; Barcelona, ES)
- 11:15 **Aldosterone escape is associated with insulin resistance in patients with heart failure- findings in the ALiskiren Observation of heart Failure Treatment trial (ALOFT).** 240
 – I.K. Tsorlalis, E.M. Freel, J.D. Lewsey, R. Latini, A.P. Maggioni, B. Pitt, S.D. Solomon, A. Verma, J.M.C. Connell, J.J.V. McMurray (Glasgow, GB; Milan and Florence, IT; Ann Arbor and Boston, US)
- 11:30 **The novel biomarker Red cell Distribution Width (RDW) has incremental prognostic value, in addition to B-type natriuretic peptide (BNP), in patients with acute decompensated heart failure.** 241
 – C.E. Jackson, V. Bezlyak, I.K. Tsorlalis, J.R. Dalzell, R.C. Myles, R. Spooner, I. Ford, M.C. Petrie, S.M. Cobbe, J.J.V. McMurray (Glasgow, GB)
- 11:45 **Vitamin D deficiency is common in patients with chronic heart failure and relates to the severity of the condition.** 242
 – K. Witte, R.C. Cubbon, C.P. Gale, M.B. Kahn, A. Rajwani, L.C. Falk, M.T. Kearney (Leeds, GB)
- 12:00 **Increased levels of cytokines, vasoactive peptides, and growth factors in alveolar macrophages in heart failure.** 243
 – C.P. Dahl, L.I.B. Sikkeland, A.K. Andreassen, E. Gude, L. Gullestad, J. Kongerud, P. Aukrust, E. Oie (Oslo, NO)
- 12:15 **Statin treatment further deteriorates systolic function in doxorubicine treated mice.** 244
 – H. Kilter, J.C. Reil, D. Steffen, M. Boehm (Homburg, DE)

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

SYNCOPE AND IMPLANTABLE LOOP RECORDERS: GOOD VALUE FOR MONEY?

Abstracts

Chairperson(s): J.-J. Blanc (Brest, FR); B. Gorenek (Eskisehir, TR)

- 08:30 **REVISE (Reveal in the Investigation of Syncope and Epilepsy) study.** 245
 – S. Petkar, P. Iddon, W. Bell, N. Rice, D. Mckee, N. Curtis, P. Cooper, A. Fitzpatrick (Manchester and Salford, GB)
- 08:45 **Implantable loop recorders in diagnostics of recurrent syncope in children with apparently normal heart.** 246
 – M. Shkolnikova, S. Termosesov, E. Polyakova, R. Garipov, Y.A. Volkova, I. Ilich (Moscow, RU)
- 09:00 **Holter monitoring in syncope: good diagnostic yield in octogenarians.** 247
 – M. Kuhne, B. Schaer, C. Sticherling, S. Osswald (Basel, CH)
- 09:15 **Living with the Sleuth: patient experience of a second generation remotely monitored implantable loop recorder.** 248
 – P.S.G. Hong, J. Hunt, R.A. Veasey, S. Shubber, U. Shanker, S.S. Furniss, G.W. Lloyd, N.R. Patel, A.N. Sulke (Eastbourne, GB)
- 09:30 **Early use of implantable loop recorders in the assessment of patients presenting to secondary care with syncope or severe palpitations with pre-syncope.** 249
 – A. Bajpai, D. Eruchie, K.N. Asress, A. Yavari, D. Cotterill, K. Dickinson, E.T. McWilliams, D.M. Walker (Hastings, GB)
- 09:45 **Prodrome in syncope: A predictor of cause?** 250
 – P.S.G. Hong, R.A. Veasey, J. Hunt, A. Nahhas, M. Fonseka, C. Athlumudali, S.S. Furniss, G.W. Lloyd, N.R. Patel, A.N. Sulke (Eastbourne, GB)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

OUT OF HOSPITAL CARDIAC ARREST: THE FIGHT GOES ON

Abstracts

Chairperson(s): H.J. Wellens (Maastricht, NL); P. Sritara (Bangkok, TH)

- 11:00 **Temporal improvement in survival from out of hospital cardiac arrest - The Dublin cardiac arrest registry.** 251
 – R. Margey, L. Browne, E. Murphy, H.A. Mccann, G. Blake, N.G. Mahon, J. Galvin, D. Sugrue (Dublin, IE)
- 11:15 **Ventricular fibrillation may be provoked by chest compression during post-shock organized rhythms in out-of-hospital cardiac arrest.** 252
 – D. Aschieri, V. Pelizzoni, S. Ferraro, A.M. Andreoli, A. Capucci (Piacenza and Ancona, IT)
- 11:30 **A logistic regression model to predict the occurrence of ventricular fibrillation in out of hospital cardiac arrest.** 253
 – A. Hamilton, K.J. Cairns, A.A.J. Adgey, F. Kee (Belfast, GB)
- 11:45 **Efficacy of biphasic 150j and 200j shocks in out-of-hospital ventricular fibrillation.** 254
 – D. Mueller, G. Moehl, J. Breckwoldt, H.-R. Arntz (Berlin, DE)
- 12:00 **Sport-related sudden cardiac death in the community. Time for action.** 255
 – E. Marijon, M. Tafflet, F. Tchatchum, F. Dumas, N. Benameur, S. Narcisse, J.F. Toussaint, J.P. Empana, X. Jouven (Paris, Lille and Orleans, FR)
- 12:15 **Early defibrillation in out-of-hospital cardiac arrest: ten years experience of the Italian project Piacenza-Progetto Vita.** 256
 – D. Aschieri, V. Pelizzoni, S. Ferraro, A. Rosi, M.S. Pisati, E. Bonibaldoni, M. Arvedi, A. Capucci (Piacenza and Ancona, IT)

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

HOW TO OPTIMISE TREATMENT FOR HEART FAILURE IN THE ELDERLY. WHAT ARE WE AFRAID OF? **Symposium**

Chairperson(s): H. Krum (Melbourne, AU); A. Stromberg (Linköping, SE)

- | | | |
|-------|---|------------|
| 08:30 | Should beta-blockers be used in the elderly? | 257 |
| | – A. Di Lenarda (Trieste, IT) | |
| 08:52 | Can elderly tolerate combinations of neurohumoral antagonists? | 258 |
| | – A. Cohen-Solal (Paris, FR) | |
| 09:14 | Aldosterone antagonist in the elderly. | 259 |
| | – B. Pitt (Ann Arbor, US) | |
| 09:36 | Devices in the elderly. | 260 |
| | – A. Auricchio (Lugano, CH) | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

HEART FAILURE AND CANCER

Symposium

Chairperson(s): H. Drexler (Hannover, DE); E. Roig (Barcelona, ES)

- | | | |
|-------|---|------------|
| 11:00 | Cardiovascular disease in patients with cancer. | 261 |
| | – D. Cardinale (Milan, IT) | |
| 11:22 | Heart failure and cancer - public health nightmares. | 262 |
| | – S. Stewart (Melbourne, AU) | |
| 11:44 | Cardiotoxic anti-cancer treatments. | 263 |
| | – J. Baselga (Barcelona, ES) | |
| 12:06 | Common mechanisms of cachexia in cancer and heart failure. | 264 |
| | – S.D. Anker (Berlin, DE) | |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

**FLUID MANAGEMENT OF PATIENTS
ADMITTED WITH ACUTE HEART FAILURE**

Clinical Seminar

Chairperson(s): J. Nanas (Athens, GR); T.A. McDonagh (London, GB)

- | | | |
|-------|---|-----|
| 08:30 | Non-potassium sparing diuretics.
– G. Cotter (Durham, US) | 265 |
| 08:48 | Renal replacement therapy.
– G. Jondeau (Paris, FR) | 266 |
| 09:06 | Vasopressin antagonists.
– M. Gheorghiu (Chicago, US) | 267 |
| 09:24 | Adenosine antagonists.
– D.J. van Veldhuisen (Groningen, NL) | 268 |
| 09:42 | What is different in the elderly?
– A. Ahmed (Birmingham, US) | 269 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)



BIOMARKERS IN ACUTE CARDIAC CARE, NEW ROLES IN DIAGNOSIS AND PROGNOSIS **Clinical Seminar**

Chairperson(s): D.T. Kremastinos (Athens, GR); N. Danchin (Paris, FR)

- | | | |
|-------|---|-----|
| 11:00 | Natriuretic peptides and midregional biomarkers.
– A. Maisel (San Diego, US) | 270 |
| 11:22 | New sensitive markers for myocardial ischaemia/necrosis.
– C. Mueller (Basel, CH) | 271 |
| 11:44 | Inflammatory and stress biomarkers.
– L.M. Biasucci (Rome, IT) | 272 |
| 12:06 | Markers of renal dysfunction.
– J.T. Parissis (Athens, GR) | 273 |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)



NEWS AND VIEWS ON CARDIAC SODIUM CHANNELS – Symposium
FROM BENCH TO BEDSIDE

Chairperson(s): K.R. Sipido (Leuven, BE); R.L. Page (Seattle, US)

- | | | |
|-------|--|-----|
| 08:30 | Functional expression and localisation of sodium channels in myocardium. | 274 |
| | – M.R. Rosen (New York, US) | |
| 08:52 | Modulation of sodium channel function by unusual suspects - potassium channel chaperones. | 275 |
| | – D. Fedida (Vancouver, CA) | |
| 09:14 | Modulation of cardiac sodium channels: are they good targets to treat arrhythmias? | 276 |
| | – L.S. Maier (Göttingen, DE) | |
| 09:36 | Sodium channel diseases in the clinical arena. | 277 |
| | – S.K.G. Maier (Wurzburg, DE) | |

S
U
N
D
A
Y
A
M

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)



INHERITED ARRHYTHMIA SYNDROMES: APPROACH TO SYMPTOMATIC AND ASYMPTOMATIC INDIVIDUALS **Symposium**

Chairperson(s): A.A.M. Wilde (Amsterdam, NL); S.G. Priori (Pavia, IT)

- | | | |
|-------|---|-----|
| 11:00 | How to approach an asymptomatic Brugada patient. | 278 |
| | – V. Probst (Nantes, FR) | |
| 11:22 | Long QT silent gene carriers in childhood: should they all receive beta-blockers? | 279 |
| | – S. Kaab (Munich, DE) | |
| 11:44 | Early repolarisation and lethal arrhythmias. | 280 |
| | – F. Sacher (Bordeaux Pessac, FR) | |
| 12:06 | The role of drugs and implantable cardioverter-defibrillator in catecholaminergic polymorphic ventricular tachycardia. | 281 |
| | – J. Brugada Terradellas (Barcelona, ES) | |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

UPDATE ON BIOMARKERS IN ACUTE CARDIAC CARE

Abstracts

Chairperson(s): C. Mueller (Basel, CH); A. Maisel (San Diego, US)

- 08:30 **Diagnostic and prognostic value of high sensitive troponin T in patients with acute coronary syndromes.** 282
 – M. Weber, H. Moellmann, H. Nef, S. Mayer, C. Liebetrau, M. Woelken, C. Hamm (Bad Nauheim, DE)
- 08:45 **Mid Regional pro-Adrenomedullin shows additional prognostic value when used in combination with N terminal Pro B-type Natriuretic Peptide in patients with non ST elevation myocardial infarction.** 283
 – O.S. Dhillon, S.Q. Khan, N. Mohammed, I.B. Squire, J.E. Davies, L.L. Ng (Leicester, GB)
- 09:00 **Prognostic value of pentaxin3 in patients with chest pain.** 284
 – K. Inoue, S. Suwa, S. Okazaki, S. Ito, M. Kawamura, I. Okai, M. Sumiyoshi, T. Kodama, H. Daida (Tokyo and Shizuoka, JP)
- 09:15 **Copeptin for prediction of outcome in patients with cardiogenic shock.** 285
 – B. Meyer, P. Wexberg, J. Struck, A. Bergmann, N.G. Morgenthaler, G. Heinz, R. Pacher, M. Huelsmann (Vienna, AT; Hennigsdorf, DE)
- 09:30 **A new high-sensitive cardiac troponin I assay allows identification of the vast majority of patients with acute coronary syndromes.** 286
 – B. Lindahl, S. James, N. Johnston, P. Venge (Uppsala, SE)
- 09:45 **Pregnancy associated plasma protein A, a marker for outcome in patients with low-risk acute coronary syndrome.** 287
 – K.K. Iversen, M. Dalsgaard, A. Teisner, B. Teisner, P. Grande, H. Nielsen, P. Clemmesen (Copenhagen and Odense, DK)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

ADVANCES IN CARDIOPULMONARY RESUSCITATION

Abstracts

Chairperson(s): L.L. Bossaert (Edegem-Antwerp, BE); A.S. Manolis (Glyfada-Athens, GR)

- 11:00 **Outcome of mild induced hypothermia after out-of-hospital sudden cardiac arrest in non-selected patients.** 288
 – U. Pitti, D. Lehmann, S. Erbs, E. Grebe, S. Gielen, G. Schuler, H. Thiele (Leipzig, DE)
- 11:15 **Electrocardiographic disturbances induced by mild therapeutic hypothermia after cardiac arrest.** 289
 – P. Salinas Sanguino, E. Lopez De Sa, A. Viana-Tejedor, L. Pena-Conde, E. Armada, J.R. Rey-Blas, S. Garcia-Blas, D. Iglesias, M.C. Monedero, J.L. Lopez-Sendon (Madrid, ES)
- 11:30 **In vivo systemic effects of catheter based selective unilateral profound cerebral hypothermia.** 290
 – D. Meerkin, S.P. Lownie, C.J. Prestigiacomo, R.J. Solar (Jerusalem, IL; London, CA; Newark and San Diego, US)
- 11:45 **Therapeutic hypothermia improves myocardial function and stabilizes the hemodynamic situation in patients after cardiac arrest.** 291
 – C. Jacobshagen, A. Pax, S. Schmidt-Schweda, B.W. Unsoeld, T. Seidler, G. Hasenfuss, L.S. Maier (Göttingen, DE)
- 12:00 **Moderate hypothermia induces severe diastolic changes in a porcine model.** 292
 – A. Espinoza, V. Kerans, A. Opdahl, P.S. Halvorsen, H. Skulstad, L. Hoff, J.F. Bugge, T. Edvardsen (Oslo and Horten, NO)
- 12:15 **Randomized comparison of percutaneous left ventricular assist device with open chest cardiac massage and surgical left ventricular assist device in ischemic cardiac arrest.** 293
 – V. Tuset, R.J. Pettersen, K. Grong, T. Wentzel-Larsen, R. Haaverstad, R. Fanelop, J.E. Nordrehaug (Bergen, NO)

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

ATRIAL FIBRILLATION 2009: CONTEMPORARY THERAPIES FOR THE NEW EPIDEMIC

Main Session

Chairperson(s): P. Brugada Terradellas (Brussels, BE); S. Levy (Marseille, FR)

08:30	Atrial remodelling in atrial fibrillation and its implications for therapy. – J.R. Ehrlich (Frankfurt, DE)	294
08:52	Future of antiarrhythmic drug therapy: are we making progress? – T. Meinertz (Hamburg, DE)	295
09:14	Outcomes and complications of atrial fibrillation ablation. – C. Pappone (Milan, IT)	296
09:36	Antiarrhythmic drugs versus ablation: what do we learn from prospective trials? – D.L. Packer (Rochester, US)	297

SUNDAY
AM

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

ATRIAL FIBRILLATION ABLATION: PATIENT SELECTION, PROCEDURE, AND FOLLOW-UP **Symposium**

Chairperson(s): J. Kautzner (Prague, CZ); K.M. Monahan (Boston, US)
The European Society of Cardiology and the American College of Cardiology

11:00	Integrated imaging in patient selection. – J. Steinberg (New York, US)	298
11:22	How to ablate atrial fibrillation in 2009. – K.-H. Kuck (Hamburg, DE)	299
11:44	Anticoagulation before, during, and after ablation of atrial fibrillation. – N.A.M. Estes (Boston, US)	300
12:06	How do we define success of the ablation procedure? – C. Pratola (Ferrara, IT)	301

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)



THE BEAT GOES ON – GENESIS AND MAINTENANCE OF THE CARDIAC CONDUCTION TISSUE Symposium

Chairperson(s): R. Kelly (Marseille, FR); S. Bhattacharya (Oxford, GB)

- | | | |
|-------|--|------------|
| 08:30 | Molecular control of node formation in the embryonic heart. | 302 |
| | – D. Franco Jaime (Jaen, ES) | |
| 08:52 | Mechanical control of cardiac conduction system formation. | 303 |
| | – D. Sedmera (Prague, CZ) | |
| 09:14 | Embryonic and postnatal patterning of the peripheral ventricular conduction tissue. | 304 |
| | – L. Miquerol (Marseille, FR) | |
| 09:36 | Effect of ageing on the cardiac conduction system. | 305 |
| | – T. Brand (Wurzburg, DE) | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

- | | | |
|-------------|---|------------|
| 10:15–10:45 | How to submit an abstract to the ESC | 306 |
| | – E. Picano (Pisa, IT) | |



GENETICS OF HEART (DYS)MORPHOGENESIS Symposium

Chairperson(s): D. Franco Jaime (Jaen, ES); H. Schunkert (Lubeck, DE)

- | | | |
|-------|---|------------|
| 11:00 | Integrating cardiac regulatory networks in (dys)morphogenesis. | 307 |
| | – S. Sperling (Berlin, DE) | |
| 11:22 | Epigenetic control of cardiac development. | 308 |
| | – S. Bhattacharya (Oxford, GB) | |
| 11:44 | Genetics of Tetralogy of Fallot and transposition of great arteries. | 309 |
| | – B. Marino (Rome, IT) | |
| 12:06 | Somatic mutations in congenital heart diseases. | 310 |
| | – T. Borlak (Hannover, DE) | |



**INFLAMMATION AND ATHEROSCLEROSIS:
EVIDENCE AND IMPLICATIONS**

Main Session

Webcast

Chairperson(s): R. De Caterina (Chieti, IT); J. Chapman (Paris, FR)

The European Society of Cardiology and the European Atherosclerosis Society

08:30	Genetics of inflammation and atherosclerosis.	311
	– H. Schunkert (Lubeck, DE)	
08:52	Inflammation and plaque rupture.	312
	– G.K. Hansson (Stockholm, SE)	
09:14	Inflammatory biomarkers and therapeutic implications.	313
	– A.C. Newby (Bristol, GB)	
09:36	Body fat, inflammation and vascular health.	314
	– C. Stehouwer (Maastricht, NL)	

SUNDAY
AM

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

**CORONARY BIFURCATIONS:
STILL A CHALLENGE FOR PERCUTANEOUS
REVASCLARISATION?**

Clinical Seminar

Chairperson(s): R.-L. Gao (Beijing, CN); L. Thuesen (Aarhus, DK)

11:00	Classification and flow dynamics.	315
	– R. Albiero (Orme, IT)	
11:22	Stenting techniques and their limitations.	316
	– G. Stankovic (Belgrade, RS)	
11:44	Thrombosis and restenosis.	317
	– T. Lefevre (Massy, FR)	
12:06	New technologies.	318
	– S. Verheye (Antwerp, BE)	

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

**HOW TO EVALUATE LEFT VENTRICULAR
FUNCTION**

Clinical Seminar

Chairperson(s): D. Leung (Liverpool, AU); W.A. Zoghbi (Houston, US)

- | | | |
|-------|--|------------|
| 08:30 | Interpretation of pressure-volume loops.
– K. Onishi (Tsu, JP) | 319 |
| 08:52 | Volumes and ejection fraction are all I need.
– R.R. Brandt (Bad Nauheim, DE) | 320 |
| 09:14 | Deformation parameters are mandatory.
– T.H. Marwick (Brisbane, AU) | 321 |
| 09:36 | How left-ventricular function predicts outcome.
– J.L. Lopez-Sendon (Madrid, ES) | 322 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

**DEBATED CONCEPTS IN DIASTOLIC
FUNCTION**

Clinical Seminar

Chairperson(s): S. Nagueh (Houston, US); F. Flachskampf (Erlangen, DE)

- | | | |
|-------|--|------------|
| 11:00 | Which parameters should we measure?
– T.C. Gillebert (Ghent, BE) | 323 |
| 11:22 | Should we grade diastolic function?
– O.A. Smiseth (Oslo, NO) | 324 |
| 11:44 | Diastolic stress test.
– J.K. Oh (Rochester, US) | 325 |
| 12:06 | Which therapeutic consequences?
– B.M. Pieske (Graz, AT) | 326 |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)



PRENATAL COUNSELLING: ITS IMPACT ON CONGENITAL HEART DISEASE **Clinical Seminar**

Chairperson(s): E.V.O. Jokinen (Helsinki, FI); W. Budts (Leuven, BE)

- | | | |
|-------|---|------------|
| 08:30 | Will foetal echo screening decrease the incidence of congenital heart disease?
– S.-A. Clur (Amsterdam, NL) | 327 |
| 08:52 | The effects of prenatal diagnosis on perinatal care in congenital heart disease.
– R. Anjos (Carnaxide, PT) | 328 |
| 09:14 | The potential of three-dimensional echo in foetal echocardiography.
– J. Simpson (London, GB) | 329 |
| 09:36 | How to counsel a patient with Marfan disease who wants to get pregnant?
– E. Arbustini (Pavia, IT) | 330 |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

THE RIGHT VENTRICLE AND PULMONARY VALVE REPLACEMENT **Clinical Seminar**

Chairperson(s): L. Iserin (Paris, FR); E. Acarturk (Adana, TR)

- | | | |
|-------|--|------------|
| 11:00 | New echocardiographic tools to analyse right-ventricular function.
– L. Mertens (Toronto, CA) | 331 |
| 11:22 | Cardiovascular magnetic resonance of the right ventricle to guide timing of pulmonary valve replacement.
– E. Valsangiacomo Buechel (Zurich, CH) | 332 |
| 11:44 | Surgical pulmonary valve replacement: which valve to chose?
– V.T. Tsang (London, GB) | 333 |
| 12:06 | Results of transcatheter pulmonary valve replacement.
– P. Bonhoeffer (London, GB) | 334 |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

MITRAL REGURGITATION: WHAT'S NEW?

Abstracts

Chairperson(s): P. Punjabi (London, GB); J. Stepinska (Warsaw, PL)

- 08:30 **Myocardial systolic velocities and deformation assessed by speckle tracking for the early detection of cardiac dysfunction in asymptomatic patients with severe primary mitral regurgitation.** 335
 – M. Florescu, D. Benea, R. Sisu, O. Enescu, L.S. Magda, G. Cerin, M. Diena, M. Cinteza, D. Vinereanu (Bucharest, RO; Novara, IT)
- 08:45 **Prospective validation of the prognostic usefulness of BNP in asymptomatic patients with chronic severe mitral regurgitation.** 336
 – R. Pizarro, P. Oberti, A. Arias, M. Falconi, F. Achilli, J. Krauss, A. Cagide, O. Bazzino (Buenos Aires, AR)
- 09:00 **Prognostic impact of pulmonary arterial hypertension in patients with severe mitral regurgitation due to flail leaflets: a multicenter long-term international study.** 337
 – F. Bursi, F. Grigioni, A. Barbieri, C. Tribouilloy, J.F. Avierinos, A. Branzi, M.G. Modena, M. Enriquez-Sarano (Modena and Bologna, IT; Amiens and Marseille, FR; Rochester, US)
- 09:15 **Functional mitral regurgitation as a predictor of atrial fibrillation following acute myocardial infarction.** 338
 – F. Bahouth, D. Mutlak, S. Dabbah, H. Hammerman, Y. Agmon, D. Aronson (Haifa, IL)
- 09:30 **Matrix metalloproteinase-1 mitral expression and -1607 1g/2g gene promoter polymorphism in patients with mitral chordae tendinae rupture.** 339
 – T.H. Lin, S.F. Yang, C.C. Chiu, Y.T. Lee, H.M. Su, W.C. Voon, W.T. Lai, S.H. Sheu (Kaohsiung, TW)
- 09:45 **Hybrid approach for patients with mitral valve disease and coronary artery disease: a pilot study on the association of minimally invasive video- assisted mitral valve surgery and PCI.** 340
 – C. Trana, F. Mangiacapra, A. Ntalianis, J. Bartunek, F. Van Praet, F. Casselman, E. Barbato, H. Vanermen, B. De Bruyne (Aalst, BE)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

THERAPEUTIC INTERVENTIONS AND OUTCOMES IN CARDIOMYOPATHIES

Abstracts

Chairperson(s): P. Spirito (Genoa, IT); U. Baandrup (Hjorring, DK)

- 11:00 **Bromocriptine promotes recovery of cardiac function and survival in patients with PPCM: first randomized study.** 341
 – K. Sliwa, K. Tibazarwa, L. Blauwet, E. Libhaber, J.P. Smedema, A. Becker, D. Hilfiker-Kleiner (Johannesburg and Cape Town, ZA; Rochester, US; Hannover, DE)
- 11:15 **Survival of 644 consecutive patients with severe HOCM after transcatheter ablation of septal hypertrophy (TASH). A single centre experience.** 342
 – T. Lawrenz, C. Leuner, M. Bartelsmeier, M. Schloesser, F. Lieder, C. Stellbrink, H. Kuhn (Bielefeld, DE)
- 11:30 **Enzyme replacement therapy delays the onset of cardiac involvement in Fabry disease.** 343
 – V. Serra, L. Perez De Isla, A. Calli, J. Paniagua, V. Valverde, A. Ribera, J. Herrera, J. Zamorano (Madrid, ES)
- 11:45 **The systemic cardiac amyloidoses: disease profiles and clinical courses of the three main etiologic forms.** 344
 – C.C. Quarta, L. Riva, S. Perlini, S. Longhi, P. Ciliberti, M.L. Fonte, G. Galati, E. Biagini, G.P. Merlini, C. Rapezzi (Bologna and Pavia, IT)
- 12:00 **Clinical outcome in patients with hypertrophic cardiomyopathy and implantable cardioverter defibrillator therapy.** 345
 – C. Schukro, R. Rosenhek, T. Pezawas, G. Stix, J. Kastner, M. Wolzt, H. Schmidinger (Vienna, AT)
- 12:15 **Clinical management and therapeutic strategies in patients with tako- tsubo-cardiomyopathy: results of the German tako- tsubo registry.** 346
 – B. Schneider, A. Athanasiadis, W. Pistner, R. Schamberger, W. Toepel, R. Schoeller, U. Gottwald, B. Gerecke, J. Schwab, U. Sechtem (Lubeck, Stuttgart, Aschaffenburg, Bad Neustadt/Saale, Idar-Oberstein, Berlin, Celle, Wolfsburg and Nuremberg, DE)

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

CORONARY COMPUTED TOMOGRAPHY TO IDENTIFY HIGH-RISK ASYMPTOMATIC SUBJECTS **Debate**

Chairperson(s): P. Perrone-Filardi (Naples, IT); I.V. Vassiliadis (Athens, GR)

Coronary calcium scoring is useless.

08:30	Pro. – J. Airaksinen (Turku, FI)	347
08:45	Contra. – L.J. Shaw (Atlanta, US)	348
	Rebuttal.	
09:00	Pro. – J. Airaksinen (Turku, FI)	349
09:05	Contra. – L.J. Shaw (Atlanta, US)	350
09:10	Conclusion.	351
	Coronary computed tomography angiography is useless.	
09:15	Pro. – W. Wijns (Aalst, BE)	352
09:30	Contra. – P.J. De Feyter (Rotterdam, NL)	353
	Rebuttal.	
09:45	Pro. – W. Wijns (Aalst, BE)	354
09:50	Contra. – P.J. De Feyter (Rotterdam, NL)	355
09:55	Conclusion.	356

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

CARDIAC COMPUTED TOMOGRAPHY: WHEN, FOR WHOM AND HOW? **Symposium**

Chairperson(s): C. Anagnostopoulos (London, GB); P. Marzullo (Pisa, IT)

11:00	Cardiac computed tomography in coronary artery disease. – J.D. Schuijf (Leiden, NL)	357
11:22	Cardiac computed tomography in the emergency room: is there an indication? – S. Schroeder (Goepingen, DE)	358
11:44	The role of cardiac computed tomography beyond the coronaries. – T. Chua (Singapore, SG)	359
12:06	New techniques of dose reduction and fusion imaging. – P.A. Kaufmann (Zurich, CH)	360

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

MANAGEMENT OF INFECTIVE ENDOCARDITIS Clinical Seminar
IN PARTICULAR SUBGROUPS

Chairperson(s): R.J.C. Hall (Norwich, GB); F. Delahaye (Bron, FR)

08:30	The elderly. – C. Naber (Essen, DE)	361
08:52	The patient with diabetes. – B.D. Prendergast (Oxford, GB)	362
09:14	The patient with negative blood cultures. – J.A. San Roman Calvar (Valladolid, ES)	363
09:36	Cardiac device related infected endocarditis. – G. Habib (Marseille, FR)	364

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

THE TRICUSPID VALVE

Symposium

Chairperson(s): M.J. Antunes (Coimbra, PT); H.K. Najm (Riyadh, SA)

11:00	How to assess the tricuspid valve prior to mitral valve surgery. – L.D. Gillam (New York, US)	365
11:22	Three-dimensional echo assessment of the tricuspid valve. – J. Marek (London, GB)	366
11:44	Assessment of tricuspid valve function with cardiovascular magnetic resonance. – W.A. Helbing (Rotterdam, NL)	367
12:06	Which operation and when? – M. Sousa Uva (Lisbon, PT)	368

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)



**RADICAL NEWS: REDOX SIGNALLING IN THE
CARDIOVASCULAR SYSTEM**

Symposium

Chairperson(s): R. Schulz (Essen, DE); U. Landmesser (Zurich, CH)

- | | | |
|-------|--|-----|
| 08:30 | Mitochondria at the heart of reactive oxygen species production.
– E. Murphy (Bethesda, US) | 369 |
| 08:52 | Oxidant-induced activation of PKA and PKG: relevance to cardiac and vascular function.
– P. Eaton (London, GB) | 370 |
| 09:14 | Oxidation-dependent activation of calcium/calmodulin-dependent protein kinase II - a new pathway involved in myocardial remodelling.
– M.E. Anderson (Iowa City, US) | 371 |
| 09:36 | Clinical impact of nitric oxide-superoxide interactions.
– K. Channon (Oxford, GB) | 372 |

S
U
N
D
A
Y
A
M

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)



VASA VASORUM: INVOLVEMENT IN ATHEROSCLEROSIS. FROM BENCH TO BEDSIDE **Symposium**

Chairperson(s): R. Erbel (Essen, DE); C. De Wit (Lubeck, DE)

- | | | |
|-------|---|-----|
| 11:00 | Vasa vasorum: regulation by growth factors.
– S. Yla-Herttuala (Kuopio, FI) | 373 |
| 11:22 | Imaging of vasa vasorum.
– A.F.W. Van der Steen (Rotterdam, NL) | 374 |
| 11:44 | Clinical studies and vasa vasorum: is there a room for a new surrogate marker?
– S.B. Feinstein (Chicago, US) | 375 |
| 12:06 | Leaky vessels and intra-plaque bleeding.
– M. Daemen (Maastricht, NL) | 376 |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)



**MOLECULAR AND CELLULAR DRIVERS OF
ATHEROSCLEROTIC PLAQUE REMODELLING**

Abstracts

Chairperson(s): Z. Reiner (Zagreb, HR); J.W. Jukema (Leiden, NL)

- 08:30 **Deficient phosphorylation of p27 in serine 10 is associated with human atherosclerosis and aggravates disease progression in hypercholesterolemic mice.** **377**
 – J.J. Fuster, H. Gonzalez-Navarro, A. Vinue, M.A. Ibanez, K.I. Nakayama, K. Nakayama, C. Rodriguez, J. Martinez-Gonzalez, V. Andres (Valencia and Barcelona, ES; Fukuoka and Miyagi, JP)
- 08:45 **Endogenous SIRT1 protects against atherosclerosis by decreasing macrophage infiltration and foam cell formation.** **378**
 – M.A.S. Stein, C. Lohmann, N. Schaefer, L. Rohrer, A. Breitenstein, J. Boren, F.C. Tanner, T.F. Luescher, C.M. Matter (Zurich, CH; Gothenburg, SE)
- 09:00 **Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis.** **379**
 – C. Monaco, S.M. Gregan, T.J. Navin, B.M.J. Foxwell, A.H. Davies, M. Feldmann (London, GB)
- 09:15 **Bone marrow derived progenitor cells in murine atherosclerotic calcification.** **380**
 – C. Heeger, E.M. Ehlers, Z. Aherrahrou, J. Erdmann, H. Schunkert, L.C. Doehring (Lubeck, DE)
- 09:30 **A subset of non-foam macrophages expressing myeloid-related protein 8 and 14 is associated with rupture-prone plaque phenotype.** **381**
 – G.M. Ionita, A. Vink, P. Van Der Kraak, P. Van Den Borne, G. Pasterkamp, D.P.V. De Kleijn (Utrecht, NL)
- 09:45 **Progenitor cell mobilization is FGF-2 dependant and results in the activation of osteoclasts.** **382**
 – M. Steinmetz, B. Pelster, V. Fontaine, J.F. Arnal, G. Nickenig, N. Werner (Bonn, DE; Toulouse, FR)

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

- 10:15–10:45 **How to write a medical paper** **383**
 – S. Janssens (Leuven, BE)



**STRESS AT THE SURFACE: RISK FACTORS FOR
ENDOTHELIAL DYSFUNCTION**

Abstracts

Chairperson(s): R. Krams (London, GB); C. Weiss (Mainz, DE)

- 11:00 **Genetic deletion of JunD enhances age-related endothelial dysfunction.** **384**
 – E. Osto, G. Coppolino, B. Mateescu, A. Akhmedov, T. Malinski, R. Kubant, F. Mechta-Grigoriou, C. Matter, T.F. Luescher, F. Cosentino (Zurich, CH; Paris, FR; Athens, US)
- 11:15 **Guanlyl cyclase activation using HMR1766 improves endothelial function and reduces platelet activation in congestive heart failure.** **385**
 – A. Schaefer, D. Fraccarollo, G. Ertl, J. Bauersachs (Wurzburg, DE)
- 11:30 **Relationship of resistin levels with urinary albumin excretion in essential hypertensive subjects: introducing a novel index of diffuse vascular damage.** **386**
 – C. Tsioufis, M. Selima, K. Dimitriadis, D. Tsiachris, E. Andrikou, A. Gennadi, A. Miliou, A. Kasiakogias, C. Stefanadis (Athens, GR)
- 11:45 **Mechanisms leading to impaired endothelial-protective properties of high density lipoprotein (HDL) in patients with stable coronary disease and an acute coronary syndrome: Role of paraoxonase activity.** **387**
 – C. Besler, K. Heinrich, K. Yonekawa, C. Doerries, E. Holy, C. Manes, F.C. Tanner, A. Von Eckardstein, T.F. Luscher, U. Landmesser (Zurich, CH)
- 12:00 **Identification of miRNAs responsive to the glucose stress.** **388**
 – F. Patella, A. Mercatanti, L. Pitto, G. Rainaldi (Pisa, IT)
- 12:15 **Systemic endothelial dysfunction in normotensive offspring of preeclampsia.** **389**
 – S.F. Rimoldi, C. Sartori, S. Garcin, M. Villena, U. Scherrer, Y. Allemann (Berne and Lausanne, CH; La Paz, BO)

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

MOLECULAR IMAGING: FROM BENCH TO BEDSIDE

Abstracts

Chairperson(s): J.D. Schuijf (Leiden, NL); B. Kaufmann (Basel, CH)

- | | | |
|-------|---|------------|
| 08:30 | Large vessel inflammation detected by 11C-PK 11195 PET/CT. | 390 |
| | – F. Pugliese, F. Lamare, J.C. Mason, R. Hinz, A. Kinderlerer, M. Pickering, O.E. Rimoldi, P.G. Camici (London and Manchester, GB) | |
| 08:45 | Detection of inflammatory activity in patients with Takayasu's arteritis by Positron Emission Tomography (PET). | 391 |
| | – E. Alexanderson, A. Ricalde, M.E. Soto, J.M. Ochoa, A. Meave, P. Reyes (Mexico City, MX) | |
| 09:00 | Peri-coronary adipose tissue inflammation affects coronary atherosclerosis in patients with stable angina. | 392 |
| | – T. Mazurek, M. Kobylecka, J. Kochman, K. Filipiak, L. Krolicki, G. Opolski (Warsaw, PL) | |
| 09:15 | Molecular Imaging of neoangiogenesis within atherosclerotic plaque with radiolabeled single chain VEGF and RGD peptides. | 393 |
| | – S. Ohshima, N. Tahara, S. Fujimoto, S. Tsimikas, F.D. Kolodgie, R. Virmani, J.M. Backer, F.G. Blankenberg, A. Petrov, J. Narula (Irvine, La Jolla, Gaithersburg, Brookfield and Stanford, US) | |
| 09:30 | The feasibility of Tc-99m Annexin A5 to evaluate the anti-atherosclerotic therapy by HMG-CoA reductase inhibitor pravastatin in cholesterol-fed rabbits: comparative study with F18-FDG. | 394 |
| | – T. Doue, K. Ohtsuki, M. Ueda, K. Ogawa, A. Azuma, H. Saji, H.W. Strauss, H. Matsubara (Nantan, Kameoka, Kyoto, Kanazawa and Shiga, JP; New York, US) | |
| 09:45 | Thermal heterogeneity in atherosclerotic vascular disease. An experimental study with microwave thermography. | 395 |
| | – K. Toutouzias, A. Synetos, M. Drakopoulou, E. Tsiamis, A. Karanasos, A. Michelongona, H. Grassos, E. Stefanadi, C. Stefanadis (Athens, GR) | |

10:00 Coffee break (Exhibits, Moderated Posters, How-to Tutorials, Read with the Experts & Hands-on Tutorials)

NOVEL APPROACHES IN NUCLEAR IMAGING

Abstracts

Chairperson(s): M. Bottcher (Egaa, DK); N. Zafrir (Petah Tikva, IL)

- | | | |
|-------|--|------------|
| 11:00 | Long-term prognostic value of coronary flow reserve assessed with 13N-Ammonia PET. | 396 |
| | – B.A. Herzog, L. Husmann, R.R. Buechel, I. Valenta, O. Gaemperli, I.A. Burger, P.T. Siegrist, C.A. Wyss, P.A. Kaufmann (Zurich, CH) | |
| 11:15 | Impact of ischemia, hibernation and scar on mortality in patients undergoing PET perfusion / viability studies. | 397 |
| | – D. Verhaert, Y.M. Smyth, V. Menon, R. Brunken, A. Bhargava, P. Houghtaling, M. Cerqueira, W.A. Jaber (Cleveland, US) | |
| 11:30 | Phase 1 human safety, dosimetry, biodistribution, and rest-stress myocardial imaging characteristics of the new F-18 labeled BMS747158 myocardial perfusion PET tracer. | 398 |
| | – J. Maddahi, F. Bengel, S. Huang, J. Czernin, J. Case, C. Schiepers, H. Schelbert, Q. Zhu, J. Lazewatsky, M. Phelps (Los Angeles, Baltimore, Kansas City and Billerica, US) | |
| 11:45 | Low-dose fast hybrid cardiac imaging: a breakthrough in non-invasive assessment of ischemic coronary artery disease. | 399 |
| | – B.A. Herzog, L. Husmann, R.R. Buechel, I.A. Burger, O. Gaemperli, I. Valenta, C.A. Wyss, U. Landmesser, P.A. Kaufmann (Zurich, CH) | |
| 12:00 | The correlation between the Duke coronary artery disease prognostic index and stress myocardial SPECT. | 400 |
| | – C. Shiba, T. Chikamori, H. Tanaka, Y. Igarashi, S. Hida, Y. Usui, T. Hatano, K. Hirose, Y. Ohtaki, A. Yamashina (Tokyo, JP) | |
| 12:15 | Infarct size in primary angioplasty without on-site cardiac surgical backup versus transfer to a tertiary center: a single photon emission computed tomography study. | 401 |
| | – V.A. Umans, P. Knaapen, M. De Mulder, F. Van Der Zant, J.H. Cornel (Alkmaar and Amsterdam, NL) | |

12:30 Lunch (Young Investigators' Awards Sessions & Meet the Experts Sessions)

POSTER SESSION 1

Posters must be set up between 08:00 and 08:30, removed between 12:30 and 13:00 and be on display between 08:30 and 12:30. The presenter should be present throughout the coffee break (10:00 and 11:00) in order to discuss the poster.

**MODERATED POSTER 1
SPECIAL ELECTROPHYSIOLOGIC ACTIONS OF ANTIARRHYTHMIC AGENTS**

Chairperson(s): J.-Y. Le Heuzey (Paris, FR); C. Wolpert (Mannheim, DE)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 10:00 and 11:00.

- | | | |
|-------|--|-------------|
| 10:00 | A unique modification of spiral wave reentry by bepridil: relating to ion channel blocking action and inhibition of calmodulin. | P402 |
| | – H. Takanari, Y. Takemoto, S. Kato, Y.S. Ishiguro, M. Harada, Y. Okuno, H. Honjo, I. Sakuma, K. Kamiya, I. Kodama (Nagoya and Tokyo, JP) | |
| 10:05 | Adenosine-resistance in patients receiving amiodaron. | P403 |
| | – S. Nedios, M. Tang, G. Ye, J.-H. Gerds-Li, E. Fleck, C. Kriatselis (Berlin, DE) | |
| 10:10 | Preferential use-dependent block of cardiac late sodium current by ranolazine. | P404 |
| | – S. Rajamani, N. El-Bizri, J. Shryock, J. Makielski, L. Belardinelli (Palo Alto and Madison, US) | |
| 10:15 | Electrophysiological effects of the potassium channel opener nicorandil in transgenic rabbits with long QT-syndrome 1. | P405 |
| | – M. Brunner, J. Biermann, K. Wu, S. Asbach, M. Hartmann, G. Koren, X. Peng, C. Bode, M. Zehender (Freiburg im Breisgau, DE; Providence and Hershey, US) | |
| 10:20 | Cardioprotective effects of CYP-dependent omega-3 fatty acid metabolites. | P406 |
| | – R. Fischer, C. Schmidt, M. Marcovic, G. Wallukat, M. Rothe, F.C. Luft, D. Muller, W.H. Schunck (Berlin, DE) | |
| 10:25 | Preoperative HMG-CoA reductase inhibitors and atrial fibrillation in patients undergoing CABG: a prospective randomised trial. | P407 |
| | – G. Melina, E. Angeloni, G. Di Nucci, U. Benedetto, B. Fiorani, G. Sclafani, C. Comito, E. Tonelli, S. Refice, R. Sinatra (Rome, IT) | |
| 10:30 | Effects of bepridil on stretch-induced arrhythmia in isolated chick ventricles. | P408 |
| | – G. Iribe, H. Jin, K. Naruse (Okayama, JP) | |
| 10:35 | Electrophysiological evaluation of novel blockers of I_f current. | P409 |
| | – M. Del Lungo, M. Melchiorre, L. Sartiani, M. Biel, A. Varro, M.N. Romanelli, E. Cerbai (Florence, IT; Munich, DE; Szeged, HU) | |
| 10:40 | Discussion. | P410 |

**MODERATED POSTER 2
HEART FAILURE: BENCH TO BEDSIDE**

Chairperson(s): J.E. Sanderson (Birmingham, GB); T.F. Luescher (Zurich, CH)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 10:00 and 11:00.

- 10:00 **Alpha-adrenergic stimulation decreases myocardial stiffness: a novel PKC mediated-effect.** P411
 – A.P. Fontes-Sousa, L. Lopes-Conceicao, N.S. Pereira-Goncalves, V.F. Monteiro-Cardoso, C. Bras-Silva, A.F. Leite-Moreira (Porto, PT)
- 10:05 **A novel risk factor for heart failure development: uric acid.** P412
 – G. Levantesi, R.M. Marfisi, M.G. Franzosi, A.P. Maggioni, G.L. Nicolosi, C. Schweiger, M.G. Silletta, L. Tavazzi, G. Tognoni, R. Marchioli (Santa Maria Imbaro, Milan, Florence, Pordenone, Passirana Di Rho and Cotignola, IT)
- 10:10 **The degree of lung fluid accumulation is different between preserved and reduced systolic function in patients with acute heart failure.** P413
 – A. Nakagawa, G. Hamano, T. Taniguchi, Y. Utsunomiya, M. Koide, M. Yamato, N. Sasaki, K. Hirooka, Y. Koretsune, Y. Yasumura (Osaka, JP)
- 10:15 **Diastolic asynchrony in heart failure: which patients?** P414
 – D.C. Cozma, C. Mornos, L. Petrescu, D. Lighezan, D. Gaita, S.I. Dragulescu (Timisoara, RO)
- 10:20 **Paracrine effects of stem cells on cardiac remodelling in placebo-controlled clinical trial involving patients with congestive heart failure.** P415
 – E.Z. Golukhova, L.A. Bockeria, T.T. Kakuchaya, M.V. Ereemeva, N.A. Chigogidze, I.P. Aslanidi, T.G. Nikitina, I.V. Shurupova, R.A. Serov, A.V. Svobodov (Moscow, RU)
- 10:25 **Myocardial inflammation and non-ischaeamic heart failure - is there a role for C-reactive protein?** P416
 – O. Zimmermann, M. Bienek-Ziolkowski, B. Wolf, M. Vetter, R. Baur, V. Mailander, V. Hombach, J. Torzewski (Ulm, DE)
- 10:30 **Obstructive ventilatory disorder in heart failure: is it really COPD?** P417
 – S. Brenner, G. Gueder, K. Froehlich, G. Gelbrich, R. Jahns, B. Jany, G. Ertl, S. Stoerk, C.E. Angermann (Wurzburg and Leipzig, DE)
- 10:35 **Adiponectin levels is strongly associated with NT-Brain Natriuretic Peptide levels, LV diameters and ejection fraction in patients with heart failure.** P418
 – U.O. Turk, E. Alioglu, B. Kirilmaz, G.S. Tamer, I. Tengiz, N. Tuzun, E. Ercan (Izmir, Canakkale and Kocaeli, TR)
- 10:40 **Discussion.** P419

ASSESSING RISK IN ACUTE CORONARY SYNDROMES: FROM BIOMARKERS TO IMAGING

- Low-density lipoprotein cholesterol paradox in patients with acute myocardial infarction.** P420
 – J.H. Lee, S.C. Chae, M.H. Jeong, Y.J. Kim, K.S. Kim, S.H. Hur, I.W. Seong, T.J. Hong, M.C. Cho, C.J. Kim (Daegu, Gwangju, Daejeon, Pusan, Cheongju and Seoul, KR)
- Predictors of left ventricular dysfunction in patients admitted with a first acute coronary syndrome.** P421
 – A.T. Timoteo, A. Lousinha, A. Toste, R. Ramos, J.A. Oliveira, M.L. Ferreira, R.C. Ferreira (Lisbon, PT)
- Adiponectin as a predictor of left ventricular remodeling after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.** P422
 – K. Piestrzeniewicz, K. Luczak, J. Drozd (Lodz, PL)
- Short and long-term prognostic value of hemoglobin on admission: STE vs NSTEMI acute coronary syndromes.** P423
 – F. Vagnarelli, L. Cinti, F. Semprini, S. Nanni, A. Branzi, G. Melandri (Bologna, IT)
- Short and long-term prognostic value of glomerular filtration rate: STE vs NSTEMI acute coronary syndromes.** P424
 – F. Vagnarelli, L. Cinti, F. Semprini, S. Nanni, A. Branzi, G. Melandri (Bologna, IT)
- Admission blood glucose level as a long term risk factor in patients after acute myocardial infarction in dependence of presence diabetes mellitus.** P425
 – R. Adamkova, S. Janousek, A. Tomasek, J. Tumova, Z. Cermakova, J. Spinar (Brno, CZ)
- Searching for the best outcome predictor post myocardial infarction: kidney function or blood glucose?** P426
 – S. Monteiro, R. Teixeira, C. Lourenco, R. Batista, E. Jorge, F. Saraiva, N. Antonio, P. Monteiro, M. Freitas, L. Providencia (Coimbra, PT)
- Predictors of 30-day stent thrombosis after primary percutaneous coronary intervention.** P427
 – I. Mrdovic, L. Savic, M. Asanin, J. Perunicic, R. Lasica, J. Marinkovic, Z. Vasiljevic, M. Ostojic (Belgrade, RS)
- Post acute myocardial infarction outcome: admission glycaemia says it all.** P428
 – S. Monteiro, R. Batista, C. Lourenco, R. Teixeira, E. Jorge, N. Antonio, F. Saraiva, P. Monteiro, M. Freitas, L. Providencia (Coimbra, PT)
- Serial haemoglobin measures after acute coronary syndrome: a strong, simple and independent predictor of cardiovascular outcomes.** P429
 – D.S.C. Ang, M.P.C. Kao, C.C. Lang, A.D. Struthers (Dundee, GB)
- White blood cell subtypes after STEMI - temporal evolution and association with CMR-derived infarct size.** P430
 – O. Husser, V. Bodi, J. Sanchis, J. Nunez, L. Mainar, E. Rumiz, M.P. Lopez-Lereu, J.V. Monmeneu, F.J. Chorro, A. Llacer (Valencia, ES)
- Incidence, type and prognostic impact of bleeding complications with radial primary PCI of STEMI: The pitie-salpetriere experience.** P431
 – O. Barthelemy, J. Silvain, A. Bellemain-Appaix, F. Beygui, J.P. Collet, R. Choussat, N. Vignolles, G. Montalescot (Paris, FR)
- Prognostic relevance and magnetic resonance imaging findings in aborted myocardial infarction after primary angioplasty.** P432
 – I. Eitel, S. Desch, G. Fuernau, M. Sareban, M. Gutberlet, G. Schuler, H. Thiele (Leipzig, DE)
- The prognostic value of an echographic risk score in acute coronary syndromes: comparison with the TIMI and the GRACE risk score.** P433
 – G. Bedetti, L. Gargani, R. Sicari, M.L. Gianfaldoni, S. Molinaro, E. Picano (Imola, Pisa and Empoli, IT)
- Presentation and outcome of patients with acute coronary syndromes in Europe 2006-2008: lessons from the Euro Heart Survey ACS registry.** P434
 – A.K. Gitt, M. Gierlotka, M. Tubaro, M. Hochadel, W. Wojakowski, M. Tenders, H. Katus, H. Bueno, F. Schiele, J.P.P. Bassand (Ludwigshafen am Rhein and Heidelberg, DE; Zabrze and Katowice, PL; Rome, IT; Madrid, ES; Besançon, FR)

- Persistent high levels of circulating whole blood tissue factor procoagulant activity in diabetic patients with acute coronary syndromes.** P435
 – E. Guasch, X. Bosch, R. Hernandez, F. Verbal, M. Heras, E. Borquez, A. Galan, G. Escolar (Barcelona, ES)
- Prognostic impact on one-year survival of simple routine laboratory measurements at the acute stage of MI: the FAST-MI registry.** P436
 – J. Ferrieres, V. Bataille, B. Maillier, L. Ledain, P. Bonnet, G. Mulak, B. Pace, J.P. Cambou, T. Simon, N. Danchin (Toulouse, Troyes, La Rochelle, Le Havre and Paris, FR)
- Heart rate is a predictor of left ventricular remodeling in patients with acute myocardial infarction.** P437
 – S. Okino, S. Fukuzawa, J. Sugioka, A. Ikeda, J. Maekawa, S. Ichikawa, T. Uchiyama, M. Inagaki (Funabashi, JP)
- Brain natriuretic peptide and glycated haemoglobin A1c as predictors of mortality and new ischemic events after acute coronary syndrome.** P438
 – A. Garcia-Alvarez, A. Sionis, F. Bisbal, P. Ramos, M. Farrero, X. Bosch, M. Heras (Barcelona, ES)
- Heart rate at admission independently predicts outcome in acute coronary syndrome patients.** P439
 – N. Antonio, C. Lourenco, R. Teixeira, R. Baptista, E. Jorge, M.F. Saraiva, P. Lazaro, P. Monteiro, M. Freitas, L.A. Providencia (Coimbra, PT)
- Major adverse cardiac events in patients with glucose metabolism disturbances, ICA, GADA autoantibodies after myocardial infarction - three years follow-up.** P440
 – T. Zielinska, A. Zielinska-Meus, J. Kowalczyk, R. Lenarczyk, M. Swierad, O. Kowalski, K. Oleszczyk, Z. Kalarus (Zabrze and Tarnowskie Gory, PL)
- Shape and time-course prognostic value of admission and fasting glucose in diabetic and non-diabetic patients with acute coronary syndrome.** P441
 – A.B. Cid Alvarez, F. Gude, J.M. Garcia-Acuna, E. Gonzalez Babarro, C. Cadarso Suarez, M.X. Rodriguez-Alvarez, R. Trillo Nouche, J. Garcia Seara, A. Varela-Roman, J.R. Gonzalez-Juanatey (Santiago De Compostela, ES)
- Repolarization duration as a prognostic marker of cardiac death in patients with anterior myocardial infarction treated with primary PCI- results of prospective 36 months follow-up.** P442
 – K. Szydlo, K. Wita, M. Trusz-Gluza, Z. Tabor (Katowice, PL)
- Predictors of 30-day major adverse cardiovascular events after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel.** P443
 – I. Mrdovic, L. Savic, M. Asanin, J. Perunicic, R. Lasica, J. Marinkovic, Z. Vasiljevic, M. Ostojic (Belgrade, RS)
- Prognostic value of sCD40 Ligand in outpatients after acute myocardial infarction.** P444
 – M. Radosavljevic Radovanovic, Z. Vasiljevic, N. Radovanovic, P. Mitrovic, J. Marinkovic, S. Stankovic, L. Savic, B. Stefanovic, G. Krljanac, R. Lasica (Belgrade, RS)
- Matrix metalloproteinase-2 predicts cardiac mortality and heart failure hospitalization after acute myocardial infarction.** P445
 – K. Yajima, N. Ohte, S. Tanaka, T. Kawamiya, T. Fujimaki, K. Kato, T. Hibino, K. Yokoi, G. Kimura (Tajimi and Nagoya, JP)
- Brain natriuretic peptide and left ventricular volume and function recovery after myocardial infarction: determinants and clinical utility of early and follow-up measurements.** P446
 – J. Zalewski, N. El Massri, E. Stepien, K. Zmudka (Krakow, PL)
- Determinants of survival in the current era of cardiac ventricular rupture after acute myocardial infarction.** P447
 – A. Koh, Y.J. Loh, Y.P. Lim, J.L. Tan (Singapore, SG)
- Depression of initial values of overall heart rate variability and risk of reinfarction.** P448
 – Y.G. Kevorkova, R.D. Kurbanov (Tashkent, UZ)
- Worsening renal function but not baseline creatinine levels adversely affects one year mortality in patients with myocardial infarction. The HEROES registry.** P449
 – G. Lazaros, D. Tsiachris, A. Patialiakas, A. Karavidas, S. Vogiatzoglou, S. Archontakis, C. Masoura, C. Vlachopoulos, D. Tousoulis, C. Stefanadis (Athens, GR)

MECHANISMS OF DISEASE IN ACUTE AND CHRONIC CORONARY SYNDROMES

- ACS in patients with and without spontaneous dissections of coronary arteries. The DISCOVERY study.** P450
 – A. Fontanelli, L. La Vecchia, A. Benettin, C. Bonanno, E. Cabianna, A. Desideri, A. Santarelli, A. Manari, A. Benassi, L. Pagliani (Vicenza, Treviso, Castelfranco Veneto, Rimini, Reggio Emilia, Modena and Padua, IT)
- Myocardial infarction in patients without significant lesions in coronary arteries.** P451
 – A.M. Frycz-Kurek, M. Gasior, T. Kurek, M. Gierlotka, D. Kawecki, E. Nowalany-Kozielska, Z. Kalarus, L. Polonski (Zabrze, PL)
- Thin fibrous cap and plaque rupture predict worse outcome of thrombolytic therapy. An optical coherence tomography study.** P452
 – M. Riga, K. Toutouzias, A. Karanasos, A. Synetos, M. Drakopoulou, E. Tsiamis, A. Androulakis, D. Tousoulis, E. Stefanadi, C. Stefanadis (Athens, GR)
- Arterial stiffness, carotid intima media thickness and systemic inflammation are gradually associated with increasing duration of erectile dysfunction.** P453
 – N. Ioakeimidis, C. Vlachopoulos, K. Aznaouridis, D. Terentes-Printzios, A. Bratsas, D. Tsekoura, A. Tsokanis, K. Rokkas, T. Askitis, C. Stefanadis (Athens, GR)
- Cardiac microvascular dysfunction in diabetes and insulin treatment: role of glucose-induced PKC-βII activity.** P454
 – Z. Yin, H.C. Wang, L.P. Wel (XIAN, CN)
- Insulin induces the release of endothelial barrier stabilizing factor from platelets via PI3K/Akt-Nitric Oxide pathway.** P455
 – D. Guenduez, J. Thom, M. Aslam, I. Hussain, F.V. Haertel, M. Grebe, A. Erdogan, D. Sedding, T. Noll, H. Tillmanns (Giessen, DE)
- Mean platelet volume on admission correlates with impaired reperfusion in patients with acute myocardial infarction treated with thrombolysis.** P456
 – D. Pereg, M. Mosseri (Kfar Saba, IL)
- Factors influencing mobilisation of endothelial progenitor cells and cytokines after an extensive acute myocardial infarction.** P457
 – N. Rodríguez Losada, A. Dominguez Franco, F.J. Gonzalez, J.A. Marchal, F.J. Cabrera Bueno, E. Carrillo, A. Arenega, E. De Teresa Galvan (Malaga and Granada, ES)
- TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality in non-diabetic individuals.** P458
 – A.C. Pereira, A.G.P. Sousa, G.F. Marquezine, N. Lopes, W.A. Hueb, J.E. Krieger (Sao Paulo and Natal, BR)
- Abnormal, Tako-Tsubo-like, apical deformation in symptomatic patients during the development of a left ventricular cavity pressure gradient - the role of dobutamine stress echo.** P459
 – A.T. Baltabaeva, V. Leon, C. Parsai, B. Bijnens, G.R. Sutherland (London, GB; Barcelona, ES)
- Antiendothelial cell antibodies in acute and chronic coronary artery disease: an emerging immune system spark in the coronaries.** P460
 – D.P. Papadopoulos, M. Daskalaki, S. Massias, A. Bratsas, E. Michalopoulou, A. Chatzizacharias, C. Thomopoulos, V. Votteas, T.H. Makris (Athens, GR)
- Perturbation of T-cell network in acute coronary syndromes: aggressive immune responses arising from a lack of regulation.** P461
 – R.A. Montone, G. Liuzzo, M. Gabriele, A. Severino, G. Ferrante, G. Niccoli, L.M. Biasucci, F. Crea (Rome, IT)
- Progression of coronary artery disease is mirrored by an increased MMP-9/TIMP-1-ratio in peripheral circulating CD14⁺ monocytes.** P462
 – S. Brunner, J.-O. Kim, H. Methe (Munich, DE)
- Factor Seven Activating Protease (FSAP): a link between inflammation and coagulation in coronary artery disease.** P463
 – M. Parahuleva, R. Maj, B. Parviz, H. Hoelschermann, H. Tillmanns, A. Erdogan, S. Kanse (Giessen and Bad Homburg, DE)
- The omega-3 fatty acid docosahexaenoate attenuates insulin-induced CD36 expression in human microvascular endothelial cells.** P464
 – R. Madonna, D. Schiavone, R. De Caterina (Chieti, IT)

- Tissue factor-protein disulphide isomerase interactions in migrating human vascular smooth muscle cells.** P465
 – E. Pena, G. Arderiu, L. Badimon (Barcelona, ES)
- Unfavourable endothelial expression of adhesion molecules in erectile dysfunction patients with or without coronary artery disease.** P466
 – K. Aznaouridis, C. Vlachopoulos, N. Ioakeimidis, K. Rokkas, I. Dima, D. Terentes-Printzios, C. Antoniadis, D. Tousoulis, A. Askitis, C. Stefanadis (Athens, GR)
- Emergence of myeloid dendritic cells in the myocardium after acute myocardial infarction.** P467
 – A. Yilmaz, B. Dietel, I. Cicha, R. Hausmann, W.G. Daniel, C.D. Garlichs, C. Stumpf (Jena and Erlangen, DE; Basel, CH)
- Brain natriuretic peptide mediates the effect of creatinine clearance on developing left ventricular systolic dysfunction in patients with acute coronary syndrome.** P468
 – C. Chrysohoou, P. Aggelopoulos, C. Pitsavos, J. Skoumas, G. Metallinos, A. Aggelis, C. Kastorini, C. Liontou, C. Stefanadis (Athens, GR)
- Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris.** P469
 – H. Ikejima, T. Imanishi, H. Tsujioka, A. Kuroi, T. Tanimoto, H. Kitabata, N. Nakamura, K. Hirata, A. Tanaka, T. Akasaka (Wakayama, JP)
- Ce-magnetic resonance imaging in patients with takotsubo cardiomyopathy.** P470
 – R. Scardala, G. Benedetti, M. Mancone, F. Sconci, I. Carbone, M. Francone, F. Igual Perez, A. Di Rome, G. Sardella, F. Fedele (Rome, IT)
- Microvascular damage in patients with severe renal dysfunction after successful primary angioplasty for acute myocardial infarction.** P471
 – R. Ogura, Y. Hiasa, S. Miyazaki, T. Takahashi, S. Hosokawa, K. Kishi, R. Ohtani (Komatsushima, JP)
- Association between chromosome 9p21.3 variation and coronary heart disease.** P472
 – W. Koch, W. Latz, S. Tuerk, A. Erl, P. Hoppmann, A. Schoemig, A. Kastrati (Munich, DE)
- Pathophysiologic considerations for the complex interaction between erectile dysfunction and coronary artery disease in men complaining of sexual dysfunction after an acute myocardial infarction.** P473
 – C. Vlachopoulos, N. Ioakeimidis, D. Terentes-Printzios, K. Rokkas, K. Aznaouridis, A. Aggelis, G. Antoniou, A. Askitis, C. Stefanadis (Athens, GR)
- Atherosclerosis progression in the coronary arteries among patients with acute myocardial infarction treated with primary angioplasty.** P474
 – M. Hawranek, M. Gasior, M. Gierlotka, A. Spatuszko, G. Slonka, M. Tajstra, D. Pres, J. Sikora, A. Lekston, L. Polonski (Zabrze, PL)
- Gender difference in prognosis after acute MI among 45,852 Chinese patients in COMMIT/CCS2.** P475
 – Y. Chen, L.X. Jiang, M. Smith, J. Xie, H. Pan, L. Liu, R. Collins, Z.M. Chen (Oxford, GB; Beijing, CN)

MECHANICS AND FUNCTION ASSESSED BY ECHOCARDIOGRAPHY

- Factors affecting the ratio of transmitral flow velocity to mitral annulus velocity.** P476
 – H. Sonoda, H. Takase, T. Toriyama, T. Okado, A. Hagikura, Y. Dohi, G. Kimura (Hamamatsu and Nagoya, JP)
- Tissue Doppler imaging-derived echocardiographic techniques in predicting left ventricle reverse remodeling after Cardiac Resynchronization Therapy (CRT) implantation.** P477
 – D. Czarnecka, W. Wojciechowska, J. Wilinski, M. Kloch-Badelek, A. Kwiecien-Sobstel, M. Jastrzebski, B. Baciór, K. Kawecka-Jaszcz (Krakow, PL)
- Left ventricular systolic dyssynchrony is associated with pulmonary arterial hypertension in patients with coronary artery disease.** P478
 – G.H. Yan, M. Wang, W.S. Yue, K.H. Yiu, C.W. Siu, H.T. Chan, Y.L. Dai, T.H. Luk, C.P. Lau, H.F. Tse (Hong Kong, HK)

- Non-invasive quantitative imaging of arterial wall elasticity using supersonic shear imaging.** P479
 – M. Couade, M. Pernot, M. Tanter, C. Prada, C. Perri, J. Emmerich, M. Fink, E. Messas (Aix en Provence and Paris, FR)
- Estimation of Flow Velocity Fields from Color Doppler Ultrasound Data: Numerical Validation of Vector Flow Mapping.** P480
 – T. Uejima, H. Sawada, T. Aizawa, T. Okada, A. Harada (Tokyo, JP)
- Estimation of myocardial viscoelastic moduli by shear-wave method in live swine.** P481
 – C. Pislaru, M.W. Urban, I.Z. Nenadic, J.F. Greenleaf (Rochester, US)
- Head to head comparison of the reproducibility of different measures of systolic left ventricular function.** P482
 – A. Thorstensen, H. Dalen, B.H. Amundsen, A. Stoylen (Trondheim, NO)
- The impact of function-flow interaction on left ventricular efficiency - a particle image velocimetry study.** P483
 – E. Gurel, K. Hristova, M. Szulik, R. Faludi, L. Van Casteren, R. Willems, J. D'Hooge, F. Rademakers, J.U. Voigt (Leuven, BE)
- Feasibility of two-dimensional speckle tracking in murine model of myocardial infarction.** P484
 – E. Szymczyk, P. Lipiec, M. Krzeminska-Pakula, M. Plewka, K. Kaminski, M. Kurpisz, J.D. Kasprzak (Lodz, Bialystok and Poznan, PL)
- Echocardiographic particle image velocimetry for the detailed analysis of left ventricular flow patterns.** P485
 – E. Gurel, K. Hristova, M. Szulik, R. Faludi, J. D'Hooge, F. Rademakers, J.U. Voigt (Leuven, BE)
- Evaluation of stiffness parameters with a new non-invasive ultrasound method.** P486
 – S. Mannarino, M. Pasotti, A. Serio, F.I. Gambarin, V. Favalli, C. Codazzi, E. Arbustini (Pavia, IT)
- Effects of accessory pathway location on left ventricular dyssynchrony in canine model of Wolff-Parkinson-White syndrome.** P487
 – S.-A. Chang, H.-E. Park, E.-K. Choi, S.-I. Oh, Y.-S. Choi (Seoul, KR)
- Exercise-induced myocardial ischemia causes diastolic dysfunction in patients with stable effort angina: a tissue Doppler echocardiographic study.** P488
 – Y. Ohara, M. Kusunose, Y. Take, S. Sahara, K. Banba, M. Nishimoto, K. Yamamoto (Kochi, JP)
- Usefulness of echocardiographic 2D-strain imaging for early detection of patients with allograft coronary artery disease after heart transplantation.** P489
 – M. Dandel, H. Lehmkuhl, C. Knosalla, M. Bettmann, O. Grauhan, D. Kemper, R. Hetzer (Berlin, DE)
- Pattern of left ventricular systolic activation by tissue velocity imaging in patients with left ventricular systolic dysfunction with and without left bundle branch block.** P490
 – H. Sadeghian, M. Lotfi-Tokaldany, B. Esalmi, A. Zoroufian, A. Kasemisaeid, A. Yaminisharif, S. Sadeghian, G.H. Davoodi (Tehran, IR)
- Tissue-Doppler derived strain and strain rate underestimates myocardial deformation compared with Speckle-tracking measurements in patients with chronic severe mitral regurgitation.** P491
 – J.A. De Agustin Loeches, J. Zamorano, L. Perez De Isla, C. Almeria, J.L. Rodrigo, P. Marcos-Alberca, C. Fernandez-Golfín, A. Aubele, D. Herrera, C. Macaya (Madrid, ES)
- 3D-wall motion tracking: a new and faster tool for myocardial strain assessment.** P492
 – L. Perez De Isla, J. Zamorano, D. Vivas Balcones, C. Almeria, J.L. Rodrigo, C. Fernandez-Golfín, P. Marcos-Alberca, A. Aubele, D. Herrera, C. Macaya (Madrid, ES)
- Assessment of mitral annular velocities by speckle tracking echocardiography versus tissue Doppler imaging: validation, feasibility and reproducibility.** P493
 – B.M. Van Dalen, J.G. Bosch, O.I.I. Soliman, W.B. Vletter, F. Kauer, F.J. Ten Cate, M.L. Geleijnse (Rotterdam, NL)
- The utility of tissue Doppler imaging for the noninvasive determination of left ventricular filling pressures in patients with septic shock.** P494
 – N. Mousavi, A. Czarniecki, R. Ahmadi, T. Fang, K. Kumar, M. Lytwyn, A. Kumar, D. Jassal (Winnipeg, CA)

- Marked differences in presence of intraventricular mechanical dyssynchrony between tissue Doppler imaging and real-time three-dimensional echocardiography.** P495
 – S. Kleijn, J. Van Dijk, C.C. De Cock, C.P. Allaart, A.C. Van Rossum, O. Kamp (Amsterdam, NL)
- Ethnic differences in left ventricular function and structure: A population study of UK Indian Asians and European whites.** P496
 – N.S. Chahal, T.K. Lim, P. Jain, J.C. Chambers, J.S. Kooner, R. Senior (Harrow and London, GB)
- Assessment of left ventricular torsion using speckle tracking imaging before and after transcatheter device closure of atrial septal defect.** P497 (W)
 – L. Dong, X. Shu, F. Zhang, D. Zhou, L. Guan (Shanghai, CN)
- Fast and accurate assessment of left ventricular volumes and ejection fraction by 3D echocardiography.** P498
 – J. Hansegaard, S. Urheim, K. Lunde, S. Malm, S.I. Rabben (Oslo, Harstad and Horten, NO)
- Dynamic left ventricular mechanical dyssynchrony in hypertensive diastolic heart failure.** P499
 – C.M. Yu, P.W. Lee, J.K. Song, Q. Zhang, G.W.K. Yip, T.G. Zhu, C.M. Li, Y.Y. Lam (Hong Kong and Beijing, CN; Seoul, KR)
- Assessment of systolic function by speckle tracking echocardiography in hypertrophic cardiomyopathy. Correlation with B-type natriuretic peptide.** P500
 – A. Manovel Sanchez, B.C.F. Smith, S. Sulemane, D. Dawson, P. Nihoyannopoulos (London, GB)
- A comparison between right heart catheterization and a comprehensive hemodynamic assessment by Doppler echocardiography.** P501
 – O. Bech-Hanssen, F. Lindgren, N. Selimovic, B. Rundqvist (Gothenburg, SE)
- Pulmonary arterial hypertension worsened intra ventricular systolic dyssynchrony in patients with coronary artery disease.** P502 (W)
 – G.H. Yan, M. Wang, W.S. Yue, Y.L. Dai, T.H. Luk, C.P. Lau, H.F. Tse (Hong Kong, HK)
- Myocardial determinants of right ventricular ejection in pulmonary hypertension: 2D strain rate and spectral Doppler study.** P503
 – A. Calcutteea, P. Linqvist, W. Li, M. Hodson, M.Y. Henein (Umea, SE; London, GB)
- Is there any echocardiographic parameter that can predict right ventricular pump function in pulmonary hypertension?** P504
 – G. Teixido, R. Aguilar, E. Domingo, M. Lopez-Meseguer, A. Roman (Barcelona, ES)
- Multivariate analysis of factors affecting right ventricular systolic pressure in the absence of aortic or mitral valve disease.** P505
 – M. Matangi, D.W. Armstrong, G. Tsimiklis, J.R. Vyselaar, G. Barber (Kingston, CA)
- Assessment of right ventricular volumes and function by 3D real-time transthoracic echocardiography in children.** P506
 – S. Hascouet, G. Briere, G. Caudron, S. Abadir, Y. Dulac, S. Paranon, G. Ohanessian, P. Acar (Toulouse, FR)
- Long-term follow up of apical versus septal right ventricular permanent pacing shows similar effects on cardiac synchrony and function.** P507
 – R.C. Sisu, A.D. Margulescu, C. Silieste, M. Florescu, M. Cinteza, D. Vinereanu (Bucharest, RO)
- Quantification of right ventricular function by 2D speckle imaging: comparison with MRI.** P508
 – M.-A. Arnould, S. Gougnot, S. Lemoine, L. Freysz, O. Huttin, B. Popovic, Y. Juilliere, C. Selton-Suty (Paris, Metz and Vandoeuvre les Nancy, FR)
- Improved left- and right ventricular function after exercise training in COPD patients.** P509
 – C. Bjork Ingul, E. Bronstad, A.E. Tjonna, O. Rognmo, H. Dalen, U. Wisloff, S. Steinshamn (Trondheim, NO)
- Evaluation of longitudinal strain and strain rate of the right and left interventricular septum with a new echocardiographic 2D based method in normal subjects.** P510
 – C. Bussadori, M. Di Donato, C. Arcidiacono, D. Negura, L. Piazza, A. Micheletti, M. Chessa, G. Butera, J.S. Dua, M. Carminati (San Donato Milanese, IT)

- Right ventricular impact of on-pump cardiac surgery.** P511
– N. Hammoudi, O. Merceron, C. El Khebir, C. Chalah, R. Dorent, P.L. Michel (Paris, FR)
- Cardiovascular complications in sickle cell disease: echocardiographic features.** P512
– I.Z. Cabrita, C. Ruisanchez, M. Layton, F.J. Pinto, P. Nihoyannopoulos, S.J.R. Gibbs (London, GB; Santander, ES; Lisbon, PT)
- Ultrasound lung comets as a long-term prognostic determinant in systemic sclerosis.** P513
– L. Gargani, M. Doveri, M. Bazzichi, G. Agoston, M.F. Costantino, A. Nigro, S. Bombardieri, R. Sicari, A. Varga, E. Picano (Pisa and Potenza, IT; Szeged, HU)
- Depressed longitudinal and circumferential deformation and preserved radial deformation in patients with metabolic syndrome.** P514
– B. Pirat, H. Bozbas, V. Simsek, L.E. Sade, E. Turk, A. Yildirim, H. Muderrisoglu (Ankara, TR)
- Two-dimensional speckle tracking strain imaging in the acute phase can predict final transmural extent of myocardial infarction.** P515
– C. Raineri, M. Calcagnino, F. Fava, S. Leonardi, M. Bonardi, C. Dellabianca, M. Cottini, E. Ferrara, A. Raisaro, M. Previtalli (Pavia, IT)
- Tissue Doppler parameters of right ventricle function, prognostic impact on mortality after heart transplantation.** P516
– L. Alizadeh, S.H. Varnous, R. Makri, M. Laali, F. Fernandez, J.L. Golmard, P. Leprince, I. Gandjbakhch, A. Pavie (Paris, FR)
- Measurement of post systolic shortening during exercise to detect myocardial viability after a first acute myocardial infarction.** P517
– G.P.J. Pierre-Justin, L.A. Piérard (Liège, BE)
- Deceleration time of the left ventricular outflow tract flow velocity: a surrogate Doppler echocardiographic parameter for central pulse pressure.** P518 (W)
– C.Y. Shim, S. Park, W.I. Yang, S.A. Kim, S.J. Lee, E.Y. Choi, N. Chung, H.W. Ha (Seoul, KR)
- Spatial characterization of myocardial shortening and rate of relaxation in left ventricular hypertrophy and relation with clinical status: a 2-dimensional speckle tracking study.** P519
– K. Savino, A. Lilli, R. Lauciello, S. D'Addario, E. Bordoni, V. Giglio, E. Grikstaite, C. Cavallini, G. Ambrosio (Perugia and Lido Di Camaiore, IT)
- Assessment of left ventricular twist in patients with secundum atrial septal defect using speckle tracking imaging.** P520
– L.L. Dong, X.H. Shu, L.H. Guan, H.Y. Chen, C.Z. Pan, H.Z. Chen (Shanghai, CN)
- Assessment of right ventricular function with longitudinal two dimensional strain: comparison between low and intermediate risk pulmonary embolism.** P521
– V. Descotes, R. Chopard, J. Dutheil, M. Morel, N. Meneveau, F. Schiele, Y. Bernard, M.F. Seronde, J.P. Bassand (Besançon, FR)
- Echocardiographic assessment of left ventricular structure and function in patients with symptomatic peripheral arterial disease.** P522
– J.-C. Lubanda, M. Chochola, P. Varejka, P. Prochazka, O. Dostal, S. Beran, V. Mrazek, A. Linhart (Prague, CZ)
- Can strain rate imaging predict the recovery of regional myocardial function after primary percutaneous coronary intervention?: comparison with coronary flow velocity pattern.** P523
– S.-J. Kim, E.-S. Shin, S.-G. Lee (Ulsan, KR)

MECHANISMS OF CARDIOVASCULAR DISEASE: GENES AND ENVIRONMENT

- Genetic polymorphism on interleukin-6 gene is associated with onset age of coronary atherosclerosis: the role of endothelial function and inflammation.** P524
– G. Hatzis, D. Tousoulis, C. Antoniadis, A. Miliou, V. Psari, A. Antonopoulos, N. Papageorgiou, E. Stefanadi, K. Marinou, C. Stefanadis (Athens, GR)
- Cytokine genes polymorphisms and expression profiles in peripheral blood leukocytes of healthy individuals and patients with essential hypertension.** P525
– Y. Timasheva, T.R. Nasibullin, I.A. Tuktarova, A.N. Zakirova, O.E. Mustafina (Ufa, RU)

- A gain-of-function TBX20 mutation causes human congenital cardiac atrial septal and valve defects.** **P526**
 – M.G. Posch, M. Gramlich, M. Sunde, K.R. Schmitt, A. Perrot, R. Dietz, F. Berger, R.P. Harvey, C. Ozcelik (Berlin, DE; Sydney, AU)
- Notch and BMP2 act in concert to regulate a cardiac valve-forming field.** **P527 (W)**
 – J.L. De La Pompa, L. Luna-Zurita, J. Grego-Bessa, B. Prados, G. Del Monte, G. Luxan, A. Benguria, R.H. Adams, J.M. Perez-Pomares (Madrid and Malaga, ES; Munster, DE)
- Plasma aldosterone levels predict increased cardiovascular mortality.** **P528**
 – A. Tomaschitz, S. Pilz, B.R. Winkelmann, B.O. Boehm, W. Maerz (Graz, AT; Frankfurt-Sachsenhausen, Ulm and Heidelberg, DE)
- Chemerin, vaspin, visfatin and adiponectin expression in human pericoronary and apical epicardial fat: correlation with coronary atherosclerosis.** **P529**
 – S. Spiroglou, C. Kostopoulos, J. Varakis, H. Papadaki (Patras, GR)
- Reactive Oxygen Species (ROS) control mitochondrial motility.** **P530**
 – M. Saotome, G. Hajnoczky, H. Hayashi (Hamamatsu, JP; Philadelphia, US)
- Proteomic analyses reveal evolving protein expression changes during atrial profibrillatory remodelling in congestive heart failure.** **P531**
 – A.I. De Souza, S. Cardin, R. Wait, N. Patel, A.J. Camm, S. Nattel (London, GB; Montreal, CA)
- Neural cell adhesion molecule is a cardioprotective factor upregulated by metabolic stress.** **P532**
 – K. Nagao, K. Ono, T. Horie, H. Nishi, M. Kinoshita, Y. Kuwabara, Y. Tamaki, Y. Kojima, Y. Iwanaga, T. Kita (Kyoto, Osaka and Hyogo, JP)
- Family history and coronary disease risk. Interaction with genetic and behaviour factors.** **P533**
 – R. Palma Dos Reis, A. Pereira, A.C. Sousa, A.I. Freitas, S. Freitas, I. Ornelas, A. Brehm, M.I. Mendonca (Funchal, PT)
- Paraoxonase polymorphism is a predictor of 5-year mortality in patients with stable multivessel coronary artery disease.** **P534**
 – L.A.F. Ferri, A.C. Pereira, E.G. Lima, R.D. Vieira, R. Rahmi, L.A.M. Cesar, J.A.F. Ramires, J.E. Krieger, W. Hueb, N.H. Lopes (Sao Paulo, BR)
- Analysis of different polymorphisms and the risk of restenosis after coronary stent placement.** **P535**
 – F. Rolandi, D. Grinfeld, J. Scaglia, I. Rifourcat, P. Pollono, D. Berrocal, L. Grinfeld (Buenos Aires and La Plata, AR)
- The impact of the genetic polymorphism G455A on fibrinogen b-chain gene on fibrinogen levels, low-grade inflammatory process and endothelial function in patients with advanced atherosclerosis.** **P536**
 – N. Papageorgiou, D. Tousoulis, A. Miliou, G. Hatzis, C. Antoniadis, A. Giolis, C. Toutouzas, M. Kozanitou, E. Bosinakou, C. Stefanadis (Athens, GR)
- Role of atherosclerosis-related genetic polymorphisms on morbidity of ischaemic heart disease.** **P537**
 – C. Carpeggiani, M. Coceani, N. Botto, S. Fantinato, D. Adlerstein, E. Shehi, T. Sampietro, D. Neglia, A. L'Abbate, M.G. Andreassi (Pisa and Nervino, IT)
- Apolipoprotein E polymorphism predicts cardiovascular events in patients with stable multivessel coronary artery disease.** **P538**
 – N.H. Lopes, L.A.F. Ferri, E.G. Lima, R.D. Vieira, P.R. Soares, L.A. Cesar, W. Hueb, J.E. Krieger, A.C. Pereira, J.A.F. Ramires (Sao Paulo, BR)
- Tagging SNP analysis of a locus on chromosome 9 associated with myocardial infarction.** **P539**
 – W. Koch, C. Ganser, A. Erl, S. Tuerk, A. Pfeufer, P. Hoppmann, A. Schoemig, A. Kastrati (Munich and Neuherberg, DE)
- Influence of 9p21.3 genetic variants on clinical outcome in early-onset myocardial infarction.** **P540**
 – P.A. Merlini, A. Pisani, D. Lina, F. Notarangelo, F. Mauri, D. Ardissino (Milan and Parma, IT)

- A common variant at chromosome 9p21.3 is associated with age of onset of coronary disease but not subsequent mortality in coronary disease cohorts.** P541
 – K.L. Ellis, A.P. Pilbrow, B.R. Palmer, C.M. Frampton, R.N. Doughty, C.J. Ellis, T.G. Yandle, R.W. Troughton, A.M. Richards, V.A. Cameron (Christchurch and Auckland, NZ)
- Association between left ventricular mass and telomere length in a population study.** P542
 – T. Kuznetsova, V. Codd, S. Brouillette, L. Thijs, Y. Jin, T. Richart, J.A. Staessen, N.J. Samani (Leuven, BE; Leicester, GB)
- Enhanced angiogenesis mediated by vascular endothelial growth factor plasmid-loaded thermo-responsive amphiphilic hydrogel in rat myocardial infarction model.** P543
 – J.S. Kwon, I.K. Park, J.J. Min, M.H. Jeong, W.J. Kim, S.H. Pun, J.G. Cho, J.C. Park, J.C. Kang, Y. Ahn (Gwangju and Pohang, KR; Seattle, US)
- THE MULTI-FACETED RESPONSE TO CARDIOVASCULAR INJURY**
- Factor VII activating protease (FSAP) alters the pericellular proteolysis balance in the vessel wall during neointima formation.** P544
 – J.M. Daniel, O. Uslu, K. Hersemeyer, O. Rannou, L. Muhl, H.H. Tillmanns, K.T. Preissner, D.G. Sedding, S.M. Kanse (Giessen, DE)
- Combined superoxide dismutase mimetic and peroxynitrite scavenger protects against neointima formation after endarterectomy in association with decreased proliferation and nitro-oxidative stress.** P545
 – K. Hirschberg, T. Radovits, S. Korkmaz, S. Loganathan, S. Zoellner, B. Seidel, S.Z. Pali, B. Merkely, M. Karck, G. Szabo (Heidelberg, DE; Budapest, HU)
- Chronic heart rate reduction with ivabradine prevents the increase in cerebrovascular compliance induced by severe dyslipidemia in mice.** P546
 – V. Bolduc, A. Drouin, M.-A. Gillis, P. Gluais, M. Bouly, J.-C. Tardif, E. Thorin (Montreal, CA; Suresnes and Courbevoie, FR)
- Effect of autologous mononuclear bone marrow stem cells on mobilization of BM-CPCs in patients with PAD.** P547
 – R.G. Turan, I. Bozdog-T, C.H. Turan, J. Ortak, I. Akin, H. Schneider, S. Kische, H. Ince, C. Nienaber (Rostock, DE)
- Transplantation of ex vivo engineered mononuclear.** P548
 – J. Herold, A. Franke, S. Weinert, A. Schmeisser, R.H. Strasser, R.C. Braun-Dullaeus (Magdeburg and Dresden, DE)
- Structural alterations of subcutaneous small resistance arteries in obese patients.** P549
 – C. De Ciuceis, E. Porteri, D. Rizzoni, C. Corbellini, E. La Boria, G.E.M. Boari, S. Paiardi, A. Pilu, M. Castellano, E. Agabiti Rosei (Brescia, IT)
- Role of the phosphatase PTEN during vascular remodeling.** P550
 – R. Widmer-Teske, A. Mueller, P. Stieger, H. Tillmanns, R.C. Braun-Dullaeus, D. Sedding (Giessen and Magdeburg, DE)
- The emerging role of osteoprotegerin in essential hypertension: associations with low-grade inflammation, arterial stiffening and asymmetric dimethylarginine levels.** P551
 – C. Tsioufis, K. Dimitriadis, A. Aggelis, N. Trikalinos, I. Darladimos, D. Syrseloudis, S. Sideris, C. Thomopoulos, D. Tousoulis, C. Stefanadis (Athens, GR)
- Contribution of calmodulin and Ca²⁺/calmodulin-dependent kinases to the stretch-induced force response in human atrial myocardium.** P552
 – M. Khafaga, B. Doleschal, D. Von Lewinski, H. Machler, J. Kockskamper, B. Pieske (Graz, AT)
- Conduction delay in the infarct border zone during epicardial stimulation in a rabbit model of myocardial infarction.** P553
 – R.C. Myles, F.L. Burton, S.M. Cobbe, G.L. Smith (Glasgow, GB)
- Process of the progression of ventricular remodeling and arrhythmia in the systemic hyper-oxidative state. A study in glutathione depleted rat model.** P554
 – S. Kurokawa, S. Niwano, H. Niwano, M. Kiryu, H. Fukaya, T. Izumi (Sagamihara, JP)
- Influence of dexamethasone on early tachycardia-induced electrical remodeling in rabbit atrium.** P555
 – R. Laszlo, C. Eick, B. Schreiner, K. Goehring-Frischholz, S. Weretka, H.J. Weig, J. Schreieck (Tubingen, DE)

- Angiotensin II and TNF α as mediators of ATP-dependent potassium channels remodeling in post-infarction heart failure.** **P556**
 – C.H. Montessuit, N. Isidoro Tavares, P. Philip-Couderc, R. Lerch, A.J. Baertschi (Geneva, CH)
- Losartan attenuates heart fibrosis induced by chronic endurance training in an animal mode.** **P557**
 – G. Gay-Jordi, B. Benito, E. Guasch, L. Mont, V. Sirenko, J. Brugada, A. Serrano-Mollar (Barcelona, ES)
- miRNAs regulate smooth muscle cell function during neointima formation.** **P558**
 – W. Bielenberg, A. Prock, P. Stieger, H. Tillmanns, D. Sedding (Giessen, DE)
- Structural alterations in the microcirculation are potent predictors of changes of the renal function in hypertensive patients.** **P559**
 – G.E.M. Boari, D. Rizzoni, E. Porteri, C. De Ciuceis, M. Mazza, A. Brignani, C. Agabiti Rosei, L. Caimi, E. Agabiti Rosei (Brescia, IT)
- Role of SIRT1 in VSMC function and vascular remodeling.** **P560**
 – D. Sedding, S. Vogel, H. Koenig, J.M. Daniel, H. Tillmanns (Giessen, DE)
- MYOCARDIAL ELECTRICS: SPIKES, WAVES AND STORUS**
- Expression of FKBP 12.6 is reduced and sarcoplasmic calcium leak is increased in myocardium of diabetic mice.** **P561**
 – S. Groenke, D. Hoyer, K. Frank, C. Zobel, J. Mueller-Ehmsen, H. Reuter (Cologne, DE)
- JTV 519 attenuates diastolic sarcoplasmic reticulum calcium leak induced by Na accumulation in cardiomyocytes.** **P562**
 – F.R. Heinzl, M. Sacherer, S. Sedej, M.A. Vos, B. Pieske (Graz, AT; Maastricht, NL)
- Conditional cardiac survivin deficiency results in global atrial, AV-nodal and ventricular conduction disturbances in the mouse heart.** **P563**
 – J.W. Schrickel, T. Lewalter, R. Andrie, M. Linhart, F. Stoeckigt, G. Nickenig, L.M. Lickfett, B. Levkau (Bonn, Paderborn and Essen, DE)
- Effect of adenosine A1 receptor activation on cyclic AMP-dependent modulation of intracellular calcium handling in human atrial myocytes.** **P564**
 – J. Fernandes, C.E. Molina, A. Llach, J. Padro, J. Cinca, L. Hove-Madsen (Barcelona, ES)
- Acute inhibition of the Na⁺/Ca²⁺ exchanger by SEA0400 reduces proarrhythmia in an experimental model of chronic heart failure.** **P565**
 – P. Milberg, C. Pott, M. Paul, G. Frommeyer, T. Matsuda, A. Baba, N. Osada, G. Breithardt, L. Eckardt (Munster, DE; Osaka, JP)
- Sustained intraventricular stretch promotes ventricular arrhythmias decreasing conduction velocity and shortening refractoriness, in the isolated swine whole heart.** **P566**
 – J. Moreno Planas, J.G. Quintanilla, T. Archondo, E. Usandizaga, N. Perez Castellano, I. Nunez, R. Fernandez Cavazos, C. Macaya, J. Perez-Villacastin (Madrid, ES)
- Ranolazine normalizes action potential duration in angiotensin II exposed HL-1 cells: role of late sodium current.** **P567**
 – S. Casini, A. Bianchini, L. Sartiani, S. Suffredini, L. Belardinelli, A. Mugelli, E. Cerbai (Florence, IT; Palo Alto, US)
- Cardiac Rac 1 GTPase upregulation increases atrial load and induces local atrial conduction defects in the mouse.** **P568**
 – J.-C. Reil, O. Adam, C.H. Mewis, M. Boehm, U. Laufs, M. Allessie, H.R. Neuberger (Homburg/Saar, DE; Maastricht, NL)
- Knock out of Caspase 3 prevents from persistent atrial fibrillation in pigs.** **P569**
 – K. Trappe, K. Kelemen, O. Bikou, R. Soucek, M. Koch, S. Huntscha, B. Menrath, H.A. Katus, A. Bauer (Heidelberg, DE)
- Arrhythmic risk during childhood in a paediatric LQTS population of probands.** **P570**
 – V. Probst, F. Floch, A. Maltret, E. Villain, J.M. Lupoglazoff, A. Leenhardt, H. Le Marec, I. Denjoy (Nantes and Paris, FR)
- Relationship of common candidate gene variants to electrocardiographic T-wave peak to T-wave end interval.** **P571**
 – K. Porthan, A. Marjamaa, M. Viitasalo, H. Vaananen, L. Toivonen, M.S. Nieminen, A. Jula, V. Salomaa, K. Kontula, L. Oikarinen (Helsinki, Espoo and Turku, FI)

- Electrical conduction across human adult epicardium-derived cells is influenced by epithelial-to-mesenchymal transition: Novel mechanistic insights into cardiogenesis-related arrhythmias?** P572
 – D.A. Pijnappels, N.A.M. Bax, D.L. Ypey, A. Van Der Laarse, A.A.F. De Vries, M.J. Schalij, D.E. Atsma, A.C. Gittenberger-De Groot (Leiden, NL)
- Isl-1 expression in the sinus venosus delineates a RhoA expressing cell population in the development of the sinoatrial and atrioventricular node in the chick embryo.** P573
 – R. Vicente Steijn, D.P. Kolditz, E.A.F. Mahtab, L.M. Van Der Graaf, L.J. Wisse, M.R.M. Jongbloed, M.J. Schalij, A.C. Gittenberger-De Groot, R.E. Poelmann (Leiden, NL)
- Effects of an atorvastatin treatment on atrial ion currents in rabbit.** P574
 – C. Eick, R. Laszlo, A. Menzel, B. Schreiner, J. Schreieck (Tubingen, DE)
- Forward Na⁺-Ca²⁺ exchange exaggerates beat-to-beat variability of repolarization duration in a cellular model of long-QT1 syndrome.** P575
 – D.M. Johnson, C.E. Pollard, J.P. Valentin, H.J.G.M. Crijns, N. Abi-Gerges, P.G.A. Volders (Maastricht, NL; Macclesfield, GB)
- Effects of rapid augmentation of L-type calcium current on the voltage dependence of calcium release from the sarcoplasmic reticulum in rat ventricular myocytes.** P576
 – M. El Kadri, G. Hart, M. Hussain (Liverpool and Bradford, GB)
- The role of the myocardial fibre orientation in homogenizing transmural electrical activation.** P577
 – R. Sebastian, B.H. Bijnens, A.F. Frangi (Barcelona, ES)
- Adenosine A_{2A} receptor inhibition stabilizes the rate dependent beat-to-beat response of L-type calcium current in human atrial myocytes.** P578
 – C.E. Molina, A. Llach, J. Fernandes, C. Munoz-Guijosa, J. Cinca, L. Hove-Madsen (Barcelona, ES)
- Propafenone and Flecainide increase the current through human cardiac Kir2.1 channels.** P579
 – R. Caballero, R. Gomez, A. Barana, I. Amoros, D. Ponce-Balbuena, J.A. Sanchez-Chapula, J. Tamargo, E. Delpon (Madrid, ES; Colima, MX)
- CARDIAC REHABILITATION**
- The Italian Survey on cardiac Rehabilitation (ISYDE-2008). Patients characteristics and current provision of cardiac rehabilitation.** P580
 – R. Tramarin, S. De Feo, M. Ambrosetti, C. Riccio, M. Piepoli, F. Fattirolli, P.L. Temporelli, R. Griffo (Cernusco, Peschiera del Garda, Cunardo, Caserta, Piacenza, Florence, Veruno and Arenzano, IT)
- Comparison of hospital-based versus home-based exercise training in patients with heart failure: effects on functional capacity, quality of life, psychological symptoms, and hemodynamic parameters.** P581
 – H.K. Karapolat, E.D. Demir, Y.T.B. Turan Bozkaya, S.E. Eyigor, S.N. Nalbantgil, B.D. Durmaz, M. Zoghi (Izmir, TR)
- Changes in lifestyle and anthropometric measures in a novel family-centred community-based programme for cardiovascular disease prevention and rehabilitation.** P582
 – J. Jones, A. Mead, C. Jennings, E.L. Turner, S.B. Connolly, K. Kotseva, A. Holden, G. Fiumicelli, J. Stevenson, M. Hunjan (London, GB)
- Adiponectin is reduced by exercise training in chronic heart failure patients. A prospective randomized controlled study.** P583
 – A.S. Ferraz, E.A. Bocchi, R.S. Meneghelo, C.H.V.B.G. Carvalhais, A.M. Doi, G.V. Guimaraes, A.R.C.N. Fuchs, L.E. Mastrocolla, A.G.M.R. Sousa (Sao Paulo, BR)
- Anemia does not preclude increments in cardiac performance during a short period of intensive, exercised based cardiac rehabilitation.** P584
 – F. Bellotto, P. Palmisano, L. Compostella, P. Guida, M. Zaccaria, T. Setzu, A. Cati, A. Maddalozzo, S. Favale, S. Illiceto (Padua, Bari and Cortina D'Ampezzo, IT)
- Functional evaluation in octogenarians patients undergoing a cardiac rehabilitation program: correlation between six minute walking test and Rivermead Mobility Index.** P585
 – F. Scimia, I. Casadei, E. Cerquetani, M. Piccoli, A. Villa, S. La Carrubba, A. Salustri (Rome, IT)

- Sustained control of cardiac risk factors in a community multi-vascular prevention program at one year: comparisons of coronary artery disease, non-disabling stroke and peripheral artery disease.** P586
 – N.B. Giacomantonio, W. Firth (Halifax, CA)
- Inter-practice variation in assessed needs for cardiac rehabilitation.** P587
 – N. Peek, R. Goud, M.M. Van Engen-Verheul, I.M. Hellemans, A. Hasman, N.F. De Keizer (Amsterdam, NL)
- A low glyceic and insulinemic diet (LOGI) is superior to the traditional low fat diet in improving cardiac function and metabolic syndrome in spite of a 55% reduction of antidiabetic therapy.** P588
 – H. Von Bibra, G. Wulf, P. Heilmeyer (Munich and Isny, DE)
- Long-term beneficial effects of an expanded cardiac rehabilitation after an acute myocardial infarction or coronary artery by-pass grafting: a five year follow-up of a randomized controlled study.** P589
 – C. Edstrom-Pluss, E. Billing, C. Held, P. Henriksson, A. Kiessling, M. Rydell Karlsson, N.H. Wallen (Stockholm and Uppsala, SE)
- Survival after coronary artery bypass grafting in adult and elderly patients.** P590
 – F. Cacciatore, F. Mazzella, G. Longobardi, A. Nicolino, G. Furgi, C. Naples, F. Rengo (Telese Terme and Naples, IT)
- Prior exercise training improves survival, infarct healing and left ventricular function after myocardial infarction.** P591
 – D.J.G.M. Duncker, M.C. De Waard (Rotterdam, NL)
- Cardiovascular risk benefits of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) program are maintained for four years: randomised controlled trial.** P592
 – L. Neubeck, J. Redfern, T. Briffa, R. Ascanio, S.B. Freedman (Sydney and Perth, AU)
- New model of home-based tele-ecg-monitored cardiac rehabilitation in patients with heart failure: safety, effectiveness, quality of life and compliance.** P593
 – E. Piotrowicz, M. Stepnowska, R. Baranowski, M. Bilinska, M. Piotrowska, T. Zielinski, R. Piotrowicz (Warsaw, PL)
- Less weight gain and a healthier lifestyle after quitting smoking in EUROACTION: a family based preventive cardiology programme for coronary patients.** P594
 – A. Mead, C. Jennings, J. Jones, E.L. Turner, S.B. Connolly, K. Kotseva, G. De Backer, D. De Bacquer, G. Frost, D. Wood (London, GB; Ghent, BE)
- 12-month patterns of supportive therapies in acute coronary syndrome patients undergoing PCI in 2007-08: results from the AntiPlatelet Treatment Observational Registry (APTOR).** P595
 – A. Bakhai, A. Iniguez, J. Ferrieres, C. Schmitt, M. Sartral, M. Belger, U. Zeymer (Barnet and Windlesham, GB; Vigo, ES; Toulouse and Paris, FR; Ludwigshafen, DE)

SPORT AND EXERCISE PHYSIOLOGY

- Prognostic value of exercise echocardiography in patients with suspected but not previously known coronary artery disease and normal exercise ECG.** P596
 – A. Bouzas Mosquera, J. Peteiro, F.J. Broullon, N. Alvarez Garcia, V.X. Mosquera, A. Garcia Campos, O. Prada, J.P. Abugattas, L. Garcia Bueno, A. Castro Beiras (A Coruna, ES)
- Exercise stress test results in patients with bare metal stents or drug eluting stents: pathophysiological and clinical implications.** P597
 – A. Di Monaco, R. Nerla, G.A. Sgueglia, C. Aurigemma, R. Mollo, L. Barone, G. Pinnacchio, C. Pisanello, G.A. Lanza, F. Crea (Rome, IT)
- Endothelial dysfunction in normotensive adolescents with exaggerated blood pressure response during treadmill test.** P598
 – A. Gonzalez, E. Silva, G. Bermudez, J. Villasmil, S. Briceno, M. Bracho, C. Esis (Maracaibo, VE)
- Screening for anomalous proximal coronary artery trees in 360 competitive athletes and non-athletes with 3-Dimensional MR coronary angiography: feasibility for clinical implication and findings.** P599
 – N.H.J. Prakken, M.J. Cramer, M.A. Olijmulder, B.K. Velthuis (Utrecht, NL)

- The impact of race on electrocardiographic repolarisation changes in highly trained female athletes: relevance to pre-participation ECG screening for cardiomyopathy.** P600
 – J.C. Rawlins, F. Carre, M. Papdakis, N. Chandra, C. Edwards, S. Sharma (London, GB; Rennes, FR)
- The athlete's heart: influence of gender on cardiac morphological and electric patterns.** P601
 – G. Kervio, J. Gueneron, L. Uzan, H. Douard, F. Carre, N. Ville (Rennes, Paris and Bordeaux, FR)
- Impact of physical exercise on parameters of arterial stiffness and wave intensity measured at carotid artery level.** P602
 – O. Vriz, F. Antonini-Canterin, S. Carerj, M. Bettio, D. Pavan, E. Leiballi, R. Enache, E. Bossone, G.L. Nicolosi (San Daniele Del Friuli, Pordenone, Messina, San Vito Al Tagliamento and Lecce, IT; Bucharest, RO)
- Early changes in VEGF, angiopoietin-2 and erythropoietin in response to acute exposure to hypoxia: differentiation between resting and submaximal exercise challenge.** P603
 – M. White, M.G. Sirois, J. Laramee, L. Bussieres, C. Poirier, P. Nguyen, A. Mathieu, H. Ross, P. Mayer (Montreal and Toronto, CA; Sion, CH)
- Initial experience with real time exercise magnetic resonance imaging.** P604
 – G.V. Szanatho, M.S. Turner, R. Duerden, R. Greenwood, A.G. Stuart, J. Fulford, M.P. Frenneaux, M.C.K. Hamilton (Bristol, Exeter and Birmingham, GB)
- Intense physical exercise adversely affects monocyte function.** P605
 – F.S. Czepluch, R. Barres, K. Caidahl, A. Krook, J. Zierath, J. Waltenberger (Maastricht, NL; Stockholm, SE)
- Chronic physical exercise produces an electrophysiological stabilizer effect on ventricular myocardium that is independent of the myocardial cholinergic neurons activity.** P606
 – M. Zarzoso, J. Guerrero, L. Such-Miquel, I. Trapero, G. Parra, B. Diaz, A. Cebría, L. Such Belenguer, F.J. Chorro, A. Alberola (Valencia, ES)
- Hypertensives with an exaggerated exercise blood pressure response are characterized by arterial stiffening, augmented asymmetric dimethylarginine and osteopontin levels.** P607
 – K. Dimitriadis, C. Tsioulfis, D. Syrseloudis, C. Thomopoulos, D. Chatzis, E. Tsiamis, E. Andrikou, D. Tousoulis, A. Michaelides, C. Stefanadis (Athens, GR)
- Haemostatic balance disorders and the exaggerated blood pressure response to exercise treadmill testing in pre-hypertensive non-smoking men.** P608
 – O. Papazachou, A. Bratsas, S. Massias, C. Thomopoulos, D.P. Papadopoulos, M. Daskalaki, E. Michalopoulou, M. Fragkaki, T.H. Makris (Athens, GR)
- Minimizing right ventricular pacing in patients with DDDR pacemaker improves cardiopulmonary exercise test results and reduces BNP level.** P609
 – T. Chwyczko, R. Dabrowski, A. Maciag, A. Borowiec, A. Labecka, M. Sterlinski, M. Pytkowski, I. Kowalik, J. Janas, H. Szwed (Warsaw, PL)
- Safety of cardiopulmonary exercise test in hypertrophic cardiomyopathy.** P610
 – C. Blank, B. Pfeiffer, A. Neugebauer, H. Seggewiss (Schweinfurt, DE)
- Peak circulatory power is a powerful predictor of arrhythmic events in patients with implantable cardioverter-defibrillator.** P611
 – R. Cale, M. Mendes, J. Brito, P. Sousa, P. Carmo, R. Gomes, A. Ferreira, P. Adragao, J. Calqueiro, J. Aniceto Silva (Lisbon, PT)
- The influence of dynamic mitral regurgitation on exercise capacity in patients with chronic heart failure.** P612
 – M. Izumo, Y. Akashi, K. Yoneyama, K. Suzuki, N. Osada, F. Miyake (Kawasaki, JP)
- Cardiopulmonary exercise testing in adult survivor's of operated fallot's tetralogy: CPEX results may be better than symptoms.** P613
 – D. Mcaroe, L.J. Freeman (Norwich, GB)
- Cardiopulmonary exercise testing for predicting outcomes in patients with heart failure - advantage of a multivariable score?** P614
 – A. Toste, R.M. Soares, J. Feliciano, V. Andreozzi, A. Mamede, A. Lousinha, A. Abreu, L. Ferreira, R.C. Ferreira (Lisbon, PT)
- Maximal exercise capacity in adults with congenital heart disease.** P615
 – R. Buys, W. Budts, C. Decluse, A. Stevens, S. Amandels, S. Onkelinx, T. Thomaes, L. Vanhees (Leuven, BE)

- Treadmill exercise electrocardiography and mortality risk in patients with an intermediate pretest probability of coronary artery disease.** P616
 – S. Balakrishnan Nair, R. Rezaei, W. Turkie, R.S. Khattar (Manchester, GB)

AGING AND SEX

- Variation in myocardial mass is associated with aortic stiffness and endothelial function in low risk individuals by early adult life.** P617
 – I. Kyliantreas, M. Lazdam, I. Bechar, J. Diesch, C. Trevitt, J.M. Francis, S. Neubauer, P. Leeson (Oxford, GB)
- Determinants of circulating leukocyte telomere length in patients with acute myocardial infarction.** P618
 – S. Saliques, M. Zeller, C. Vergely, S. Amoureux, P. Sicard, J.E. Wolf, A. Donzel-Javouhey, Y. Cottin, J.R. Teysier, L. Rochette (Dijon, FR)
- Regular aerobic exercise corrects age-related declines in endothelial function.** P619
 – M. Deljanin Ilic, S. Ilic, G. Kocic, R. Pavlovic, V. Stoickov (Niska Banja and Nis, RS)
- Normotensive salt sensitivity in the elderly: possible role of endothelin-1 and sodium-potassium pump.** P620
 – G.V. Simonia, I.T. Andronikashvili, P.A. Nozadze, N.M. Kantaria, T.V. Kristesiasvili (Tbilisi, GE)
- Prognostic value of brain natriuretic peptide before emergency surgery.** P621
 – C. Sankin, T. Marko, T. Stojakovics, S. Archan, N. Vicenzi (Graz, AT)
- Red cell distribution width is an independent indicator of outcome in elderly patients with coronary artery disease.** P622
 – O. Pfister, S. Muzzarelli, L. Grize, M.E. Pfisterer (Basel, CH)
- Progression from paroxysmal atrial fibrillation to more sustained forms: clinical correlates and therapeutical consequences.** P623
 – C.B. De Vos, R. Pisters, R. Nieuwlaet, M.H. Prins, R.G. Tieleman, M.A. Allesie, H.J.G.M. Crijns (Maastricht, NL)
- Contribution of resting heart rate to mortality and coronary heart disease events in free-living older adults. The three city study.** P624
 – C. Legeai, X. Jouven, J.F. Dartigues, C. Helmer, K. Ritchie, P. Amouyel, C. Tzourio, P. Ducimetiere, J.P. Empana (Paris, Bordeaux, Montpellier, Lille and Villejuif, FR)
- The inflammatory component of cardiovascular aging on albuminuria and arterial stiffness in essential hypertensive subjects.** P625
 – K. Dimitriadis, C. Tsioufis, D. Tsiachris, A. Kasiakogias, H. Tatsis, C. Papastasinou, A. Aggelis, N. Trikalinos, I. Kallikazaros, C. Stefanadis (Athens, GR)
- The effect of oestrogen on bone morphogenetic protein receptor signal pathway in pulmonary arterial endothelial cells.** P626
 – H. Ichimori, S. Kogaki, H. Ishida, J. Narita, T. Uchikawa, S. Maekawa, S. Matsumoto, Y. Okada, K. Ozono (Suita, JP)
- Females undergoing percutaneous coronary intervention have increased risk of contrast induced nephropathy compared to males.** P627
 – E. Chong, L. Shen, K.K. Poh, H.Y. Ong, C.Y. Soon, H.C. Tan (Singapore, SG)
- Females have a higher rate of mortality after primary PCI.** P628
 – K.S. Rathod, D. Jones, E. Wicks, C. Knight, M.T. Rothman, A. Wragg (London, GB)
- Gender differences in management and outcomes of European patients with symptomatic atherothrombotic disease in the REACH Registry.** P629
 – J. Morrell, U. Zeymer, I. Baumgartner, T. Limbourg, P.G. Steg, D.L. Bhatt (St Leonards On Sea, GB; Ludwigshafen am Rhein, DE; Berne, CH; Paris, FR; Boston, US)
- Female gender and vascular disease are true risk factors for stroke in patients with atrial fibrillation: data from the Euro Heart Survey.** P630
 – R. Pisters, R. Nieuwlaet, G.Y.H. Lip, D.A. Lane, C.B. De Vos, H.J.G.M. Crijns (Maastricht, NL; Hamilton, CA; Birmingham, GB)
- Spectacular decrease in mortality in women with STEMI: an effect of public awareness campaigns?** P631
 – T. Simon, J.M. Lablanche, J.J. Dujardin, P. Gueret, D. Blanchard, G. Mulak, E. Drouet, J.P. Cambou, J. Ferrieres, N. Danchin (Paris, Lille, Douai, Creteil, Tours and Toulouse, FR)

- Evolution of myocardial infarction prognosis by sex in the last 30 years.** P632
 – M. Grau, A. Sureda, C. Sala, J. Vila, R. Elosua, J. Sala, R. Masia, R. Ramos, J. Marrugat (Barcelona, Girona and Manresa, ES)
- Correlation of estimated glomerular filtration rate with left ventricular hypertrophy and remodeling in women.** P633
 – A. Yoshikawa, S. Hamasaki, S. Ishida, T. Kataoka, K. Saihara, H. Okui, T. Shinsato, S. Yoshino, K. Nakashiki, C. Tei (Kagoshima, JP)
- Role of abdominal fat compartmentation on wave reflections: differences between men and women.** P634
 – V. Katsi, G. Moustakas, E. Chatzistamatiou, D. Tousoulis, E. Androulakis, C. Vlachopoulos, C. Stefanadis, I. Kallikazaros (Athens, GR)
- Inflammatory indices and glycaemic control in Post-menopausal diabetic women.** P635
 – T.H. Gialernios, K. Gialernios, A. Triantafyllou, S. Kougialis, E. Skopelitis, A. Antonopoulos, M. Lambropoulos, A. Polydorou (Athens, GR)
- Gender-specific differences in initial clinical presentation and outcome of idiopathic dilated cardiomyopathy.** P636
 – J. Franke, L. Frankenstein, P. Ehlermann, A. Remppis, C. Zugck, H.A. Katus (Heidelberg, DE)
- Impaired fasting glucose, diabetes and early phase of menopause are the strongest determinants of premature coronary artery disease in women.** P637
 – E. Skora, B. Lubiszewska, M. Kruk, G. Broda, E. Ksiezycka, P. Kurjata, W. Piotrowski, W. Ruzyllo (Warsaw, PL)
- Association between endogenous serum testosterone concentrations and arterial stiffness in erectile dysfunction patients.** P638
 – A. Aggelis, C. Vlachopoulos, D. Terentes-Printzios, N. Ioakeimidis, K. Rokkas, K. Aznaouridis, N. Alexopoulos, G. Sakellariou, C. Fassoulakis, C. Stefanadis (Athens, GR)
- PERCUTANEOUS CORONARY INTERVENTION: LONG-TERM OUTCOME AND PREDICTOR FACTORS OF FAILURE**
- High-sensitivity C-reactive protein predicts long-term survival in a sirolimus-eluting stent population. Insights from 6 years of follow-up in the RESEARCH registry.** P639
 – R.M. Oemrawsingh, Y. Onuma, M. Degertekin, H.P. Stoll, E. Boersma, P.W. Serruys, R.T. Van Domburg (Rotterdam, NL; Istanbul, TR; Waterloo, BE)
- Long-term mortality after PCI in patients with diabetes mellitus. Results from Swedish coronary angiography and angioplasty registry.** P640
 – A. Norhammar, B. Lagerqvist, N. Saleh (Stockholm and Uppsala, SE)
- 5-year incidence and risk factors of late definite thrombosis of paclitaxel-eluting stents.** P641
 – X. Flores Rios, J.P. Abugattas De Torres, G. Aldama Lopez, P. Pinon Esteban, R. Calvino Santos, J.M. Vazquez Rodriguez, N. Vazquez Gonzalez, A. Castro Beiras (A Coruna, ES)
- Sirolimus-eluting versus bare-metal stents for the reduction of coronary restenosis: 3-year clinical outcome and economic analysis of the GERSHWIN study.** P642
 – S. Willich, B. Brueggenjuergen, D. McBride, C. Bode, C. Hamm, K.H. Kuck (Berlin, Freiburg im Breisgau, Bad Nauheim and Hamburg, DE)
- Clinical and angiographic predictors of stent thrombosis after drug-eluting stent implantation: results from the prospective multicentre German drug-eluting stent registry (DES.DE).** P643
 – R. Toelg, M. Sherif, S. Schneider, A. Khattab, G. Richardt, S. Janko, C. Bode, M. Haude (Bad Segeberg, Ludwigshafen am Rhein, Munich, Freiburg and Neuss, DE)
- Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials.** P644
 – K. Tiroch, A. Dibra, S. Schulz, J. Mehilli, A. Schoemig, A. Kastrati (Munich, DE)
- Relative impact of ischemic complications and varying definitions of major bleeding on one year mortality in patients with AMI: results from the HORIZONS-AMI trial.** P645
 – R. Mehran, H. Parise, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, S.J. Pocock, G.D. Dangas, A.J. Lansky, G.W. Stone (New York and Greensboro, US; Berlin, DE; Bergamo, IT; Lodz, PL; London, GB)

- Sirolimus- and paclitaxel-eluting stents compared to bare-metal stents in a real world setting - results from the prospective multicenter German DES.DE registry.** P646
 – I. Akin, C.A. Nienaber, S. Schneider, J. Senges, T. Fetsch, G. Richardt, K.H. Kuck (Rostock, Ludwigshafen am Rhein, Munich, Bad Segeberg and Hamburg, DE)
- First in man application of bevacizumab eluting stent: a novel approach for the inhibition of plaque neovascularisation. Long term results.** P647
 – K. Toutouzas, E. Stefanadi, J. Karamelas, A. Synetos, E. Tsiamis, D. Tousoulis, N. Kipshidze, C. Stefanadis (Athens, GR; New York, US)
- Impact of body mass index on mortality in patients with acute myocardial infarction.** P648
 – E. Omerovic, O. Angeros, B. Lagerqvist, K. Karason, G. Matejka, T. Ramunddal, P. Albertsson (Gothenburg, Trollhattan and Uppsala, SE)
- Circulating endothelial progenitor cells in patients who underwent late coronary stent thrombosis.** P649
 – E. Lev, D. Leshem, A. Mager, N. Harel, A. Solodky, A. Assali, A. Battler, R. Kornowski (Petah Tikva, IL)
- Mortality rate after coronary stent thrombosis in patients treated with drug-eluting or bare metal stents. From Western Denmark heart registry.** P650
 – L.O. Jensen, A. Kaltoft, P. Thayssen, H.H. Tilsted, M. Maeng, J.F. Lassen, K.N. Hansen, J. Ravkilde, M. Madsen, L. Thuesen (Odense, Aarhus and Aalborg, DK)
- Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stent.** P651
 – Z.J. Wang, Y.J. Zhou, Y.L. Liu, M. Yu, D.M. Shi, Y.X. Zhao (Beijing, CN)
- Antiplatelet therapy discontinuation and stent thrombosis of sirolimus-eluting stent: observation from the RESTART (Registry of Stent Thrombosis for review And Re-evaluation).** P652
 – T. Kimura, T. Aizawa, T. Isshiki, K. Mitsudo, S. Miyazaki, T. Yamaguchi, E. Hiyoshi, E. Nishimura (Kyoto, Tokyo, Okayama and Osaka, JP)
- Proton pump inhibitors increase the risk of major adverse cardiovascular events in post-PCI patients who are on clopidogrel.** P653
 – S. Banerjee, C. Varghese, R. Weideman, M. Weideman, B.B. Little (Dallas and Stephenville, US)
- QT dispersion modifications predict late survival after percutaneous coronary intervention.** P654
 – M. Zimarino, A. Corazzini, A. Tatasciore, V. Cicchitti, E. Genovesi, R. Tommasi, C. Rossi, R. De Caterina (Chieti, IT)
- Efficacy of statins in patients after percutaneous coronary interventions: relation with baseline CRP values and with post-procedural TnI.** P655
 – C. Auguadro, F. Scalise, M. Bonadies, E. D'Elia, V. Pacher, V. Casali, M. Manfredi, G. Specchia (Monza, IT)
- Time dependent differences in the demographics and clinical outcome of stent thrombosis of sirolimus-eluting stent: observations from the RESTART.** P656
 – T. Kimura, T. Aizawa, T. Isshiki, K. Mitsudo, S. Miyazaki, T. Yamaguchi, E. Hiyoshi, E. Nishimura (Kyoto, Tokyo, Okayama and Osaka, JP)
- Risks and benefits of drug-eluting stent in patients with atrial fibrillation.** P657
 – F. Marin Ortuno, J.M. Ruiz-Nodar, J. Sanchez-Paya, J.A. Hurtado, J. Valencia, S. Manzano-Fernandez, V. Roldan, F. Sogorb, M. Valdes, G.Y. Lip (Murcia and Alicante, ES; Birmingham, GB)
- Antiplatelet treatment and noncardiac surgery in patients with prior coronary stent implantation.** P658
 – T.H. Bampali, A. Konstantinidis, B. Salma, T.H. Pappas, K. Kalantzi, A. Papanthanasidou, C.H. Katsouras, J. Goudevenos (Ioannina, GR)
- The impact of unsuccessful percutaneous coronary intervention on short and long-term mortality in STEMI and NSTEMI.** P659
 – M. Mazurek, J. Kowalczyk, R. Lenarczyk, A. Swiatkowski, O. Kowalski, A. Sedkowska, T. Was, M. Swierad, L. Polonski, Z. Kalarus (Zabrze, PL)

- Evaluation of 5 years follow up of myocardial function after primary percutaneous intervention by Cardiac MRI.** P660
 – T. Springeling, S.W. Kirschbaum, T. Baks, Y. Karamermer, A. Moelker, G.P. Krestin, P.J. De Feijter, R.J.M. Van Geuns (Rotterdam, NL)
- Scoring of percutaneous coronary intervention events (ScoPE): results of the Delphi-RAND analysis of predictive risk factors for long term outcomes following PCI.** P661
 – R. Denton-Beaumont, A.S. Banning, M.P. Holt, N.I. Siddiqi, K.R. Abrams, A.H. Gershlick (Leicester, GB)
- Outcome of non-cardiac surgery after stent implantation in the DES era: results of the surgery after stent (SAS) registry.** P662
 – M.F. Brancati, M. Giammarinaro, F. Burzotta, C. Trani, I. Porto, A. Tommasino, A.M. Leone, G. Niccoli, G. Schiavoni, F. Crea (Rome, IT)
- The GRACE risk score- usefulness for predicting 5-year survival of patients with ST-elevation myocardial infarction treated invasively.** P663
 – A. Kozieradzka, K.A. Kaminski, D. Maciorkowska, M. Olszewska, S. Dobrzycki, K. Nowak, P. Kralisz, P. Prokopczuk, W.J. Musial (Bialystok, PL)
- Quality of life after percutaneous coronary intervention in the elderly.** P664
 – R.J. Li, B. Yan, M. Zhang, Q. Zhang, Q.H. Zhang, M. Dong, G.W.K. Yip, C.P. Chan, D. Ding, C.M. Yu (Hong Kong, CN)
- Prognostic impact of drug eluting stent supported percutaneous coronary intervention for chronic total occlusion of left anterior descending artery.** P665
 – R. Valenti, G. Giuliani, A. Migliorini, G. Cerisano, N. Carrabba, G. Parodi, A. Santini, E. Dovellini, D. Antonucci (Florence, IT)
- Clinical outcomes in diabetic versus non-diabetic patients after treatment with drug-eluting stents in a real world setting - results from the prospective multicenter German DES.DE registry.** P666
 – I. Akin, A. Bufo, L. Eckardt, H. Reinecke, G. Richardt, S. Schneider, K.H. Kuck, C.A. Nienaber (Rostock, Wuppertal, Munster, Bad Segeberg, Ludwigshafen am Rhein and Hamburg, DE)
- A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus non-diabetic patients.** P667
 – T. Bental, A. Assali, S. Fuchs, H. Vaknin-Assa, E. Lev, D. Brosh, I. Teplitsky, R. Kornowski (Petah Tikva, IL)
- Clinical implications of stent fracture after sirolimus-eluting stent implantation at 20-month follow-up.** P668
 – K. Kadota, K. Mitsudo, T. Goto, H. Yamamoto, Y. Fuku, S. Hosogi, H. Tanaka, S. Habara, D. Hasegawa, M. Imai (Kurashiki, JP)
- Increased bleeding complications early and late after angioplasty and coronary stenting due to combined antiplatelet and anticoagulant therapy.** P669
 – A. Hoffmann, C. Haelg, C. Kaiser, R. Jeger, S. Osswald, M. Pfisterer, H. Brunner-La Rocca (Basel, CH)
- No association of chromosome 9p21 variation with angiographic and clinical outcomes after placement of drug-eluting stents in coronary arteries.** P670
 – W. Koch, P. Hoppmann, M. Eichinger, U. Weiss, A. Schoemig, A. Kastrati (Munich, DE)
- Long term clinical outcomes in the patients treated with a new generation drug eluting stent.** P671
 – B. Chevalier, S. Silber, E. Garcia, W. Wijns, S. Worthley, I. Meredith, H. Suryapranata, K. Hauptmann, G. Schuler, L. Thuesen (Massy, FR; Munich, Trier and Leipzig, DE; Madrid, ES; Aalst, BE; Adelaide and Clayton, AU; Zwolle, NL; Aarhus, DK)
- Comparison of 4 years efficacy and durability of drug-eluting stent implantation in non-bifurcation and bifurcation lesion of unprotected left main coronary arteries: multicenter registry in Asia.** P672
 – S. Nakamura, H. Ogawa, J.H. Bae, Y.H. Cahyadi, W. Udayachalerm, D. Tresukosol, S. Tansuphaswadikul (Chiba and Kumamoto, JP; Daejeon, KR; Jakarta, ID; Bangkok, TH)
- Possible stent thrombosis: fact or fiction?** P673
 – C.A. Kaiser, R. Jeger, B. Friedli, P. Rickenbacher, H.P. Brunner-La Rocca, M.E. Pfisterer (Basel and Bruderholz, CH)

- The routine early invasive strategy in women with non-ST-segment elevation acute coronary syndrome: is it time for a paradigm shift?** P674
 – A.L. Guler, R. Elkoustef (Farmington, US)
- Effects of proton-pump inhibitors on outcome of patients discharged on dual-antiplatelet therapy after percutaneous coronary intervention and stent implantation.** P675
 – R. Jarai, I. Brosovic, I. Tentzeris, S. Farhan, G. Unger, K. Huber (Vienna, AT)
- Cytochrome p450 2C19 genotype is a major determinant of clopidogrel response and a predictor of post-stenting ischemic event occurrence.** P676
 – P.A. Gurbel, K. Bliden, K. Ryan, W. Herzog, U.S. Tantry, A. Shuldiner (Baltimore, US)
- Long-term outcomes of 1921 patients following percutaneous coronary intervention without on-site surgery.** P677
 – A.C.C. Ng, A. Yong, R. Alcock, V. Chow, C. Cheruvu, B. Aliprandi-Costa, L. Kritharides, H. Lowe, D. Brieger (Sydney, AU)
- Should all STEMI patients who have successful thrombolysis undergo routine pre-discharge angiography? A single centre experience.** P678
 – A. Hailan, J. Silberbauer, P. Prior, M. Asgari, R. Heppell, I. Mirza, J. Fisher, K. Kamalvand (Ashford, GB)
- Is the phenotype of n-acetylation a predictor of coronary stents fate in mid-term follow-up after stenting with bare metal stents?** P679
 – D. Iosseliani, I. Kuznetsova, S. Semitko, O. Sukhorukov, D. Guranda (Moscow, RU)
- The use of fractional flow reserve to defer revascularisation of moderate coronary stenoses and to re-classify multi-vessel disease: a 2.5 year follow up study.** P680
 – T. Lockie, D. Perera, K. Naeem, I. Webb, S. Redwood (London, GB)
- Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting.** P681
 – U.S. Tantry, M.J. Antonino, E. Mahla, K. Bliden, P.A. Gurbel (Baltimore, US)
- Are drug eluting stents safe in warfarin-treated patients?** P682
 – A.-P. Annala, P.P. Karjalainen, P. Porela, M. Niemela, K. Nyman, M. Puurunen, S. Vikman, A. Ylitalo, K.E.J. Airaksinen (Pori, Turku, Oulu, Jyvaskyla, Helsinki and Tampere, FI)
- Reduction of infarct size and left ventricular remodeling after prehospital thrombolysis in patients with early presentation of STEMI transferred for mechanical reperfusion.** P683
 – J. Legutko, P. Kleczynski, T. Rakowski, Z. Siudak, L. Rzeszutko, L. Bryniarski, A. Brzozowska-Czarnek, A. Urbanik, J. Dubiel, D. Dudek (Krakow, PL)
- Long-term outcomes with paclitaxel- and sirolimus-eluting stents for unprotected left main coronary artery disease.** P684
 – J. Mehilli, A. Kastrati, R.A. Byrne, S. Schulz, J. Pache, M. Seyfarth, S. Kufner, O. Bruskina, A. Schomig (Munich, DE)
- Comparison between percutaneous coronary intervention and coronary-artery bypass graft for the treatment of left main disease: results from a multicenter registry.** P685
 – C. Ruperto, A. Caggegi, G. Barrano, G. Cincotta, M. Miano, M.E. Di Salvo, S. Tolaro, L. Patane', A.M. Calafiore, C. Tamburino (Catania, IT)
- First clinical application of an actively reversible direct factor IXa inhibitor in elective percutaneous coronary intervention.** P686
 – M.G. Cohen, D.A. Purdy, J.S. Rossi, L.R. Grinfeld, L.H. Aberle, A.B. Greenbaum, E.T. Fry, J.A. Alexander, C.P. Rusconi, R.C. Becker (Miami, Black Hills, Chapel Hill, Durham, Detroit and Indianapolis, US; Buenos Aires, AR)
- Unprotected left main coronary stenting in high-risk patients in a non-surgical centre.** P687
 – G. Pulikal, K.W. Lee, J. Tomson, M. Pitt (Birmingham, GB)
- LATE INSTENT RESTENOSIS AFTER DRUG ELUTING STENT IMPLANTATION**
- Late catch-up in restenosis following sirolimus-eluting stent implantation.** P688
 – M. Kimura, O. Matsuda, T. Ito, N. Tanaka, K. Nasu, Y. Kinoshita, M. Ehara, E. Tsuchikane, Y. Asakura, T. Suzuki (Toyohashi, JP)
- Late restenosis in sirolimus eluting stent, is it late catch up?** P689
 – S. Takahashi, S. Saito (Kamakura, JP)

- Late restenosis of sirolimus-eluting stent implantation for aorto-ostial lesions: comparison of right coronary artery and left main artery.** P690
 – S. Otsuru, K. Kadota, D. Hasegawa, S. Habara, H. Tanaka, S. Hosogi, Y. Fuku, H. Yamamoto, T. Goto, K. Mitsudo (Kurashiki, JP)
- Peri-strut ulcer-like appearance, a unique finding of optical coherence tomography after sirolimus eluting stent implantation: the prevalence and the clinical characteristics.** P691
 – S. Hosogi, H. Shimizu, H. Tanaka, Y. Fuku, H. Katoh, H. Yamamoto, S. Fujii, T. Goto, K. Kadota, K. Mitsudo (Kurashiki, JP)
- The difference of restenosis pattern between overlapping TAXUS and overlapping Cypher stents for diffuse lesion from analysis using intravascular ultrasound.** P692
 – H. Mukawa, T. Sone, H. Tsuboi, I. Morishima, M. Uesugi (Ogaki, JP)
- High re-restenosis after treatment of diffuse sirolimus-eluting stent restenosis irrespective of devices for target lesion revascularisation.** P693
 – H. Kitahara, Y. Kobayashi, H. Takebayashi, Y. Fujimoto, Y. Nakamura, N. Kuroda, T. Himi, A. Miyazaki, S. Haruta, I. Komuro (Chiba, Fukuyama, Kisarazu and Ichihara, JP)
- RANTES gene promoter polymorphisms and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention.** P694
 – K. Vogiatzi, V. Voudris, S. Apostolakis, G.E. Kochiadakis, S. Thomopoulou, A. Zaravinos, D.A. Arfanakis, D.A. Spandidos, P.E. Vardas (Heraklion and Athens, GR)
- Coronary in-stent-restenosis: local delivery of fluid paclitaxel - 3 years follow up of LOCAL TAX ISR register.** P695
 – C.S. Zuern, K. Goehring-Frischholz, A.E. May, M. Gawaz, C. Herdeg (Tübingen, DE)
- Evaluation of intra-stent neointima hyperplasia in the approach trial (assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history).** P696
 – H.M. Garcia-Garcia, P.W. Serruys, H.C. Gerstein, C.P. Cannon, G.A. Van Es, N.S. Kolatkar, B.G. Kravitz, C. Huang, D.M. Miller, R.W. Nesto (Rotterdam, NL; Hamilton, CA; Boston, Philadelphia and Burlington, US)
- C-reactive protein serum levels predict in-stent restenosis pattern after drug eluting stent implantation.** P697
 – G. Niccoli, M. Conte, N. Cosentino, G. Ferrante, D. Todaro, S. Brugaletta, F. Burzotta, C. Trani, F. Crea (Rome, IT)
- FROM ACUTE PULMONARY EMBOLISM TO CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION**
- Symptomatic and silent pulmonary embolism (PE): risk factors and prognosis at 3 months.** P698
 – S. Accassat, D. Delsart, C. Chapelle, N. Moulin, K. Rivron-Guillot, A. Buchmuller-Cordier, S. Laporte, P. Mismetti (Saint-Etienne, FR)
- Rheolytic thrombectomy in patients with massive and submassive acute pulmonary embolism.** P699
 – G. Spaziani, S. Vecchio, T. Chechi, G. Giuliani, F. Giannotti, C. Arcangeli, A. Rubboli, M. Margheri (Florence, Bologna and Ravenna, IT)
- Right ventricular reverse remodeling and pulmonary artery flow dynamics in the clinical follow-up of patients with acute pulmonary embolism: initial experience with cardiac MRI.** P700
 – F.A. Klok, S. Romeih, J.J.M. Westenberg, L.J.M. Kroft, M.V. Huisman, A. De Roos (Leiden, NL)
- Derivation and validation of a simple prediction rule for prognostication in patients with acute pulmonary embolism.** P701
 – S. Vanni, F. Succi, G. Viviani, G. Polidori, P. Nazerian, E. Bondi, G. Pepe, F. Moroni, S. Ponchietti, S. Grifoni (Florence, IT)
- Angioscopic detection of pulmonary thromboemboli and their classification.** P702
 – K. Shimizu, Y. Uchida, T. Tomaru (Sakura, JP)
- Surgical embolectomy as primary management for acute massive pulmonary embolism.** P703
 – S.C. Huang, H.Y. Yu, N.H. Chi, I.H. Wu, Y.S. Chen, W.J. Ko, S.S. Wang (Taipei, TW)

- Endothelin is not elevated in acute pulmonary embolism.** P704
 – M. Kostrubiec, J. Pedowska-Wloszek, M. Ciurzynski, P. Bienias, S. Pacho, P. Pruszczyk (Warsaw, PL)
- Brain natriuretic peptide and troponin I kinetics in pulmonary embolism.** P705
 – E. Ferrari, C. Crouzet, L. Drogoul, P. Lanfranchi (Nice, FR)
- Application of 64-MDCT in pulmonary embolism with emphasize to incidental findings.** P706
 – C. Sohns, S. Sossalla, G. Hasenfuss, S. Obenauer (Gottingen, DE)
- Renal function improves troponin-based short term prognosis in patients with acute pulmonary embolism.** P707
 – M. Kostrubiec, A. Labyk, J. Pedowska-Wloszek, A. Hrynkiewicz, K. Jankowski, S. Pacho, P. Dul, A. Wojciechowski, P. Pruszczyk (Warsaw, PL)
- Tissue Doppler myocardial imaging of right ventricular deformation in patients with acute pulmonary embolism.** P708
 – K. Hristova, G. Pencheva, R. Radeva, S. Milanov, D. Petrov (Sofia, BG)
- The role of ST-segment elevation in lead aVR of ECG in patients with acute pulmonary embolism.** P709
 – T.H. Hoechtl, K.J. Janata, C.W. Wenzel, R.J. Jarai, B.F. Fellner, V.H. Havranek, A.G. Geppert, J.W. Wojta, K.H. Huber (Vienna, AT)
- Role of MDCT in detection of ventricular dysfunction and pulmonary obstruction index in patients with acute pulmonary embolism.** P710
 – D. Nassar, S. Omar, A. Ibrahim, F. Zeinoh (Cairo, EG)
- Anticoagulation after pulmonary embolism secondary to a reversible risk factor: till death do us apart?** P711
 – R. Baptista, E. Jorge, R. Teixeira, P. Mendes, S. Monteiro, F. Goncalves, P. Monteiro, G. Castro, M. Freitas, L.A. Providencia (Coimbra, PT)
- Thromboembolic right heart failure in the elderly: is age a contraindication to pulmonary endarterectomy?** P712
 – M. Morsolini, G. Silvaggio, S. Nicolardi, D. Berwick, C. Monterosso, A.M. D'Armini, M. Viganò (Pavia, IT)
- Platelet function in patients with chronic thromboembolic pulmonary hypertension.** P713
 – R. Sadushi, S. Panzer, D. Bonderman, N. Skoro-Sajer, W. Klepetko, I.M. Lang (Vienna, AT)
- Persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism is associated with chronic thromboembolic pulmonary hypertension.** P714
 – S. Vanni, G. Viviani, F. Soggi, G. Pepe, S. Magazzini, A. Petrioli, G. Polidori, S. Grifoni (Florence, IT)
- A role for PECAM-1 in venous thrombus resolution.** P715
 – B. Redwan, J. Kellermaier, M.-K. Renner, H. Panzenboeck, J. Jakowitsch, P. Petzelbauer, D. Bonderman, I.-M. Lang (Vienna, AT)
- Isobaric analysis of pulmonary arterial compliance of idiopathic and chronic thromboembolic pulmonary hypertension: correlation with right ventricular remodeling.** P716
 – J.C. Grignola, M.J. Ruiz-Cano, P. Escribano, M.A. Gomez-Sanchez, R. Tello De Meneses, J. Delgado, C. Jimenez Lopez-Guarch, C. Saenz De La Calzada (Madrid, ES)
- Exercise capacity and pulmonary artery pressure-flow relations in patients after successful pulmonary endarterectomy.** P717
 – D. Bonderman, A. Martischign, K. Vonbank, M. Nikfardjam, B. Meier, G. Heinz, R. Naejje, I.M. Lang (Vienna, AT; Brussels, BE)
- Impaired pulmonary compliance in patients with long term residual pulmonary hypertension after endarterectomy for chronic thromboembolic pulmonary hypertension.** P718
 – J.C. Grignola, M.J. Ruiz-Cano, P. Escribano, J. Cortina, T. Velazquez, M.A. Gomez-Sanchez, J. Delgado, C. Saenz De La Calzada (Madrid, ES)
- Prevalence and predictors of thromboembolic pulmonary hypertension in the long term follow-up of patients with acute pulmonary embolism.** P719
 – S. Vanni, F. Soggi, G. Viviani, F. Moroni, P. Nazerian, A. Petrioli, B. Paladini, S. Grifoni (Florence, IT)

- Effects of pulmonary thromboendarterectomy on echocardiographic parameters in patients with chronic thromboembolic pulmonary hypertension: one-year follow-up.** P720
 – T. Palecek, D. Ambroz, P. Jansa, J. Lindner, K. Taborska, M. Vitovec, P. Polacek, P. Kuchynka, M. Aschermann, A. Linhart (Prague, CZ)
- Electrocardiographic detection of pulmonary hypertension after prior pulmonary embolism.** P721
 – I.R. Henkens, U. Hoke, M.J. Schalijs, E.E. Van Der Wall, A. Boonstra, C.A. Swenne, A. Vonk Noordegraaf, H.W. Vliegen (Leiden and Amsterdam, NL)
- Sildenafil therapy for both operable and inoperable chronic thromboembolic pulmonary hypertension.** P722
 – E. Leci, M. Palazzini, A. Manes, L. Negro, A. Marinelli, S. Gambetti, E. Beciani, E. Conficoni, A. Branzi, N. Galie' (Bologna, IT)
- Assessment of early outcome and residual pulmonary hypertension after pulmonary endarterectomy by preoperative analysis of dynamic right ventricular afterload.** P723
 – J.C. Grignola, M.J. Ruiz-Cano, P. Escribano, J. Cortina, T. Velazquez, M.A. Gomez-Sanchez, J. Delgado, C. Saenz De La Calzada (Madrid, ES)
- Impact of thrombus borne active endothelin on the vasoconstrictive capacity of thrombi from patients with chronic thromboembolic pulmonary hypertension.** P724
 – C. Adlbrecht, C. Plass, B. Redwan, J. Jakowitsch, D. Bonderman, A. Panzenboeck, W. Klepetko, I.M. Lang (Vienna, AT)
- PULMONARY CIRCULATION AND RIGHT VENTRICULAR FUNCTION**
- Size of pulmonary right-to-left shunt predict migraine with aura.** P725
 – M.C. Post, M.W.F. Van Ghent, H.W.M. Plokker, C.J.J. Westermann, J.J. Mager, W.J. Schonewille, V. Thijs, R.J. Snijder (Nieuwegein, NL; Leuven, BE)
- Bosentan improves pulmonary microvascular endothelial function in adults with pulmonary arterial hypertension.** P726
 – R. Ilisar, J. Levitt, M.R. Adams, D.S. Celermajer (Sydney, AU)
- Sympathetic nervous system activation is an independent prognostic factor of clinical deterioration in pulmonary arterial hypertensive patients.** P727
 – A. Ciarka, V. Phuong, S. Huez, J.L. Vachieri, R. Naeije, P. Van De Borne (Brussels, BE)
- Arterial stiffness evaluation in patients with systemic sclerosis: an interesting correlation with right ventricular function and cardiopulmonary performance.** P728
 – P. Marchese, G. Delle Donne, A. Nuzzo, F. Franchi, F. Rollini, D. Giuggioli, C. Ferri, R. Rossi, M.G. Modena (Modena, IT)
- Increased pulmonary vascular resistance in chronic heart failure is linked to parallel stiffening of pulmonary and systemic arteries.** P729
 – V. Melenovsky, H. Al Hiti, T. Gazdic, M. Kotrc, I. Malek, J. Kettner, J. Kautzner (Prague, CZ)
- The prevalence of pulmonary hypertension in patients with untreated Graves disease.** P730
 – K.I. Cho, B.H. Kim, J.H. Suk (Pusan, KR)
- Compliance has greater influence than resistance on Cardiac Index in Pulmonary arterial hypertension.** P731
 – G. Teixido, E. Domingo, R. Aguilar, M. Lopez-Meseguer, A. Roman (Barcelona, ES)
- Relaxin is a candidate drug for lung preservation.** P732
 – K. Alexiou, K. Matschke, G. Baumann, K. Stangl, T. Dschietzig (Dresden and Berlin, DE)
- Left ventricular diastolic dysfunction as an early initiator of pulmonary hypertension relating to hypoxemia in acute mountain sickness syndrome (amss).** P733
 – J. Nakata, M. Takayama, T. Matsuzaki, I. Takagi, M. Tsurumi, M. Kawamoto, Y. Kobayashi, H. Mihara, K. Mizuno (Tokyo and Kanagawa, JP)
- Pharmacogenomic tailoring of warfarin dose in pulmonary hypertension patients: beyond inr control.** P734
 – R. Baptista, E. Jorge, J. Pego, M. Lourenco, I. Marques, P. Monteiro, G. Castro, L.A. Providencia, F. Antunes (Coimbra, PT)
- INCIDENCE OF pulmonary hypertension in Italian ulTrasonography's laboratories.** P735
 – I. Enea, S. Ghio, A. Bongarzone, F. Casazza, A.M. D'Armini, G. Favretto, L. Roncon, A. Rubboli, P. Zonzin, C. D'Agostino (Caserta, Pavia, Milan, Treviso, Rovigo, Bologna and Bari, IT)

- Impact of left ventricle diastolic function in the prognosis of pulmonary arterial hypertension.** **P736**
 – R. Placido, P. Loureiro, J. Marques, S. Martins, C. David, A. Diogo, S. Ribeiro, A. Almeida, M. Lopes (Lisbon, PT)
- Contrast echocardiography guides treatment of pulmonary right-to-left shunt.** **P737**
 – M.W.F. Van Ghent, M.C. Post, R.J. Snijder, M.J. Swaans, H.W.M. Plokker, C.J.J. Westermann, T. Overtoom, J.J. Mager (Nieuwegein, NL)
- Pulmonary artery pressure and right ventricular function in healthy children and adolescents after rapid ascent to 3450 m.** **P738**
 – S.F. Rimoldi, T. Stuber, S.F. De Marchi, H. Duplain, S. Garcin, C. Sartori, U. Scherrer, Y. Allemann (Berne and Lausanne, CH; London, GB)
- A Novel 3D echocardiographic geometrical model of the tricuspid valve for the assessment of different modalities of right ventricular remodeling.** **P739**
 – J. Grapsa, D. Pandis, D. Stefanou, D. Dawson, L.S.G.E. Howard, J.S.R. Gibbs, P.P. Punjabi, P. Nihoyannopoulos (London, GB)
- Assessment of right-ventricular size and function by real-time three-dimensional echocardiography - comparison with magnetic resonance imaging.** **P740**
 – G. Leibundgut, A. Rohner, A. Kessel, A. Bernheim, M. Zellweger, P. Buser, M. Handke (Basel, CH)
- Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension.** **P741**
 – I. Falcao-Pires, N. Goncalves, T. Henriques-Coelho, D. Moreira-Goncalves, R. Roncon-Albuquerque Jr, A.F. Leite-Moreira (Porto, PT)
- Right ventricular response to abnormal loading conditions in mice.** **P742**
 – B. Bartelds, A. Smit-Van Oosten, J. Takens, M. Nederhoff, L.J. De Windt, W.H. Van Gilst, R.M.F. Berger (Groningen and Utrecht, NL)
- Interest of tricuspid annular displacement in evaluation of right ventricular ejection fraction.** **P743**
 – T. Hugues, F. Lemoigne, D. Ducreux, F. Berthier, N. Saoudi, P. Gibelin (Monaco, MC; Nice, FR)
- Right ventricular function angiographic assessment.** **P744**
 – S. Estrada Gomez, I. Santos, J. Martin Moreiras, I. Cruz-Gonzalez, J. Rodriguez-Collado, M.J. Ruiz, M. Diego, M. Cascon, J.M. Gonzalez-Santos, C. Martin-Luengo (Salamanca, ES)
- Echocardiographic predictors of long-term survival in adults with pulmonary hypertension.** **P745**
 – R.A. Krasuski, S.A. Hart, A. Wang, J.K. Harrison, T. Bashore (Cleveland and Durham, US)
- Three-dimensional echocardiography in pulmonary arterial hypertension: echocardiographic validation of a new method for right ventricular volumes quantification.** **P746**
 – J. Silva Marques, S. Martins, A.G. Almeida, A. Nunes Diogo, S. Ribeiro, A. Feijao, C. Bastos, M.G. Lopes (Lisbon, PT)
- D-dimer indicates patients with right ventricle overload in acute pulmonary embolism.** **P747**
 – M. Kostrubiec, A. Labyk, J. Pedowska-Wloszek, S. Pacho, A. Hrynkiwicz, B. Lichodziejewska, K. Kurnicka, P. Dul, A. Wojciechowski, P. Pruszczyk (Warsaw, PL)
- Right ventricular speckle tracking in right and left heart disease. Correlation with conventional two dimensional echocardiographic indices.** **P748**
 – J. Grapsa, D. Dawson, S. Sulemane, L.S.G.E. Howard, J.S.R. Gibbs, P. Nihoyannopoulos (London, GB)
- The assessment of right ventricular function by tissue Doppler imaging in patients with end-stage idiopathic pulmonary fibrosis referred for lung transplantation.** **P749**
 – J. Nowak, W. Streb, D. Jastrzebski, P. Rozentryt, M. Kalinowski, B. Hudzik, L. Polonski, T. Kukulski (Zabrze, PL)
- Measurement of right ventricular size and function by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and M-mode measurements.** **P750**
 – L. Badano, E. Zakja, M.T. Grillo, R. Onut, D. Muraru, D. Ermacora, P. Gianfagna, P.M. Fioretti (Udine, IT)

- Right and left ventricular and atrial function assessed by Speckle Tracking in patients with arrhythmogenic right ventricular cardiomyopathy and in their relatives.** P751
 – S. Comenale Pinto, R. Ancona, P. Caso, C. Cavallaro, S. De Vivo, F. Vecchione, A. D'Onofrio, V. Di Palma, R. Calabro* (Naples, IT)
- Follow up of right ventricular remodeling in idiopathic pulmonary arterial hypertension with 3D echocardiography and cardiac MRI.** P752
 – J. Grapsa, H. Pavlopoulos, D. Dawson, P. Nihoyannopoulos (London, GB)
- Impaired preoperative right ventricular function is associated with increased postoperative intensive care unit length of stay in patients with mitral regurgitation.** P753
 – A. Chrustowicz, A. Gackowski, J. Sadowski, W. Piwowarska (Krakow, PL)
- ATRIAL FIBRILLATION: FOLLOW UP**
- A novel double balloon technique for atrial fibrillation: cryoablation of pv la junction with occlusion of ipsilateral pulmonary artery.** P754
 – K.H. Kuck, N. Coulombe, M. Dubuc, P. Guerra, F. Ouyang (Hamburg, DE; Montreal, CA)
- Cost-effectiveness model of Implantable Cardiac Monitors (ICM) for patients treated with radiofrequency catheter ablation for atrial fibrillation (PAAF).** P755
 – J.L. Merino, J.M. Rodriguez-Barrios, M. Brosa, S. Tsintzos (Madrid and Barcelona, ES; Tolochenaz, CH)
- His bundle pacing. A new option for no option patients, not suitable for or after unsuccessful AF ablation, low ejection fraction and narrow QRS.** P756
 – P. Dabrowski, E. Kozluk, P. Stefanczyk, A. Kleinrok, G. Opolski (Zamosc and Warsaw, PL)
- Right ventricular rapid pacing in cryoballoon catheter ablation of atrial fibrillation.** P757
 – K.J. Chun, A. Fuernkranz, A. Metzner, I. Koester, B. Schmidt, T. Zerm, R. Titz, F. Ouyang, K.H. Kuck (Hamburg, DE)
- Surgical versus catheter ablation of lone AF determination of acute and long term success rate. SCALAF study design.** P758
 – A. Elvan, H.T. Sie, W.P. Beukema, P.P.H.M. Delnoy, J. Minten, B. Kleijnen, A.R. Ramdat Misier (Zwolle, NL)
- Termination or persistence of atrial fibrillation during left atrial substrate modification does not correlate with long-term outcome in longstanding, Persistent atrial fibrillation.** P759
 – K. Otomo, K. Uno, Y. Nagata, H. Taniguchi, H. Fujiwara, Y. Iesaka (Hamburg, DE; Tsuchiura, JP)
- Long-term follow-up on success rate, anti-arrhythmic therapy, anticoagulation and embolism event after catheter ablation of paroxysmal atrial fibrillation.** P760
 – Y. Lin, Y. Xia, Z. Chu, D. Chang, P. Cong, S. Zhang, D. Yang, X. Yin, L. Gao, Y. Yang (Dalian, CN)
- Incidence of atrial tachycardias after cryoballoon pulmonary vein ablation in patients with paroxysmal or persistent atrial fibrillation.** P761
 – L. Koch, H. Schuett, U. Zacharzowsky, E. Safak, S. Spencker, H.-P. Schultheiss, A. Schirdewan (Berlin, DE)
- Long-term survival in patients with atrial fibrillation after pulmonary vein isolation in comparison to atrioventricular junction ablation with PM/ICD implantation and to antiarrhythmic therapy.** P762 (W)
 – K. Sonne, D. Patel, L. Riedlbauchova, L. Armaganijan, M. Ali, C.-T. Wu, L. Di-Biase, A. Natale (Bad Berka, DE; Austin and Cleveland, US; Prague, CZ)
- Clinical results of vagal denervation guided by evoked vagal reflex to treat atrial fibrillation.** P763
 – C.F. Pisani, S. Lara, D. Hachul, F. Darrieux, E. Sosa, M. Scanavacca (Sao Paulo, BR)
- First clinical application of three-dimensional rotational angiography for cryoablation of paroxysmal atrial fibrillation: A safety and feasibility study.** P764
 – S. Kircher, G. Hindricks, T. Gaspar, C. Eitel, A. Bollmann, D. Husser, U. Wetzel, P. Sommer, A. Arya, C. Piorkowski (Leipzig, DE)
- First experience in long-term follow-up of patients with atrial fibrillation after pulmonary vein isolation with the high density mesh ablator.** P765
 – P. Maagh, M.V.B. Van Bracht, R.B. Borchard, M.C. Christ, G.P. Plehn, T.B. Butz, H.J.T. Trappe, A.M. Meissner (Herne, DE)

- Significantly improved left ventricular ejection fraction after ablation of atrial fibrillation in patients with heart failure and impaired LV function.** **P766**
 – P. Sommer, C. Piorkowski, A. Arya, A. Bollmann, U. Wetzel, H. Kottkamp, G. Hindricks (Leipzig, DE; Zurich, CH)
- Device safety with the use of remote magnetic navigation.** **P767**
 – S. Johar, D.G. Jones, J.C. Lyne, R.A. Kaba, T. Wong, V. Markides, J.R. Clague, J.A. Till, S. Ernst (London, GB)
- Feasibility of real time magnetic resonance imaging in interventional electrophysiology using a novel carbon catheter.** **P768**
 – P. Nordbeck, W.R. Bauer, F. Fidler, M. Warmuth, K.H. Hiller, M. Nahrendorf, J. Broscheit, P.M. Jakob, O. Ritter (Wurzburg, DE; Boston, US)
- P-wave modifications after wide area circumferential ablation of atrial fibrillation.** **P769**
 – S.S. Bun, D.G. Latcu, P. Ricard, T. Hugues, N. Zarqane, K. Yaici, J.P. Rinaldi, N. Saoudi (Monaco, MC)
- Ablation of perimitral flutter following catheter ablation of atrial fibrillation: impact on outcomes from a randomized study.** **P770**
 – L. Di Biase, J.D. Burkhardt, R. Horton, J. Sanchez, P. Mohanty, S. Bailey, D. Patel, R. Hongo, S. Baheiry, A. Natale (Austin and San Francisco, US)
- Can concomitant beta-blocker treatment increase Amiodarone effectiveness in maintaining sinus rhythm in patients with persistent atrial fibrillation?** **P771**
 – M. Mezzetti, M. Marconi, G. Piovaccari (Rimini, IT)
- Mid-term results of minimally invasive surgical treatment of lone atrial fibrillation.** **P772**
 – P. Piccoli, A. Repossini, A. Curnis, A. Negri, A. Moggi, A. Manzato, C. Muneretto (Brescia, IT)
- First episode of auricular fibrillation during acute coronary syndrome identifies patients at risk of thromboembolism. Implications for treatment at discharge.** **P773**
 – L. Nombela Franco, A. Garcia-Touchard, C. Gutierrez-Landaluce, J.M. Escudier, J.A. Fernandez-Diaz, L. Silva-Melchor, I. Fernandez-Lozano, J. Goicolea Ruigomez, F.J. Ortigosa Aso, L. Alonso-Pulpon (Madrid, ES)
- Prevalence and prognostic value of atrial fibrillation in patients with stroke.** **P774**
 – H. Ribeiro, R. Margato, S. Carvalho, C. Ferreira, J. Gabriel, A. Velon, P. Guimaraes, A. Ferreira, P. Mateus, I. Moreira (Vila Real, PT)
- ARRHYTHMIAS IN CHILDREN**
- Low incidence of sudden infant death syndrome but high incidence of Non-autopsied cases.** **P775**
 – B.G. Winkel, A.G. Holst, J. Theilade, J.H. Svendsen, S. Haunsoe, J. Tfelt-Hansen (Copenhagen, DK)
- Multi-center study of the effectiveness of ICDs in children and young adults with heart disease.** **P776**
 – N. Von Bergen, D.L. Atkins, M. Dick, D.J. Bradley, S.P. Etheridge, E.V. Saarell, P.S. Fischbach, S. Balaji, N. Sreeram, I.H. Law (Iowa City, Salt Lake City, Atlanta, Portland and Las Vegas, US; Cologne, DE)
- Dyssynchrony and left ventricular strain in pediatric patients paced at right ventricular outflow versus apical septum.** **P777**
 – R. Juneja, S. Ramakrishnan, C. Vyas, N. Naik, S.S. Kothari, A. Saxena, V.K. Bahl (New Delhi, IN)
- Cardiac synchrony and function with chronic single-site left versus right ventricular epicardial pacing in paediatric patients after patch closure of ventricular septal defects.** **P778**
 – M. Tomaske, O.A. Breithardt, U. Bauersfeld (Zurich, CH; Coburg, DE)
- Catheter ablations in children with ventricular tachycardia.** **P779**
 – E. Pokushalov, A. Romanov, S. Artemenko, P. Shugaev, A. Turov, N. Shirokova (Novosibirsk, RU)
- Specific features of the heart electric field in children with Long QT Syndrome by body surface potential mapping.** **P780**
 – M. Shkolnikova, I. Polyakova, L. Kalinin (Moscow, RU)

- Prevalence of interatrial block in healthy school-aged children: definition by P wave duration or morphological analysis.** P781
 – P.E. Dilaveris, L. Raftopoulos, G. Giannopoulos, S. Katinakis, D. Maragiannis, D. Roussos, K. Gatzoulis, A. Michaelides, C.H. Stefanadis (Athens, GR)
- Asymptomatic ventricular preexcitation in children.** P782
 – G. Fazio, L. D'Angelo, G. Novo, S. Novo (Palermo, IT)
- The utility of the implantable loop recorder in a national paediatric cardiology centre.** P783
 – B. Hynes, A. Babikar, K. Walsh, N. Ward, P. Oslizok, D. Keane (Dublin, IE)
- Compound heterozygous SCN5A mutations in an asymptomatic child: a case report in the Brugada syndrome cohort of the San Raffaele hospital.** P784
 – E. Sommariva, M. Vatta, K. Samani, S. Sala, T. Ai, F.M. Sacco, V. Santinelli, C. Pappone, M. Ferrari, S. Benedetti (Milan, IT; Houston, US)
- Regional differences in bipolar voltages during post-operative atrial tachyarrhythmias in patients with congenital heart disease: clinical implications.** P785
 – N.M.S. De Groot, N.A. Blom, W.K. Chan, M. Bartelings, M.J. Schalij (Leiden, NL)
- Recurrent syncope caused by asystole provoked by vasovagal reaction during venipuncture in children.** P786
 – M. Shkolnikova, E. Polyakova, S. Termosov, V. Berezniatskaya, E. Bortsova, R. Garipov, I. Ilich (Moscow, RU)
- ANTIBRADYCARDIA DEVICES**
- Efficacy of CPAP therapy in patients with obstructive sleep apnoea syndrome and nocturnal asystoles.** P787
 – N. Kurlykina (Moscow, RU)
- Comparison of the efficiency and safety of the implantation of definitive pacemaker and ICD through dissection of cephalic vein vs puncture of subclavian vein.** P788
 – T. Ripoll Vera, X. Fosch Mur, L. Socias Crespi, A. Garcia Sanchez, M. Borges Sa, J.M. Gamez Martinez, J. Torres Marques, D. Cremer Luengos, E. Moranta Ribas, J. Serra Creus (Palma De Mallorca, ES)
- Antiarrhythmia device implantation is safe under dual antiplatelet therapy.** P789
 – H. Dreger, A. Grohmann, H. Bondke, G. Baumann, C. Melzer (Berlin, DE)
- Low device implant rates in the UK: 24 hours of monitoring is just not long enough.** P790
 – M. Kalla, V. Brooks, G.R. Ellis, R.A. Bleasdale (Cardiff, GB)
- Can knowledge of coronary angiography followed by coronary revascularisation change the indication and the need for pacemaker implantation?** P791
 – D. Herman, P. Osmancik, P. Stros, L. Pavkova, T. Budesinsky, J. Dvorak, V. Kocka, L. Lisa, P. Widimsky (Prague, CZ)
- Atrial pacing with or without antiarrhythmic drug therapy for the prevention of atrial fibrillation in sick sinus syndrome.** P792
 – P. Flevvari, D. Leftheriotis, D. Katsaras, S. Lagou, V. Souridis, D. Kremastinos (Athens, GR)
- Mode of death in patients with pacemaker and implantable cardioverter defibrillator.** P793
 – M. Sepsi, M. Sindler, K. Muckova, L. Krivan, M. Kozak, J. Vlasinova (Brno, CZ)
- Definitive pacemaker implantation after cardiac surgery.** P794
 – S. Iacopino, G. Fabiano, P. Sorrenti, A. Talerico, G. Campagna, G. Colangelo, R. Alemanni, G. Martinelli, M. Cassese (Catanzaro, IT)
- Direct His Bundle pacing preserves the mechanical atrial function compared to right ventricular apical pacing: a mid-term cross-over study.** P795
 – F. Zanon, S. Aggio, G. Pastore, E. Baracca, L. Conte, C. Piergentili, G. Rigatelli, G. Braggion, D. Cavazzini, L. Roncon (Rovigo and Adria, IT)
- Prospective and randomized comparison of skin adhesive and absorbable intracutaneous suture for the implantation of cardiac rhythm devices.** P796 (W)
 – S. Spencker, N. Coban, L. Koch, A. Schirdewan, D. Mueller (Berlin, DE)
- Far-field-R-wave sensing avoidance through the use of a lead with very short tip-to-ring spacing.** P797
 – C. Kolb, G. Noelker, U. Lotze, H. Jetter, K. Puerner, K. Lang, L. Binner, V. Schibgilla (Munich, Coburg, Naumburg, Memmingen, Ebersberg, Ottweiler, Ulm and Ebermannstadt, DE)

- Prevalence and outcome of bacterial endocarditis.** **P798**
 – S.H. Zaky, A.W. Andraos, K.H. Hussein, S.H. Omar, G. Hamed, D. Ragab, A. Alazab (Cairo, EG)
- The feasibility of day-case electrophysiology procedures.** **P799**
 – J.P. Boullin, A. Rajwani, C. Campbell-Cole, N. Gall, F. Murgatroyd (London, GB)
- Atrial pacing improves atrial mechanical function only in patient with sinus nodes disease with paroxysmal atrial fibrillation existing atrial dyssynchrony.** **P800**
 – M. Wang, C.P. Lau, K. Lee, X.H. Zhang, C.H.W. Siu, H.F. Tse (Hong Kong, HK)
- Which is the optimal site for atrial lead implantation in myotonic dystrophy patients? A two years follow-up study.** **P801**
 – G. Nigro, V. Russo, A. De Chiara, A. Rago, G. Arena, L. Politano, P. Golino, R. Calabro' (Naples, IT)
- The role of pacemaker in hypersensitive carotid sinus syndrome.** **P802**
 – R. Lopes, A. Goncalves, J. Campos, C. Frutuoso, A. Gouveia, C. Touguinha, J. Freitas, M.J. Maciel (Porto, PT)
- Ventricular Arrhythmias in Pacemaker Population: VAPP study.** **P803**
 – M. Guenoun, M. Hero (Marseille and Boulogne-Billancourt, FR)
- Good correlation between LV dyssynchrony and ECG (QRS duration & axis) guides the selection of the optimal RV pacing sites in patients with permanent pacemaker indication.** **P804**
 – H. Alhous, A. Hannah, G.R. Small, G.S. Hillis, P. Broadhurst (Aberdeen, GB; Sydney, AU)
- Efficiency of an anticoagulation algorithm in patients undergoing intracardiac device implants.** **P805**
 – B. Thibault, H. Chakor, L. Vaillancourt, M. Robitaille, M. Dubuc, P. Khairy, L. Macle, D. Roy, M. Talajic, P. Guerra (Montreal, CA)
- Vagal stimulation by transvenous permanent lead implantation to modulate av node function: safety and feasibility in humans.** **P806**
 – S. Bianchi, P. Rossi, A. Della Scala, P. Schauerte, P. Azzolini (Rome and Viterbo, IT; Aachen, DE)
- Chronic intracardiac neurostimulation in atrial fibrillation.** **P807**
 – K. Mischke, M. Zarse, C. Gemein, N. Hatam, M. Schmid, O. Rana, E. Saygili, C. Knackstedt, M. Kelm, P. Schauerte (Aachen, DE)
- Atrial-based dual chamber pacing improve atrial mechanical function immediately in sinus nodes disease with or with paroxysmal atrial fibrillation.** **P808**
 – M. Wang, C.P. Lau, K. Lee, D. Siu, X.H. Zhang, H.F. Tse (Hong Kong, HK)
- Magnetic resonance imaging of pacemakers and implantable cardioverter-defibrillators without specific absorption rate restriction.** **P809**
 – M. Mollerus, G. Albin, M. Lipinski, J. Lucca (Duluth, US)

NEUROENDOCRINE MECHANISMS IN HEART FAILURE

- Renal specific designer natriuretic peptide with GFR enhancing but no hypotensive properties.** **P810**
 – H. Chen, A. Cataliotti, J. Schirger, F. Martin, J. Burnett (Rochester Mn, US)
- Prognostic values of big endothelin and NT-proBNP in predicting of mortality in patients with heart failure.** **P811**
 – J. Zhang, K.M. Goode, J.G.F. Cleland, F. Fruhwald, A. Fahrleitner-Pammer, A.L. Clark, A. Rigby (Hull, GB; Graz, AT)
- Interleukin-1beta induces myocardial systolic dysfunction in the mouse through a PI3K-gamma dependent pathway.** **P812**
 – B.W. Van Tassell, I.M. Seropian, J.L. Harrington, A.C. Menna, A.W. Scharf, A. Varma, R. Robati, F.N. Salloum, A. Abbate (Richmond, US)
- Post-operative B-type natriuretic peptide predicts mortality after gastrointestinal surgery.** **P813**
 – T. Cahill, P. Bowes, E. Duncan, E. Drye, S. Sen, S. Reshamwalla, C. Andrew, M. Ward, A. Bakhai (London, GB)

- Combination of plasma cardiac troponin I and NT-proBNP for predicting mortality in patients with chronic heart failure.** P814
 – T. Tsutamoto, C. Kawahara, K. Nishiyama, T. Yamaji, T. Yamamoto, M. Fujii, M. Horie (Otsu, JP)
- Differential cardiac autonomic modulation in different variants of Takotsubo cardiomyopathy.** P815
 – H. Bonnemeier, J. Ortak, C. Burgdorf, B. Weidtmann, M. Reppel (Lubeck, DE)
- Adjusting for clinical covariates improves the ability of BNP to distinguish cardiac from non-cardiac dyspnea.** P816
 – A.D. Michaels, R. Rogers, G. Stoddard, T. Green, S.P. Collins, W.F. Peacock, P. Clopton, A.D. Maisel, R. Nowak, J. Stehlik (Salt Lake City, Cincinnati, Cleveland, San Diego and Detroit, US)
- Usefulness of Apelin measurement in identification of subclinical LV dysfunction in essential hypertension.** P817
 – W. Kosmala, T. Kotwica, M. Przewlocka-Kosmala, W. Mazurek (Wroclaw, PL)
- Angiotensin 1-7 acute myocardial effects and their modulation by the endocardial endothelium.** P818
 – P.M. Castro-Chaves, M. Pintalhao, R. Fontes-Carvalho, R. Cerqueira, A.F. Leite-Moreira (Porto, PT)
- Restoration of adrenal GRK2-mediated catecholamine production is an underlying mechanism for reduction of sympathetic activation by exercise training in heart failure.** P819
 – G. Rengo, A. Lympieropoulos, C. Zincarelli, M. Marchese, A. Rengo, E. Avallone, A. Filippelli, N. Ferrara, W.J. Koch, D. Leosco (Telese Terme, Naples and Campobasso, IT; Philadelphia, US)
- The arterial vasodilator action of apelin is abolished in heart failure.** P820
 – J.R. Dalzell, J.P. Rocchiccioli, N. Padmanabhan, R.C. Myles, C.E. Jackson, A. Rankin, M. Dunne, G.L. Smith, M.C. Petrie, J.J.V. McMurray (Glasgow, GB)
- A potential pathophysiological role for serum soluble ST2 in post-infarction ventricular and infarct remodelling.** P821
 – R.A.P. Weir, A.M. Miller, S. Clements, T. Steedman, J.M.C. Connell, I.B. Macinnes, H.J. Dargie, J.J.V. McMurray (Glasgow, GB)
- Plasma aldosterone as predictor of myocardial fibrosis in paucisymptomatic patients with nonischemic cardiomyopathy patients.** P822
 – P.G. Masci, A. Barison, G. Vergaro, G.D. Aquaro, M. Fontana, M. Lombardi, C. Passino, M. Emdin (Pisa, IT)
- Sex differences in novel cardiovascular biomarkers and implications for diagnosis of acute heart failure.** P823
 – L.B. Daniels, S. Cammarata, P. Clopton, S.D. Anker, R. Christenson, C. Muller, R. Nowak, W.F. Peacock, A. Wu, A.S. Maisel (San Diego, Baltimore, Detroit, Cleveland and San Francisco, US; Berlin, DE; Basel, CH)
- The chromogranins A and B are regulated differently in the myocardium and circulation during heart failure development; complimentary cardiac biomarkers?** P824
 – H. Rosjo, C. Husberg, M.B. Dahl, M. Stridsberg, I. Sjaastad, A.V. Finsen, C.R. Carlson, E. Oie, T. Omland, G. Christensen (Lorenskog and Oslo, NO; Uppsala, SE)
- The utility of cardiac biomarkers in early detection of cardiotoxicity anthracycline-induced.** P825
 – C. Mandric, A.G. Dimitriu, I. Miron, I. Dumitriu, B. Gurzu, M. Mihaila, A. Covic (Iasi, RO)
- Predictive value of serum aldosterone levels on long term clinical outcomes in Japanese patients.** P826
 – K. Inoue, N. Makita, K. Matsuo, Y. Shiono, A. Matsuo, H. Fujita, M. Kitamura (Kyoto, JP)
- N-terminal fragment of proBNP is a marker of risk for right ventricular dysfunction and cardiac complications in thalassemia major.** P827
 – A. Pepe, L. Zyw, A. Meloni, C. Passino, A. Agazio, V. Positano, F. Fabrizio, M.A. Romeo, M. Lombardi, M. Emdin (Pisa and Catania, IT)
- Sequential measurements of emerging neurohormones in chronic heart failure.** P828
 – S. Neuhold, M. Huelsmann, G. Strunk, J. Struck, C. Adlbrecht, M. Elhenicky, R. Pacher (Vienna, AT; Hennigsdorf, DE)

- Reliability of NT-pro BNP kinetics and left ventricular inotropic reserve at beta adrenergic stimulation in assessing prognosis in dilated cardiomyopathy.** **P829**
 – F. Parthenakis, A.P. Patrianakos, E.A. Zacharis, E. Nyktari, D. Arfanakis, D. Hatziliadou, I. Saloustros, C. Goudis, P.E. Vardas (Heraklion, GR)

MISCELLANEOUS

- The relationship between the long pentraxin 3 and B-type natriuretic peptide in patients admitted with acute coronary syndromes.** **P830**
 – T. Brugger-Andersen, V. Ponitz, F. Kontrny, H. Staines, H. Grundt, K. Miyamoto, C. Miyazawa, T. Matsuura, M. Sagara, D.W.T. Nilsen (Stavanger and Oslo, NO; Balmullo, GB; Tokyo, JP)

- The effect of cardiac resynchronisation therapy on plasma apelin.** **P831**
 – B. Chandrasekaran, R. Sharma, J. Donovan, J. Stirrup, K. Wechalekar, J. Hooper, S.R. Underwood, M.R. Cowie, T. McDonagh (London, GB)

- The preserved autonomic functions can avoid the development of heart failure symptoms in patients with left ventricular systolic dysfunction.** **P832**
 – S.A. Kocaman, G. Tacoy, M. Ozdemir, S.K. Acikgoz, A. Cengel (Ankara, TR)

- Benefits of catheter ablation of atrial flutter in patients with heart failure and structural heart disease.** **P833**
 – K.L. Leow, S.H. Ewe, L.W. Khin, K.L. Ho, Z.P. Ding, S.C. Chuah, B. Kwok, P.P. Goh, G. Leong, L.F. Hsu (Singapore, SG)

- Impact of a heart failure management program on hospital readmission and functional status of patients with advanced heart failure.** **P834**
 – A. Khan, S.S. Kassim, M. O'Sullivan, K. Daly, J. Crowley (Galway, IE)

- Functional mitral regurgitation is a main determinant of adverse outcome in patients with heart failure due to non-ischemic dilated cardiomyopathy.** **P835**
 – C. Bergamini, A. Rossi, M. Ciccoira, M. Toniolo, L. Zanolla, C. Vassanelli (Verona, IT)

- Secondary hyperparathyroidism and disturbances of calcium and phosphorus metabolism are associated with decreased cardiac and renal function and poor prognosis in chronic heart failure.** **P836**
 – E.V. Reznik, G.E. Gendlin, G.I. Storozhakov, V.M. Guschina, V.M. Volinkina, I.I. Baranich, M.E. Tursheva, A.V. Melekhov (Moscow, RU)

- Urocortin-2 induced decrease in myocardial stiffness - contribution of PKA and PKC.** **P837**
 – C. Bras-Silva, M. Almeida, A.P. Fontes-Sousa, A.F. Leite-Moreira (Porto, PT)

- Utility of end-diastolic strain rate for evaluation of end diastolic pressure.** **P838**
 – T. Ishizu, Y. Seo, T. Machino, M. Yamamoto, R. Kawamura, R. Kawano, K. Aonuma (Tsukuba, JP)

- Device monitoring of heart failure.** **P839**
 – J. Porterfield, L.M. Porterfield, S.L. Beau, R. Corbisiero, G.S. Greer, C. Love, F. Garcia, R. Kawasaki (Memphis, Little Rock, Browns Mills, Columbus, Philadelphia and Lombard, US)

- Prevalence and implications of donor-transmitted coronary allograft vasculopathy on outcomes of heart transplant recipients.** **P840**
 – R. Estevez Loureiro, M.G. Crespo-Leiro, R.A. Calvino-Santos, M.J. Paniagua-Martin, J.M. Vazquez-Rodriguez, J. Salgado-Fernandez, N. Vazquez-Gonzalez, J.A. Rodriguez-Fernandez, J.J. Cuenca-Castillo, A. Castro-Beiras (A Coruna, ES)

- Corticoids withdrawal one year after heart transplantation. Experience in 265 patients.** **P841**
 – T. Garcia-Camarero, M.F. Llano Cardenal, L. Fernandez-Friera, M. Cobo Belaustegui, A. Canteli Alvarez, C. Castrillo Bustamante, V. Exposito Garcia, F. Gonzalez Vilchez, J.A. Vazquez-Fernandez (Santander, ES)

- Heart failure-induced skeletal myopathy is associated with mitochondrial dysfunction.** **P842**
 – A. Schreppler, M. Schwarzer, P. Amorim, F.W. Mohr, T. Doenst (Leipzig, DE)

- Extracellular matrix in Tako-Tsubo cardiomyopathy: a potential cause for structural defects and myocardial dysfunction.** **P843**
 – H.M. Nef, H. Moellmann, C.B. Behrens, S. Voss, C. Troidl, S. Kostin, P. Hilpert, M. Weber, C.W. Hamm, A. Elsaesser (Bad Nauheim and Oldenburg, DE)

- Echocardiographic predictors of mortality change with aging in patients with chronic heart failure due to reduced systolic function.** **P844**
 – G. Bajraktari, P. Fontanive, S. Elezi, V. Berisha, A.M. Naples, F.L. Dini (Prishtina, UN; Pisa, IT)
- The effect of transient changes in laboratory parameters on distant mortality of patients hospitalized for heart failure.** **P845**
 – K. Kaminski, K.M. Goode, J. Zhang, A.L. Clark, J.G.F. Cleland (Bialystok, PL; Hull, GB)
- Lack of association between albuminuria and outcome in patients with heart failure.** **P846**
 – K. Damman, T. Jaarsma, A.A. Voors, G. Navis, H.L. Hillege, D.J. Van Veldhuisen (Groningen, NL)
- Mortality predictors in patients with dilated cardiomyopathy in the current era: relevance of Chagas disease.** **P847**
 – M.C. Pereira Nunes, M.M. Barbosa, A.L.P. Ribeiro, L.M.A. Fenelon, M.M.P. Filho, L.C. Calazans, M.O.C. Rocha (Belo Horizonte, BR)
- Medical therapy fails to restore optimal functional capacity in heart failure patients with atrial fibrillation.** **P848**
 – E. Cronin, M. Carey, A. Headon, S. Fall, V. Maher (Dublin, IE)
- Left ventricular assist devices improve autonomic imbalance in patients with severe heart failure.** **P849**
 – A. Gardiwal, H. Oswald, T. Koenig, U. Luesebrink, G. Klein (Hannover, DE)
- SURGERY**
- Myocardial assistance by cell therapy associated with collagen.** **P850**
 – J.C. Trainini, J.C. Chachques, N. Lago, J. Herreros, J. Bordone, J.L. Barisani, J. Mouras, A. Christen, M. Redruello, O. Masoli (Buenos Aires, AR)
- NT-pro-BNP is an important predictor of major morbidity following surgical ventricular restoration.** **P851**
 – A. Ballotta, A. Kunkl, H. El Baghdady, F. Bettini, M. Ranucci, M. Di Donato, E. Bossone, L. Menicanti, S. Castelveccchio, R.H. Metha (San Donato Milanese and Salerno, IT; Durham, US)
- Mid- term reverse remodelling of left ventricular geometry after left ventricular reconstruction - MRI study.** **P852**
 – C. Alexandrescu, F. Civaia, L. Iacuzio, F. Montiglio, V. Dor (Monte- Carlo, MC)
- Levosimendan pre-treatment in critically ill patients undergoing cardiac surgery is associated with better post-operative outcome.** **P853**
 – P. Cattaneo, M. Baravelli, A. Rossi, M. Romano, D. Imperiale, C. Anza' (Castellanza, IT)
- Ischemia-associated changes in the atrial and ventricular myocardium during coronary artery bypass grafting with the use of cardiopulmonary bypass.** **P854**
 – W.T. Ruirok, B.D. Westenbrink, R.A. De Boer, I.J. Den Hamer, M.E. Erasmus, H.E. Mungroop, A.H. Epema, A.A. Voors, D.J. Van Veldhuisen, W.H. Van Gilst (Groningen, NL)
- Enlarged heart size and postoperative heart functioning are associated with intraoperative microembolic load in cardiac surgery patients.** **P855**
 – E.Z. Golukhova, L.A. Bockeria, A.G. Polunina, N.P. Lefterova, K.V. Shumkov, S.V. Zhuravleva (Moscow, RU)
- Alternate listing transplantation is a cost-effective treatment for end-stage heart failure patients.** **P856**
 – M. Russo, K. Hong, J. Chen, M. Argenziano, R. Davies, D. Ascheim, A. Moskowitz, A. Gelijns, M. Oz, Y. Naka (New York, US)
- LV reverse remodelling in patients with idiopathic dilated cardiomyopathy undergoing restrictive mitral annuloplasty with and without cardiac support device.** **P857**
 – A. Ciarka, J. Braun, V. Delgado, E.E. Van Der Wall, M.J. Schalij, R. Klautz, J.J. Bax, N. Van De Veire (Leiden, NL)
- Institutional experience with bridge-to-transplant recipients predicts post-transplantation outcomes.** **P858**
 – M. Russo, K. Hong, J. Chen, E. Rose, Y. Naka, A. Gelijns (New York, US)

- Poor quality of life reflects impaired diastolic function in chronic heart failure patients.** **P859**
 – C. Chrysohoou, G. Metallinos, S. Athanasopoulou, C. Kastorini, S. Brili, J. Barbetseas, A. Aggelis, C. Pitsavos, C. Stefanadis (Athens, GR)
- Clinical outcome of cardiac contractility modulation in patients with drug-refractory chronic heart failure.** **P860**
 – C. Schukro, M. Wolzt, G. Stix, T. Pezawas, J. Kastner, H. Schmidinger (Vienna, AT)
- Ultrafiltration reduces the hospitalization rate of inotrope-depended end-stage heart failure patients.** **P861**
 – E. Repasos, J. Terrovitis, E. Grapsa, E. Kaldara, F. Katsaros, L. Katsaros, N. Diakos, E. Tselioui, I. Pozios, J. Nanas (Athens, GR)

OUTCOME IN HYPERTENSION

- Evaluation of arterial blood pressure and cardiovascular structure and function in women with previous preeclampsia.** **P862**
 – M. Salvetti, F. Prefumo, A. Paini, G. Gatti, E. Belotti, C. Agabiti Rosei, C. Aggiusti, E. Agabiti Rosei, T. Frusca, M.L. Muiesan (Brescia, IT)
- Impact of stroke volume on cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy. A LIFE substudy.** **P863**
 – M.T. Lonnebakken, E. Gerds, K. Boman, K. Wachtell, B. Dahlof, R.B. Devereux (Bergen, NO; Umeaa and Gothenburg, SE; Copenhagen, DK; New York, US)
- Plasma concentration of soluble TNF receptors type I and 2 and left ventricular mass in essential hypertension.** **P864**
 – M. Rivera Otero, E. Rosello-Lleti, J.R. Gonzalez Juanatey, P. Morillas, T. Lozano, P. Orosa, L. Martinez Dolz, A. Jordan, M. Portoles, V. Bertomeu (Valencia, Santiago de Compostela, Alicante, Villajoyosa and Gandia, ES)
- Isolated systolic hypertension in patients with asymptomatic aortic stenosis (A SEAS substudy).** **P865**
 – A.E. Rieck, D. Cramariuc, E.M. Staal, B.P. Lund, E. Gerds (Bergen and Stavanger, NO)
- Association of pulse pressure with new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.** **P866**
 – I. Ariansen, A.C. Larstorp, K. Wachtell, M. Hecht Olsen, H. Ibsen, R.B. Devereux, P.M. Okin, S.E. Kjeldsen, B. Dahlof (Oslo, NO; Copenhagen, Copenhagen and Holbaek, DK; New York, US; Gothenburg, SE)
- Beta thalassaemia minor and cardiovascular risk in hypertensives.** **P867**
 – G. Vyssoulis, E. Karpanou, S.-M. Kyvelou, V. Tzamou, D. Adamopoulos, G. Theodosiadis, A. Triantafyllou, D. Cokkinos, C. Stefanadis (Athens, GR)
- Diagnostic value of 99mTc-tetrofosmin myocardial perfusion SPECT in hypertensives with ischemic-like ST segment changes.** **P868**
 – A. Kisko, M. Vereb, J. Kmec, J. Cencarik, P. Gazdic, R. Spratek (Presov, SK)
- Enhanced prognostic significance of chronic kidney disease estimated according to creatinine clearance formula for major cardiovascular events in hypertension: a Greek 6-year follow-up study.** **P869**
 – D. Tsiachris, C. Tsioufis, E. Vezali, K. Dimitriadis, A. Agelis, D. Roussos, D. Syrseloudis, E. Andrikou, I. Kalikazaros, C. Stefanadis (Athens, GR)
- Left ventricular mass regression and remodeling assessed by echocardiography after percutaneous transluminal renal angioplasty with brachytherapy of renal arteries guided by intravascular ultrasound.** **P870**
 – T. Niklewski, A. Lekston, K. Wilczek, M. Gasior, T. Zebik, M. Zebala, L. Polonski (Zabrze, PL)
- Evolution of stroke and cardiovascular mortality risk in a hypertensive population in Belgium: results of one year follow-up in the Belgica Stroke study.** **P871**
 – P. Van Der Niepen (Brussels, BE)
- Does pulsatile component of blood pressure explain CV risk associated with age?** **P872**
 – P. Jankowski, D. Czarnicka, K. Styczkiewicz, M. Brzozowska-Kiszka, M. Kloch-Badelek, J. Wilinski, L. Bryniarski, D. Debicka-Dabrowska, D. Dudek, K. Kawecka-Jaszcz (Krakow, PL)

- Effect of aortic pulse and fractional pulse pressures on early patency of saphenous vein grafts.** P873
 – S. Cayli, G. Cagirci, Y. Balbay, R. Atak, O. Maden, S. Aydogdu (Ankara, TR)
- Evolution of cerebrovascular risk, blood pressure and lipid parameters in hypertensive coronary patients in the prospective BELGICA-STROKE study.** P874
 – P. Van De Borne (Brussels, BE)
- Arterial compliance vs arterial distensibility as a determinant of outcome.** P875
 – B.A. Haluska, L. Jeffriess, S.G. Carlier, T.H. Marwick (Brisbane, AU)
- Arterial load and ventricular-arterial coupling: Assessment of physiologic relations with body size and effect of obesity.** P876 (W)
 – J. Chirinos Medina, E. Rietzschel, M. De Buyzere, D. De Bacquer, T. Gillebert, P. Segers (Philadelphia, US; Ghent, BE)
- Functional characterization of the coronary microcirculation by myocardial contrast echocardiography in arterial hypertensive heart disease.** P877
 – J. Coucello, L. Soares, J. Azevedo, L.C. Bronze Carvalho, A. Aleixo (Lisbon and Portimao, PT)
- Cardiovascular risk in treated hypertensive patients and circadian blood pressure variation.** P878
 – T.H. Gialernios, A. Triantafyllou, K. Gialernios, S. Kougialis, M. Lambropoulou, H. Skopelitis, E. Logothetis, E. Kouskouni, A. Polydorou (Athens, GR)
- Left ventricular diastolic dysfunction reflects reduced exercise tolerance in newly diagnosed essential hypertensives.** P879
 – D. Chatzis, C. Tsioufis, D. Tsiachris, C. Thomopoulos, E. Stefanadi, D. Syrseloudis, C. Papastasinou, A. Michaelides, C. Stefanadis (Athens, GR)
- High intraluminal pressure reduces angiotensin II-induced tachyphylaxis in arterioles by increasing the functional availability of AT1 receptors.** P880
 – A. Koller, Z.S. Bagi (Pecs, HU; Valhalla, US)

**YOUNG INVESTIGATORS' AWARDS SESSION
POPULATION SCIENCES**

Abstracts

Chairperson(s): M.J. Salvador Taboada (Barcelona, ES); E.E. Van der Wall (Leiden, NL)

Judges.

– S. Carerj (Messina, IT), M.J. Salvador Taboada (Barcelona, ES), H. Saner (Berne, CH), E.E. Van der Wall (Leiden, NL), H.J. Wellens (Maastricht, NL)

- | | | |
|-------|--|------------|
| | | 881 |
| | Judges. | |
| | – S. Carerj (Messina, IT), M.J. Salvador Taboada (Barcelona, ES), H. Saner (Berne, CH), E.E. Van der Wall (Leiden, NL), H.J. Wellens (Maastricht, NL) | |
| 12:40 | The NSAID diclofenac increases cardiovascular risk among young and healthy individuals after short treatment duration: a nationwide study. | 882 |
| | – E. Fosbol, G.H. Gislason, L. Kober, C. Torp-Pedersen (Copenhagen, DK) | |
| 12:55 | Usefulness of triglycerides-to-HDL ratio to predict the first coronary event in active male workers: a case-control study. | 883 |
| | – A. Cordero, E. Andres, B. Ordonez, M. Leon, E. Alegria, E. Luengo, I. Pascual, F. Civeira, M. Pocovi, J.A. Casasnovas (Alicante and Pamplona, ES) | |
| 13:10 | Ten-year risk of cancer mortality according to lipid levels and use of lipid-lowering drugs in the French general population. | 884 |
| | – E. Berard, V. Bongard, P. Amouyel, D. Arveiler, J. Dallongeville, A. Wagner, D. Cottel, B. Haas, J.B. Ruidavets, J. Ferrieres (Toulouse, Lille and Strasbourg, FR) | |
| 13:25 | Italian smoking regulation decreased hospital admissions for acute coronary events: effect modification by age and day of the week. | 885 |
| | – F. Barone Adesi, L. Vizzini, F. Merletti, L. Richiardi (Turin, IT) | |

**YOUNG INVESTIGATORS' AWARDS SESSION
CLINICAL SCIENCE**

Abstracts

Chairperson(s): D.V. Cokkinos (Athens, GR); P.M. Fioretti (Udine, IT)

- | | | |
|-------|--|------------|
| | Judges. | 886 |
| | – D.V. Cokkinos (Athens, GR), P.M. Fioretti (Udine, IT), A.D. Kugelmass (Detroit, US), A.N. Neskovic (Belgrade, RS), Z. Reiner (Zagreb, HR) | |
| 12:40 | Long-term outcome of a randomized trial of prophylactic coronary revascularisation in cardiac high-risk patients undergoing major vascular surgery. | 887 |
| | – O. Schouten, J.P. Van Kuijk, W.J. Flu, H. Boersma, T.A. Winkel, S.E. Hoeks, H.J.M. Verhagen, Y.R.B.M. Van Gestel, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL) | |
| 12:55 | A variant at chromosome 9p21 is associated with recurrent myocardial infarction after acute coronary syndrome: the GRACE genetics study. | 888 |
| | – I. Buyschaert, K. Carruthers, D. Dunbar, E. Rietzschel, A. Belmans, T. De Meyer, A. Budaj, F. Van De Werf, D. Lambrechts, K.A.A. Fox (Leuven and Ghent, BE; Edinburgh, GB; Warsaw, PL) | |
| 13:10 | Circulating Factor Seven Activating Protease (FSAP) is associated with clinical outcome in acute coronary syndrome, but not with complexity of coronary artery disease. | 889 |
| | – M. Parahuleva, C. Neuhof, H. Hoelschermann, H. Tillmanns, A. Erdogan, S. Kanse (Giessen and Bad Homburg, DE) | |
| 13:25 | Association of outcome with left ventricular parameters measured by two- and three-dimensional echocardiography. | 890 |
| | – C. Jenkins, T. Stanton, T.H. Marwick (Brisbane, AU) | |

**YOUNG INVESTIGATORS' AWARDS SESSION
THROMBOSIS**

Abstracts

Chairperson(s): R. De Caterina (Chieti, IT); J.C.A. Morais (Leiria, PT)

Judges.

– R. De Caterina (Chieti, IT), A.K. Gitt (Ludwigshafen, DE), S.D. Kristensen (Aarhus, DK), J.C.A. Morais (Leiria, PT), J. Narula (Orange, US)

- | | | |
|-------|---|------------|
| | | 891 |
| | | |
| 12:40 | Despite similar cholesterol removing abilities, recombinant HDL-Milano exerts greater anti-inflammatory properties than wild type-HDL. | 892 |
| | – B. Ibanez, G. Cimmino, C. Giannarelli, A. Pintero, C.G. Santos-Gallego, G. Vilahur, V. Fuster, L. Badimon, J.J. Badimon (New York, US; Barcelona, ES) | |
| 12:55 | Composition of a single atherosclerotic plaque predicts systemic cardiovascular outcome. | 893 |
| | – W. Peeters, W.E. Hellings, D.P.V. De Kleijn, J.P.P.M. De Vries, F.L. Moll, G. Pasterkamp (Utrecht and Nieuwegein, NL) | |
| 13:10 | Higher stent thrombosis rate after coronary stenting in patients on dual antiplatelet treatment and concomitant treatment with proton pump inhibitors. | 894 |
| | – N. Sarafoff, D. Sibbing, U. Sonntag, S. Schulz, A. Schoemig, A. Kastrati (Munich, DE) | |
| 13:25 | Strong decrease of the clopidogrel antiplatelet effect with esomeprazole, but not with ranitidine and recovering of the antiplatelet effect by doubling the dosage of clopidogrel. | 895 |
| | – P. Mocerì, L. Drogoul, E. Ferrari (Nice, FR) | |

YOUNG INVESTIGATORS' AWARDS SESSION
CORONARY PATHOPHYSIOLOGY AND MICROCIRCULATION

Abstracts

Chairperson(s): F. Alfonso Manterola (Madrid, ES); T.F. Luescher (Zurich, CH)

Judges.

896

- T. Akasaka (Wakayama, JP), F. Alfonso Manterola (Madrid, ES), F. Crea (Rome, IT), L.M. Goncalves (Coimbra, PT), T.F. Luescher (Zurich, CH)

12:40 **Incomplete stent apposition and delayed tissue coverage are more frequent in drug eluting stents implanted during primary percutaneous coronary intervention for ST elevation myocardial infarction.**

897

- N. Gonzalo Lopez, P. Barlis, P.W. Serruys, H.M. Garcia-Garcia, Y. Onuma, J. Ligthart, E. Regar (Rotterdam, NL)

12:55 **Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation.**

898

- G. Chalikias, D.N. Tziakas, D. Stakos, I. Tentes, D. Papazoglou, A. Thomaidi, S. Manousakis, A. Grapsa, J.C. Kaski, H. Boudoulas (Alexandroupolis and Athens, GR; London, GB)

13:10 **Augmented expression of extracellular matrix-degrading enzymes by low Endothelial Shear Stress (ESS) promotes the formation of coronary atheromata with thin fibrous caps.**

899

- Y.S. Chatzizisis, A.B. Baker, G.K. Sukhova, R. Beigel, M. Jonas, A.U. Coskun, P. Libby, C.L. Feldman, P.H. Stone, E.R. Edelman (Boston and Cambridge, US)

13:25 **Natural course of lipid-rich plaques assessed with combination of intra-vascular ultrasound and optical coherence tomography.**

900

- K. Ishibashi, S. Takarada, T. Tanimoto, H. Kitabata, T. Kubo, K. Hirata, N. Nakamura, M. Mizukoshi, T. Imanishi, T. Akasaka (Wakayama, JP)



**YOUNG INVESTIGATORS' AWARDS SESSION
BASIC SCIENCE**

Abstracts

Chairperson(s): B. Casadei (Oxford, GB); A.R. Pries (Berlin, DE)

Judges.

– L. Badimon (Barcelona, ES), B. Casadei (Oxford, GB), H.M. Piper (Dusseldorf, DE),
A.R. Pries (Berlin, DE), L. Tokgozogl (Ankara, TR)

- | | | |
|-------|--|------------|
| | | 901 |
| | | |
| 12:40 | Lack of cardiomyocyte PPARgamma leads to myocardial inflammation resulting in cardiac insulin resistance. | 902 |
| | – E. Caglayan, K. Mueller-Wellensiek, M. Kreissl, D. Stout, H. Schelbert, W.A. Hsueh, S. Rosenkranz (Cologne and Wurzburg, DE; Los Angeles and Houston, US) | |
| 12:55 | Atrial fibrillation leads to electrical remodelling of Na currents. Role of INa inhibition by ranolazine on arrhythmias and contractility. | 903 |
| | – S. Sossalla, B. Kallmeyer, S. Wagner, U. Maurer, G. Hasenfuss, L. Belardinelli, L.S. Maier (Göttingen, DE; Palo Alto, US) | |
| 13:10 | c-kit+/ cd45- cardiac stem cells generate polygonal stromal cells and secrete myxoid matrix in atrial myxomas. | 904 |
| | – D. Torella, G.M. Ellison, C. Vicinanza, V. Galuppo, I. Mendicino, I. Aquila, M. Torella, M. Cotrufo, C. Indolfi, B. Nadal-Ginard (Catanzaro and Naples, IT; Liverpool, GB; Madrid, ES) | |
| 13:25 | Impaired elastin function increases features of plaque instability in ApoE-deficient mice. | 905 |
| | – J.L. Van Herck, G.R.Y. De Meyer, W. Martinet, H. Bult, C.J. Vrints, A.G. Herman (Edegem and Wilrijk, BE) | |

**APPLYING THE UNIVERSAL DEFINITION OF ACUTE
MYOCARDIAL INFARCTION: QUESTIONS AND
CONTROVERSIES**

Symposium

Chairperson(s): J.-P. Bassand (Besançon, FR); H.D. White (Auckland, NZ)

- | | | |
|-------|---|------------|
| 12:45 | What is and what is not a type 2 acute myocardial infarction? | 906 |
| | – J.S. Alpert (Tucson, US) | |
| 12:57 | How to use the universal criteria in low resource countries? | 907 |
| | – K. Thygesen (Aarhus, DK) | |
| 13:09 | How will new high sensitive cardiac troponin assays affect the criteria? | 908 |
| | – H.A. Katus (Heidelberg, DE) | |
| 13:21 | How to use the criteria for percutaneous coronary intervention related events? | 909 |
| | – A. Jaffe (Rochester, US) | |



ENDOCARDITIS: COPING WITH THE GUIDELINES

Chairperson(s): A. Vahanian (Paris, FR)

Meet the Experts



- | | | |
|-------|---|------------|
| 12:45 | A patient with a vegetation.
– A. Vahanian (Paris, FR) | 910 |
| 12:55 | Panel discussion.
– P. Tornos Mas, G. Habib, R. Dion (Barcelona, ES; Marseille, FR; Genk, BE) | 911 |
| 13:10 | A patient with persisting fever.
– A. Vahanian (Paris, FR) | 912 |
| 13:20 | Panel discussion.
– P. Tornos Mas, G. Habib, R. Dion (Barcelona, ES; Marseille, FR; Genk, BE) | 913 |
| 13:35 | What do the guidelines tell us?
– A. Vahanian (Paris, FR) | 914 |



**PREGNANCY AND HEART DISEASE:
DANGEROUS LIAISONS**

Meet the Experts

Chairperson(s): R.J.C. Hall (Norwich, GB)

- | | | |
|-------|--|-----|
| 12:45 | Pregnancy after major repair of complex congenital heart disease.
– G. Boccuzzi (Turin, IT) | 915 |
| 12:50 | Panel discussion.
– G. Boccuzzi, J.W. Roos-Hesselink, L.J. Freeman (Turin, IT; Rotterdam, NL; Norwich, GB) | 916 |
| 13:00 | Pregnancy and coarctation - its problems and dangers.
– J.W. Roos-Hesselink (Rotterdam, NL) | 917 |
| 13:05 | Panel discussion.
– G. Boccuzzi, J.W. Roos-Hesselink, L.J. Freeman (Turin, IT; Rotterdam, NL; Norwich, GB) | 918 |
| 13:15 | Pregnancy and pulmonary hypertension - a very high risk situation.
– L.J. Freeman (Norwich, GB) | 919 |
| 13:20 | Panel discussion.
– G. Boccuzzi, J.W. Roos-Hesselink, L.J. Freeman (Turin, IT; Rotterdam, NL; Norwich, GB) | 920 |
| 13:30 | What do the Guidelines tell us?
– R.J.C. Hall (Norwich, GB) | 921 |

HEART RATE, A NEW TARGET IN CORONARY ARTERY DISEASE **Satellite**

Chairperson(s): R. Ferrari (Ferrara, IT); K.M. Fox (London, GB)

Satellite Symposium organised by Servier

- | | | |
|-------|---|------------|
| 12:45 | Introduction.
– K.M. Fox (London, GB) | 922 |
| 12:48 | Cardioprotective benefits of heart rate reduction.
– M. Boehm (Homburg/Saar, DE) | 923 |
| 13:01 | Impact of heart rate reduction in cardiovascular prognosis.
– J.S. Borer (New York, US) | 924 |
| 13:14 | Heart rate reduction in clinical practice.
– A. Hjalmarson (Gothenburg, SE) | 925 |
| 13:27 | Conclusion.
– R. Ferrari (Ferrara, IT) | 926 |

**BREAKING GROUND IN ATRIAL FIBRILLATION (AF):
NEW STRATEGIES TO REDUCE VASCULAR EVENTS**

Satellite

Chairperson(s): S. Yusuf (Hamilton, CA); H.J.G.M. Crijns (Maastricht, NL)

Satellite Symposium organised by sanofi-aventis and Bristol-Myers Squibb

- | | | |
|-------|--|------------|
| 12:45 | Welcome and introduction: learning objectives. | 927 |
| | – S. Yusuf, H.J.G.M. Crijns (Hamilton, CA; Maastricht, NL) | |
| 12:50 | The clinical impact of AF on vascular events. | 928 |
| | – H.J.G.M. Crijns (Maastricht, NL) | |
| 13:00 | Evidence and guidelines on management of patients with AF & vascular risk. | 929 |
| | – A.J. Camm (London, GB) | |
| 13:10 | Changing directions in vascular protection of AF patients: the ACTIVE-A trial. | 930 |
| | – S.J. Connolly (Hamilton, CA) | |
| 13:25 | Panel discussion / Q & A. | 931 |
| | – A.J. Camm, S.J. Connolly, H.J.G.M. Crijns, S. Yusuf (London, GB; Hamilton, CA; Maastricht, NL) | |

**GROWING EVIDENCE OF THE LAST GENERATION
ANGIOTENSIN-CONVERTING ENZYME-INHIBITION (ACE-I) TO
PROTECT AGAINST CARDIOVASCULAR DISEASE**

Satellite

Chairperson(s): C. Erol (Ankara, TR); C. Borghi (Bologna, IT)
Satellite Symposium organised by Menarini International

- 12:45 **How pharmacological properties are leading to clinical evidences?** 932
– D. Vinereanu (Bucharest, RO)
- 13:08 **SMILE studies: a continuing project.** 933
– C. Borghi (Bologna, IT)



DIABETES AND THE HEART: SPECIAL CARE

Meet the Experts

Chairperson(s): L. Ryden (Stockholm, SE)

- | | | |
|-------|---|------------|
| 12:45 | Hidden diabetes in coronary artery disease - how to detect and is it worth while? | 934 |
| | – E. Standl (Munich, DE) | |
| 12:55 | Panel discussion. | 935 |
| | – E. Standl, F. Cosentino, L. Mellbin (Munich, DE; Rome, IT; Stockholm, SE) | |
| 13:10 | The combination of coronary artery disease and diabetes - a therapeutic challenge. | 936 |
| | – L. Mellbin (Stockholm, SE) | |
| 13:20 | Panel discussion. | 937 |
| | – E. Standl, F. Cosentino, L. Mellbin (Munich, DE; Rome, IT; Stockholm, SE) | |
| 13:35 | What do the Guidelines say? | 938 |
| | – L. Ryden (Stockholm, SE) | |

3 IN 1 COMBINATIONS: A NEW FRONTIER IN HYPERTENSION MANAGEMENT **Satellite**

Chairperson(s): M. Weir (Baltimore, US); R. Duesing (Bonn, DE)

Satellite Symposium organised by Novartis Pharma AG

- | | | |
|-------|--|-----|
| 12:45 | Welcome and opening remarks.
– R. Duesing (Bonn, DE) | 939 |
| 12:48 | Renin-angiotensin-aldosterone system blockade as foundation therapy.
– M. Weir (Baltimore, US) | 940 |
| 13:00 | Benefits of single-pill combinations.
– B. Dahlöf (Gothenburg, SE) | 941 |
| 13:12 | Beyond dual therapy: what next?
– M.A. Weber (New York, US) | 942 |
| 13:24 | Closing remarks.
– M. Weir (Baltimore, US) | 943 |

REFINING THE TREATMENT GOALS IN PULMONARY ARTERIAL HYPERTENSION: CASE-BASED LEARNING **Satellite**

Chairperson(s): N. Galie (Bologna, IT); M.A. Gomez Sanchez (Madrid, ES)
Satellite Symposium organised by Pfizer Inc.

- 12:45 **Treatment strategies in pulmonary arterial hypertension - Challenging the current paradigm.** 944
– N. Galie (Bologna, IT)
- 13:05 **Pulmonary arterial hypertension: a targeted approach for a progressive disease.** 945
– M.A. Gomez Sanchez (Madrid, ES)

13:45–15:15

**READING OF CORONARY COMPUTED
TOMOGRAPHY ANGIOGRAPHY DATASETS
(LEVEL II)**

Hands-on Tutorial

Chairperson(s): M. Marwan (Erlangen, DE)
Hands-on Tutorial organised by Siemens AG, Healthcare Sector

15:30–17:00

**CARDIOVASCULAR MAGNETIC
RESONANCE IN CARDIOMYOPATHIES AND
MYOCARDITIS (LEVEL II)**

Hands-on Tutorial

Chairperson(s): G. von der Recke (Bonn, DE)
Hands-on Tutorial organised by Siemens AG, Healthcare Sector

14:00–15:00

**REVASCULARISATION AND THE PATIENT
WITH DIABETES: KEY ISSUES? SHOULD WE
STILL PERFORM PERCUTANEOUS
CORONARY INTERVENTION IN DIABETIC
PATIENTS WITH MULTI-VESSEL DISEASE?**

Hands-on Tutorial

Chairperson(s): C. Spaulding (Paris, FR)

Hands-on Tutorial organised by Cordis, a Johnson & Johnson Company

15:30–17:00

**VASCULAR CLOSURE DEVICE WORKSHOP.
INFORMATION AND PRACTICE ON THE
DEPLOYMENT OF NEW CORDIS VASCULAR
CLOSURE DEVICE**

Hands-on Tutorial

Chairperson(s): To be announced

Hands-on Tutorial organised by Cordis, a Johnson & Johnson Company



**POPULATION VERSUS HIGH-RISK APPROACH IN
CARDIOVASCULAR PREVENTION**

Debate



Chairperson(s): J.H.A.J. De Sutter (Ghent, BE); P. Puska (Helsinki, FI)

	Population approach in coronary prevention: the method of choice.	
14:00	Pro. – T. Jorgensen (Glostrup, DK)	946
14:15	Contra. – G. De Backer (Ghent, BE)	947
	Rebuttal.	
14:30	Pro. – T. Jorgensen (Glostrup, DK)	948
14:35	Contra. – G. De Backer (Ghent, BE)	949
14:40	Conclusion.	950
	Genetic screening of coronary predisposition is coming to clinical practice.	
14:45	Pro. – H. Schunkert (Lubeck, DE)	951
15:00	Contra. – C.M. van Duijn (Rotterdam, NL)	952
	Rebuttal.	
15:15	Pro. – H. Schunkert (Lubeck, DE)	953
15:20	Contra. – C.M. van Duijn (Rotterdam, NL)	954
15:25	Conclusion.	955

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)



**REHABILITATION: INSTEAD OR AFTER PERCUTANEOUS
CORONARY INTERVENTION**

Debate

Chairperson(s): J.J. Piek (Amsterdam, NL); D. Baumgart (Essen, DE)

	In chronic angina: the best approach is percutaneous coronary intervention.	
16:30	Pro. – A.P. Banning (Oxford, GB)	956
16:45	Contra. – S. Gielen (Leipzig, DE)	957
	Rebuttal.	
17:00	Pro. – A.P. Banning (Oxford, GB)	958
17:05	Contra. – S. Gielen (Leipzig, DE)	959
17:10	Conclusion.	960
	After complete revascularisation and optimal medical treatment: there is a place for cardiac rehabilitation.	
17:15	Pro. – J. Niebauer (Salzburg, AT)	961
17:30	Contra. – S. De Servi (Legnano, IT)	962
	Rebuttal.	
17:45	Pro. – J. Niebauer (Salzburg, AT)	963
17:50	Contra. – S. De Servi (Legnano, IT)	964
17:55	Conclusion.	965



SMOKING CESSATION: EVERYONE IS CONCERNED

Symposium

Chairperson(s): W.J.M. Scholte Op Reimer (Amsterdam, NL); S.K. Malyutina (Novosibirsk, RU)

- | | | |
|-------|--|-----|
| 14:00 | Tobacco addiction: a worldwide problem.
– R. Peto (Oxford, GB) | 966 |
| 14:22 | Genetics of smoking addiction.
– J. Kaprio (Helsinki, FI) | 967 |
| 14:44 | What motivates smokers? Pleasure and pain.
– E.S. Froelicher (San Francisco, US) | 968 |
| 15:06 | Smoking cessation programmes - are they effective?
– E.S. Froelicher (San Francisco, US) | 969 |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

15:35–16:25

MEET THE TRIALIST 1

Chairperson(s): S.D. Kristensen (Aarhus, DK)

- | | | |
|-------|--|-----|
| 15:35 | Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial.
– L.C. Wallentin (Uppsala, SE) | 970 |
|-------|--|-----|



YEARS TO LIFE OR LIFE TO YEARS: THE IMPORTANCE OF QUALITY OF LIFE

Symposium

Chairperson(s): P. Giannuzzi (Veruno, IT); B.G.A. Fridlund (Jonkoping, SE)

- | | | |
|-------|---|-----|
| 16:30 | What is quality of life - and is it important in cardiovascular care?
– S. Hofer (Innsbruck, AT) | 971 |
| 16:48 | How to measure health related quality of life?
– H. McGee (Dublin, IE) | 972 |
| 17:06 | Quality of life in patients with heart disease? The EuroHeartQoL.
– N.B. Oldridge (Glendale, US) | 973 |
| 17:24 | What matters most: quantity or quality of life as an outcome measure in clinical trials?
– P. Wahrborg (Gothenburg, SE) | 974 |
| 17:42 | The future of quality of life measurement in cardiovascular diseases.
– H. Saner (Berne, CH) | 975 |



RISKS FOR CARDIOVASCULAR DISEASE – NEW INSIGHTS

Abstracts

Chairperson(s): L. Ryden (Stockholm, SE); W. Benzer (Feldkirch, AT)

- 14:00 **Systemic vascular dysfunction in children conceived by assisted reproductive technologies.** 976
 – S.F. Rimoldi, T. Stuber, S.F. De Marchi, S. Garcin, H. Duplain, M. Germond, C. Sartori, U. Scherrer, Y. Allemann (Berne and Lausanne, CH; London, GB)
- 14:15 **Impact of behavioural and biologic cardiovascular risk factors on the relationship between stature and all-cause mortality: 8-years follow-up study in a cohort of Chilean adults.** 977
 – E. Koch, T. Romero, C. Romero, M. Paredes, L. Manriquez, M. Bravo, D. Sandoval, C. Roman, A. Taylor (Santiago, San Francisco De Mostazal and Rancagua, CL; San Diego, US)
- 14:30 **A smoking ban in public places may reduce the incidence of acute coronary syndrome among non-smoking men.** 978
 – T. Gudnason, T. Viktorsson, K. Andersen (Reykjavik, IS)
- 14:45 **The impact of achieving risk factor targets on CVD events in a community-based study.** 979
 – E. Zomer, D. Liew, A. Owen, D. Magliano, C. Reid (Melbourne, AU)
- 15:00 **Underestimation of the importance of isolated systolic hypertension in older people.** 980
 – R. Clarke, J.R. Emberson (Oxford, GB)
- 15:15 **Mediterranean dietary habits predict prognosis in post-MI patients: results of the GOSPEL study.** 981
 – P. Giannuzzi, R. Marchioli, P.L. Temporelli, M. Gattone, R.M. Marfisi, R. Griffo, S. Urbinati, A.P. Maggioni, L. Tavazzi, D. Vanuzzo (Veruno, Santa Maria Imbaro, Passirana, Bologna, Florence, Cotignola and Udine, IT)

15:30 **Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)**

15:35–16:25

MEET THE TRIALIST 2

Chairperson(s): A.J. Camm (London, GB)

- 15:35 **A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke. RELY trial.** 982
 – S.J. Connolly (Hamilton, CA)



TOO MANY RISK FACTORS FOR CARDIOVASCULAR DISEASE?

Abstracts

Chairperson(s): I.M. Graham (Dublin, IE); U. Goldbourt (Tel Aviv, IL)

- 16:30 **Association between anthropometric obesity measures and coronary artery disease - a cross-sectional survey of 16,657 subjects from 444 Polish cities.** 983
 – B. Kaess, J. Jozwiak, W. Lukas, M. Mastej, A. Windak, W. Piwowarska, A. Tykarski, K. Rygiel, N. Samani, M. Tomaszewski (Regensburg, DE; Zabrze, Katowice, Krakow and Poznan, PL; Leicester, GB)
- 16:45 **Thirty novel biomarkers as predictors of clinically incident diabetes.** 984
 – V. Salomaa, A.S. Havulinna, T. Zeller, O. Saarela, K. Kuulasmaa, S. Blankenberg (Helsinki, FI; Mainz, DE)
- 17:00 **A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease.** 985
 – U. Petersson, C.J. Ostgren, L. Brudin, P.M. Nilsson (Linkoping and Malmo, SE)
- 17:15 **Cardiovascular risk prediction in an Australian population: the old versus the new Framingham equation.** 986
 – E. Zomer, A. Owen, D. Magliano, C. Reid, D. Liew (Melbourne, AU)
- 17:30 **Prognostic ability of a simple dietary score in cohort of 12,513 patients at high risk of cardiovascular risk followed by 860 Italian GPs: preliminary analysis of the risk & prevention trial.** 987
 – M.G. Sillelta, R. Marchioli, F. Avanzini, V. Caimi, I. Marzona, R. Pioggiarella, M.C. Roncaglioni, M. Scarano, G. Tognoni, M. Tombesi (Santa Maria Imbaro, Milan and Monza, IT)
- 17:45 **Identifying novel predictors of 30-day mortality for acute coronary syndromes: diagnosis differential and the Myocardial Ischaemia National Audit Project (MINAP).** 988
 – E.A. Metcalfe, C.P. Gale, B.A. Cattle, A.D. Simms, R.M. West, P.D. Baxter (Leeds, GB)



HIGH-DENSITY LIPOPROTEIN: POT OF GOLD OR BOX OF PANDORA? **Symposium**

Chairperson(s): V. Fuster (New York, US); S. Agewall (Oslo, NO)

- | | | |
|-------|--|-----|
| 14:00 | High-density lipoprotein: a fall from grace?
– J.J.P. Kastelein (Amsterdam, NL) | 989 |
| 14:22 | Enlightenment from ILLUMINATE?
– P.J. Barter (Sydney, AU) | 990 |
| 14:44 | Novel high-density lipoprotein raising strategies.
– S. Nicholls (Cleveland, US) | 991 |
| 15:06 | Value of fibrates and niacin.
– F. Ruschitzka (Zurich, CH) | 992 |

15:30 **Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)**

OPTICAL COHERENCE TOMOGRAPHY: DIFFICULT TO DO, EASY TO INTERPRET

Read with the Experts

Chairperson(s): C. Di Mario (London, GB); T. Akasaka (Wakayama, JP)

- | | | |
|-------|---|-----|
| 15:35 | Optical coherence tomography in unstable lesions.
– F. Prati (Rome, IT) | 993 |
| 15:45 | Panel discussion.
– F. Prati, E. Regar (Rome, IT; Rotterdam, NL) | 994 |
| 16:00 | Optical coherence tomography for stent implantation.
– E. Regar (Rotterdam, NL) | 995 |
| 16:10 | Panel discussion.
– F. Prati, E. Regar (Rome, IT; Rotterdam, NL) | 996 |

OVERLOOKED ISSUES IN CARDIOVASCULAR TRIALS

Symposium

Chairperson(s): D. Atar (Oslo, NO); W.H. van Gilst (Groningen, NL)

- | | | |
|-------|--|------|
| 16:30 | Cardiovascular safety and antidiabetic drugs.
– J.G.F. Cleland (Kingston upon Hull, GB) | 997 |
| 16:52 | Dual and triple renin-angiotensin-aldosterone-system blockade.
– M. Boehm (Homburg/Saar, DE) | 998 |
| 17:14 | Cancer and lipid lowering drugs.
– C. Borghi (Bologna, IT) | 999 |
| 17:36 | Antithrombotic therapy in heart failure.
– G.Y.H. Lip (Birmingham, GB) | 1000 |

HEART TRANSPLANTATION AND LEFT VENTRICULAR ASSIST DEVICES: AN EXPANDING HORIZON

Abstracts

Chairperson(s): G.D. Dreyfus (Harefield, GB); A. Moritz (Frankfurt/Main, DE)

- 14:00 **Heterotopic heart transplantation for congenital or acquired heart disease with elevated pulmonary vascular resistance: mid and long term hemodynamic results.** 1001
 – A. Gamba, A. Vassileva, R. Fiocchi, R. Sebastiani, A. Iacovoni, A. Fontana, O. Valsecchi (Bergamo, IT)
- 14:15 **Diabetic patients with good metabolic control have similar 1-year survival and morbidity after heart transplantation as non-diabetic patients.** 1002
 – N. Antonio, M.J. Guimaraes, D. Prieto, J. Ferrao De Oliveira, M.J. Antunes (Coimbra, PT)
- 14:30 **Microvascular dysfunction precedes epicardial coronary stenosis in heart transplant patients with cardiac allograft vasculopathy.** 1003
 – E. Osto, F. Tona, A. Gambino, A. Maddalozzo, A.L.P. Caforio, R. Montisci, A. Ramondo, G. Gerosa, S. Illiceto (Padua and Cagliari, IT)
- 14:45 **Mechanical circulatory support in patients of advanced age.** 1004
 – T. Drews, T. Krabatsch, E. Potapov, M. Pasic, Y. Weng, R. Hetzer (Berlin, DE)
- 15:00 **Main predictors of long-term cardiac stability after explantation of ventricular assist devices in patients with unloading-induced myocardial recovery.** 1005
 – M. Dandel, Y. Weng, M. Pasic, H. Siniawski, H.B. Lehmkühl, T. Drews, T. Krabatsch, E. Potapov, C. Knosalla, R. Hetzer (Berlin, DE)
- 15:15 **Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: longterm follow-up of a randomized trial (ISAR-SHOCK).** 1006
 – M. Seyfarth, D. Sibbing, T. Gloeck, L. Bott-Fluegel, I. Bauer, A. Kastrati, A. Schomig (Munich, DE)

15:30 **Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)**

AORTIC DISSECTION: THERAPEUTIC CHALLENGES

Abstracts

Chairperson(s): O. Oto (Izmir, TR); M.F. Kenda (Ljubljana, SI)

- 16:30 **Long-term outcome of aortic dissection with patent false lumen. Clinical and imaging predictors of poor prognosis.** 1007
 – G. Teixido, A. Evangelista, A. Ribera, I. Ferreira, H. Cuellar, V. Pineda, J. Rodriguez-Palomares, T. Gonzalez-Alujas, P. Mahia, D. Garcia-Dorado (Barcelona, ES)
- 16:45 **Ulcerlike lesions in intramural haematoma. Long-term follow-up and management implications.** 1008
 – Z. Gomez Bosch, A.E. Evangelista, H.C. Cuellar, T.G.A. Gonzalez-Alujas, J.R.P. Rodriguez Palomares, G.T. Teixidor, P.M. Mahia, A.D. Dugoni, M.T. Thomas, D.G.D. Garcia-Dorado (Barcelona, ES)
- 17:00 **Asymptomatic postoperative troponin release is associated with poor long-term outcome after vascular surgery.** 1009
 – O. Schouten, T.A. Winkel, W.J. Flu, S.E. Hoeks, Y.R.B.M. Van Gestel, D. Goei, J.P. Van Kuijk, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL)
- 17:15 **Differences in the long-term evolution of aortic dissection and intramural haematoma types B.** 1010
 – G. Teixido, A. Evangelista, I. Ferreira, A. Ribera, J. Rodriguez, T. Gonzalez-Alujas, A. Salas, A. Dugoni, M. Thomas, D. Garcia-Dorado (Barcelona, ES)
- 17:30 **Hybrid approach to type A aortic dissection: use of a new multibranched Dacron graft to obtain a fixed Elephant trunk for second endovascular stage.** 1011
 – G.P.E. Esposito, C.S. Sacra, R.A.P. Pennetta, K.V.F. Vaziri Farahani, S.B. Bichi, A.M.C. Cricco, L.S. Specchia, N.C. Corvaja (Lecce, IT)
- 17:45 **Outcome of patients suffering from acute Stanford type B aortic dissection: A retrospective single center analysis of 136 patients.** 1012
 – J. Garbade, M. Jenniches, R. Battellini, M. Borger, D. Scheinert, M. Gutberlet, T. Walther, F.W. Mohr (Leipzig, DE)



A GLOBAL PERSPECTIVE ON HYPERTENSION

Abstracts

Chairperson(s): R. Cifkova (Prague, CZ); G. Grassi (Monza, IT)

- 14:00 **Association of candidate gene polymorphisms with chronic kidney disease in Japanese individuals with hypertension.** 1013
 – K. Kato, T. Yoshida, Y. Yamada, K. Yokoi, M. Oguri, K. Yajima, T. Fujimaki, T. Hibino, G. Kimura, T. Murohara (Tsu, Inabe, Tajimi and Nagoya, JP)
- 14:15 **The importance of anthropometric indices in the prediction of 5-year incidence of hypertension in apparently healthy individuals: the ATTICA Study.** 1014
 – C. Chrysohoou, D. Panagiotakos, C. Pitsavos, J. Skoumas, J. Lentzas, A. Katinoti, C. Masoura, A. Zeibekis, L. Papadimitriou, C. Stefanadis (Athens, GR)
- 14:30 **Impact of alcohol and smoking habits on the risk of new-onset atrial fibrillation in hypertensive patients with ecg left ventricular hypertrophy: the life study.** 1015
 – I. Ariansen, K. Wachtell, M. Hecht Olsen, H. Ibsen, R.B. Devereux, P.M. Okin, S.E. Kjeldsen, B. Dahlöf (Oslo, NO; Copenhagen, Copenhagen and Holbaek, DK; New York, US; Gothenburg, SE)
- 14:45 **Rural residence and higher level of physical activity lessen the probability of hypertension in the Africans. Results from the Vitaraa study.** 1016
 – D. Lemogoum, P.H. Van De Borne, J.R. M'buyamba, J.J. Pik, M. Leeman, J. Toto Moukoko, J.P. Degaute (Brussels, BE; Kinshasa, ZR; Clermont Oise, FR; Douala, CM)
- 15:00 **Blood pressure control and cardiovascular risk profile of hypertensive patients in central and east European countries: results of the BP-care study.** 1017
 – G. Grassi, R. Cifkova, S. Erdine, S. Laurent, K. Narkiewicz, J. Redon, M. Viigimaa, G. Seravalle, G. Mancia (Monza and Milan, IT; Prague, CZ; Istanbul, TR; Paris, FR; Gdansk, PL; Valencia, ES; Tallin, EE)
- 15:15 **Cardiovascular risk factor management in Australian general practice.** 1018
 – E. Heeley, D. Peiris, A. Weekes, C. Morgan, A. Cass, C. Anderson, A. Patel, J. Chalmers (Sydney and Melbourne, AU)

15:30 **Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)**



PATHOPHYSIOLOGY OF HYPERTENSION

Abstracts

Chairperson(s): E. Agabiti-Rosei (Brescia, IT); S.C. Uppal (Amsterdam, NL)

- 16:30 **CaMK4 participates in the settings of the hypertensive phenotype: a human genome wide analysis supported by animal model.** 1019
 – G. Santulli, M. Illario, G.L. Palumbo, D. Sorriento, E. Cipolletta, V. Trimarco, C. Del Giudice, M. Ciccarelli, B. Trimarco, G. Iaccarino (Naples, IT; Philadelphia, US)
- 16:45 **Uric acid: arterial friend or foe? Linking urate levels with arterial stiffness and wave reflections in never-treated hypertension.** 1020
 – P. Xaplanteris, C. Vlachopoulos, G. Vyssoulis, K. Aznaouridis, I. Dima, K. Baou, C. Stefanadis (Athens, GR)
- 17:00 **Valsartan was effective in dyslipidemic patients: a sub-analysis of JIKEI heart study.** 1021
 – K. Ikewaki, M. Shimizu, M. Yoshimura, B. Dahlöf, S. Mochizuki (Tokorozawa, Kashiwa and Tokyo, JP; Gothenburg, SE)
- 17:15 **Genetic polymorphism A1675G on type 2 angiotensin receptor increases cardiovascular risk in hypertensive individuals: effects on inflammatory mechanisms.** 1022
 – N. Koumallos, D. Tousoulis, C. Antoniadis, A. Miliou, A. Antonopoulos, D. Mentzikof, K. Marinou, K. Toutouzas, E. Kalikazarou, C. Stefanadis (Athens, GR)
- 17:30 **Endothelin-1 pathway during methionine-induced homocysteinemia, mediates endothelial dysfunction in hypertensive individuals.** 1023
 – G. Bouras, D. Tousoulis, C. Antoniadis, K. Marinou, A. Antonopoulos, N. Papageorgiou, E. Stefanadi, G. Latsios, C. Tentolouris, C. Stefanadis (Athens, GR)
- 17:45 **Effects of continuous positive airway pressure therapy on sympathovagal balance and arterial stiffness in obstructive sleep apnoea.** 1024
 – K. Shiina, H. Tomiyama, H. Saruhara, K. Kato, Y. Hashimura, C. Matsumoto, M. Yoshida, Y. Usui, Y. Takata, A. Yamashina (Tokyo, JP)

SUNDAY PM

CLINICAL TRIAL UPDATE I

Clinical Trial Update

Chairperson(s): F.T. Chiang (Taipei, TW); P. Ponikowski (Wroclaw, PL)



- | | | |
|-------|--|------|
| 14:00 | B-CONVINCED. Beta-blocker CONTInuation Versus INTerruption in patients with Congestive heart failure hospitalized for a decompensation episode. | 1025 |
| | – G. Jondeau (Paris, FR) | |
| 14:10 | Discussant. | 1026 |
| | – K. Swedberg (Gothenburg, SE) | |
| 14:15 | The impact of achieved heart rate and reduction in heart rate on cardiovascular outcomes: an analysis of the Ivabradine arm of the BEAUTIFUL trial. | 1027 |
| | – K.M. Fox (London, GB) | |
| 14:25 | Discussant. | 1028 |
| | – M. Boehm (Homburg/Saar, DE) | |
| 14:30 | Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. | 1029 |
| | – A.P. Maggioni (Florence, IT) | |
| 14:40 | Discussant. | 1030 |
| | – H.J.G.M. Crijns (Maastricht, NL) | |
| 14:45 | Heart failure events assessment in the Rosiglitazone Evaluation for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD). | 1031 |
| | – M. Komajda (Paris, FR) | |
| 14:55 | Discussant. | 1032 |
| | – K. Dickstein (Stavanger, NO) | |
| 15:00 | Characteristics of patients enrolled in the Predictors of Response to CRT (PROSPECT) trial: comparison of subgroups according to extent of LV reverse remodeling. | 1033 |
| | – R.J. van Bommel (Leiden, NL) | |
| 15:10 | Discussant. | 1034 |
| | – C. Linde (Stockholm, SE) | |
| 15:15 | Cardiac Resynchronization Therapy Induces Major Structural and Functional Reverse Remodeling In Mild Heart Failure. 24 month results of the REVERSE trial. | 1035 |
| | – S. Ghio (Pavia, IT) | |
| 15:25 | Discussant. | 1036 |
| | – J.G.F. Cleland (Kingston upon Hull, GB) | |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)



SYNCOPE 2009: A NEW PERSPECTIVE FOR AN OLD ENTITY

Symposium

Chairperson(s): J.-J. Blanc (Brest, FR); R. Ruiz Granell (Valencia, ES)
The Committee for Practice Guidelines



- | | | |
|-------|--|------|
| 16:30 | Risk stratification and diagnostic strategy in patients with syncope. | 1037 |
| | – A. Moya I Mitjans (Barcelona, ES) | |
| 16:52 | Syncope unit: utopia or a necessity. | 1038 |
| | – M. Brignole (Lavagna, IT) | |
| 17:14 | Specific aspects of syncope in the elderly: a growing problem. | 1039 |
| | – A. Ungar (Florence, IT) | |
| 17:36 | Future directions in diagnosis and management of syncope. | 1040 |
| | – D.G. Benditt (Minneapolis, US) | |

CONTROVERSIES IN PERCUTANEOUS CORONARY REVASCULARISATION: TRIALS VERSUS PRACTICE

Debate

Chairperson(s): G.S. Werner (Darmstadt, DE); M.R. Thomas (London, GB)

14:00	Multivessel disease: functional assessment is essential to guide intervention. Pro. – J. Rieber (Munich, DE)	1041
14:15	Contra. – B. Meier (Berne, CH) Rebuttal.	1042
14:30	Pro. – J. Rieber (Munich, DE)	1043
14:35	Contra. – B. Meier (Berne, CH)	1044
14:40	Conclusion.	1045
	Chronic total occlusion: intervention improves clinical outcome.	
14:45	Pro. – S.T. Lim (Singapore, SG)	1046
15:00	Contra. – J. Marco (Toulouse, FR) Rebuttal.	1047
15:15	Pro. – S.T. Lim (Singapore, SG)	1048
15:20	Contra. – J. Marco (Toulouse, FR)	1049
15:25	Conclusion.	1050

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

UNRESOLVED ISSUES IN PRIMARY PERCUTANEOUS INTERVENTION

Symposium

Chairperson(s): I.R. Al Rashdan (Safat, KW); G. Montalescot (Paris, FR)

16:30	No reflow: the major issue. – E. Eeckhout (Lausanne, CH)	1051
16:52	Aspiration thrombectomy: universal or selective use. – U. Limbruno (Grosseto, IT)	1052
17:14	Drug-eluting or bare metal stents? – B. Merkely (Budapest, HU)	1053
17:36	How to deal with multivessel disease? – D. Dudek (Krakow, PL)	1054

No session

S
U
N
D
A
Y
P
M

15:30–18:00

SUBSTRATES OF SUDDEN CARDIAC DEATH.

Chairperson(s): G. Hindricks (Leipzig, DE); N. Cardim (Lisbon, PT)
Discussants from WG17 and EHRA

15:45 **Live-video demonstration.**

– C. Basso (Padua, IT)

1055

16:45 **Hands-on specimen demonstration.**

1056

14:00–15:30

COMPUTED TOMOGRAPHY IMAGING IN CORONARY DISEASE – WHEN IS IT HELPFUL?

FOCUS Session

Chairperson(s): S. Achenbach (Erlangen, DE); L. Badano (Udine, IT)

Introduction.	1057
From primary prevention to acute coronary syndromes.	1058
Ruling in and ruling out coronary artery disease.	1059
Acute chest pain.	1060
CT guided coronary interventions.	1061
Case presentations from workstation.	1062
Recommendations for CT coronary angiography: Present and future.	1063
Panel.	1064
– F. Cademartiri (Parma, IT), E.M. Martuscelli (Rome, IT), K. Nieman (Rotterdam, NL)	



SUNDAY PM

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

16:30–18:00

HIGHLIGHTS FROM EUROPCR 2009.

FOCUS Session

Chairperson(s): B. Chevalier (Massy, FR); J. Marco (Toulouse, FR)
In collaboration with EuroPCR-EAPCI



Stent for life.	1065
Patients with multi vessel coronary artery disease: how to integrate FFR and SYNTAX into the decision making process. Recorded video.	1066
Acute coronary syndrome multi vessel disease in diabetic patients: how to integrate imaging and FFR into the decision making process. Recorded video.	1067
Complication: the most educative case.	1068
Overview of the meeting highlights.	1069
Panel.	1070
– O. Alfieri (Milan, IT), E. Eeckhout (Lausanne, CH), P. Kala (Brno, CZ), M.R. Thomas (London, GB), M. Valgimigli (Ferrara, IT), P. Widimsky (Prague, CZ)	



14:00–15:30

PERCUTANEOUS CORONARY INTERVENTION: FOCUS Session
ANTITHROMBOTIC THERAPY

Chairperson(s): P. Widimsky (Prague, CZ); S. Silber (Munich, DE)
In collaboration with EuroPCR-EAPCI

 Webcast

- Patient with chronic stable angina and atrial fibrillation scheduled for elective coronary angiography.** 1071
- Patient with prosthetic mitral valve and acute ST-elevation myocardial infarction.** 1072
- Patient three months after DES implantation in complex coronary anatomy requiring urgent non-cardiac surgery.** 1073
- Panel.** 1074
- A. Baumbach (Bristol, GB), M. Noc (Ljubljana, SI), D. Poldermans (Rotterdam, NL)



15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

16:30–18:00

HEART FAILURE MANAGEMENT IN COMPLEX CLINICAL SITUATIONS FOCUS Session

Chairperson(s): J.J.V. McMurray (Glasgow, GB); D.J. van Veldhuisen (Groningen, NL)

- Failing heart, failing kidney: double trouble.** 1075
- Blood pressure and heart failure: the hate-love relationship.** 1076
- Atrial fibrillation and worsening heart failure: chicken or egg?** 1077
- Panel.** 1078
- P. Ponikowski (Wroclaw, PL), K. Witte (Leeds, GB), F. Zannad (Dommartin-Les-Toul, FR)





**MANAGEMENT OF ST ELEVATION MYOCARDIAL
INFARCTION: UPDATE 2009**

Main Session

Webcast

Chairperson(s): D. Zahger (Beer Sheva, IL); F. Van de Werf (Leuven, BE)

14:00	Prehospital challenges. – P.M. Clemmensen (Copenhagen, DK)	1079
14:22	Evolving strategies for reperfusion therapy. – N. Danchin (Paris, FR)	1080
14:44	Optimal antithrombotic therapy. – L.C. Wallentin (Uppsala, SE)	1081
15:06	Late-comers: which options? – A. Abbate (Richmond, US)	1082

S
U
N
D
A
Y
P
M

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

NON-OBSTRUCTIVE CORONARY ARTERY DISEASE: IS IT ALWAYS BENIGN? Symposium

Chairperson(s): T.J. Gardner (Wilmington, US); A.M. Zeiher (Frankfurt, DE)

16:30	The burden of angina and 'normal' coronary arteries. – J.C. Kaski (London, GB)	1083
16:52	Syndrome X: diagnosis, prognosis and treatment. – F. Crea (Rome, IT)	1084
17:14	Syndrome X: in patients with acute coronary syndrome. – R. Bugiardini (Bologna, IT)	1085
17:36	Insights from the WISE study. – V. Vaccarino (Atlanta, US)	1086

DIABETES MELLITUS MEETS HEART FAILURE

Symposium

Chairperson(s): D. Horstkotte (Bad Oeynhausen, DE); W. Banasiak (Wroclaw, PL)

- | | | |
|-------|---|-------------|
| 14:00 | Epidemiology and prognosis of diabetes in acute and chronic heart failure. | 1087 |
| | – R. Latini (Milan, IT) | |
| 14:22 | How does diabetes lead to heart failure? | 1088 |
| | – G. Sinagra (Trieste, IT) | |
| 14:44 | Hyperglycaemia and insulin resistance in heart failure. | 1089 |
| | – W. Doehner (Berlin, DE) | |
| 15:06 | Treating diabetes in heart failure. | 1090 |
| | – M.R. MacDonald (Glasgow, GB) | |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

HEART FAILURE AND ANAEMIA: WHERE ARE WE IN 2009?

Symposium

Chairperson(s): K. Swedberg (Gothenburg, SE); T.A. McDonagh (London, GB)

- | | | |
|-------|---|-------------|
| 16:30 | Pathogenesis, pathophysiology and prognosis. | 1091 |
| | – P. Van Der Meer (Dronrijp, NL) | |
| 16:52 | Today's management strategies for anaemia. | 1092 |
| | – S.D. Anker (Berlin, DE) | |
| 17:14 | Safety of erythropoiesis stimulating agents: lessons from other disease areas. | 1093 |
| | – H. Krum (Melbourne, AU) | |
| 17:36 | Relevant ongoing trials. | 1094 |
| | – M. Pfeffer (Boston, US) | |

NEUROHORMONES AND HEART FAILURE: THE SEARCH GOES ON!

Abstracts

Chairperson(s): A.D. Struthers (Dundee, GB); To be announced

- 14:00 **Serial measurements of natriuretic peptides are predictive of not-high-dose anthracycline-induced cardiotoxicity in a 1-year follow-up.** 1095
 – S. Romano, G. Stifano, V. Procaccini, M. Mancini, S. Fratini, E. Ricevuto, C. Ficarella, M. Penco (L'aquila, IT)
- 14:15 **Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in noncardiac surgery.** 1096
 – E.S. Jeon, D.K. Cho, Y.B. Song, J.Y. Hahn, S.H. Choi, J.H. Choi, H.C. Gwon, D.K. Kim, S.H. Lee, J.K. Oh (Seoul and Jeju, KR; Rochester, US)
- 14:30 **BNP-guided heart failure therapy: a meta-analysis of randomized control trials.** 1097
 – P. Porapakham, P.L. Porapakham, H. Zimmel, B. Billah, H. Krum (Melbourne, AU)
- 14:45 **Emergency department short term mortality in acute heart failure: results of the international BACH trial.** 1098
 – W.F. Peacock, R. Nowak, S.X. Neath, R. Christenson, P. Clopton, S. Disomma, S.D. Anker, A. Maisel, G. Filippatos, M. Mockel (Cleveland, Detroit, San Diego and Baltimore, US; Rome, IT; Berlin, DE; Athens, GR)
- 15:00 **Plasma renin activity retains a strong prognostic value in patients with chronic HF, independent of ACE inhibitor or beta-blocker therapy. Data from the Valsartan Heart Failure (Val-HeFT) trial.** 1099
 – S. Masson, S. Solomon, L. Angelici, R. Latini, I.S. Anand, M. Prescott, A.P. Maggioni, G. Tognoni, J.N. Cohn (Milan, Florence and Santa Maria Imbaro, IT; Boston, Minneapolis and East Hanover, US)
- 15:15 **Osteoprotegerin predicts long-term all-cause mortality in patients with chronic heart failure.** 1100
 – T. Ueland, P. Aukrust, J. Kjekshus, J. Hulthe, M. Lindberg, J. Wikstrand, L. Gullestad (Oslo, NO; Gothenburg and Molndal, SE)

15:30 **Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)**

NEW DRUGS AND THERAPEUTIC STRATEGIES IN HEART FAILURE

Abstracts

Chairperson(s): F. Follath (Zurich, CH); A. Gavazzi (Bergamo, IT)

- 16:30 **Increased symptom-improvement with the novel vasodilator, relaxin, in Acute Heart Failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study.** 1101
 – J.R. Teerlink, M. Metra, A.A. Voors, G.M. Felker, P. Ponikowski, G.S. Filippatos, B.H. Greenberg, S.L. Teichman, B.D. Weatherley, G. Cotter (San Francisco, Durham, San Diego and San Mateo, US; Brescia, IT; Groningen, NL; Wroclaw, PL; Athens, GR)
- 16:45 **Erythropoietin for anaemia in heart failure: a meta-analysis of exercise tolerance, symptoms and clinical outcome improvement.** 1102
 – D. Kotecha, K. Ngo, J. Walters, L. Manzano, A. Palazzuoli, D.J. Van Veldhuisen, M. Flather (London, GB; Hobart, AU; Madrid, ES; Siena, IT; Groningen, NL)
- 17:00 **Combined therapy with angiotensin receptor antagonists and ACE inhibitors versus standard therapy in patients with heart failure: a meta-analysis of randomized controlled trials.** 1103
 – A.J. Nordmann, A. Kuenzli, H.C. Bucher, I. Anand, G. Arutiunov, L.C. Kum, R. Mckelvie, R. Afzal, M. White (Basel, CH; Minneapolis, US; Moscow, RU; Hong Kong, CN; Hamilton and Montreal, CA)
- 17:15 **Time course analysis of the effect of n-3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI-HF trial.** 1104
 – R. Marchioli, M.P. Aldegheri, L. Borghese, M.G. Franzosi, R. Latini, R.M. Marfisi, A.P. Maggioni, G.L. Nicolosi, G. Tognoni, L. Tavazzi (Santa Maria Imbaro, Legnago, Conegliano Veneto, Milan, Florence, Pordenone and Cotignola, IT)
- 17:30 **Safety and tolerability profile of aliskiren added to optimized therapy in elderly and very elderly patients with heart failure.** 1105
 – S.D. Solomon, J.J. McMurray, A.P. Maggioni, R. Latini, B.A. Smith, C. Bush, D.L. Keefe, B. Pitt (Boston, East Hanover and Ann Arbor, US; Glasgow, GB; Florence and Milan, IT)
- 17:45 **Thyroid hormone, amiodarone therapy and prognosis in chronic heart failure.** 1106
 – M. Coceani, S. Molinaro, M. Scalese, C. Carpeggiani, A. L'Abbate, G. Iervasi, A. Pingitore (Pisa, IT)

CLINICAL ELECTROCARDIOGRAM REVISITED: NEW OBSERVATIONS, NEW CHALLENGES

Abstracts

Chairperson(s): L. Antoniades (Nicosia, CY); A. Battler (Petah Tikva, IL)

- 14:00 **Prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome screening.** **1107**
 – L. Ferreira Santos, E. Correia, B. Rodrigues, R. Faria, L. Nunes, A. Costa, J. Lopes Carvalho, C. Henriques, A. Matos, J. Oliveira Santos (Viseu, PT)
- 14:15 **High prevalence of early repolarization in the German general population.** **1108**
 – M.F. Sinner, W. Reinhard, B.M. Beckmann, E. Martens, M. Grassl, C. Meisinger, A. Peters, S. Perz, C. Hengstenberg, S. Kaab (Munich, Regensburg and Neuherberg, DE)
- 14:30 **Mode of onset in idiopathic ventricular fibrillation; early repolarization-J wave syndrome vs. Brugada syndrome.** **1109**
 – G.B. Nam, E.S. Jin, K.J. Choi, Y.H. Kim (Seoul, KR)
- 14:45 **Outcome of individuals with an electrocardiogram of coved-type ST-segment elevation in a single right precordial lead.** **1110**
 – S. Richter, A. Sarkozy, T. Boussy, S. Henkens, G. Paparella, G.B. Chierchia, R. Brugada, J. Brugada, P. Brugada (Brussels, BE; Girona and Barcelona, ES)
- 15:00 **Electrocardiographic differentiation of stress induced cardiomyopathy and acute myocarditis.** **1111**
 – H.W.P. Park, Y.J.H. Hong, J.H.K. Kim, Y.K.A. Ahn, M.H.J. Jeong, J.G.C. Cho, J.C.P. Park, J.C.K. Kang (Gwangju, KR)
- 15:15 **Prevalence of the early repolarization aspect in a healthy women population.** **1112**
 – U. Vinsonneau, A. Brondex, C. Vergez-Larroquet, L. Leroy, A. Lecoat, A. Vigneau-Vinsonneau, S. Geneau De La Marliere, G. Quiniou (Brest, FR)

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

HOW TO PREDICT THE PROGNOSIS IN VENTRICULAR TACHYARRHYTHMIAS

Abstracts

Chairperson(s): M. Borggreffe (Mannheim, DE); A.S. Manolis (Glyfada-Athens, GR)

- 16:30 **Long-term outcome of patients with ventricular tachycardia and ventricular fibrillation within 48 hours of acute myocardial infarction.** **1113**
 – H. Bonnemeier, D. Rzepka, A. Heinke, D. Heckmann, M. Reppel, H. Schunkert (Lubeck, DE)
- 16:45 **Non-invasive identification of ventricular tachycardia related conducting channels with MRI in patients with chronic myocardial infarction: a case-control study.** **1114**
 – E. Perez-David, R. Del Castillo, L. Atea, A. Arenal, E. Arbelo, V. Celorrio, I. Gomez Anta, J. Lafuente, J. Bermejo, F. Fernandez Aviles (Madrid and Las Palmas de Gran Canaria, ES)
- 17:00 **Prognostic value of three-dimensional electroanatomic voltage mapping in patients with arrhythmias of right ventricular origin.** **1115**
 – M. Bevilacqua, M. Silvano, L. Leoni, F. Migliore, A. Zorzi, C. Basso, G. Buja, G. Thiene, S. Iliceto, D. Corrado (Padua, IT)
- 17:15 **Myocardial mechanical dispersion in long QT syndrome identifies individuals with high risk for cardiac arrhythmias.** **1116**
 – K.H. Haugaa, T. Edvardsen, T.P. Leren, O.A. Smiseth, J.P. Amlie (Oslo, NO)
- 17:30 **Electrophysiologic-guided quinidine therapy in brugada syndrome: an alternative to ICD therapy.** **1117**
 – D. Fourey, A. Glick, R. Rosso, Y. Michowitch, S. Viskin, B. Belhassen (Tel Aviv, IL)
- 17:45 **Integration of MRI derived 3D scar maps with electroanatomical mapping during catheter ablation of scar-related ventricular tachycardia late after myocardial infarction.** **1118**
 – A.P. Wijnmaalen, R.J. Van Der Geest, H.J. Siebelink, L. Kroft, J.J. Bax, J.H.C. Reiber, M.J. Schalij, K. Zeppenfeld (Leiden, NL)

THE RIGHT VENTRICLE: THE NEGLECTED CHAMBER IN CARDIOLOGY AND CARDIAC SURGERY Symposium

Chairperson(s): A.G. Fraser (Cardiff, GB); N. De Michelis (Orange, US)

- | | | |
|-------|---|------|
| 14:00 | The right ventricle: response to overload.
– R.N. Naeije (Brussels, BE) | 1119 |
| 14:22 | Non-invasive evaluation of the right ventricle.
– S. Gallina (Chieti, IT) | 1120 |
| 14:44 | Assessing and managing right ventricular function before cardiac surgery.
– G. Athanassopoulos (Athens, GR) | 1121 |
| 15:06 | Assessing and managing right ventricular function after cardiac surgery.
– J.I. Fragata (Lisbon, PT) | 1122 |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

DIASTOLIC DYSFUNCTION: CAN IT BE BETTER UNDERSTOOD? Abstracts

Chairperson(s): B.M. Pieske (Graz, AT); D.L. Brutsaert (Kontich, BE)

- | | | |
|-------|--|------|
| 16:30 | Reduced cardiac performance and exercise capacity due to exercise-induced diastolic dysfunction in HFNEF. Bicycle exercise 3D echocardiography.
– M. Kasner, R. Gaub, D. Sinning, J. Lober, D. Westermann, D. Milicic, H.-P. Schultheiss, C. Tschoepe (Berlin, DE; Zagreb, HR) | 1123 |
| 16:45 | Advanced left ventricular diastolic dysfunction is associated with longitudinal systolic impairment in patients with systemic hypertension.
– F.L. Dini, M. Ciavarella, E. De Marco, C. De Gregorio, L. Badano, V. Di Bello, S. Gallina, P.N. Marino, S. Mondillo, M. Galderisi (Pisa, Rome, Messina, Udine, Chieti, Novara, Siena and Naples, IT) | 1124 |
| 17:00 | Relation between desmin remodeling and cardiac diastolic dysfunction.
– A. Pawlak, E. Czarnowska, A.I. Gziut, J. Rzezak, R.J. Gil (Warsaw, PL) | 1125 |
| 17:15 | Echocardiographic diagnosis of diastolic dysfunction: E/e is superior to complex algorithms in predicting a clinical impairment in exercise capacity.
– A. Kockskaemper, H. Post, S. Kleta, R. Wachter, L. Binder, B. Pieske (Graz, AT; Gottingen, DE) | 1126 |
| 17:30 | Pressure half-time as an independent predictor of prognosis in patients with nonischemic dilated cardiomyopathy.
– A. Hirashiki, H. Izawa, T. Okumura, K. Ohshima, M. Sakakibara, H. Funahashi, M. Yokota, T. Murohara (Nagoya, JP) | 1127 |
| 17:45 | Inhibition of the endogenous proteasome-system impairs cardiac diastolic function.
– C. Wohlert, J. Herrmann, D. Loeffler, L. Lerman, R. Erbel, A. Lerman (Essen, DE; Rochester, US) | 1128 |

TELEMONITORING IN CARDIOLOGY: WHO BENEFITS?

Symposium

Chairperson(s): M.J. Schalij (Leiden, NL); P. Notarstefano (Ferrara, IT)

- | | | |
|-------|---|-------------|
| 14:00 | Are the patients the major beneficiaries? | 1129 |
| | – I. Fernandez Lozano (Madrid, ES) | |
| 14:22 | A win-win situation: taxpayers and health providers. | 1130 |
| | – H. Heidbuchel (Leuven, BE) | |
| 14:44 | Is the industry the main stakeholder to gain? | 1131 |
| | – G. Boriani (Bologna, IT) | |
| 15:06 | Moving towards an era of more personalised care? | 1132 |
| | – P.E. Vardas (Heraklion, GR) | |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

IMPLANTABLE MONITORS; TOWARDS PERSONALISED CARE

Symposium

Chairperson(s): A.N. Parkhomenko (Kiev, UA); C.W. Siu (Hong Kong, HK)

- | | | |
|-------|---|-------------|
| 16:30 | Implantable cardiac monitor in patients with syncope. | 1133 |
| | – R. Sutton (London, GB) | |
| 16:52 | Implantable loop recorders in atrial fibrillation clinical trials. | 1134 |
| | – W. Jung (Villingen-Schwenningen, DE) | |
| 17:14 | Implantable device to monitor heart failure. | 1135 |
| | – G.K. Andrikopoulos (Athens, GR) | |
| 17:36 | Implantable cardiac devices to monitor anticoagulation. | 1136 |
| | – L. Padeletti (Florence, IT) | |



GENETIC FOOTPRINTING IN ARRHYTHMIAS

Symposium

Chairperson(s): P.J. Schwartz (Pavia, IT); U. Ravens (Dresden, DE)

- | | | |
|-------|---|------|
| 14:00 | What to expect from genetic footprinting in clinical arrhythmology. | 1137 |
| | – S.G. Priori (Pavia, IT) | |
| 14:22 | Preventing sudden cardiac death based on genetic risk calculation. | 1138 |
| | – C. Wolpert (Mannheim, DE) | |
| 14:44 | The genotype is not the whole story. | 1139 |
| | – R. Brugada Terradellas (Girona, ES) | |
| 15:06 | Implementing routine genetic screening as part of clinical practice. | 1140 |
| | – A.A.M. Wilde (Amsterdam, NL) | |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

**THE FUTURE OF ATRIAL FIBRILLATION THERAPY:
THE 2ND AFNET/EHRA CONSENSUS CONFERENCE**

Symposium

Chairperson(s): G. Breithardt (Munster, DE); A.J. Camm (London, GB)

- | | | |
|-------|--|------|
| 16:30 | When to start ‘upstream therapy’, and in whom? | 1141 |
| | – H.J.G.M. Crijns (Maastricht, NL) | |
| 16:52 | New anticoagulants - a promise of better stroke prevention? | 1142 |
| | – F.W.A. Verheugt (Amsterdam, NL) | |
| 17:14 | Catheter ablation in atrial fibrillation patients - what to do when pulmonary vein isolation fails? | 1143 |
| | – J.F.R. De Sousa (Lisbon, PT) | |
| 17:36 | Comprehensive cardiovascular risk management - the future of atrial fibrillation therapy? | 1144 |
| | – P. Kirchhof (Munster, DE) | |

BLOOD, KIDNEY AND THE HEART: NEW LINKS

Abstracts

Chairperson(s): J.-P. Bassand (Besançon, FR); J. Eikelboom (Hamilton, CA)

- 14:00 **Red blood cell distribution width and mortality after acute myocardial infarction.** 1145
– D. Aronson, M. Kapeliovich, R. Beyar, H. Hammerman, S. Dabbah (Haifa, IL)
- 14:15 **Early stage chronic kidney disease is associated with coronary spastic angina.** 1146
– S. Koga, S. Ikeda, T. Yasunaga, T. Nakata, M. Takeno, Y. Koide, S. Kohno, K. Maemura (Nagasaki, JP)
- 14:30 **Effect of anemia in high-risk subgroups of patients with myocardial infarction treated with primary coronary intervention.** 1147
– T. Kurek, R. Lenarczyk, J. Kowalczyk, A. Swiatkowski, O. Kowalski, J. Stabryla-Deska, G. Honisz, A. Lekston, Z. Kalarus, T. Kukulski (Zabrze, PL)
- 14:45 **Impact of anemia and reduced left ventricular ejection fraction on in-hospital outcome of acute coronary syndromes. Euro Heart Survey ACS III registry (2006-2008).** 1148
– W. Wojakowski, M. Tendera, M. Tubaro, M. Gierlotka, H. Bueno, B. Lindahl, M. Hochadel, Y. Hasin, J.P. Bassand, A.K. Gitt (Katowice and Zabrze, PL; Rome, IT; Madrid, ES; Uppsala, SE; Ludwigshafen am Rhein, DE; Tiberias, IL; Besançon, FR)
- 15:00 **Estimation of renal function in acute coronary syndromes: MDRD or Cockcroft-Gault?** 1149
– S. Nabais, A. Gaspar, S. Rocha, S. Ribeiro, P. Azevedo, J. Costa, M. Alvares Pereira, A. Correia (Braga, PT)
- 15:15 **Glucose and creatinine as risk factors in patients with acute myocardial infarction: importance and interactions.** 1150
– M.D. Andrade, J.C. Nicolau, L.M. Baracioli, R.R.C.V. Giraldez, C.V. Serrano, R.C. Moraes, F.G. Lima, M. Franken, K.D. Rosa, C.C.F. Fernandes (Sao Paulo, BR)

15:30 **Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)**



INFLAMMATION AND MICROVASCULAR DAMAGE: FROM CELLS TO HUMANS

Abstracts

Chairperson(s): G.K. Hansson (Stockholm, SE); E. Arbustini (Pavia, IT)

- 16:30 **Genetic loci influencing C-reactive protein levels and risk of coronary heart disease: a Mendelian Randomisation experiment in 130,000 people.** 1151
– J.C. Chambers, P. Elliot, J. Sehmi, J.S. Kooner (London, GB)
- 16:45 **Toll-Like Receptor-4 (TLR-4) and Monocyte Chemoattractant Protein-1 (MCP-1) play a key role in myocardial remodelling after acute myocardial infarction.** 1152
– G. Vilahur, X. Duran, L. Badimon (Barcelona, ES)
- 17:00 **C-reactive protein inhibits endothelial cell migration via upregulation of pten.** 1153
– S. Goetze, C. Schneeweiss, M. Roser (Berlin, DE)
- 17:15 **Improved ventricular remodeling after acute myocardial infarction in transgenic mice lacking the IL-1 receptor type I.** 1154
– A. Abbate, F. Salloum, L. Smithson, A. Varma, I. Seropian, N.N. Hoke, V. Chau, B.W. Van Tassell (Richmond, US)
- 17:30 **Levels of endothelial progenitor cells are increased in thrombectomy-aspirated blood of ST-elevation myocardial infarction patients and correlate with microvascular damage.** 1155
– I. Porto, G.L. De Maria, L.M. Biasucci, L. Di Vito, A.M. Leone, A. Tritarelli, G. Di Rocco, A. Paglia, M.C. Capogrossi, F. Crea (Rome, IT)
- 17:45 **Myocardial ischemia/reperfusion injury in murine cardiac allografts: Erythropoietin inhibits leukocyte adhesion without affecting coronary microcirculatory dysfunction.** 1156
– R. Schramm, S. Kirsch, H.J. Schaeffers, Y. Harder, M.D. Menger (Homburg, DE)



NOVEL ANTITHROMBOTIC DRUGS

Symposium

Chairperson(s): H. Arnesen (Oslo, NO); F. Andreotti (Rome, IT)

- | | | |
|-------|---|-------------|
| 14:00 | New adenosine diphosphate receptor blockers. | 1157 |
| | – D.J. Angiolillo (Jacksonville, US) | |
| 14:22 | Direct antithrombins. | 1158 |
| | – H. Darius (Berlin, DE) | |
| 14:44 | Direct and indirect factor Xa inhibitors. | 1159 |
| | – H.J. Rupprecht (Russelsheim, DE) | |
| 15:06 | Thrombin receptor antagonists. | 1160 |
| | – J. Weitz (Hamilton, CA) | |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

BACK TO THROMBOLYSIS

Clinical Seminar

Chairperson(s): F. Andreotti (Rome, IT); D. Milicic (Zagreb, HR)

- | | | |
|-------|---------------------------------------|-------------|
| 16:30 | In stroke. | 1161 |
| | – J. Sobesky (Cologne, DE) | |
| 16:52 | In myocardial infarction. | 1162 |
| | – K. Huber (Vienna, AT) | |
| 17:14 | In pulmonary embolism. | 1163 |
| | – S.V. Konstantinides (Göttingen, DE) | |
| 17:36 | Critical limb ischaemia. | 1164 |
| | – A.F. Gallino (Bellinzona, CH) | |



STEM CELLS FOR REPAIR: WHICH CELLS, WHAT MECHANISMS

Symposium



Chairperson(s): F. Fernandez-Aviles (Madrid, ES);
G. Condorelli (Milan, IT)

- | | | |
|-------|---|------|
| 14:00 | Circulating endothelial progenitor cells and acute myocardial infarction.
– S. Dimmeler (Frankfurt, DE) | 1165 |
| 14:22 | Pretreatment of stem cells and recipient tissues.
– K. Lunde (Oslo, NO) | 1166 |
| 14:44 | Induced cells as a source for cardiomyocytes.
– U. Martin (Hannover, DE) | 1167 |
| 15:06 | Cardiac stem cells.
– D. Torella (Catanzaro, IT) | 1168 |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

- | | | |
|-------------|---|------|
| 15:45–16:15 | How to write a medical paper
– F.E. Rademakers (Leuven, BE) | 1169 |
|-------------|---|------|



NEW THERAPEUTIC TARGETS IN HEART FAILURE

Symposium

Chairperson(s): G. Condorelli (Milan, IT); P.A.F.M. Doevendans (Utrecht, NL)

- | | | |
|-------|--|------|
| 16:30 | Cell cycle regulation in postmitotic cells.
– R. Von Harsdorf (Toronto, CA) | 1170 |
| 16:52 | Focus on reductive stress.
– I. Benjamin (Salt Lake City, US) | 1171 |
| 17:14 | Oxidative stress in cardiac remodelling.
– A.M. Shah (London, GB) | 1172 |
| 17:36 | The ubiquitin-proteasome system - targeting protein turnover.
– L. Carrier (Hamburg, DE) | 1173 |

HOW TO APPLY INTRACORONARY DIAGNOSTIC TOOLS FOR CLINICAL DECISION MAKING **How-to Session**

Chairperson(s): N.H.J. Pijls (Eindhoven, NL); F. Alfonso Manterola (Madrid, ES)

- 14:00 **How can intravascular ultrasound help?** **1174**
– G. Finet (Lyon, FR)
- 14:45 **How can intracoronary pressure management help?** **1175**
– E. Barbato (Aalst, BE)

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

SOUND, LIGHT OR PRESSURE IN THE CATH LAB? **Clinical Seminar**

Chairperson(s): E. Regar (Rotterdam, NL); G. Pavlides (Athens, GR)

- 16:30 **Which modality to determine lesion severity?** **1176**
– F. Schiele (Besançon, FR)
- 16:52 **What is most useful to guide percutaneous intervention?** **1177**
– W. Wijns (Aalst, BE)
- 17:14 **Which technique to assess safety and efficacy of drug-eluting stents?** **1178**
– S. Windecker (Berne, CH)
- 17:36 **How evaluate endothelial function?** **1179**
– H.H. Pereira (Almada, PT)

NEW INSIGHTS INTO MYOCARDIAL FUNCTION USING ECHOCARDIOGRAPHY

Symposium

Chairperson(s): L.A. Brodin (Huddinge, SE); Z. Vered (Zerifin, IL)

- | | | |
|-------|--|------|
| 14:00 | Technical background of two-dimensional speckle tracking techniques.
– J.U. Voigt (Leuven, BE) | 1180 |
| 14:22 | Validation studies of two-dimensional speckle tracking.
– T. Helle-Valle (Oslo, NO) | 1181 |
| 14:44 | Current clinical role in coronary artery disease.
– M.-M. Becker (Aachen, DE) | 1182 |
| 15:06 | Clinical value in cardiomyopathies and valve disease.
– L.E. Sade (Ankara, TR) | 1183 |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

THE LINK BETWEEN DISTURBED ELECTRICAL CONDUCTION AND MECHANICAL FUNCTION IN HEART FAILURE

Clinical Seminar

Chairperson(s): G.A. Derumeaux (Bron, FR); O.A. Breithardt (Erlangen, DE)

- | | | |
|-------|---|------|
| 16:30 | Pathophysiology of dyssynchrony.
– F.W. Prinzen (Maastricht, NL) | 1184 |
| 16:52 | Assessing dyssynchrony by delayed electrical activation.
– C. Leclercq (Rennes, FR) | 1185 |
| 17:14 | Assessing mechanical dyssynchrony by echocardiography.
– C. Parsai (London, GB) | 1186 |
| 17:36 | How to assess electromechanical delay.
– K. Russell (Oslo, NO) | 1187 |

PULMONARY HYPERTENSION IN CONGENITAL HEART DISEASE **Symposium**

Chairperson(s): N. Galie (Bologna, IT); L. Mertens (Toronto, CA)

- | | | |
|-------|---|-------------|
| 14:00 | Pathophysiology.
– R.M.F. Berger (Groningen, NL) | 1188 |
| 14:22 | Cardiac imaging.
– P. Trigo Trindade (Zurich, CH) | 1189 |
| 14:44 | Biomarkers.
– H. Baumgartner (Munster, DE) | 1190 |
| 15:06 | Management.
– J.L. Vachieri (Brussels, BE) | 1191 |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

CONGENITAL CARDIOLOGY IN ADULTS: LATEST NEWS FROM AROUND THE WORLD **Symposium**

Chairperson(s): F.J. Meijboom (Utrecht, NL); B.J.M. Mulder (Amsterdam, NL)

The European Society of Cardiology and the International Society for Adult Congenital Heart Disease

- | | | |
|-------|--|-------------|
| 16:30 | Catheter interventions in congenital cardiology: latest developments.
– To be announced | 1192 |
| 16:52 | Management of pregnancy in patients with heart disease: risk and pitfalls.
– P.G. Pieper (Groningen, NL) | 1193 |
| 17:14 | What's new in imaging of congenital heart diseases?
– W.R. Davidson (Hershey, US) | 1194 |
| 17:36 | Aortic stenosis: the role of statins and percutaneous treatment.
– H. Baumgartner (Munster, DE) | 1195 |



ESC WILLIAM HARVEY LECTURE ON BASIC SCIENCE **ESC Lecture**

Chairperson(s): R. Ferrari (Ferrara, IT); J. Waltenberger (Maastricht, NL)

- 14:00 **Announcement by the chairpersons.** 1196
 14:01 **Presentation of the awardee.** 1197
 – R. De Caterina (Chieti, IT)
 14:05 **Calcium handling in cardiac myocytes: at the interface between contractility and arrhythmias.** 1198
 – K.R. Sipido (Leuven, BE)
 14:25 **Diploma by the chairpersons.** 1199

ESC ANDREAS GRUENTZIG LECTURE ON INTERVENTIONAL CARDIOLOGY **ESC Lecture**

Chairperson(s): R. Ferrari (Ferrara, IT); J. Waltenberger (Maastricht, NL)

- 14:26 **Announcement by the chairpersons.** 1200
 14:27 **Presentation of the awardee.** 1201
 – C. Di Mario (London, GB)
 14:31 **Biomarkers in interventional cardiology.** 1202
 – C.W. Hamm (Bad Nauheim, DE)
 15:01 **Diploma by the chairpersons.** 1203



ESC KETTY SCHWARTZ LECTURE ON BASIC SCIENCE **ESC Lecture**

Chairperson(s): R. Ferrari (Ferrara, IT); J. Waltenberger (Maastricht, NL)

- 15:02 **Announcement by the chairpersons.** 1204
 15:03 **Presentation of the awardee.** 1205
 – P. Gueret (Creteil, FR)
 15:07 **Familial hypertrophic cardiomyopathy: from gene mutations to proteasome alterations.** 1206
 – L. Carrier (Hamburg, DE)
 15:27 **Diploma by the chairpersons.** 1207

15:30 **Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)**



CLINICAL AND GENETIC MARKERS IN CARDIOMYOPATHIES **Abstracts**

Chairperson(s): Y. Tamman (Damascus, SY); J. Mogensen (Aarhus, DK)

- 16:30 **Long-term outcome of patients with end-stage idiopathic dilated cardiomyopathy and evidence for autoantibodies against beta-1 adrenoceptors after immunoglobulin adsorption therapy.** 1208
 – M. Dandel, G. Wallukat, H.B. Lehmkühl, A. Englert, R. Hetzer (Berlin, DE)
 16:45 **Genotype-phenotype correlation in ARVC patients carrying a causative mutation of the different disease genes encoding for desmosome components.** 1209
 – I. Rigato, B. Bauce, A. Rampazzo, A.K. Steriotis, E. Mazzotti, C. Basso, G.A. Danieli, G. Thiene, A. Nava (Padua, IT)
 17:00 **Noncompaction Cardiomyopathy; mutation spectrum, distribution of disease genes and implications for diagnostic strategies.** 1210
 – Y.M. Hoedemaekers, K. Caliskan, M. Van Tienhoven, M. Michels, F.J. Ten Cate, D.F. Majoor Krakauer, D. Dooijes (Rotterdam, NL)
 17:15 **Late gadolinium-enhanced CMR predicts atrial fibrillation in hypertrophic cardiomyopathy: Implications for a new proposed risk scale.** 1211
 – F. Marin Ortuno, A. Garcia-Honrubia, X. Fernandez, M.J. Oliva, J. Gonzalez, V. Climent, G. De La Morena, R. Soler, M. Valdes, L. Monserrat (Murcia, Alicante and A Coruna, ES)
 17:30 **Prevalence of double or compound heterozygosity in a consecutive series of genotyped patients with hypertrophic cardiomyopathy.** 1212
 – M. Tagliani, M. Pasotti, A. Serio, F.I. Gambarin, M. Grasso, N. Marziliano, A. Pilotto, S. Ghio, L. Scelsi, E. Arbustini (Pavia, IT)
 17:45 **Prognostic value of a systematic familial screening in idiopathic dilated cardiomyopathy. The experience of trieste heart muscle disease.** 1213
 – M. Moretti, M. Merlo, G. Barbati, G. Sabbadini, L. Mestroni, F. Brun, A. Di Lenarda, G. Sinagra (Trieste, IT; Denver, US)

**THE ROLE OF IMAGING IN EVALUATING
REVASCULARISED PATIENTS**

Symposium

Chairperson(s): R. Martin (Atlanta, US); S. Carerj (Messina, IT)

- | | | |
|-------|---|------|
| 14:00 | When is imaging useful in asymptomatic patients? | 1214 |
| | – M.J. Zellweger (Basel, CH) | |
| 14:22 | Coronary computed tomography for evaluating stents and bypass grafts. | 1215 |
| | – P.A. Kaufmann (Zurich, CH) | |
| 14:44 | Is single-photon emission computed tomography predicting prognosis in revascularised patients? | 1216 |
| | – S.R. Underwood (London, GB) | |
| 15:06 | Anatomy, function or both for evaluating patients after revascularisation? | 1217 |
| | – H. Sochor (Vienna, AT) | |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

QUANTITATIVE IMAGING OF MYOCARDIAL PERFUSION: FROM TECHNIQUES TO CLINICAL USE **Symposium**

Chairperson(s): E. Alexanderson Rosas (Mexico, MX); P. Perrone-Filardi (Naples, IT)

- | | | |
|-------|---|------|
| 16:30 | How to measure myocardial perfusion in absolute terms. | 1218 |
| | – J.M. Knuuti (Turku, FI) | |
| 16:52 | Perfusion imaging and microvascular dysfunction. | 1219 |
| | – P.G. Camici (London, GB) | |
| 17:14 | Quantifying regional perfusion in coronary artery disease: which advantage for the clinicians? | 1220 |
| | – H.J. Ukkonen (Turku, FI) | |
| 17:36 | Myocardial perfusion and heart failure. | 1221 |
| | – D. Neglia (Pisa, IT) | |

VALVULAR HEART DISEASE IN WOMEN

Clinical Seminar

Chairperson(s): C. Gohlke-Baerwolf (Bad Krozingen, DE); R. Rosenhek (Vienna, AT)

- | | | |
|-------|---|------|
| 14:00 | Why are females and the mitral valve the predominant target in rheumatic heart disease?
– R. Ribeiras (Carnaxide, PT) | 1222 |
| 14:22 | Do we need different criteria for valve surgery in women?
– A. Sambola Ayala (Barcelona, ES) | 1223 |
| 14:44 | Risk of pregnancy in valve disease.
– P.G. Pieper (Groningen, NL) | 1224 |
| 15:06 | What type of prosthetic valves?
– L.S. De Santo (Naples, IT) | 1225 |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)

THE AORTIC VALVE AND THE AORTA: WHAT THE CLINICIAN NEEDS TO KNOW

Clinical Seminar

Chairperson(s): B.D. Prendergast (Oxford, GB); L. Moura (Matosinhos, PT)

- | | | |
|-------|---|------|
| 16:30 | Marfan disease. Evolving concepts and treatments.
– C.M. Otto (Seattle, US) | 1226 |
| 16:52 | Bicuspid aortic valve.
– J.J. Kaden (Mannheim, DE) | 1227 |
| 17:14 | Aortic dissections. Lessons from the IRAD registry.
– A. Evangelista Masip (Barcelona, ES) | 1228 |
| 17:36 | Surgical options for the dilated aorta at the time of aortic valve replacement.
– A. Nobre (Lisbon, PT) | 1229 |



NOVEL BIOLOGICAL MECHANISMS IN EARLY DEVELOPMENT OF CARDIOVASCULAR DISEASE

Chairperson(s): M. Skilton (Lyon, FR); C. Napoli (Naples, IT)

Symposium

Webcast

- | | | |
|-------|--|------|
| 14:00 | C-reactive protein and other plasma markers, of incremental value in risk prediction.
– W. Koenig (Ulm, DE) | 1230 |
| 14:22 | The endothelial surface layer/glycocalyx: an emerging player in vascular health and disease.
– H. Vink (Amsterdam, NL) | 1231 |
| 14:44 | The impact of early diet and interventions on the vasculature in animal models.
– C. Torrens (Southampton, GB) | 1232 |
| 15:06 | Impact of endothelial dysfunction on atherosclerosis development in childhood.
– P. Leeson (Oxford, GB) | 1233 |

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)



TAKING MYOCARDIAL PROTECTION TO THE CLINICAL ARENA Symposium

Chairperson(s): D. Garcia-Dorado Garcia (Barcelona, ES); R. Schulz (Essen, DE)

- | | | |
|-------|--|------|
| 16:30 | New mitochondrial targets for the clinician.
– M. Ovize (Lyon, FR) | 1234 |
| 16:52 | Erythropoietin as a cardioprotectant with clinical potential.
– R. Latini (Milan, IT) | 1235 |
| 17:14 | Protection of the diabetic heart.
– T.T. Nielsen (Aarhus, DK) | 1236 |
| 17:36 | Adult cardiac protection - does remote preconditioning show promise?
– D.J. Hausenloy (London, GB) | 1237 |



CALCIUM STORES IN TIME AND SPACE

Abstracts

Chairperson(s): D.A. Eisner (Manchester, GB); A. Gomez (Montpellier, FR)

- 14:00 **CPVT related RYR2 mutation: impact of an arrhythmogenic disorder on the mechanical properties of myocardium. Insights from a transgenic mouse model.** 1238
 – R. Coppini, C. Ferrantini, F. Stillitano, S. Priori, C. Poggesi, E. Cerbai (Florence and Pavia, IT)
- 14:15 **nNOS gene disruption reduces the diastolic calcium leak from the ryanodine receptor: implications for excitation-contraction coupling in heart failure.** 1239
 – G.B.S. Lim, M.H. Zhang, Y.H. Zhang, B. Casadei (Oxford, GB)
- 14:30 **Role of the cytosolic adenosine level in the regulation of calcium release from the sarcoplasmic reticulum in human atrial myocytes.** 1240
 – A. Llach, C.E. Molina, J. Fernandes, J. Montiel, J. Cinca, L. Hove-Madsen (Barcelona, ES)
- 14:45 **Chronic mechanical unloading of rat hearts disrupts local calcium-induced calcium release in isolated cardiomyocytes.** 1241
 – C. Terracciano, A. Al-Masri, U. Siedlecka, G.K. Soppa, M. Navaratnarajah, S. Hadjiphilippou, M. Ibrahim, M.H. Yacoub (London, GB; Riyadh, SA)
- 15:00 **Nuclear envelope and nucleoplasmic reticulum in cardiac myocytes act as functional calcium stores to regulate nucleoplasmic calcium concentration.** 1242
 – M. Khafaga, T. Mittler, G. Leitinger, S. Jaeger, M. Asgarzoei, L. Seidlmayer, S. Walther, H. Maechler, B. Pieske, J. Kockskaemper (Graz, AT; Gottingen, DE)
- 15:15 **Stimulation of the calcium receptor: A new positive inotropic intervention of the post-ischemic heart.** 1243
 – R. Schreckenber, Y. Abdallah, K.D. Schlueter (Giessen, DE)

15:30 Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)



DAMAGE LIMITATION: VASCULAR REGENERATION AND REPAIR

Abstracts

Chairperson(s): A.C. Newby (Bristol, GB); I. Hoefer (Utrecht, NL)

- 16:30 **A switch between arterial regeneration or chronic inflammation regulated by myeloid notch signaling.** 1244
 – A. Limbourg, C. Napp, L. Hu, J. Larmann, M. Meier, R.H. Adams, G. Theilmeier, H. Drexler, F.P. Limbourg (Hannover and Munster, DE)
- 16:45 **A biological self assembling amphiphilic peptide enhances Endothelial Progenitor Cells growth and paracrine release.** 1245
 – R. Di Stefano, M.C. Barsotti, A. Magera, H. Hosseinkhani, F. Chiellini, D. Dinucci, M. Alderighi, R. Solaro, A. Balbarini (Pisa, IT; Tsukuba, JP)
- 17:00 **The transcription factor FoxP1 modulates vascular formation and endothelial proliferation and is upregulated in growing collateral arteries.** 1246
 – S. Grundmann, R. Herpers, I.E. Hoefer, J. Sluijter, M.J. Goumans, M. Moser, C. Bode, S. Schulte-Merker, G. Pasterkamp, D.P.V. De Kleijn (Freiburg im Breisgau, DE; Utrecht, NL)
- 17:15 **Positioning of transgenic endothelial cells to injured mouse carotid artery by magnetic nanoparticles.** 1247
 – U.M. Becher, A. Hofmann, D. Wenzel, B.K. Fleischmann, G. Nickenig, A. Pfeifer (Bonn, DE)
- 17:30 **Protein Kinase A (PKA) plays a key-role in late ischemic preconditioning-induced protection of endothelial cells from apoptosis.** 1248
 – A. Bellis, D. Castaldo, V. Trimarco, M.G. Monti, B. Trimarco, C. Morisco (Naples, IT)
- 17:45 **The protective effect of T-cadherin on vascular endothelial cells under endoplasmic reticulum stress.** 1249
 – E. Kyriakakis, M. Philippova, M.B. Joshi, V. Bochkov, P. Erne, T.J. Resink (Basel and Lucerne, CH; Vienna, AT)

CARDIOVASCULAR MAGNETIC RESONANCE: A NEW WINDOW ON ISCHAEMIC HEART DISEASE

Abstracts

Chairperson(s): P.T. Buser (Basel, CH); A.C. Van Rossum (Amsterdam, NL)

- 14:00 **The prognostic impact on identification of silent myocardial ischaemia and unrecognized myocardial infarction by cardiac magnetic resonance imaging in diabetic patients.** 1250
 – C.W.S. Chan, S.C.W. Cheung, J. Ho, S. Ho, M. Sun, W.K. Tso, S. Lee, H.F. Tse (Hong Kong, HK)
- 14:15 **Predicting late myocardial recovery during the hyperacute phase of ST-elevation myocardial infarction by contrast-enhanced magnetic resonance imaging.** 1251
 – E. Larose, J. Rodes-Cabau, P. Pibarot, S. Rinfret, C.M. Nguyen, J.-P. Dery, O. Gleeton, L. Roy, R. Delarochelliere, O.F. Bertrand (Quebec, CA)
- 14:30 **Prediction of improvement of myocardial function after recanalisation of a chronic total coronary occlusion: usefulness of combined viability assessment using cardiac magnetic resonance imaging.** 1252
 – S.W.M. Kirschbaum, A. Rossi, H. Boersma, T. Springeling, M. Van Den Ent, G.P. Krestin, D. Duncker, P.W. Serruys, P.J. Feyter, R.J.M. Van Geuns (Rotterdam, NL)
- 14:45 **Clinical correlates of myocardial salvage index in acute ST-segment elevation myocardial infarction: a cardiac magnetic resonance imaging study.** 1253
 – P.G. Masci, J. Ganame, E. Strata, G.D. Aquaro, W. Desmet, V. Valenti, S. Dymarkowski, M. Lombardi, F. Van De Wef, J. Bogaert (Pisa and Rome, IT; Leuven, BE)
- 15:00 **Troponin elevation and delayed gadolinium enhancement (DGE) in patients post-percutaneous coronary intervention (PCI).** 1254
 – S. Watkins, R. McGeoch, M.-J. McLaughlin, T. Steedman, J. Lyne, I. Ford, H.J. Dargie, K.G. Oldroyd (Glasgow and London, GB)
- 15:15 **European Cardiovascular Magnetic Resonance (EuroCMR) registry - Results of the German pilot phase.** 1255
 – O. Bruder, T. Dill, V. Hombach, J. Schulz-Menger, E. Nagel, M. Lombardi, A.C. Van Rossum, A. Wagner, J. Schwitter, H. Mahrholdt (Essen, Bad Nauheim, Ulm, Berlin and Stuttgart, DE; London, GB; Pisa, IT; Amsterdam, NL; Durham, US; Zurich, CH)

15:30 **Coffee break (Exhibits, Moderated Posters, Meet the Trialist, Read with the Experts, How-to Tutorials & Hands-on Tutorials)**

CARDIAC COMPUTED TOMOGRAPHY: FROM MOLECULES TO CLINICS

Abstracts

Chairperson(s): R. Kornowski (Petah Tikva, IL); H.E. Botker (Aarhus, DK)

- 16:30 **Computed tomography with N1177 can identify ruptured atherosclerotic plaques in rabbit model of atherosclerosis.** 1256
 – J.L. Van Herck, G.R.Y. De Meyer, W. Martinet, R.A. Salgado, B. Shivalkar, H. Bult, A.G. Herman, C.J. Vrints (Edegem and Wilrijk, BE)
- 16:45 **Is there a correlation between coronary artery plaque burden assessed by cardiac CT and serum levels of inflammatory biomarkers for the detection of coronary atherosclerosis?** 1257
 – J. Rixe, A. Rolf, A. Koch, H. Nef, H. Moellmann, H. Steiger, D. Erkapic, C.W. Hamm, T. Dill (Bad Nauheim, DE)
- 17:00 **Coronary CT angiographic screening of subclinical coronary atherosclerosis in patients with acute stroke.** 1258
 – Y.E. Yoon, K.H. Jeon, E.J. Chun, S.I. Choi, H.J. Bae, J.W. Suh, D.J. Choi, C.H. Kim, H.J. Chang (Seoul, KR)
- 17:15 **Multislice computed tomography coronary angiography predicts long-term outcome in patients with suspected coronary artery disease.** 1259
 – M. Pasowicz, T. Miszalski-Jamka, P. Klimeczek, R. Barys, M. Krupinski, K. Bury, K. Nycz, M. Lada, B. Laskowicz (Krakow, PL)
- 17:30 **Impact of prospective ECG-triggered sequential scanning in coronary CT angiography on radiation dose and image quality: A subgroup analysis of the PROTECTION I study.** 1260
 – B. Bischoff, T. Meyer, F. Hein, M. Hadamitzky, A. Will, S. Martinoff, J. Hausleiter (Munich, DE)
- 17:45 **Diagnostic accuracy of non-invasive coronary angiography with 320-slice dynamic volume computed tomography.** 1261
 – A. Nasis, M.C. Leung, P.R. Antonis, J.D. Cameron, I.T. Meredith, W.S. Moir, S.A. Hope, J.M. Troupis, M.P. Crosssett, S.K. Seneviratne (Melbourne, AU)

POSTER SESSION 2

Posters must be set up between 13:30 and 14:00, removed between 18:00 and 18:30 and be on display between 14:00 and 18:00. The presenter should be present throughout the coffee break (15:30 and 16:30) in order to discuss the poster.

**MODERATED POSTER 1
CLINICAL AND GENETIC ASPECTS OF CARDIOMYOPATHIES**

Chairperson(s): O. Dubourg (Boulogne-Billancourt, FR); F. Cecchi (Florence, IT)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 15:30 and 16:30.

- | | | |
|-------|--|------------------|
| 15:30 | Myocardial fibrosis as an independent predictor of atrial fibrillation in HCM. A cardiovascular magnetic resonance study. | P1262 |
| | – R. O'Hanlon, C. Bucciarelli-Ducci, A. Grasso, R. Wage, J.C. Moon, D. Dawson, W.J. McKenna, P. Elliott, D.J. Pennell, S.K. Prasad (London, GB) | |
| 15:35 | Primary malignant tumours of the heart: which treatment? | P1263 |
| | – C. Lestuzzi, F. Santini, A. De Paoli, S. Frustaci, E. Viel, M. Telesca, L. Tartuferi, V. Canzonieri, A. Mazzucco, N. Meneguzzo (Aviano and Verona, IT) | |
| 15:40 | Prevalence and quantification of Parvovirus-B19 genome in endomyocardial biopsies of different forms of heart failure. | P1264 (W) |
| | – R. Dennert, S. Velthuis, S. Felix, R.J. Van Suylen, L. Eurlings, P. Wolffs, C. Bruggeman, H.J.G.M. Crijns, S. Heymans (Maastricht, NL) | |
| 15:45 | Diagnostic contribute of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy. | P1265 |
| | – C. Chimenti, A. Cioppa, R. Verardo, M. Rossi, M. Agrusta, M.A. Russo, P. Rubino, A. Frustaci (Rome and Mercogliano, IT) | |
| 15:50 | Short- and long-term prognosis of Tako-tsubo cardiomyopathy in the Italian Multicenter Registry. | P1266 |
| | – M. Previtali, A. Repetto, R. Camporotondo, P. Faggiano, E. Baldini, R. Citro, D. Bovelli, G. Pasquetto, E. Bossone, C. Klersy (Pavia, Brescia, Legnano, Vallo Della Lucania, Terni, Mirano and Cava Dei Tirreni, IT) | |
| 15:55 | Tissue determinants of ECG abnormalities in arrhythmogenic right ventricular cardiomyopathy: a study performed by cardiac contrast-enhanced magnetic resonance. | P1267 |
| | – M. Perazzolo Marra, B. Bauce, A.K. Steriotis, F. Corbetti, I. Rigato, E. Mazzotti, D. Corrado, L. Cacciavillani, C. Basso, A. Nava (Padua, IT) | |
| 16:00 | Long-term outcome of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. | P1268 |
| | – L. Faber, D. Welge, H. Seggewiss, D. Hering, O. Oldenburg, D. Horstkotte (Bad Oeynhausen and Schweinfurt, DE) | |
| 16:05 | Genotype-to-phenotype correlations in dilated and hypertrophic cardiomyopathy: initial results from the German Heart Failure Network. | P1269 |
| | – S. Waldmueller, G. Gelbrich, P. Binner, M. Loeffler, H. Schunkert, T. Scheffold (Dortmund, Leipzig and Lubeck, DE) | |
| 16:10 | Discussion. | P1270 |

MODERATED POSTER 2
ACUTE CORONARY SYNDROMES – PITFALLS AND DILEMMIAS

Chairperson(s): M.A. Alonso Garcia (Madrid, ES); J. Mirat (Zagreb, HR)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 15:30 and 16:30.

- 15:30 **Abciximab vs placebo in patients without ST-elevation acute myocardial infarction undergoing non emergent percutaneous coronary interventions: an updated meta-analysis of randomised trials.** P1271
 – G. Ferrante, F. Andreotti, G. Niccoli, G. Liuzzo, R.A. Montone, N. Cosentino, P. Barlis, D. Locca, A.G. Rebuzzi, F. Crea (Rome, IT; Victoria, AU; London, GB)
- 15:35 **More than three simultaneous antithrombotic drugs: no benefit, just higher bleeding risk. Metaanalysis of nine randomized trials.** P1272
 – R. Petr, P. Widimsky, Z. Motovska (Prague, CZ)
- 15:40 **Beyond the anticoagulant activity: different effect of glyco-anticoagulants and oligosaccharides on angiogenesis and vasculogenesis.** P1273
 – R. Di Stefano, M.C. Barsotti, E. Da Pozzo, S. Bendinelli, C. Martini, A. Balbarini (Pisa, IT)
- 15:45 **Combined results and long-term follow-up in NORVIT and WENBIT with 6837 coronary artery disease patients: Homocysteine-lowering B-vitamin treatment does not prevent major cardiovascular events.** P1274
 – M. Ebbing, K.H. Bonna, J.E. Nordrehaug, P.M. Ueland, E. Arnesen, H. Refsum, I. Njolstad, D.W. Nilsen, K. Rasmussen, O. Nygard (Bergen, Tromso, Oslo and Stavanger, NO)
- 15:50 **Clinical evaluation plus Nt-proBNP versus exercise testing for decision making in acute chest pain of uncertain origin.** P1275
 – E. Santas, J. Sanchis, X. Bosch, V. Bodi, J. Nunez, A. Doltra, M. Heras, L. Mainar, E. Bragulat, A. Llacer (Valencia and Barcelona, ES)
- 15:55 **Beneficial effect of preinfarction angina on in-hospital outcome in patients with acute myocardial infarction.** P1276
 – Y. Pak, E. Lykasova, V. Todosiychuk, V. Kuznetsov (Tyumen, RU)
- 16:00 **Is there an influence of age on the results of percutaneous coronary interventions (PCI) in patients with non ST-elevation acute coronary syndromes (NSTEMI-ACS)? Results from the ALKK PCI registry.** P1277
 – R. Zahn, M. Hochadel, U. Zeymer, H. Darius, S. Kerber, K.E. Hauptmann, J. Senges, H. Mudra (Ludwigshafen am Rhein, Berlin, Bad Neustadt, Trier and Munich, DE)
- 16:05 **Coronary artery spasm in unstable angina pectoris: assessment of plaque morphology and dynamic state of vasoconstriction by optical coherence tomography.** P1278
 – M. Mizukoshi, A. Tanaka, S. Takarada, H. Kitabata, T. Tanimoto, K. Hirata, K. Komukai, K. Ishibashi, T. Imanishi, T. Akasaka (Wakayama, JP)
- 16:10 **Discussion.** P1279

SCREENING OF CORONARY ARTERY DISEASE

- Relationship between carotid and femoral intima-media thickness and symptomatic coronary atherosclerosis.** P1280
 – A. Mirek, W. Ruminski (Lublin, PL)
- Comparison of IVUS and QCA in patients presenting with atypical chest pain, inconclusive stress testing and significant lesions detected by MDCT-64.** P1281
 – G.B. Pedrazzini, I. D'Angeli, F. Faletra, C. Klersy, E. Pasotti, T. Moccoetti, A. Auricchio (Lugano, CH; Pavia, IT)
- Abnormal coronary vasoreaction in patients with suspected CAD but normal coronary arteries (ACOVA study).** P1282
 – P.E. Ong, A. Athanasiadis, G. Meinhardt, S. Hill, H. Mahrholdt, U. Sechtem (Stuttgart, DE)
- Diagnostic power of different pretest algorithms in patients with chest pain.** P1283
 – M. Elkheyr, N. Houe, O. May (Herning, DK)
- Prognostic power of different pretest algorithms regarding major cardiovascular events in patients with chest pain.** P1284
 – N. Houe, M. Elkheyr, O. May (Herning, DK)
- Dual-source CT angiography versus exercise ECG for assessment of stable chest pain in a population with low disease prevalence.** P1285
 – K. Nieman, T. Galema, A. Weustink, A. Moelker, L. Neefjes, N. Mollet, P. Musters, R. De Visser, P. De Feyter (Rotterdam, NL)
- A review of outcome of patients with chest pain in rapid access chest pain clinic. A district general hospital experience.** P1286
 – M. Batra, P. Batra (Crewe, GB)
- Genetic variability of fibrinogen a-chain gene defines fibrinogen levels between healthy individuals and patients with documented atherosclerosis: effects on prothrombotic profile.** P1287
 – N. Papageorgiou, D. Tousoulis, G. Hatzis, A. Miliou, C. Antoniadis, M. Kozanitou, A. Giolis, C. Tentolouris, E. Bosinakou, C. Stefanadis (Athens, GR)
- Can BNP and Troponin T predict coronary artery disease and mortality in patients with chronic kidney disease at initiation of renal replacement therapy?** P1288
 – A. Tanaka, Y. Suzuki, K. Miki, N. Yasuda, T. Hirai, N. Suzuki, H. Asada, T. Tanaka (Okazaki, JP)
- Prognostic value of C-reactive protein in subjects with no apparent heart disease but daily-life silent myocardial ischemia.** P1289
 – M.R. Mouridsen, T. Intzilakis, Z. Binici, O.W. Nielsen, A. Sajadieh (Copenhagen, DK)
- Is spot urinary albumin or albumin to creatinine ratio more useful for predicting coronary artery disease?** P1290
 – E. Ural, T. Kilic, F. Aygun, U. Bildirici, G. Oner, M. Cekmen, D. Ural (Kocaeli, TR)
- Clinical assessment of ischemia modified albumin and heart- fatty acid binding protein in early diagnosis of non ST elevation acute coronary syndrome in emergency department.** P1291
 – S. Charpentier, J.L. Ducasse, M. Cournot, F. Maupas-Schwalm, M. Elbaz, H. Juchet, D. Lauque (Toulouse and Foix, FR)
- Asymmetric dimethylarginine (ADMA) levels correlate with the angiographic extent of coronary artery disease in patients with stable angina and/or abnormal stress test.** P1292
 – N. Ioakeimidis, C. Vlachopoulos, D. Terentes-Printzios, K. Baou, G. Antoniou, P. Xaplanteris, G. Lazaros, G. Roussakis, C. Aggeli, C. Stefanadis (Athens, GR)
- Serum adiponectin, resistin and angiogenin as predictors of major adverse cardiac events (MACE) in 1-year follow-up of patients with stable, multivessel coronary artery disease.** P1293
 – R. Krecki, J. Drozd, P. Szczesniak, J.D. Kasprzak, P. Lipiec, K. Wierzbowska-Drabik, D. Orszulak-Michalak, M. Krzeminska-Pakula (Lodz, PL)
- Multiple marker approach to risk stratification in patients with stable coronary artery disease.** P1294
 – R. Schnabel, E. Lubos, P.S. Wild, T. Zeller, C.R. Sinning, T. Kempf, K. Wollert, K.J. Lackner, T.F. Munzel, S. Blankenberg (Mainz and Hannover, DE)

- Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris.** P1295
 – E.R. Pedersen, T. Ueland, R. Seifert, H. Schartum-Hansen, P. Aukrust, M. Ebbing, G. Svingen, O. Bleie, J.E. Nordrehaug, O. Nygaard (Bergen and Oslo, NO)
- Severity of coronary atherosclerosis and platelets activity in patients with coronary artery disease.** P1296
 – T. Pavlova, D. Duplyakov, G. Saveleva, V. Polyakov, S. Khokhlunov (Samara, RU)
- Relationships of serum angiogenin with biochemical risk factors and angiographic severity of multivessel coronary disease.** P1297
 – R. Krecki, J. Drozd, P. Szczesniak, J.D. Kasprzak, P. Lipiec, K. Wierzbowska-Drabik, D. Orszulak-Michalak, M. Krzeminska-Pakula (Lodz, PL)
- High-sensitive cardiac troponin I in patients with stable cardiovascular disease and indication for heart catheterisation.** P1298
 – O. Schulz, M. Reinicke, G. Berghoefer, R. Bensch, J. Kraemer, I. Schimke, A.S. Jaffe (Berlin, DE; Rochester, US)
- Pregnancy associated plasma protein A, a marker for outcome in patients with stable coronary heart disease.** P1299
 – K.K. Iversen, P. Grande, P. Clemmesen, P. Winkel, C. Gluud, J. Kastrup (Copenhagen, DK)
- Correlation between carotid and coronary disease in patients with acute coronary disease.** P1300
 – L. Franceschini, E. Zorzi, R. Abukaresh, M.P. Donataggio, N. Cicorella, E. Battaia, C. Vassanelli (Verona, IT)

NEW ADVANCES IN STEMI

- CHADS2 score accurately predicts early and late mortality in patients presenting for STEMI.** P1301
 – F. Beygui, O. Barthelemy, A. Bellemain-Appaix, J. Silvain, J.P. Collet, N. Vignolles, G. Montalescot (Paris, FR)
- Microcalcifications in culprit lesions of patients with ST-elevation acute myocardial infarction are associated with osteopontin and C- reactive protein - a thrombectomy study.** P1302
 – X. Li, M.C. Kramer, C.M. Van Der Loos, K.T. Koch, J.G.P. Tijssen, R.J. De Winter, A.C. Van Der Wal (Amsterdam, NL)
- Early assessment of ST-segment resolution, residual ST-segment elevation and Q waves in relation to left ventricular function, size and extent of infarction, and microvascular injury in AMI.** P1303
 – R. Nijveldt, P.A. Van Der Vleuten, A. Hirsch, A.M. Beek, R.A. Tio, J.G.P. Tijssen, J.J. Piek, A.C. Van Rossum, F. Zijlstra (Amsterdam and Groningen, NL)
- Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction.** P1304
 – H. Tsujioka, T. Imanishi, H. Ikejima, A. Kuroi, T. Tanimoto, H. Kitabata, S. Takarada, K. Hirata, A. Tanaka, T. Akasaka (Wakayama, JP)
- Circulating cytochrome c is a new candidate biomarker of reperfusion injury in ST-segment elevation acute myocardial infarction.** P1305
 – G. Marenzi, M. Giorgio, M. Trinei, M. Moltrasio, P. Ravagnani, D. Cardinale, F. Ciceri, A. Cavallero, C.M. Cipolla, A.L. Bartorelli (Milan, IT)

PLATELETS AND CORONARY THROMBOSIS

- Influence of mean platelet volume on post-procedural coronary flow and in-hospital and long term mortality in patients with stemi treated by primary PCI.** P1306
 – M. Kucuk, A. Belgi Yildirim, I. Basarici (Antalya, TR)
- Platelet reactivity assessed by flow cytometric VASP phosphorylation is an independent predictor of death and cardiovascular death in unselected patients undergoing PCI.** P1307
 – S. El Ghannudi, P. Ohlmann, M.L. Wiesel, B. Radulescu, P. Bareiss, M. Chauvin, C. Gachet, O. Morel (Strasbourg and Strasbourg, FR)

- Effects of lower platelet aspirin and clopidogrel response on long-term outcomes in patients with acute STEMI.** P1308
 – D. Milicic, D. Lovric, B. Skoric, J. Samardzic, I. Gornik, K. Narancic Skoric, I. Skorak, D. Puljevic (Zagreb, HR)
- Comparative assessment of platelet P2Y12 signaling in type 2 diabetes mellitus versus non diabetic subjects.** P1309
 – P. Capranzano, J.L. Ferreira, D. Kodlipet, R. Alissa, A. Darlington, R.K. Charlton, B. Desai, L.A. Guzman, T.A. Bass, D.J. Angiolillo (Jacksonville, US)
- Cangrelor inhibits the binding of clopidogrel and prasugrel active metabolites to the P2Y12 receptor.** P1310
 – R. Buckland, H.M. Judge, A. Sugidachi, J.A. Jakubowski, R.F. Storey (Sheffield, GB; Tokyo, JP; Indianapolis, US)
- Insufficient platelet aggregation inhibition by pre-hospital clopidogrel alone vs additional high dose Tirofiban in patients with acute STEMI undergoing primary PCI resulting in worse clinical outcome.** P1311
 – J.J.J. Smit, J.W. Van Werkum, A.A.C.M. Heestermaans, S. Postma, R.S. Hermanides, T. Dill, C. Hamm, E. Kolkman, J.M. Ten Berg, A.W.J. Van 't Hof (Zwolle and Nieuwegein, NL; Bad Nauheim, DE)
- Impact of platelet poor responsiveness to clopidogrel on cardiovascular outcome in type 2 Diabetes mellitus patients treated by percutaneous coronary angioplasty.** P1312
 – S. El Ghannudi, P. Ohlmann, M.L. Wiesel, B. Radulescu, P. Bareiss, M. Chauvin, C. Gachet, O. Morel (Strasbourg and Strasbourg, FR)
- A double-blind and randomized study on the existence and prevention of a rebound phenomenon of platelet aggregation after cessation of clopidogrel treatment.** P1313
 – D. Sibbing, J. Stegherr, J. Mehilli, S. Schulz, S. Braun, I. Graf, W. Vogt, A. Kastrati, N. Von Beckerath, A. Schomig (Munich, DE)
- Levels of platelet microparticles are increased in thrombectomy-aspirated blood of ST-elevation myocardial infarction patients and correlate with thrombus burden of the culprit lesion.** P1314
 – G.L. De Maria, I. Porto, L.M. Biasucci, L. Di Vito, G.P. Niccoli, F. Burzotta, A. Tritarelli, A. Paglia, M.C. Capogrossi, F. Crea (Rome, IT)
- Does the continuous clopidogrel administration overcome the platelet poor response to the drug in patients with acute coronary syndrome and clopidogrel resistance?** P1315
 – K. Kalantzi, A. Dimitriou, H. Milionis, A. Tselepis, I. Goudevenos (Ioannina, GR)
- Impact of renal function on clopidogrel-induced antiplatelet effects in diabetes mellitus patients with coronary artery disease.** P1316
 – D.J. Angiolillo, E. Bernardo, P. Capranzano, M. Sabate, P. Jimenez-Quevedo, F. Alfonso, R. Hernandez-Antolin, T.A. Bass, C. Macaya, A. Fernandez-Ortiz (Jacksonville, US; Madrid, ES)
- Monitoring P2Y12 receptor inhibition with light transmission aggregometry: a comparison with vasodilator stimulated phosphoprotein phosphorylation assay.** P1317
 – D. Aradi, A. Vorobcsuk, M. Tokes-Fuzesi, T. Magyarlaki, I.G. Horvath, A. Komocsi (Pecs, HU)
- Residual platelet activation: Too many methods for an accurate definition in clinical practice.** P1318
 – F.J. Pastor-Perez, J. Rivera, J.A. Hurtado, L. Navarro, J.M. Ruiz-Nodar, V. Roldan, D. Hernandez-Romero, V. Vicente, M. Valdes, F. Marin Ortuno (Murcia and Alicante, ES)
- Clopidogrel administration significantly attenuates the platelet meditative inflammatory response on patients with acute coronary syndrome.** P1319
 – K. Kalantzi, A. Dimitriou, H. Milionis, A. Tselepis, I. Goudevenos (Ioannina, GR)
- Preoperative aspirin discontinuation and perioperative myocardial infarction in patients undergoing CABG procedure.** P1320
 – D. Plicner, Z. Zietkiewicz, R. Stapor, B. Kapelak, A. Pazdan, I. Gorkiewicz-Kot, M. Sniezek-Maciejewska, A. Undas, J. Sadowski (Krakow, PL)
- Pregnane X receptor (PXR) 6 base pair (bp) deletion has no impact on platelet function after a loading dose of 600 mg clopidogrel.** P1321
 – J. Kaufmann, A. Koster, P. Stawowy, A. Mueller, T. Hauptmann, H. Meyborg, T. Berg, K. Graf, E. Fleck (Berlin, DE)

- Increased whole blood platelet aggregation in coronary artery disease patients with a high platelet turnover.** P1322
 – E.L. Grove, A.M. Hvas, S.B. Mortensen, S.B. Larsen, S.D. Kristensen (Aarhus, DK)
- The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists-inducibile platelet reactivity.** P1323
 – T. Gremmel, C.W. Kopp, D. Seidinger, R. Koppensteiner, S. Steiner, S. Panzer (Vienna, AT)
- The impact of premature discontinuation of dual antiplatelet therapy on patients with second generation DES implantation.** P1324
 – C. Patsa, K. Toutouzias, E. Tsiamis, C. Tsioufias, A. Synetos, A. Spanos, C. Liasidis, A. Androulakis, E. Stefanadi, C. Stefanadis (Athens, GR)
- Cardiovascular death and nonfatal MI in ACS patients are predicted by residual platelet reactivity to ADP in the absence of CYP2C19*2 allele: beyond genetic screening.** P1325
 – R. Marcucci, B. Giusti, A.M. Gori, R. Paniccia, C. Saracini, A. Vestri, C. Nanna, A. Cordisco, G.F. Gensini, R. Abbate (Florence, IT)
- Comparison of antiplatelet effects of single versus twice daily dose of aspirin in diabetic coronary patients.** P1326
 – F. Addad, S. Chouchene, Z. Dridi, T. Chakroun, R. Cheaito, M. Mahjoub, M. Hassine, H. Thawaba, H. Gamra (Monastir, TN)
- Differential expression of local versus systemic platelet-monocyte complexes in the circulation of patients with acute coronary syndrome.** P1327
 – B. Majumder, M. Lowdell, C. Smith, R.D. Rakhit (London, GB)
- Baseline platelet size is increased in patients developing stent thrombosis and predicts future residual platelet reactivity despite dual antiplatelet therapy. A case-control study.** P1328
 – Z. Huczek, K.J. Filipiak, J. Kochman, M. Michalak, M. Roik, R. Piatkowski, M. Postula, G. Opolski (Warsaw, PL)
- Detrimental effects of energy drink consumption on platelet and endothelial function.** P1329
 – S. Willoughby, P. De Sciscio, A. Prabhu, R. Roberts-Thomson, C. Schultz, P. Sanders, M. Worthley (Adelaide, AU)
- Altered nitric oxide/cGMP platelet signalling pathway in platelets from patients with acute coronary syndromes.** P1330
 – M. Anselmino, L. Bergandi, P. Dalmasso, M. Cordero, C. Moiraghi, L. Ravera, D. Ghigo, G.P. Trevi, A. Bosia, S. Bergerone (Turin, IT)
- Endothelial P-selectin expression and platelet consumption during sleep in obstructive sleep apnoea.** P1331
 – H. Maruyama, M. Satoh, S. Sakai, S. Kawano, N. Shimojo, K. Tajiri, K. Yasuda, S. Watanabe, K. Aonuma (Tsukuba, JP)
- Does platelet reactivity to clopidogrel effect restenosis after DES implantation?** P1332
 – S. Schulz, D. Sibbing, T. Morath, N. Von Beckerath, J. Mehilli, R.A. Byrne, A. Schomig, A. Kastrati (Munich, DE)
- Can we override clopidogrel resistance?** P1333
 – J.-P. Collet, A. Pena, J.S. Hulot, J. Silvain, O. Barthelemy, F. Beygui, C. Funck-Brentano, G. Montalescot (Paris, FR)
- High platelet reactivity after clopidogrel correlates with the extent of coronary atherosclerosis and predicts peri-procedural outcome in patients with stable angina undergoing PCI.** P1334
 – F. Mangiacapra, O. Muller, C. Trana, A. Ntalianis, W. Wijns, B. De Bruyne, G. Heyndrickx, J. Bartunek, G. Di Sciascio, E. Barbato (Aalst, BE; Rome, IT)

CARDIOVASCULAR MAGNETIC RESONANCE ISCHAEMIC HEART DISEASE

- Three years experience on the prediction of major adverse cardiac events in patients with suspected myocardial ischaemia by adenosine stress magnetic resonance imaging.** P1335
 – W.S. Chan, S.C.W. Cheung, J. Ho, S. Ho, M. Sun, W.K. Tso, S. Lee, H.F. Tse (Hong Kong, HK)
- Complementary role of adenosine stress perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in prognostication of low to moderate cardiac risk patients.** P1336
 – C.W.S. Chan, S.C.W. Cheung, J. Ho, S. Ho, M. Sun, W.K. Tso, S. Lee, H.F. Tse (Hong Kong, HK)

- Impact of infarct size on outcome in MADIT II patients assessed by contrast-enhanced CMR.** P1337
 – C. Jensen, H.-C. Eberle, K. Nassenstein, T. Schlosser, B. Kuepper, C.K. Naber, G.V. Sabin, O. Bruder (Essen, DE)
- Mechanical dyssynchrony of peri-infarct zone during post myocardial-infarction remodeling.** P1338
 – K.H. Schuleri, M. Centola, Y. Kobayashi, K.S. Evers, R. Evers, A.C. Lardo (Baltimore, US)
- Myocardium at risk in STEMI - Validation of T2 edema imaging using magnetic resonance against the angiographic APPROACH-Score.** P1339
 – G. Fuernau, V. Franke, I. Eitel, M. Gutberlet, G. Schuler, H. Thiele (Leipzig, DE)
- Determinants and clinical impact of myocardial salvage assessed by magnetic resonance imaging in patients with STEMI undergoing primary PCI.** P1340
 – I. Eitel, G. Fuernau, M. Sareban, S. Desch, M. Gutberlet, G. Schuler, H. Thiele (Leipzig, DE)
- Failure of 3Tesla MRI to assess the aetiology of acute chest pain with low troponin elevation in patients without significant angiographic coronary artery disease.** P1341
 – I. Lafolie, L. Job, S. Tassan-Mangina, P. Nazeyrollas, C. Marcus, D. Metz (Reims, FR)
- Accuracy of magnetic resonance dual bolus quantitative myocardial perfusion for determining the myocardial area at risk in chronic coronary artery stenosis.** P1342
 – M. Wu, J. Ganame, J. D'Hooze, K. Vermeulen, S. Dymarkowski, J. Bogaert, F. Rademakers, P. Claus (Leuven, BE)
- Endothelin-1 release induced by reperfusion in patients with acute infarction as a predictor of no-reflow assessed by contrast-enhanced magnetic resonance imaging.** P1343
 – H. Thiele, M. Nowak, I. Eitel, C. Stehl, V. Adams, L. Hildebrand, G. Schuler (Leipzig, DE)
- Scar size predicts ventricular tachyarrhythmias better than ejection fraction in primary prevention patients with ischemic cardiomyopathy.** P1344
 – T.A. Meijers, S. De Haan, F. Afsharzada, A.M. Beek, A.C. Van Rossum, C.P. Allaart (Amsterdam, NL)
- Adenosine-stress magnetic resonance imaging in patients with previous percutaneous intervention and coronary bypass graft.** P1345
 – P. Bernhardt, J. Spiess, R. Gradinger, V. Hombach (Ulm, DE)
- High values of glycemia during PCI for STEMI influence intra myocardial hemorrhage lesions development identified by cardiac MRI.** P1346
 – N. Amabile, A. Jacquier, A. Shuhaib, S. Armero, O. Com, F. Paganelli, G. Moulin (Marseille, FR)
- Patterns of myocardial perfusion in the acute and chronic stage after infarction assessed by cardiac magnetic resonance.** P1347
 – A. Mayr, M. Schocke, T. Trieb, K. Pedarnig, G. Klug, W. Jaschke, O. Pachinger, B. Metzler (Innsbruck, AT)
- Pitfall of stress myocardial perfusion MRI: late arrival of coronary flow in the inferior wall.** P1348
 – K. Kitagawa, H. Sakuma, S. Kato, M. Ishida, M. Nagata, H. Miyagi, H. Nakajima, T. Kurita, Y. Ichikawa, K. Takeda (Tsu and Matsusaka, JP)
- Safety of adenosine stress cardiac MRI (SCMR) early after acute ST elevation myocardial infarction (STEMI) post primary angioplasty.** P1349
 – D.T.L. Wong, R. Das, M.C. Leung, K. Williams, B.K. Dundon, P. Molaei, G.Y.H. Liew, K.S. Teo, M.I. Worthley, S.G. Worthley (Adelaide, AU)

CARDIAC COMPUTED TOMOGRAPHY: CORONARIES

- Coronary CT angiography predicts outcome in intermediate pre-test probability individuals: a prospective study on 1157 patients.** P1350
 – G.M. Feuchtnr, I. Aglan, D. Jodocy, W. Dichtl, K. Feuchtnr, O. Pachinger, G. Friedrich (Innsbruck, AT)
- Diagnostic accuracy of 320-slice multi-slice computed tomography in the non-invasive evaluation of significant coronary artery disease.** P1351
 – F.R. De Graaf, J.D. Schuijff, J.E. Van Velzen, L.J. Kroft, A. De Roos, M.J. Schalij, F. Spano, J.W. Jukema, E.E. Van Der Wall, J.J. Bax (Leiden, NL)

- Computed tomography coronary angiography in patients with diabetes mellitus and suspected coronary artery disease: prognostic value and impact of presenting symptoms compared with nondiabetic patients.** P1352
 – S. Seitun, E. Maffei, A.A. Palumbo, C. Martini, F. Cademartiri (Parma, IT)
- Epicardial adipose tissue predicts the presence and severity of coronary artery disease detected by multidetector computed tomography coronary angiography.** P1353
 – E. Tulumen, B. Kaya, H. Yorgun, O. Ertugrul, O.S. Devenci, T. Hazirolan, K. Aytemir, S.L. Tokgozoglu, H. Ozkutlu, A. Oto (Ankara, TR)
- MSCT coronary angiography: just the coronaries.** P1354
 – D. Tavella, R. Malago, F. Beltrame, F. Cademartiri, R. Pozzi Mucelli, P. Benussi (Verona and Parma, IT)
- Atherosclerotic plaque burden and morphology: a comparison between intravascular ultrasound virtual histology and CT coronary angiography.** P1355
 – M. Ciardetti, M. Bianchi, E. Lami, M. Shlueter, M. Coceani, A. Perinazzo, A. Mazzarisi, P. Marraccini (Pisa, IT)
- Diagnostic accuracy of low-dose coronary CT angiography: comparison between prospective and retrospective ECG gating.** P1356
 – G. Pontone, D. Andreini, A.L. Bartorelli, S. Cortinovis, S. Mushtaq, E. Bertella, A. Annoni, A. Formenti, P.G. Agostoni, M. Pepi (Milan, IT)
- Feasibility and diagnostic accuracy of low dose multidetector computed tomography coronary angiography in the evaluation of coronary stent patency.** P1357
 – D. Andreini, G. Pontone, S. Mushtaq, S. Cortinovis, A. Annoni, A. Formenti, D. Trabattoni, A. Bartorelli, P.G. Agostoni, M. Pepi (Milan, IT)
- Accuracy of dual-source CT to identify coronary artery stenoses in patients with atrial fibrillation: comparison with invasive coronary angiography.** P1358
 – M. Marwan, T. Schepis, A. Renz, T. Pflederer, D. Ropers, W.G. Daniel, S. Achenbach (Erlangen, DE)
- Impact of diabetes mellitus on coronary atherosclerosis in patients with zero calcium score using 64-MDCT.** P1359
 – K. Harada, H. Fujinaga, T. Okumura, N. Kageyama, A. Saitoh, T. Yamamoto (Tokushima, JP)
- Influence of visceral fat accumulation and high-molecular-weight adiponectin levels to coronary plaque as detected by multidetector computed tomographic angiography.** P1360
 – N. Ohashi, H. Yamamoto, T. Kitagawa, E. Kunita, Y. Kihara (Hiroshima, JP)
- The association of epicardial fat volume with coronary plaque using cardiac 64-multislice computed tomography.** P1361
 – K. Okada, K. Harada, H. Funahashi, K. Arai, A. Hirashiki, M. Hayashi, H. Ishii, X.W. Cheng, M. Yokota, T. Murohara (Nagoya, JP)
- The routine use of multi-detector coronary computed tomography in the fast track evaluation of patients with acute chest pain.** P1362
 – R. Beigel, D. Oieru, O. Goitein, P. Chouraqui, E. Konen, S. Brosh, A. Shamiss, H. Hod, J. Or, S. Matetzky (Tel Hashomer, IL)
- The incremental value of mild renal function impairment on the prevalence of coronary artery disease on coronary CT angiography.** P1363 (W)
 – M. Al-Mallah, M. Ali, S. Boedeker, M. Pantelic, K. Abdul-Nour (Detroit, US)
- Usefulness of dual - source computed tomography for the detection of coronary artery disease in patients with arrhythmia - comparison to invasive angiography.** P1364
 – J. Rixe, A. Rolf, D. Erkapic, A. Koch, H. Moellmann, H. Nef, C.W. Hamm, T. Dill (Bad Nauheim, DE)
- Sleeping less than 5 hours daily is associated with increased prevalence of coronary calcification in an asymptomatic male Asian population.** P1365
 – S.Y. Tan, M.N.D. Rico, F. Keng, F.K. Cheah, J. Huang, P.H. Tan, D.S. Swee, T. Chua (Singapore, SG)
- Stent fracture detected by multislice computed tomography after in-stent restenosis caused by multiple overlapping drug-eluting stents.** P1366
 – T. Ito, M. Kimura, M. Ehara, M. Terashima, K. Nasu, Y. Kinoshita, K. Asakura, Y. Asakura, E. Tsuchikane, T. Suzuki (Toyohashi, JP)

- The assessment of radial arteries used as an access at percutaneous coronary intervention by optical coherence tomography.** P1367
 – T. Yonetsu, T. Kakuta, T. Iwamoto, T. Lee, K. Takayama, N. Kawaguchi, H. Fujiwara (Tsuchiura, JP)
- Aortic annulus and ascending aorta: comparison of preoperative and perioperative measurement in patients with aortic stenosis.** P1368
 – M. Smid, J. Ferda, J. Cech, J. Baxa, T. Hajek, R. Rokyta (Plzen, CZ)
- Effect of N-acetylcysteine on serum creatinine and cystatin C levels after cardiovascular procedures.** P1369
 – E. Alioglu, U. Turk, E. Ercan, G.S. Tamer, I. Tengiz, B. Kirilmaz, S. Saygi, N. Tuzun (Izmir, Canakkale and Kocaeli, TR)
- Di-chromatic Synchrotron Angiography- Quantitative perfusion measurements in the heart.** P1370
 – K. Walenta, B. Scheller, H.W. Schenk, T.C. Nurdan, K. Nurdan, S. Fiedler, A.H. Walenta, M. Boehm (Homburg and Siegen, DE; Grenoble, FR)
- Right ventricular remodelling in pulmonary hypertension: the importance of interventricular septum delayed contrast-enhancement on cardiac magnetic resonance.** P1371
 – M. Perazzolo Marra, G.D. Aquaro, C. Bauleo, L. Cacciavillani, C. Basso, S. Iliceto, G. Thiene, C. Marini, M. Lombardi (Padua and Pisa, IT)
- In vivo characterization by magnetic resonance imaging in patients with mild to moderate carotid atherosclerosis.** P1372
 – D. Periat, R. Wytenbach, I. Sudano, M. Oberson, M. Di Valentino, J.M. Segatto, N. Blanda, G. Noll, A. Gallino, R. Corti (Zurich and Bellinzona, CH)
- Normal values of aortic elasticity in 58 adults using Cine-MRI.** P1373
 – C. Billard Philip, A. Lalande, O. Bouchot, J.L. Philip, A. Cochet, J.C. Eicher, R. Cartier, P.M. Walker, F. Brunotte, J.E. Wolf (Dijon, FR; Montreal, CA)
- Myocardial oedema predicts myocardial injury and ventricular function after primary percutaneous intervention following ST elevation myocardial infarction as assessed by T-2 weighted cardiac MRI.** P1374
 – R. Das, D.T.L. Wong, M.C. Leung, K. Williams, G. Liew, P. Molaei, B. Dundon, K.S. Teo, M.I. Worthley, S.G. Worthley (Adelaide, AU)
- Assessment of myocardial area at risk in patients with a ST-elevation myocardial infarction; T2-weighted cardiac magnetic resonance imaging compared to angiographic and electrocardiographic methods.** P1375
 – M. Versteylen, S.C.A.M. Bekkers, M.W. Smulders, C. Mihal, M.H.M. Winkens, H.J.G.M. Crijns, A.P.M. Gorgels (Maastricht, NL)
- Adenosine stress perfusion for detection of coronary artery stenosis at 3T is not inferior to 1.5T magnetic resonance imaging in comparison to invasive coronary x-ray angiography.** P1376
 – P. Bernhardt, J. Spiess, R. Gradinger, V. Hombach (Ulm, DE)
- P wave signal averaged electrocardiogram (P-HiRes) for atrial fibrillation risk evaluation in patients with acute myocardial infarction.** P1377
 – D. Toader, R. Musetescu, D.-D. Ionescu (Craiova, RO)
- Aortic calcification is a marker of severity of coronary artery disease.** P1378
 – D. Alonso Rodriguez, J. Gaztanaga, J. Sanz, I. Iglesias Garriz, L. Fernandez, G. Pizarro, M.A. Rodriguez Garcia, M. Garcia (Leon, ES; New York, US)
- Cardio-ankle vascular index as a predictive determinant for coronary artery calcification as assessed by multi-detector row computed tomography.** P1379
 – R. Mitsutake, S. Miura, Y. Shiga, H. Sako, K. Saku (Fukuoka, JP)
- Value of 64-slice multi-detector computed tomography for predicting revascularisation in patients with coronary artery disease.** P1380
 – H.S. Lim, S.J. Tahk, H.M. Yang, J.S. Park, M. Zheng, S.K. Kim, Y.S. Kwon, B.J. Choi, S.Y. Choi, M.H. Yoon (Suwon, KR)
- Cardiac MR has superior reproducibility compared to cardiac CT for volumes and function analysis of the systemic right ventricle.** P1381
 – M.M. Winter, S.A.H. Romeih, B.J. Bouma, M. Groenink, W.A. Helbing, A.M. Spijkerboer, B.J.M. Mulder (Amsterdam and Rotterdam, NL)

- Evaluation of left ventricular volumes and ejection fraction with 320-slice multi-slice computed tomography: a head-to-head comparison to 2D-echocardiography.** P1382
 – F.R. De Graaf, J.D. Schuijf, J.E. Van Velzen, G. Nucifora, A. De Roos, J.W. Jukema, E.E. Van Der Wall, J.J. Bax (Leiden, NL)
- SIGNALLING AND METABOLIC PATHWAYS INVOLVED IN MYOCARDIAL PROTECTION**
- Investigating the signal transduction pathways underlying remote ischaemic preconditioning and postconditioning.** P1383
 – E.K. Iliodromitis, A. Papalois, G. Gritsopoulos, D.T. Kremastinos, D.M. Yellon, D.J. Hausenloy (Athens, GR; London, GB)
- The cardioprotective effect of TRO40303 is related to binding to the mitochondrial translocator protein and inhibition of the mitochondrial permeability transition pore.** P1384
 – S. Schaller, R. Assaly, S. Paradis, M.A. Ostuni, J.J. Lacapere, R. Zini, A. Berdeaux, R. Pruss, D. Morin (Marseille, Creteil and Paris, FR)
- Double-edged role of the SDF-1/Cxcr4 axis in experimental myocardial infarction.** P1385
 – E. Liehn, N. Tuchscheerer, I. Kanzler, M. Drechsler, S. Zandler, A. Schuh, M. Merx, R. Koenen, A. Schober, C. Weber (Aachen, DE)
- Oxytocin confers cardioprotection through the opening of mitochondrial ATP-sensitive potassium channels.** P1386
 – H. Nishida, T. Sato, N. Inamura, H. Nakaya (Chiba, JP)
- Calpain inhibition at reperfusion limits infarct size in vivo.** P1387
 – C.L. Sartorio, J. Inserte, V. Hernandez, M. Poncelas, D. Garcia-Dorado (Barcelona, ES)
- Role of GSK-3beta in negative regulation of mitochondrial permeability transition pore by the mitochondrial KATP channel.** P1388
 – T. Miura, Y. Terashima, O. Maas, T. Miki, M. Tanno, S. Ishikawa, K. Shimamoto (Sapporo, JP)
- Enhanced ANT-cyclophilin-D interaction underlies reduced anti-infarct tolerance and loss of protective response to erythropoietin in hypertensive hypertrophied hearts.** P1389
 – T. Miki, T. Yano, T. Miura, M. Tanno, K. Shimamoto (Sapporo, JP)
- The loss of MKK7 is beneficial in a murine model of ischemia and reperfusion.** P1390
 – J.G.J. Voelkl, G. Neely, B.J. Haubner, K. Enthofer, N. Malicki, O. Pachinger, J.M. Penninger, B. Metzler (Innsbruck and Vienna, AT)
- Bone marrow chimeric mice reveal the prosurvival potential of PI3Kgamma in the heart.** P1391
 – B.J. Haubner, G. Neely, J.G.J. Voelkl, K. Kuba, Y. Imai, O. Pachinger, J.M. Penninger, B. Metzler (Innsbruck and Vienna, AT)
- Mechanisms involved in the cardioprotective effects of ivabradine against ischemia-induced ventricular fibrillation.** P1392
 – Q. Timour, F. Vaillant, A. Mazzadi, P. Dagorn, J. Descotes, A. Tabib, B. Bui-Xan, D. Belhani, P. Chevalier (Lyon and Courbevoie, FR)
- Combined protective effects of postischemic conditioning and remote perischemic conditioning in a rat ischemic/reperfusion injury model, a comparative study with ischemic preconditioning.** P1393
 – P. Xin, W. Zhu, J. Li, M.Y. Liu, J.B. Li, A.N. Redington, M. Wei (Shanghai, CN; Toronto, CA)
- Cannabinoid receptor activation protects coronary endothelium against reperfusion induced intercellular gap formation in a cellular model of ischemia and reperfusion.** P1394
 – S.A. Kasseckert, H.M. Piper, Y. Abdallah (Giessen, DE)
- Ketamine dose-dependently interferes with diazoxide and anaesthetic pre- and postconditioning elicited cardioprotection.** P1395
 – D. Muntean, G. Gheorghiu, V. Ordodi, N. Mirica, C. Hentia, A. Raducan, O. Duicu, O. Bedreag, M. Papurica, D. Sandesc (Timisoara, RO)
- Depletion of extracellular rna reduces vascular permeability, edema formation and myocardial infarction size.** P1396
 – P. Stieger, M. Grebe, S. Fischer, K.T. Preissner, H. Tillmanns, D. Sedding (Giessen, DE)
- Ivabradine reduces heart rate without affecting metabolic fluxes of normoxic working hearts.** P1397
 – B. Lauzier, F. Vaillant, B. Bouchard, E. Thorin, P. Gluais, J. Roussel, J.C. Tardif, C. Desrosiers (Montreal, CA; Courbevoie, FR)

- PPARgamma or PPARbeta/delta activation reduces insulin responsiveness in cultured cardiomyocytes.** P1398
 – C.H. Montessuit, I. Papageorgiou, R. Lerch (Geneva, CH)
- Des-acyl ghrelin has similar anti-apoptotic and more beneficial metabolic effects than ghrelin in cardiomyocytes.** P1399
 – P.V. Lear, M.J. Iglesias, D. Rodriguez-Penas, S. Feijoo-Bandin, J.R. Gonzalez-Juanatey, M.F. Lago (Santiago de Compostela, ES)
- Diabetic and non-diabetic patients express similar adipose tissue adipokine levels.** P1400
 – E. Teijeira Fernandez, S. Eiras, L. Grigorian Shamagian, A. Salgado Somoza, J.M. Martinez Comendador, J.R. Gonzalez-Juanatey (Santiago de Compostela, ES)
- Feasibility of clinical 1.5T MRI scanners in murine cardiac examination.** P1401
 – J.G.J. Voelkl, B.J. Haubner, C. Kremser, A. Mayr, K. Pedarnig, N. Malicki, K. Enthofer, O. Pachinger, B. Metzler (Innsbruck, AT)
- SIGNALLING PATHWAYS IN CARDIAC GROWTH AND DEATH**
- The impact of MKK7 on cardiac stress adaptation.** P1402
 – B.J. Haubner, G. Neely, J.G.J. Voelkl, N. Malicki, K. Enthofer, O. Pachinger, J.M. Penninger, B. Metzler (Innsbruck and Vienna, AT)
- KMUP-1 attenuates cardiac hypertrophy in rats with isoproterenol-induced cardiac hypertrophy.** P1403
 – J.H. Hsu, J.L. Yeh, I.J. Chen, Z.K. Dai, J.R. Wu (Kaohsiung, TW)
- ANT1-overexpression compensates TGFbeta induced apoptosis via stabilization of the mitochondrial permeability transition pore.** P1404
 – J. Heger, Y. Abdallah, T. Shahzad, G. Euler, H.M. Piper, A. Doerner (Giessen and Berlin, DE)
- Myocyte stress 1 plays an important role in hypertrophy and cardioprotection via a MRTF/SRF signalling pathway.** P1405
 – A.L. Koekemoer, N.W. Chong, A.H. Goodall, N.J. Samani (Leicester, GB)
- The role of bone marrow derived stem cells in a mouse model of hypertrophy.** P1406
 – S. Voss, H.M. Nef, C. Troidl, M. Rauch, S. Kostin, C. Hamm, A. Elsaesser, J. Rixe, A. Rolf, H. Moellmann (Bad Nauheim, DE)
- Transcription factor farnesoid X receptor is expressed in rat cardiomyocytes and regulates cardiomyocytes apoptosis through a mitochondria-dependent pathway.** P1407
 – J. Pu, B. He, P. Shan, A. Yuan, L. Shen, L. Jiang (Shanghai, CN)
- AKAP121 controls mitochondrial function and survival of cardiomyocytes.** P1408
 – G.G. Schiattarella, C. Perrino, G. Gargiulo, G. Pironti, A. Feliciello, M. Saviano, L. Zaccaro, R. Guerriero, G. Esposito, M. Chiariello (Naples, IT)
- Effects of simvastatin on cellular hypertrophy in adult cardiomyocytes in long-term culture.** P1409
 – L. Guzun, V. Ivanov, I. Popovich, N. Ciobanu, M. Popovich, S. Kostin (Brasov, RO; Chisinau, MD; Bad Nauheim, DE)
- Reverse remodeling of the left ventricle during the early phase after relief of pressure overload in a mouse model.** P1410
 – J.L. Bjornstad, I. Sjaastad, S. Nygard, A.V. Finsen, A. Hasic, H. Attramadal, M.S. Ahmed, G. Christensen, T. Tonnessen (Oslo, NO)
- Myocardial expression of the E3-ubiquitin ligases MuRF1 and MafBx in patients with recent myocardial infarction.** P1411
 – V. Adams, V. Conraads, S. Moebius-Winkler, A. Linke, N. Mangner, S. Gielen, G. Schuler (Leipzig, DE; Antwerp, BE)
- The arginine competition: eNOS deficiency and polyamine metabolism.** P1412
 – R. Schreckenberger, S. Forst, K.D. Schlueter (Giessen, DE)
- Erythropoietin receptor deficient mice have impaired cardiac adaptation during voluntary exercise.** P1413
 – W.T. Ruijrok, A.H. Maass, I. Baudoin, B.D. Westenbrink, A.A. Voors, D.J. Van Veldhuisen, W.H. Van Gilst, R.A. De Boer (Groningen, NL)

- Overexpression of myocardial CCN2/CTGF prevents heart failure and improves survival after myocardial infarction.** P1414
 – J. Gravning, H. Attramadal, V.N. Martinov, M.S. Ahmed (Oslo, NO)
- Impedes Mitogenic Signal Propagation (IMP) is responsive towards neurohumoral stimulation controlling MAPK mediated development and cardiac growth.** P1415
 – T. Seidler, C. Grebe, P. Schott, B. Unsoeld, C. Boecker, A. Schmidt, K. Kurz, R. Knoell, K. Guan, G. Hasenfuss (Gottingen, DE)
- Cardiac-specific overexpression of beta3-adrenoreceptors attenuates isoproterenol-induced hypertrophy and fibrosis.** P1416
 – C. Belge, J.L. Hammond, A. Markl, A. Vanderper, B. Sekkali, A. Pouleur, D. Langin, P. Herijgers, C. Dessy, J.L. Balligand (Brussels and Leuven, BE; Toulouse, FR)
- Adenovirus-mediated overexpression of p38 MAPK isoforms induce distinct functional and structural changes in the heart.** P1417
 – H. Pennanen, H. Leskinen, R. Serpi, O. Tenhunen, J. Rysa, E. Mustonen, H. Ruskoaho (Oulu, FI)
- Protective effect of a quinasoline-type poly(ADP-ribose)polymerase inhibitor against the development of hypertensive cardiopathy.** P1418
 – E. Bartha, I. Solti, L. Kereskai, E. Plozer, K. Magyar, T. Kalai, K. Hideg, B. Sumegi, K. Toth, R. Halmosi (Pecs, HU)
- Autoregulation of human relaxin-2 critically involves relaxin and glucocorticoid receptor binding to glucocorticoid response half-sites in the relaxin-2 promoter.** P1419
 – T. Dschietzig, C. Bartsch, G. Baumann, K. Stangl (Berlin, DE)
- Hepatocyte growth factor a new marker for prognosis in acute coronary syndrome.** P1420
 – A. Konopka, J. Janas, J. Stepinska (Warsaw, PL)
- Leptin induces interleukin-18 via endothelin-1-Rho/Rho-kinase-PPAR/NF-kB pathway in cardiomyocytes.** P1421
 – T. Doi, T. Sakoda, T. Akagami, T. Naka, T. Tsujino, T. Masuyama, M. Ohyanagi (Nishinomiya, JP)
- Left ventricular fibrosis secondary to pressure overload is prevented in mice by neutralizing transforming growth factor-beta.** P1422
 – A.V. Villar, M. Cobo, M. Llano, M. Tramullas, V. Exposito, R. Martin-Duran, R. Merino, M.A. Hurle, J.F. Nistal (Santander, ES)
- The sarcolemmal calcium pump modulates the cardiac beta-adrenergic response via interaction with spatially confined nNOS.** P1423
 – T.M.A. Mohamed, D. Oceandy, N. Alatwi, F. Baudoin, E. Cartwright, L. Neyses (Manchester, GB)

INTEGRATED PATHOPHYSIOLOGY

- Kidney removal alters myocardial genes and mediates cardiac fibrosis: a kidney-heart connection in cardiorenal regulation.** P1424
 – F.L. Martin, B.K. Huntley, J. Korinek, G.E. Harders, J.C. Burnett (Rochester, US)
- Myocardial infarction mediates renal molecular and structural remodeling.** P1425
 – F.L. Martin, B.K. Huntley, S.J. Sangaralingham, P.M. Mckie, G.E. Harders, S.M. Sandberg, H.H. Chen, J.C. Burnett (Rochester, US)
- The role of interleukin-17 and RANTES in the development for prognostic factors in acute coronary syndromes.** P1426
- Sleep disordered breathing and high altitude hypoxia: gender related differences. The highcare project.** P1427
 – C. Lombardi, P. Meriggi, M. Bartesaghi, G. Caldara, K. Styckiewicz, G. Bilo, G. Savia, M. Di Rienzo, G. Mancia, G. Parati (Milan, IT; Krakow, PL)
- Increased Wnt-signaling in cardiac repair after myocardial infarction.** P1428
 – M.I.F.J. Oerlemans, M.J. Goumans, H. Clevers, P.A. Doevendans, J.P.G. Sluijter (Utrecht and Leiden, NL)
- Prolonged cardiac unloading in young healthy subjects induces physiologic cardiac atrophy with preserved LV geometry and attenuated longitudinal myocardial function.** P1429
 – M. Kozakova, E. Malshi, C. Morizzo, F. Santini, S. Pedri, M. Pagani, C. Palombo (Pisa, Florence and Milan, IT)

- Altered expression of PAP-3 (Pancreatitis Associated Protein 3) during left ventricular remodeling.** P1430
 – H. Sakkinen, H. Tokola, J. Aro, H. Leskinen, H. Ruskoaho, J. Rysa (Oulu, FI)
- Differential effects of telmisartan, ramipril and the combination in renal (pro)renin levels in diabetic rats.** P1431
 – I. Toma, S.L. Vargas, J.J. Koo, J. Peti-Peterdi (Los Angeles, US)
- Insulin-like growth factor system activity is associated with the course of coronary artery disease.** P1432
 – A. Ushakov, D. Mitrushkin, K. Selivanova, A. Gagarina (Simferopol, UA)
- Myocardial remodeling of the right atrium in patients with ventricular septal defect.** P1433
 – E. Czarnowska, A. Turska-Kmiec, M. Brudek, W. Kawalec, J. Daszkowska-York, W. Lipinski, L. Ziolkowska, M. Pronicki (Warsaw, PL)
- Effects of physical training and aortic constriction on electrical and mechanical activity in rat papillary muscles.** P1434
 – A. Scridon, D. Dobreanu, M. Perian, R.C. Serban (Targu Mures, RO)
- Effects of high altitude exposure on 24 h ambulatory blood pressure - the HIGHCARE2008 project.** P1435
 – G. Bilo, B. Bilo, M. Revera, G. Caldara, A. Giuliano, F. Gregorini, K. Styczkiewicz, A. Faini, G. Mancina, G. Parati (Milan, IT; Krakow, PL)
- Abnormal muscle vascular responses during exercise in patients with recent myocardial infarction.** P1436
 – M.U.B. Rondon, D.G. Martinez, J.C. Nicolau, R.L. Lage, M.C. Laterza, I.C. Trombetta, L.D.J. Matos, C.E. Negrao (Sao Paulo, BR)
- Decreased ventilatory response to exercise by dopamine-induced inhibition of peripheral chemosensitivity.** P1437
 – C. Janssen, S. Beloka, P. Kayembe, G. Deboeck, D. Adamopoulos, R. Naeije, P. Van De Borne (Brussels, BE)
- Isoform-specific activation of NFAT signalling in ANGII and NA-stimulated neonatal cardiomyocytes of mice.** P1438
 – I.G. Lunde, G. Christensen, C.R. Carlson (Oslo, NO)

DIABETES

- Increased cardiovascular mortality associated with glibenclamide and tolbutamide in diabetic patients with acute myocardial infarction that undergo early percutaneous coronary intervention.** P1439
 – C.H. Joergensen, G.H. Gislason, D.M. Bretler, R. Soerensen, T.K. Scramm, S.Z. Abilstroem, C. Torp-Pedersen, P.R. Hansen (Hellerup, Copenhagen and Glostrup, DK)
- Initiation and adherence to statin treatment in patients with diabetes receiving glucose-lowering medications 1996- 2007.** P1440
 – H. Dominguez, T.K.S. Schramm, G.H.G. Gislason, S.Z.A. Abidstrom, L.K. Kober, C.J. Jorgensen, M.L.N. Nygaard, T.G. Guterbaum, H.E.P. Poulsen, C.T.P. Pedersen (Copenhagen, DK)
- Effects of pioglitazone on body weight in the PROactive study population: The obesity paradox in type 2 DM patents with high risk of cardiovascular events.** P1441
 – W. Doehner, E. Erdmann, R. Cairns, J.A. Dormandy, E. Ferrannini, S.D. Anker (Berlin and Cologne, DE; Nottingham and London, GB; Pisa, IT)
- Heart rate as an independent predictor of new onset diabetes in a presumably healthy population. The IPC cohort.** P1442
 – N. Danchin, F. Thomas, K. Bean, E. Eschwege, O. Hanon, T. Simon, B. Jego, B. Panier (Paris, FR)
- New-onset diabetes mellitus and cardiovascular events: a 6 years prospective study in a cohort of 1446 Greek hypertensives.** P1443
 – D. Tsiachris, C. Tsioufis, E. Vezali, C. Thomopoulos, D. Chatzis, G. Hararis, A. Portsi, E. Taxiarchou, A. Moulakakis, C. Stefanadis (Athens, GR)

- Saxagliptin improves glycaemic control either as add-on therapy to metformin or as initial combination therapy with metformin in patients with type 2 diabetes.** P1444
 – I. Gurieva, A. Pfuetzner, M. Antsiferov, E. Allen, S. Ravichandran, R. Chen (Moscow, RU; Mainz, DE; Princeton, US)
- Preoperative oral glucose tolerance testing in vascular surgery patients; long-term cardiovascular outcome.** P1445
 – J.P. Van Kuijk, M. Dunkelgrun, F. Schreiner, W.J.P. Flu, W. Galal, R.T. Van Domburg, S.E. Hoeks, Y.R.B.M. Van Gestel, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL)
- The impact of diabetes on major cardiovascular events in patients with familial combined hyperlipidemia.** P1446
 – C. Masoura, I. Skoumas, C. Pitsavos, K. Aznaouridis, V. Metaxa, F. Platsouka, L. Papadimitriou, T. Tsokanis, N. Giotsas, C. Stefanadis (Athens, GR)
- Cardiac hypertrophy in diabetic mice is prevented by ablation of the G-protein Galpha11.** P1447
 – H. Reuter, D. Hoyer, S. Groenke, Y. Korkmaz, T. Wilkie, N. Wettschureck, S. Offermanns, K. Addicks, E. Erdmann (Cologne and Heidelberg, DE; Dallas, US)
- Acute mountain sickness and energy expenditure in type 1 diabetes during high altitude mountaineering.** P1448
 – S.T. De Vries, P. De Mol, E.J.P. De Koning, A.W.J. Van 't Hof, R.O.B. Gans, H.J.G. Bilo (Zwolle, Nijmegen, Leiden and Groningen, NL)
- Renin-angiotensin system blockade improves the prognosis in diabetic patients. The Barbanza diabetes study.** P1449
 – R.C. Vidal Perez, F. Otero-Ravina, J. Dopico-Pita, M.J. Eiris Cambre, A. Nores-Lorenzo, C. Caneda-Villar, J. Torres-Colomer, L. Grigorian, J.R. Gonzalez-Juanatey (Santiago de Compostela, ES)
- Adiponectin protects against type-2 diabetes in adult men.** P1450
 – S. Sans, T. Padro, L. Badimon (Barcelona, ES)
- Incremental value of global left ventricular systolic strain imaging for the prediction of coronary atherosclerosis in asymptomatic patients with type 2 diabetes mellitus.** P1451
 – A.J.H.A. Scholte, G. Nucifora, R. Djaberli, V. Delgado, J.D. Schuijff, J.W. Jukema, E.E. Van Der Wall, J.J. Bax (Leiden, NL)
- Effect of valsartan, an angiotensin II receptor blocker, on postchallenge hyperglycemia and hyperinsulinemia in patients with coronary artery disease.** P1452
 – S. Koga, S. Ikeda, T. Yamasa, T. Yasunaga, T. Nakata, S. Kohno, K. Maemura (Nagasaki and Sasebo, JP)
- Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes mellitus as assessed by multi-slice computed tomography.** P1453
 – R. Djaberli, J.D. Schuijff, E. Boersma, L.J.M. Kroft, J.W. Smit, A. De Roos, E.E. Van Der Wall, J.M. Van Werkhoven, J.W. Jukema, J.J. Bax (Leiden and Rotterdam, NL)
- Endothelial dysfunction related to the glycemic control as a very early vascular abnormality in young subjects with type 1 diabetes without complications.** P1454
 – R. Di Stefano, C. Palombo, L. Gnesi, C. Morizzo, F. Massart, F. Santini, M. Kozakova, P. Spontoni, A. Balbarini, G. Federico (Pisa, IT)
- Prevalence and control of hypertension and dyslipidaemia in the diabetic population.** P1455
 – N. Cortez-Dias, S. Martins, A. Belo, M. Fiuza (Lisbon, PT)
- Ominous prognosis of insulin treated patients undergoing percutaneous coronary intervention.** P1456
 – R. Castro, R. Teles, S. Lima, P. Carmo, L. Raposo, R. Cale, J. Brito, P. Goncalves, M. Almeida, J.A. Silva (Lisbon, PT)
- N-terminal pro B type natriuretic peptide in overweight and obese patients with and without diabetes: An analysis based on the body mass index and LV geometry.** P1457
 – K.I. Cho, B.H. Kim, D.W. Lee, H.G. Lee, T.I. Kim (Pusan, KR)
- Endothelial progenitor cells reduction in normoglycaemic patients with family history for type 2 diabetes and normal endothelial function.** P1458
 – R. Di Stefano, M.C. Barsotti, C. Grigoratos, L. Pucci, D. Lucchesi, L. Ghiadoni, S. Taddei, G. Penno, S. Del Prato, A. Balbarini (Pisa, IT)

- Increased left ventricular torsion in uncomplicated type 1 diabetes: the role of coronary microvascular function.** P1459
 – G. Nallur Shivu, K. Abozguia, T.T. Phan, I. Ahmed, R. Weaver, A. Wagenmakers, P. Narendran, M. Stevens, M.P. Frenneaux (Birmingham, GB)
- Relationship between the severity of obstructive sleep apnoea with results of oral glucose tolerance tests in Japanese patients with obstructive sleep apnoea.** P1460
 – A. Tamura, Y. Kawano, T. Watanabe, J. Kadota (Yufu and Oita, JP)
- Atorvastatin combined with amlodipine improves metabolic responses to a greater extent than monotherapy in the treatment of hypertensive patients.** P1461 (W)
 – K. Koh, M. Quon, S. Han (Incheon, KR; Bethesda, US)
- Impact of type 2 diabetes mellitus on diffuse inflammatory activation of de novo atheromatous lesions: implications of systemic inflammation.** P1462
 – M. Drakopoulou, K. Toutouzias, A. Synetos, E. Tsiamis, J. Karabelas, D. Tousoulis, A. Karanasos, E. Stefanadi, C. Tsioufis, C. Stefanadis (Athens, GR)
- Dysmetabolic profile in patients with established coronary heart disease.** P1463
 – V. Bongard, J.B. Ruidavets, D. Taraszkiwicz, D. Carrie, M. Galinier, J. Ferrieres (Toulouse, FR)
- Type 2 diabetes significantly modulates the impact of TCF7L2 rs7903146 variant on the risk of coronary atherosclerosis.** P1464
 – A. Muendlein, C.H. Saely, S. Rhomberg, G. Sonderegger, T. Winder, P. Rein, S. Beer, A. Vonbank, H. Drexel (Triesen, LI; Feldkirch, AT)
- Abnormal glucose metabolism in non diabetic patients treated by percutaneous coronary intervention.** P1465
 – S.B. Baptista, A.R. Ferreira, P. Magno, J.R. Loureiro, M. Nedio, C. Monteiro, P. Leal, R. Cabaco, P. Farto E Abreu, V.M. Gil (Amadora, PT)
- Levels of circulating cytokines in type 2 diabetic patients with cardiac autonomic neuropathy.** P1466
 – I. Bondar, A. Demin, O. Shabelnikova (Novosibirsk, RU)
- The effect of drug-eluting stents on clinical and angiographic outcomes in diabetic patients: multicenter registry.** P1467
 – S. Nakamura, H. Ogawa, J.H. Bae, Y.H. Cahyadi, W. Udayachalerm, D. Tresukosol, S. Tansuphaswadikul (Chiba and Kumamoto, JP; Daejeon, KR; Jakarta, ID; Bangkok, TH)
- CRP and MCP-1 - independent predictors of previously unknown abnormal glucose regulation in patients with acute STEMI.** P1468
 – E.C. Knudsen, I. Seljeflot, M. Abdelnoor, J. Eritsland, A. Mangschau, H. Arnesen, G.O. Andersen (Oslo, NO)
- Long term outcome after detection of silent myocardial ischemia in diabetic patients: a randomized study comparing isotopic and echocardiographic stress tests.** P1469
 – O. Barthelemy, S. Jacqueminet, F. Rouzet, R. Isnard, A. Bouzamondo, D. Le Guludec, A. Grimaldi, J.P. Metzger, C. Le Feuvre (Paris, FR)
- The health economic value of aspirin in the primary prevention of cardiovascular disease in diabetic patients.** P1470
 – K. Moeremans, M. Lamotte, K. Wittrup-Jensen, M. Pignone (Brussels, BE; Berlin, DE; Chapel Hill, US)
- Factors relating to inadequate control of blood pressure in diabetic hypertensive outpatients.** P1471
 – T. Livieratos, A.R. Tziouvas, N. Fountas, P.A.N. Koustas, G.E. Kordosis (Agrinio, GR)
- Relationships between carotid intima-media thickness with plaque and brachial-ankle pulse wave velocity in patients with type 2 diabetes.** P1472
 – B.H. Kim, J.S. Jang, C.W. Lee (Busan, KR)

NUTRITION

- Serum selenium concentrations and blood pressure in US adults.** P1473
 – M. Laclaustra, A. Navas-Acien, S. Stranges, J.M. Ordovas, E. Guallar (Madrid, ES; Baltimore and Boston, US; Coventry, GB)
- Coenzyme Q10 and selenium in statin-associated myopathy treatment. Results of randomized double-blind clinical study.** P1474
 – J. Fedacko, D. Pella, R. Rybar, P. Fedackova, D. Dudova (Kosice, SK)

- The acute effect of various glycemic index dietary carbohydrates on endothelial function in non-diabetic overweight and obese subjects.** P1475
 – M. Shechter, A. Karasik, N. Koren-Morag, H. Kanety, M.S. Feinberg, T. Lavi (Tel Hashomer, IL)
- Serum selenium and prognosis in cardiovascular disease results from the atherogene study.** P1476
 – C.R. Sinning, E. Lubos, R. Schnabel, P.S. Wild, T. Zeller, K.J. Lackner, D. Peetz, C. Bickel, T. Muenzel, S. Blankenberg (Mainz, DE)
- Role of serum zinc (Zn) levels and urinary Zn excretion in coronary artery disease (CAD).** P1477
 – D.M. Konstantinou, L. Kovatsi, Y.S. Chatzizisis, G.D. Giannoglou (Thessaloniki, GR)
- Blood pressure modifications after caffeine intake during cognitive tasks.** P1478
 – G. Renda, M. Zimarino, A. Tatasciore, G. Committeri, M. Zurro, F. Santarelli, G. Galati, R. De Caterina (Chieti, IT)
- Do calcium supplements lead to an increase in coronary calcification?** P1479
 – N. Van Pelt, P. Ruygrok, M.J. Bolland, G.D. Gamble, B. Mason, R. Ames, I.R. Reid (Auckland, NZ)
- Increase mortality and morbidity in acute coronary syndromes with low levels of natural anti-phosphorylcholine IgM antibodies.** P1480
 – K. Caidahl, U. De'faire, K. Petersson, J. Herlitz, M. Hartford, J. Frostegard (Stockholm and Gothenburg, SE)
- Calcium intake is independently associated with increased arterial stiffness: results from a cross-sectional follow-up study of two rheumatoid arthritis cohorts.** P1481
 – S. Provan, K. Angel, A.G. Semb, D. Atar, T.K. Kvien (Oslo, NO)
- Reversal of mitochondrial dysfunction by Coenzyme Q10 supplement improves endothelial function in patients with ischemic heart failure.** P1482
 – Y.L.E. Dai, T.H. Luk, C.W. Siu, K.H. Yiu, H.T. Chan, S. Lee, S.W. Li, S. Tam, C.P. Lau, H.F. Tse (Hong Kong, HK)
- Adherence to the Mediterranean diet and albuminuria levels in adolescents: Emerging data from the Lyceum Leontio Albuminuria (3L) study.** P1483
 – A. Mazaraki, C. Tsioufis, K. Dimitriadis, D. Syrseloudis, C. Thomopoulos, P. Tolis, M. Selima, E. Stefanadi, I. Kallikazaros, C. Stefanadis (Athens, GR)
- Antiatheromatic and hypolipidemic activity of chios mastic gum in anesthetized rabbits.** P1484
 – I. Andreadou, E.K. Iliodromitis, S. Paraschos, A. Zoga, S. Mitakou, L. Klakmanis, A.L. Skaltsounis, D.T.H. Kremastinos (Athens, GR)
- Twenty year analysis of nutrition, metabolic risk factors and cardiovascular mortality in Siberian population (1985-2005).** P1485
 – G.I. Simonova, O.M. Bragina, S.V. Shishkin, Y.U.P. Nikitin (Novosibirsk, RU)
- The association between adherence to the Mediterranean diet and fasting indices of glucose homeostasis; the ATTICA Study.** P1486
 – D. Panagiotakos, C. Chrysohoou, C. Pitsavos, J. Skoumas, J. Lentzas, A. Zeibekis, C. Paliou, C. Masoura, A. Katinoti, C. Stefanadis (Athens, GR)
- The effect of a Mediterranean diet combined with dietician supervision on soluble cellular adhesion molecules levels in subjects with abdominal obesity.** P1487
 – L. Rallidis, G. Vamvakou, A. Kolomvotsou, A. Zampelas, S. Efstathiou, E. Voltyrakis, G. Georgoula, J. Lekakis, D. Kremastinos (Athens, GR)
- Nuts and blood lipids in type 2 diabetes.** P1488
 – C.W. Kendall, J.M. Wong, J.L. Sievenpiper, T.L. Parker, S. Mitchell, M.S. Banach, S. Nishi, C.P. Meneses, J.A. Jenkins (Toronto, CA)
- Inclusion of dietary evaluation in cardiovascular disease risk prediction models increases accuracy and reduces bias of the estimations.** P1489
 – D. Panagiotakos, C. Pitsavos, C. Chrysohoou, J. Skoumas, C. Stefanadis (Athens, GR)
- Right atrial enlargement, P-wave extension, PR and QTc intervals prolongation after acute red wine assumption.** P1490
 – A. Garzia, M. Cameli, P. Ballo, E. Palmerini, M. Lisi, A. Palazzuoli, T. Spinelli, S. Mondillo (Siena and La Spezia, IT)

POLITICAL AND FINANCIAL ISSUES

- Economical benefit of the prevention of contrast-induced nephropathy in patients with chronic kidney disease.** P1491
 – H. Takano, E. Yamamoto, M. Takano, G. Takagi, K. Asai, M. Yasutake, K. Mizuno (Tokyo, JP)
- SES is cost effective in treatment of diabetic patients with multiple vessel disease, but leads to a relatively high stent thrombosis rate: the EVASTENT study.** P1492
 – C. Combescure, J. Machecourt, A. Foote, C. Castelli, N. Danchin, G. Vanzetto, J.P. Daures (Nimes, Grenoble and Paris, FR)
- Benefits of an intensified telemedical care program for patients with heart failure - outcomes of a naturalistic study.** P1493
 – F. Zucca, K. Fidorra, K. Pethig, B. Neukirch (Krefeld, Limburg and Hamm, DE)
- Cost effectiveness and clinical performance of dobutamine stress echocardiography in coronary artery disease evaluation in a district hospital setting.** P1494
 – C.A. Miller, S. Srivastava, J. Tollitt, R. Brown, R.M. Egdell, A.A. Cubukcu (Macclesfield, GB)
- Using risk adjustment methodology to improve quality and safety in percutaneous coronary intervention.** P1495
 – P. Sousa, F.J.P. Pinto, A. Sousa-Uva (Lisbon, PT)
- Impact of hospital case load on management and early mortality of patients admitted for acute myocardial infarction (AMI). A nationwide French survey of administrative data.** P1496
 – A. Neuman, P. Tuppin, N. Danchin, A. Weill, P. Ricordeau, C. De Peretti, H. Allemand (Paris, FR)
- Time of admission, quality of PCI care, and outcome of patients with ST-elevation myocardial infarction.** P1497
 – H. Theres, S. Behrens, C. Graf-Bothe, H. Kuckuck, J.-U. Roehnisch, R. Schoeller, H. Schuehlen, B. Maier (Berlin, DE)
- Euro heart survey on AF: costs of Atrial Fibrillation (AF) for ATHENA-like patients in Greece, Italy, Poland, Spain and the Netherlands.** P1498
 – E. Holstenson, E. Morais, J. Berg, R. Nieuwlaat, A. Ringborg, H. Crijns (Stockholm, SE; Paris, FR; Maastricht, NL)

STENT THROMBOSIS AND NEO INTIMAL COVERAGE

- Is there a different early and late benefit - risk balance of DES vs BMS? The role of very late stent thrombosis.** P1499
 – X. Flores Rios, A. Garcia Campos, A. Rodriguez Vilela, G. Aldama Lopez, P. Pinon Esteban, J. Salgado Fernandez, R. Calvino Santos, J.M. Vazquez Rodriguez, N. Vazquez Gonzalez, A. Castro Beiras (A Coruna, ES)
- Do drug-eluting stents really have a higher risk of stent thrombosis than bare-metal stents?** P1500
 – X. Flores Rios, E. Barge Caballero, R. Campo Perez, P. Pinon Esteban, G. Aldama Lopez, J. Salgado Fernandez, R. Calvino Santos, J.M. Vazquez Rodriguez, N. Vazquez Gonzalez, A. Castro Beiras (A Coruna, ES)
- The principle of glycocalix biomimicry: a new coating stent design for patients with unstable coronary lesions. Early results of the Camouflage registry.** P1501
 – J. Mieres, M. Rodriguez-Granillo, C. Carlos Fernandez-Pereira, G. Gustavo Risau, A. Rubilar, G. Perez, C. Llaurado, A. Incarbone, I. Di Pasquo, A. Rodriguez (Buenos Aires, AR)
- Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy.** P1502
 – M. Basalus, K.G. Van Houwelingen, M.J.K. Ankone, P.W. Serruys, C. Von Birgelen (Enschede and Rotterdam, NL)
- Greater late lumen loss after paclitaxel-eluting stent implantation is not associated with homogeneous neointimal coverage.** P1503
 – K. Fukushima, Y. Kobayashi, H. Kitahara, Y. Iwata, N. Ishio, T. Asano, N. Kuroda, I. Komuro (Chiba, JP)

- Endothelial progenitors cells, circulating endothelial cells and cd14+ monocytes in coronary artery disease: effect of stenting with bare-metal, drug-eluting and the genous cd34 antibody coated stents.** P1504
 – A. Siddique, E. Shantsila, R.A.S. Ahmad, A.D. Blann, D.L. Connolly, C. Varma, G.Y.H. Lip (Birmingham, GB)
- Optical coherence tomography analysis of vascular responses following paclitaxel-eluting stent implantation in the lesion with acute coronary syndrome.** P1505
 – M. Habara, M. Terashima, K. Nasu, M. Kimura, Y. Kinoshita, M. Ehara, E. Tsuchikane, Y. Asakura, O. Katoh, T. Suzuki (Toyohashi, JP)
- Very late stent thrombosis in sirolimus-eluting stents after ST-elevation myocardial infarction: three-year clinical outcome of the mission intervention study.** P1506
 – J.Z. Atary, B.L. Van Der Hoeven, S.S. Liem, J.W. Jukema, H. Putter, D.E. Atsma, M. Bootsma, K. Zeppenfeld, E.E. Van Der Wall, M.J. Schalij (Leiden, NL)
- Correlations between intracoronary cytokines levels and native coronary artery plaque composition as assessed by intracoronary ultrasound virtual histology.** P1507
 – S. Fuchs, I. Lavi, O. Tzang, D. Brosh, T. Bental, S. Einav, R. Kornowski (Petah Tikva and Tel Aviv, IL)
- The incidence of incomplete stent strut apposition. Insights from the randomized, multicenter OCT Resolute III substudy.** P1508
 – E. Regar, C. Dimario, C. Macaya, Y. Termijn, P. Gobbens, K. Commissaris, N. Gonzalo, P.W. Serruys (Rotterdam, NL; London, GB; Madrid, ES)
- Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall.** P1509
 – N. Gonzalo Lopez, P.W. Serruys, T. Okamura, S. Zujun, Y. Onuma, H.M. Garcia-Garcia, G. Sarno, C. Schultz, J. Ligthart, E. Regar (Rotterdam, NL)
- Rapid evaluation of vessel healing after angioplasty (REVEAL) study: an optical coherence tomography comparative study with a polyzene-f stent versus bare and drug eluting stents at 7 and 30 days.** P1510
 – A.G. La Manna, M.E. Di Salvo, D. Capodanno, A. Sanfilippo, G. Barrano, F. Prati, C. Tamburino (Catania and Rome, IT)
- Evaluation in 3 moNths Duration of nEointimAl coVerage after zOtaRolimus-eluting stent implantation by Optical Coherence Tomography (ENDEAVOR OCT).** P1511
 – J.-S. Kim, C. Fan, T.H. Kim, J.S. Kim, S.M. Park, Y.G. Ko, D. Choi, Y. Jang, W.H. Shim, S.Y. Cho (Seoul, KR)
- PRE-CLINICAL STUDIES IN PERCUTANEOUS ANGIOPLASTY**
- Vascular healing in comparator drug-eluting stents: differential response of limus-eluting stents?** P1512
 – K. Steigerwald, M. Joner, S. Chin Quee, S. Schoenhofer-Merl, M. Vorpahl, A. Kastrati, A. Schoemig, R. Virmani (Munich, DE; Santa Clara and Gaithersburg, US)
- Endovascular non-thermal irreversible electroporation, a novel electric ablation method, efficiently ablates vascular smooth muscle cells in rabbit iliac arteries evaluated at 7 and 35 days.** P1513
 – E. Maor, A. Ivorra, J. Mitchell, B. Rubinsky (Berkeley and Queensbury, US; Jerusalem, IL)
- Intravenous nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon and result in a better outcome.** P1514
 – Y. Kawai, K. Hisamatsu, H. Matsubara, K. Dan, S. Akagi, K. Miyaji, M. Munemasa, Y. Fujimoto, K.F. Kusano, T. Ohe (Fukuyama and Okayama, JP)
- Ischemia-induced delayed regional relaxation is resolved after 24 hours from percutaneous intervention.** P1515
 – M.S. Shin, B.R. Kim, O.R. Kim, W.J. Chung, S.H. Han, C.I. Moon, T.H. Ahn, I.S. Choi, E.K. Shin (Incheon and Seoul, KR)
- Efficacy of low-pressure drug delivery with a paclitaxel-coated balloon in restenosis inhibition.** P1516
 – B. Cremers, N. Hattangadi, M. Biedermann, U. Speck, D. Mahnkopf, M. Boehm, B. Scheller (Homburg, Berlin and Rottmersleben, DE; Plymouth, US)

Factors that influence measurements and accurate evaluation of stent apposition by optical coherence tomography; Assessment using a phantom model. P1517

– T. Sawada, J. Shite, T. Shinke, D. Ogasawara, H. Kawamori, H. Kato, N. Miyoshi, N. Yoshino, A. Kozuki, K. Hirata (Kobe, JP)

INTRAVASCULAR IMAGING OF ATHEROSCLEROSIS

Combined use of intravascular ultrasound, virtual histology and optical coherence tomography for detecting vulnerable and complicated atherosclerotic plaques. P1518

– G. Sanchez-Elvira, I. Coma-Canella, M. Artaiz, J.A. Paramo, J. Barba, J. Calabuig (Pamplona, ES)

Plasma HDL and LDL/HDL ratio have close correlation to coronary plaque fibrous tissue content assessed by virtual histology technique. P1519 (W)

– H. Ikenouchi, Y. Sugishita, F. Tabei, N. Itoh, A. Nozaki, T. Sugimoto (Tokyo, JP)

Plaque vulnerability and its distribution of the eccentric plaque in gray scale intravascular ultrasound: a study of virtual histology intravascular ultrasound. P1520

– H. Amano, K. Wagatsuma, J. Yamazaki (Tokyo, JP)

Coronary plaque patterns in men and women in relation to age: assessment with multi-slice computed tomography, gray-scale and virtual histology intravascular ultrasound. P1521

– G. Pundziute, J.D. Schuijf, G. Nucifora, J.E. Van Velzen, J.W. Jukema, J.M. Van Werkhoven, A. De Roos, M.J. Schalij, E.E. Van Der Wall, J.J. Bax (Leiden, NL)

Culprit lesions located in the proximal segments of the coronary arteries are characterized by more complex morphological characteristics. An optical coherence tomography study. P1522

– K. Toutouzas, A. Synetos, A. Karanasos, E. Tsiamis, C. Tsioufis, D. Tousoulis, M. Riga, M. Drakopoulou, E. Stefanadi, C. Stefanadis (Athens, GR)

In vivo analysis of ruptured plaques in patients with ST-segment elevation myocardial infarction using IVUS-VH. P1523

– M. Jaster, W. Knie, H.P. Schultheiss, B. Witzensbichler (Berlin, DE)

PHYSIOLOGY, HAEMODYNAMICS AND MICROCIRCULATION

Prognostic impact of non-HLA antibodies targeting vascular receptors for the development of microvasculopathy in biopsy after heart transplantation. P1524

– C. Renner, N.E. Hiemann, R. Meyer, E. Wellnhofer, C. Schoenemann, H. Heidecke, R. Hetzer, D. Dragun (Berlin and Luckenwalde, DE)

Microvasculopathy in biopsy following heart transplantation: 3-year results from a prospective clinical study. P1525

– N.E. Hiemann, E. Wellnhofer, C. Knosalla, H.B. Lehmkühl, R. Hetzer, R. Meyer (Berlin, DE)

Correlation between microvascular obstruction and intracoronary physiologic parameter indexes for assessment of microvascular injury in patients with acute myocardial infarction. P1526

– J.H. Koh, Y.H. Jo, D.K. Jo (Goyang, KR)

Microvascular resistance of culprit and non-culprit territories in the chronic phase of myocardial infarction and LV function. P1527

– A. Ntalianis, C. Trana, C. Baliauw, O. Muller, J. Bartunek, E. Barbato, E. Wyffels, W. Wijns, P. Vanhooenacker, B. De Bruyne (Aalst, BE)

Independent association of pulse pressure and coronary flow velocity at rest in subjects without coronary artery disease. P1528

– M. Galderisi, F. Rigo, S. Gherardi, L. Cortigiani, R. Sicari, A. D'Errico, E. Picano (Naples, Mestre, Cesena, Lucca and Pisa, IT)

N-terminal pro C-type natriuretic peptide levels and erectile function in men with or without coronary artery disease. P1529

– N. Ioakeimidis, C. Vlachopoulos, D. Terentes-Printzios, I. Dima, K. Aznaouridis, N. Alexopoulos, A. Bratsas, G. Sakellariou, C. Fassoulakis, C. Stefanadis (Athens, GR)

- Adenosine induced maximal coronary hyperemia for myocardial fractional flow reserve measurements - comparison of administration by femoral venous versus antecubital venous access.** P1530
 – M. Lindstaedt, A. Yazar, W. Bojara, T. Holland-Letz, L. Mueller, A. Muegge, A. Germing (Bochum, DE)
- Inhibition of ATP degradation reduces macromolecule permeability in rat mesentery arterioles and oedema formation in rat hearts in vivo.** P1531
 – D. Guenduez, U. Krieger, L. Becker, M. Aslam, I. Hussain, F.V. Haertel, R. Voss, M. Grebe, T. Noll, H. Tillmanns (Giessen, DE)
- The inflammatory response post percutaneous coronary intervention is associated with increased microvascular resistance in patients with stable angina.** P1532
 – B. Patel, L. Smith, A. Alahmar, P. Browning, G. Hart, M. Fisher (Liverpool, GB)
- Right ventricular and pulmonary artery pressures correlate with endomyocardial remodelling after heart transplantation.** P1533
 – N.E. Hiemann, E. Wellnhofer, J. Zoschke, R. Hetzer, R. Meyer (Berlin, DE)
- Effects of different vasodilators on no-reflow phenomenon during percutaneous coronary intervention in patients with acute myocardial infarction.** P1534
 – D. Huang, J. Ma, F. Zhang, X. Wang, L. Ge, J. Qian, J. Ge (Shanghai, CN)
- Fractional Flow Reserve (FFR) and Index of Microvascular Resistance (IMR) measurement are not influenced by beta-blockers.** P1535
 – G. Sarno, C. Trana Berza, B. De Bruyne, J. Bartunek, E. Wyffels, A. Ntalianis, F. Mangiacapra, O. Muller, W. Wijns, E. Barbato (Aalst, BE)
- Uric acid level is a predictor of coronary collateral development in patients with non st segment elevation acute coronary syndrome.** P1536
 – M.G. Kaya, A. Kasapkara, R. Topsakal, B. Sarli, A. Oguzhan, M.T. Inanc, A. Dogan, M. Duran (Kayseri, TR)
- Coronary flow velocity reserve deteriorate late (12 months) after sirolimus-eluting stent implantation.** P1537
 – Y. Miyamoto, T. Maehama, K. Saito, K. Imai, N. Okahashi, K. Obase, A. Hayashida, Y. Neishi, T. Kawamoto, K. Yoshida (Kurashiki, JP)
- Transthoracic Doppler MCE identification and analysis of perforating intra-myocardial coronary arteries - A new and early signal of LAD patency post STEMI thrombolysis.** P1538
 – J. Coucello, L. Soares, J. Azevedo, L.C. Bronze Carvalho, A. Aleixo (Lisbon and Portimao, PT)
- Impact of anemia and serum erythropoietin levels on collateral vessel development in patients with coronary artery disease.** P1539
 – B. Candemir, C. Ozdol, S. Gulec, A.O. Ozdemir, C. Erol (Ankara, TR)
- Wall shear stress as a determinante for atherosclerotic remodeling in human coronary arteries.** P1540
 – H. Hetterich, M. Gehring, A. Ibrahim, T. Potzger, T. Redel, K. Nikolaou, C. Schmidt-Tannwald, V. Klauss, J. Rieber (Munich and Forchheim, DE)
- A new angiographic method to assess coronary flow reserve.** P1541
 – H. Rittger, A. Kuper, O. Breithardt, A. Sinha, M. Schmidt, A. Jakob, B. Bluem, J. Brachmann (Coburg, DE; Rosh Hayin, IL)
- Different haemodynamic determinants of aortic pulse wave velocity and central pulse pressure augmentation index: an invasive study.** P1542
 – E. Franchi, G. De Luca, L. Giuliani, L. Venegoni, E. Rondano, G. Dell'era, S. Iorio, P. Marino (Novara, IT)
- Diastolic dysfunction alterations in diabetic patients assessed with Doppler echocardiography: relationship between atheromatosis and coronary microcirculatory disturbances.** P1543
 – H.J. Colmenarez, J. Escaned, M.C. Ferrer, P. Jimenez-Quevedo, F. Alfonso, C. Banuelos, L. Perez De La Isla, J.L. Zamorano, C. Macaya, R. Hernandez (Madrid, ES)

LONG-TERM OUTCOME AFTER PERCUTANEOUS CORONARY SYNDROME

- Improving DES revascularisation rates using new intravascular ultrasound optimization criteria.** P1544
 – R.T. Gerber, A.S.P. Sharp, A. Latib, A. Ielasi, C. Godino, A. Chieffo, M. Carlino, I. Michev, M. Montorfano, A. Colombo (Milan, IT)
- The mechanosensitive calcium-channel TRPV4 is involved in neointimal hyperplasia after coronary stent implantation.** P1545
 – H.M. Nef, H. Moellmann, C. Troidl, S. Voss, G. Markus, S. Kostin, K. Troidl, M. Weber, C.W. Hamm, A. Elsaesser (Bad Nauheim and Oldenburg, DE)
- Polymorphisms of the interleukin 8 gene and restenosis after percutaneous coronary intervention.** P1546
 – K. Vogiatzi, S. Apostolakis, V. Voudris, S. Thomopoulou, G.E. Kochiadakis, D.A. Arfanakis, D.A. Spandidos, P.E. Vardas (Heraklion and Athens, GR)
- Systemic inflammatory response after stent implantation: a randomized comparative study of sirolimus-eluting (SES) and bare metal stents (BMS).** P1547
 – D.A. Arfanakis, G.E. Kochiadakis, M.E. Marketou, E.I. Skaliadis, N.E. Igoumenidis, M.I. Hamilos, P.E. Vardas (Heraklion, GR)
- Evaluation of homeostasis model assessment of insulin resistance (HOMA-IR) index as a predictor of restenosis after percutaneous coronary intervention.** P1548
 – T. Komatsu, I. Yaguchi, K. Tanaka, K. Takizawa, Y. Sakai, K. Takayanagi (Saitama, JP)
- Impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients.** P1549
 – M. Bollati, G. Biondi-Zoccai, T. Palmerini, C. Tamburino, M. Margheri, G. Vecchi, G. Sangiorni, S. De Servi, I. Sheiban (Turin, Bologna, Catania, Florence, Ravenna, Milan and Legnano, IT)
- Long term results of drug eluting stenting in saphenous venous grafts.** P1550
 – A.E.L.R. Assali, H.V.A. Hana Vaknin-Assa, E.L. Eli Lev, I.T. Igal Teplitsky, T.B. Tamir Bental, D.B. David Brosh, D.D. Danny Dvir, S.F. Shmuel Fuchs, A.B. Alexander Battler, R.K. Ran Kornowski (Petah Tikva, IL)
- Prevalence, predictors, and long-term prognosis of discontinuation of oral antiplatelet therapy after DES implantation.** P1551
 – R. Rossini, G. Musumeci, C. Lettieri, T. Nijaradze, G. Biondi Zoccai, M. Romano, N. Lortkipanidze, N. Cicorella, A. Gavazzi, D.J. Angiolillo (Bergamo, Mantova and Turin, IT; Jacksonville, US)
- Antiplatelet treatment after coronary stent implantation. A ‘over-compliance’ situation.** P1552
 – T.H. Bampali, A. Konstantinidis, B. Salma, T.H. Pappas, K. Kalantzi, A. Papanthanasidou, C.H. Katsouras, J. Goudevenos (Ioannina, GR)
- Long-term clinical outcome of conservative versus aggressive intervention strategy in patients with multivessel coronary artery disease undergoing drug-eluting stent implantation.** P1553
 – B.J. Choi, S.J. Tahk, J.S. Park, H.S. Lim, S.Y. Choi, M.H. Yoon, H.M. Yang, M.Z. Zheng, J.W. Hwang, U.J. Choi (Suwon, KR)
- Comparison of drug eluting stents and bare metal stents in saphenous vein graft PCI: a single centre experience.** P1554
 – S. Balakrishnan Nair, S. Chacko, B. Clarke, M. El-Omar, F. Oroudbadi, D. Fraser, V. Mahadevan, R.S. Khattar, L. Neyses, M. Mamas (Manchester, GB)
- Cardiovascular events after thienopyridine discontinuation in a cohort of ‘the novo’ diabetic patients treated with drug-eluting stent implantation.** P1555 (W)
 – N. Morici, N. Mollicelli, F. Ambrogi, A. Latib, P. Boracchi, M. Montorfano, M. Carlino, A. Chieffo, A. Colombo (Milan, IT)
- Field triage of STEMI patients to primary angioplasty significantly reduces treatment delay and improves long-term prognosis.** P1556
 – S. Pedersen, P.R. Hansen, S. Galatius, U. Davidsen, R. Mogelvang, A. Iversen, U. Abildgaard, A. Galloe, J.K. Madsen, J.S. Jensen (Hellerup, DK)

- Short-term plaque regression with intravascular ultrasound predicts long-term outcomes in patients with acute coronary syndrome.** P1557 (W)
 – T. Dohi, K. Miyauchi, S. Okazaki, T. Yokoyama, H. Tamura, T. Kojima, K. Yokoyama, T. Kurata, H. Daida (Tokyo, JP)
- Local persistent hypercoagulability after drug-eluting stent implantation: sirolimus-eluting stent vs. paclitaxel-eluting stent.** P1558
 – K. Yamaguchi, T. Wakatsuki, T. Niki, K. Kusunose, K. Koshiba, T. Iwase, H. Yamada, T. Soeki, M. Akaike, M. Sata (Tokushima, JP)
- CARDIOMYOPATHIES FROM BENCH TO CLINICAL OUTCOMES**
- Brain natriuretic peptide and cardiac imaging allow for early detection of heart involvement in Chagas disease.** P1559
 – A. Garcia-Alvarez, M. Sitges, M.J. Pinazo, E. Posada, S. Poyatos, M. Heras, M. Azqueta, J. Gascon, G. Sanz (Barcelona and Madrid, ES)
- End-tidal carbon dioxide concentration can determine the appropriate recommendation to wean off extracorporeal membrane oxygenation in cardiogenic shock.** P1560
 – T. Naruke, T. Inomata, H. Imai, H. Shinagawa, T. Koitabashi, M. Nishii, I. Takeuchi, H. Takehana, N. Aoyama, T. Izumi (Sagamihara, JP)
- Cardiac energetic impairment in non-obstructive hypertrophic cardiomyopathy: relation to exercise capacity and dynamic diastolic dysfunction.** P1561
 – K. Abozguia, T.T. Phan, I. Ahmed, G. Nallur Shivu, A.R. Maher, R. Kalra, W. McKenna, H. Watkins, P.M. Elliott, M.P. Frenneaux (Birmingham, London and Oxford, GB)
- Cardiomyopathy in the course of nucleopathies, echocardiographic and clinical features.** P1562
 – M. Marchel, A. Madej, J. Kochanowski, R. Steckiewicz, K.J. Filipiak, I. Hausmanowa-Petrusewicz, G. Opolski (Warsaw, PL)
- Electrocardiographic changes in ‘apical ballooning’ versus anterior myocardial infarction.** P1563
 – B. Schneider, K. Peters, J. Stein (Lubeck, DE)
- A longitudinal clinical follow-up of tako-tsubo cardiomyopathy.** P1564
 – R. Proietti, P. Silva, A. Compare, E. Grossi (Vercelli, Milan and Bergamo, IT)
- Tako-tsubo cardiomyopathy and chronobiology.** P1565
 – R. Citro, M. Previtali, O. Vriz, M.M. Patella, C. Astarita, C. Armentano, G. Provenza, G. Gregorio, E. Bossone, R. Manfredini (Vallo Della Lucania, Pavia, San Daniele Del Friuli, Terni, Sorrento, Piacenza, Lecce and Ferrara, IT)
- Fibrosis in left ventricular hypertrophy: cardiac magnetic resonance accurately distinguishes myocardial infarction from myopathic fibrosis.** P1566
 – S.P. Page, L.A. McGill, T.R. Burchell, A. Mathur, C. Davies, M.A. Westwood, P.G. Mills, S.A. Mohiddin (London, GB)
- The non-pharmacological relief of left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.** P1567
 – R. Maczynska-Mazuruk, L.S. Chojnowska, K. Kukula, M. Klopotoski, M. Dabrowski, B. Kusmierczyk, M. Polanska, M. Demkow, A. Witkowski, W. Ruzyllo (Warsaw, PL)
- Impairment of Von Willebrand factor after exercise echocardiography: an acute effect of latent obstruction in patients with hypertrophic cardiomyopathy.** P1568
 – T. Le Tourneau, A. Millaire, N. Lamblin, S. Susen, M. Richardson, A.S. Polge, E. Van Belle, C. Bauters, B. Jude, G. Deklunder (Lille, FR)
- Immunotherapy of beta1-receptor antibody-induced cardiomyopathy with epitope-mimicking cyclopeptides: specific targeting of the B cell compartment.** P1569
 – M. Merkl, V. Kocoski, N. Beyersdorf, M. Mueller, V. Boivin, T. Kerkau, T. Huenig, M.J. Lohse, R. Jahns (Wurzburg, DE)
- National keshan disease surveillance 2006.** P1570
 – T. Wang, Q. Li, C. Jiang, H. Wei, J. Hou, B. Xu, H. Feng, L. Zhang (Harbin, CN)

CHRONIC PULMONARY INTERVENTION

- Epidemiology of pulmonary arterial hypertension: comparison between clinical trials and registries.** P1571
 – A. Manes, L. Negro, M. Palazzini, A. Marinelli, E. Leci, S. Gambetti, E. Conficoni, M.L. Bacchi-Reggiani, A. Branzi, N. Galie (Bologna, IT)
- Epidemiology of pulmonary hypertension in Spain: preliminary analysis of the Spanish pulmonary hypertension registry (REHAP).** P1572
 – M.C. Jimenez Lopez Guarch, P. Escribano, A. Roman, J.A. Barbera, M. Lopez-Meseguer, I. Blanco, F. Garcia-Hernandez, P. Morales, T. Subirana, J. Segovia (Madrid, Barcelona, Seville and Valencia, ES)
- Prevalence and prognostic value of acute pulmonary vasodilator response in children and adults with pulmonary arterial hypertension.** P1573
 – J.M. Douwes, R.L.E. Van Loon, E.S. Hoendermis, M. Talsma, R.M.F. Berger (Groningen, NL)
- French pulmonary arterial hypertension registry in children: 2-year follow-up data.** P1574
 – A. Fraisse, X. Jais, J.M. Schleich, S. Di Filippo, P. Maragnes, M. Beghetti, D. Tardy, C. Dauphin, F. Godart, D. Bonnet (Marseille, Clamart, Rennes, Lyon, Caen, Paris, Clermont Ferrand and Lille, FR; Geneva, CH)
- Changing survival in connective tissue disease associated pulmonary arterial hypertension.** P1575
 – C.J. Valerio, C. Handler, C. Das, A. Gallimore, C.E. Denton, J.G. Coghlan (London, GB)
- Survival of patients with pulmonary hypertension and sickle cell disease in the UK.** P1576
 – I.Z. Cabrita, M. Abubakar, D.M. Layton, A. Gilmore, G. Cho, J. Howard, P. Nihoyannopoulos, J.S.R. Gibbs (London, GB)
- Hemodynamic efficacy and safety of the oral soluble guanylate cyclase stimulator BAY 60-4552 in patients with biventricular heart failure.** P1577
 – V. Mitrovic, H.A. Ghofrani, B. Swidnicki, W. Mueck, N. Kirschbaum, J. Mittendorf, J.P. Stasch, G. Wensing, R. Frey, S. Lentini (Bad Nauheim, Giessen and Wuppertal, DE)
- REVEAL registry: two year outcome of patients with congenital heart disease-associated pulmonary arterial hypertension (CHD-APAH).** P1578
 – R.J. Barst, A.J. Foreman, D.D. Ivy, M.D. Mcgoon (New York, San Francisco, Aurora and Rochester, US)
- Sitaxentan (Thelin) therapy for patients with World Health Organization functional class II pulmonary arterial hypertension.** P1579
 – N. Galie, R. Benza, G. Burgess, M. Dilleen, A. Torbicki (Bologna, IT; Pittsburgh, US; Sandwich, GB; Warsaw, PL)
- Impact of anemia in patients with pulmonary hypertension.** P1580
 – S.A. Hart, R.A. Krasuski, B. Smith, A. Wang, J.K. Harrison, T.M. Bashore (Cleveland, San Antonio and Durham, US)
- Detection of agonistic autoantibodies against alpha-1 adrenergic and endothelin-1 receptors in sera of patients with pulmonary arterial hypertension.** P1581
 – M. Dandel, G. Wallukat, A. Englert, H.B. Lehmkuhl, R. Hetzer (Berlin, DE)
- Alteration of endothelial cells in patients with pulmonary arterial hypertension estimated by endothelial cell-derived microparticles.** P1582
 – H. Maruyama, S. Sakai, T. Sumida, D. Goto, S. Kawano, T. Ishizu, S. Watanabe, K. Aonuma (Tsukuba, JP)
- Influence of different eNOS- polymorphism on pulmonary artery hypertension in chronic heart failure patients.** P1583
 – M. Knappe, V. Adams, G. Schuler, S. Moebius-Winkler (Leipzig, DE)
- In vitro assessment of platelet activity in patients with pulmonary arterial hypertension.** P1584
 – M.M. Can, I.H. Tanboga, A. Ozkan, F. Koca, N. Keles, H.C. Tokgoz, B. Yaymaci, K. Sonmez, M. Saglam, C. Kaymaz (Istanbul, TR)
- Patients with pulmonary arterial hypertension related to HIV: Effects of antiretroviral and disease-specific PAH therapy.** P1585
 – T. Neumann, P. Krings, N. Reinsch, H. Kaelsch, T. Konorza, S. Esser, R. Wachter, A. Goehler, R. Erbel (Essen and Gottingen, DE; Boston, US)

- Osteopontin - A new prognostic biomarker in patients with pulmonary hypertension.** P1586
 – M. Rosenberg, F.J. Meyer, E. Gruenig, M. Lutz, D. Lossnitzer, R. Wipplinger, H.A. Katus, N. Frey (Campus Kiel and Heidelberg, DE)
- Prognostic role of right ventricular function in pulmonary hypertension: a tissue Doppler and strain imaging study.** P1587
 – L. Ernande, P.Y. Leroux, S. Huez, R. Naeije, A. Mulliez, B. Aublet Cuvelier, C. Khouatra, M. Ovize, J.F. Cordier, G.A. Derumeaux (Lyon and Clermont Ferrand, FR; Brussels, BE)
- Early pulmonary vasculopathy reflected by exercise gas exchange abnormalities in patients with scleroderma.** P1588
 – D. Dumitrescu, R.J. Oudiz, G. Karpouzas, A. Hovanesyan, A. Jayasinghe, S. Rosenkranz, K. Wasserman (Torrance, US; Cologne, DE)
- 3-year survival of patients treated with sitaxentan sodium (Thelin) for pulmonary arterial hypertension.** P1589
 – N. Galie, R. Naeije, G. Burgess, M. Dilleen (Bologna, IT; Brussels, BE; Sandwich, GB)
- Right heart catheterisation significantly outperforms echocardiography in the diagnosis of pulmonary hypertension.** P1590
 – N. Dwyer, D. Kilpatrick (Hobart, AU)
- Importance of hydration and exercise in the diagnosis of pulmonary arterial hypertension secondary to scleroderma.** P1591
 – A.T. Burns, A. La Gerche, W. Stevens, A. Macisaac, D. Prior (Melbourne, AU)
- Transthoracic echocardiography in patients with a first episode of Pulmonary Embolism (PE) for the detection of Chronic Thromboembolic Pulmonary Hypertension (CTPH).** P1592
 – D. Poli, E. Antonucci, E. Grifoni, G. Ciuti, M. Miniati, C. Arcangeli, G.F. Gensini, R. Abbate, D. Prisco (Florence, IT)
- A high-calorie diet improves survival and myocardial function, preventing cardiac cachexia and apoptosis in monocrotaline-induced pulmonary hypertension and heart failure.** P1593
 – F. Vasques-Novoa, A. Lourenco, R. Roncon-Albuquerque Jr, A.F. Leite-Moreira (Porto, PT)
- Relevance of non-invasive diagnostic procedures in the diagnosis of scleroderma-associated pulmonary hypertension.** P1594
 – D. Dumitrescu, P. Moinzadeh, F. Dodos, K. Kremer, N. Hunzelmann, S. Rosenkranz (Cologne, DE)
- Role of heme oxygenase-1 and endothelial progenitor cells in the beneficial effects of erythropoietin on flow-associated pulmonary arterial hypertension.** P1595
 – R.L.E. Van Loon, B. Bartelds, F.A.D.T.G. Wagener, M.E. Van Albada, N. Affara, S. Mohaupt, H. Wijnberg, R.M.F. Berger (Groningen and Nijmegen, NL)
- Connective tissue disease-related pulmonary hypertension: a service model of outreach care with preliminary survival data.** P1596
 – S. Reddecliffe, C. Das, C. Valerio, G. Coghlan (London, GB)
- Combined magnetic resonance and positron emission tomography imaging of the right ventricle to assess disease severity in arterial pulmonary hypertension.** P1597
 – C. Bauleo, B. Formichi, L. Bruselli, R. Pancani, E. Rizza, G.D. Aquaro, M. Lombardi, D. Neglia, C. Marini (Pisa, IT)
- Sildenafil therapy for patients with porto-pulmonary hypertension and pulmonary arterial hypertension associated with HIV infection.** P1598
 – L. Negro, M. Palazzini, A. Manes, E. Leci, E. Conficoni, A. Marinelli, C. Bachetti, E. Beciani, A. Branzi, N. Galie* (Bologna, IT)
- Cardiac troponin I in chronic obstructive pulmonary disease.** P1599
 – C. Martins, J.P. Nunes (Porto, PT)
- Is neutrophil gelatinase-associated lipocalin a marker of renotubular dysfunction in pulmonary arterial hypertension characterised by low arteriovenous perfusion gradients?** P1600
 – F. Koca, M.M. Can, I.H. Tanboga, A. Ozkan, H.C. Tokgoz, N. Keles, T. Bezgin, T. Akgun, E. Turkyilmaz, C. Kaymaz (Istanbul, TR)
- Sildenafil attenuates endothelial cell injury in children with acquired pulmonary arterial hypertension.** P1601
 – A.A. Kotby, O.A. Elmasry, N.M. Habib, S.R. Youssef, H.A. Aziz Eldin (Cairo, EG)

- Screening of patients with sickle cell disease for pulmonary hypertension and for participation in interventional trial of sildenafil therapy (walk-PHaSST).** P1602
 – R.J. Barst, M.T. Gladwin, R.F. Machado, N.A. Yovetich, K.L. Hassell (New York, Pittsburgh, Chicago, Chapel Hill and Denver, US)
- Extension of the 6MWT in children with pulmonary arterial hypertension: value of additional variables such as oxygen saturation, heart rate and Borg score in estimating disease severity and prognosis.** P1603
 – M.B. Van Der Horst, R.L.E. Van Loon, M.T.R. Roofthoof, R.M.F. Berger (Groningen, NL)
- Thrombospondin-1 as a new biomarker for shearstress in pulmonary hypertension.** P1604
 – R. Kaiser, C. Frantz, H. Wilkens (Homburg, DE)
- Characterization of platelet activity in patients with pulmonary arterial hypertension subgroups.** P1605
 – M.M. Can, I.H. Tanboga, E. Turkyilmaz, T. Akgun, F. Koca, H.C. Tokgoz, A. Ozkan, T. Bezgin, O. Ozveren, C. Kaymaz (Istanbul, Mus, Batman and Kutahya, TR)
- Evaluation of right ventricular volumes and function with three-dimensional echocardiography in patients with pulmonary hypertension.** P1606
 – E. Talini, C. Giannini, M.G. Delle Donne, R. De Lucia, R. Martino, C. Palagi, C. Nardi, C. Cuono, V. Di Bello, M. Mariani (Pisa, IT)
- Does tricuspid ring motion describe right ventricular function always reliably?** P1607
 – S. Giusca, V. Dambruskaite, C. Scheurwegs, J. D’Hooge, P. Claus, L. Herbots, M. Magro, F. Rademakers, M. Delcroix, J.U. Voigt (Leuven, BE)
- Interventricular septal curve: a new criterion of evaluation and prognosis in pulmonary arterial hypertension.** P1608
 – N. Souletie, G. Briere, B. Degano, L. Tetu, V. Bongard, D. Carrie (Toulouse, FR)
- Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels.** P1609
 – M.F. Elnoamany, A. Dawood (Shebeen Elkom Menoufyia, EG)
- Human fatty acid protein-the prognostic role of the biomarker in patients with chronic Pulmonary Hypertension (PH).** P1610
 – H. Schroetter, A. Schmeisser, D. Stolte, R.H. Strasser (Dresden and Magdeburg, DE)
- Does heart rate variability predict the prognose in patients with pulmonary arterial hypertension?** P1611
 – M.M. Can, I.H. Tanboga, H.C. Tokgoz, N. Keles, F. Koca, A. Ozkan, E. Turkyilmaz, O. Ozveren, K. Sonmez, C. Kaymaz (Istanbul, Mus and Kutahya, TR)
- Right atrial sphericity index in pulmonary hypertension: which is the direction of right atrial dilatation?** P1612
 – J. Grapsa, H. Pavlopoulos, D. Dawson, P. Nihoyannopoulos (London, GB)
- A simple non-invasive diagnostic algorithm for pulmonary hypertension.** P1613
 – A. Martischinig, P. Wexberg, H. Heinzl, R. Sadushi, C. Adlbrecht, N. Skoro-Sajer, I.M. Lang, D. Bonderman (Vienna, AT)
- Serum biomarkers of cardio pulmonary tissue remodeling in pulmonary arterial hypertension.** P1614
 – F.M. Kramer, P.M. Lepper, H. Frank, T. Wibmer, K.M. Stoiber, L. Kruska, T. Krahn, C. Schumann (Wuppertal, Ulm and Monchengladbach, DE; Berne, CH)
- ATRIAL FIBRILLATION CATHETER ABLATION**
- Long-term results after ganglionated plexi ablation for atrial fibrillation: anatomical approach versus selective approach.** P1615
 – E. Pokushalov, A. Romanov, P. Shugaev, S. Artemenko, N. Shirokova, D. Katritsis (Novosibirsk, RU; Athens, GR)
- Small balloon, single freeze, cryo isolation of the pulmonary veins is highly effective in treating paroxysmal atrial fibrillation.** P1616
 – B. Keweloh, M. Winterhalter, S. Siaplaouras, G. Calmez, F. Kleber (Berlin and Gera, DE)
- Circumferential pulmonary vein ablation: does the use of a circular mapping catheter improve results? Prospective randomized study.** P1617
 – L. Mont, D. Tamborero, A. Berruezo, E. Guasch, M. Nadal, M. Matiello, D. Andreu, M. Sitges, J. Brugada (Barcelona, ES)

- Catheter ablation of atrial fibrillation: three-dimensional transesophageal echocardiography replaces other imaging techniques for pulmonary vein visualization prior to an ablation procedure.** P1618
 – K. Kettering, S. Von Bardeleben, H. Mollnau, F. Gramley, C. Weiss (Mainz, DE)
- Biochemical markers reflecting cardiac repair predict left atrial structural changes and clinical outcome after ablation of atrial fibrillation.** P1619
 – B. Richter, M. Gwechenberger, A. Socas, G. Zorn, J. Bergler-Klein, M. Marx, C. Bieglmayer, T. Binder, J. Wojta, H.D. Goessinger (Vienna, AT)
- Left atrial appendage isolation: evidence of discrete connections between the left atrial appendage and the main chamber.** P1620
 – L. Di Biase, J.D. Burkhardt, R. Horton, J. Sanchez, G. Gallingshouse, D. Patel, S. Beheiry, D. Lakkireddy, R.A. Schweikert, A. Natale (Austin, San Francisco, Kansas City and Akron, US)
- Duty-cycled, unipolar-bipolar RF ablation via multi-electrode catheter in patients with paroxysmal atrial fibrillation.** P1621
 – S. Yuan, O. Kongstad (Lund, SE)
- Acute and long-term outcome of remote magnetic navigation for ablation of atrial fibrillation using a magnetic irrigated ablation catheter.** P1622
 – X. Chen, J.H. Svendsen, S. Pehrson (Copenhagen, DK)
- The effect of ganglionated plexi ablation on atrial fibrillation triggers: long-term results.** P1623
 – E. Pokushalov, A. Romanov, S. Artemenko, P. Shugaev, A. Turov, N. Shirokova (Novosibirsk, RU)
- Antral vs. ostial circumferential isolation of pulmonary veins in patients with atrial fibrillation; when is antral isolation needed?** P1624
 – M. Kuniss, T. Neumann, S. Zaltsberg, A. Berkowitsch, D. Erkapic, D. Pajitnev, C. Hamm, H.F. Pitschner (Bad Nauheim, DE)
- The impact of radiofrequency catheter ablation combined with percutaneous transvenous mitral commissurotomy: a less invasive hybrid therapy for atrial fibrillation associated with mitral stenosis.** P1625
 – T. Machino, H. Tada, K. Kuroki, H. Yamasaki, M. Igarashi, T. Arimoto, Y. Sekiguchi, Y. Seo, K. Kuga, K. Aonuma (Tsukuba, JP)
- Ganglionated plexi ablation for chronic atrial fibrillation: acute effects and long-term outcome.** P1626
 – E. Pokushalov, A. Romanov, S. Artemenko, P. Shugaev, A. Turov, N. Shirokova (Novosibirsk, RU)
- Mechanistic insights, results of catheter ablation, and risk factors for atrial tachycardia after ablation of AF: ostial PV ablation, circumferential PV ablation and GP - ablation.** P1627
 – A. Romanov, E. Pokushalov, P. Shugaev, S. Artemenko, A. Turov, N. Shirokova (Novosibirsk, RU)
- Is cryo-balloon isolation of the pulmonary veins safe for the oesophagus?** P1628
 – J.-S. Hermida, M. Kubala, V. Mouquet, A. Fournier, A. Jeu, S. Traulle (Amiens, FR)
- Real time lesion assessment using a combined radiofrequency and ultrasound ablation catheter.** P1629
 – M. Wright, E. Harks, F. Suijver, Y. Shi, S. Deladi, M. Barley, F. Sacher, M. Hocini, M. Haissaguerre, P. Jais (Bordeaux, FR; Eindhoven, NL)
- Catheter ablation of atrial fibrillation: radiofrequency catheter ablation for redo procedures after pulmonary vein isolation with the cryoballoon technique.** P1630
 – K. Kettering, H. Mollnau, F. Gramley, C. Weiss (Mainz, DE)
- Impact of ablation in slow pathway area on vagal modulation to atria.** P1631
 – Y. Xiaomeng, S. Zhang, L. Gao, Y. Xia, D. Yang, Y. Dong, D. Chang, Z. Lin, Y. Yang (Dalian, CN)
- Early and late recurrences after ganglionated plexi ablation for atrial fibrillation: prognostic value and the effect of reablation.** P1632
 – A. Romanov, E. Pokushalov, S. Artemenko, P. Shugaev, A. Turov, N. Shirokova (Novosibirsk, RU)

- Safety and indication of substrate-based catheter ablation of left ventricular tachycardias in patients with ICD shock deliveries. a single centre experience.** P1633
 – J. Schreieck, H.J. Weig, F. Girschbach, R. Laszlo, N. Rueb, S. Weretka, C. Freising, M. Gawaz (Tubingen, DE)
- Patient characteristics and ablation procedures in electrophysiologic centers: first results from the German ablation registry.** P1634
 – A.M. Sinha, J. Senges, K.H. Kuck, D. Andresen, E. Hoffmann, J. Brachmann (Coburg, Ludwigshafen am Rhein, Hamburg, Berlin and Munich, DE)
- Validation of PV isolation of multi-electrode duty cycled radiofrequency ablation in patients with paroxysmal and persistent atrial fibrillation.** P1635
 – A. Elvan, W.P. Beukema, J.J.J. Smit, P.P.H.M. Delnoy, A.R. Ramdat Misier (Zwolle, NL)
- Which of the methods to choose for catheter ablation of chronic atrial fibrillation: ostial PV ablation, circumferential PV ablation or GP ablation?** P1636
 – E. Pokushalov, A. Romanov, S. Artemenko, P. Shugaev, A. Turov, N. Shirokova (Novosibirsk, RU)
- Cryoballoon pulmonary vein isolation.** P1637
 – P. Insulander, F. Tabrizi, G. Kenneback, J. Schwieler, H. Bastani, F. Braunschweig, B. Sadigh, N. Drca, M. Jensen-Urstad (Stockholm, SE)
- Correlation of delayed enhancement MRI following atrial fibrillation ablation with repeat electroanatomical mapping.** P1638
 – Y. Adjei-Poku, T.J. Badger, N.S. Burgon, N. Akoum, P. Anderson, E.V.R. Dibella, R.S. Macleod, N.F. Marrouche (Salt Lake City, US)
- Long-term outcome of ablative therapy of post-operative supraventricular tachycardias in patients with univentricular hearts: an European multicenter study.** P1639
 – N.M.S. De Groot, P. Lukac, N.A. Blom, A.K. Pedersen, P.S. Hansen, E. Delacretaz, M.J. Schalij (Leiden, NL; Aarhus and Varde, DK; Berne, CH)
- Safety and efficacy of remote-controlled magnetic navigation compared to conventional navigation for atrial fibrillation ablation.** P1640
 – P. Carmo, D. Cavaco, P. Adragao, L. Parreira, K. Santos, F. Morgado, S. Marcelino, A. Silva (Carnaxide and Lisbon, PT)
- Morphology of the triangle of Koch and atrioventricular node in perinatal hearts with Ebstein malformation.** P1641
 – B. Picazo-Angelin, V. Climent, M. Murillo, D. Sanchez-Quintana, J.A. Cabrera (Marbella, Badajoz and Madrid, ES)
- Estimation of left atrial volume: comparison of multi-slice computed tomography with CARTO mapping by either remote-control magnetic navigation or manual navigation.** P1642
 – P. Carmo, P. Adragao, D. Cavaco, L. Parreira, K. Santos, F. Morgado, S. Marcelino, R. Bernardo, A. Silva (Carnaxide and Lisbon, PT)
- Comparison of left atrial volumes measured from 3-dimensional CT/MR images before and after catheter ablation in patients with atrial fibrillation.** P1643
 – L. Ren, O. Kongstad, S. Yuan (Lund, SE)
- Remote robotic navigation for ablation of atrial fibrillation: catheter stability and impact on procedural outcome.** P1644
 – R. Titz, K.R.J. Chun, A. Fuernkranz, K. Neven, B. Koektuerk, E. Wissner, A. Metzner, D. Nuyens, F. Ouyang, B. Schmidt (Hamburg, DE)
- Incidence and causes of complete atrioventricular block during ablation of atrial flutter.** P1645
 – B. Brembilla-Perrot, M. Lemdersi-Filali, P.Y. Zinzius, L. Groben, D. Beurrier, J. Cedano, P. Louis, A. Abdelaal, A. Terrier De La Chaise, O. Selton (Vandoeuvre les Nancy, FR)
- IMPLANTABLE CARDIOVERTER DEFIBRILLATOR'S SPECIAL ISSUES**
- Impact of bacterial colonization on device infection in asymptomatic ICD patients undergoing generator replacement or lead revision.** P1646
 – T. Kleemann, T. Becker, M. Strauss, U. Weisse, W. Saggau, U. Burkhardt, K. Seidl (Ludwigshafen am Rhein, DE)
- Novel intravascular defibrillator (InnerPulse PICD): defibrillation thresholds of PICD compared to Medtronic ICD in a canine model.** P1647
 – W.E. Sanders, M. Richey, S.C. Masson, T. Ransbury, M. Urtz, R.E. Ideker, R.A. Malkin (Chapel Hill, Research Triangle Park, Birmingham and Durham, US)

- Are there any clinical or electrical parameters that predict the effectiveness of defibrillation testing with a 10 joule safety margin?** P1648
 – J.J. Blanc, A. Lazarus, P. Defaye, O. Paziand, P. Chenevez, F. Halimi, J. Horvilleur, E. Mouton, A. Durand, N. Sadoul (Brest, Paris, Grenoble, St Denis, Tours, Le Chesnay, Massy, Montigny Le Bretonneux and Nancy, FR)
- Influence of time from last myocardial infarction on occurrence of therapies in patients with prophylactic ICD implantations: data from the SEARCH MI registry.** P1649
 – G. Boriani, G.L. Botto, B. Schmidt, M. Lunati, A. Proclemer, A. Erdogan, W. Rauhe, M. Biffi, M. Messier, M. Santini (Bologna, Como, Milan, Udine, Bolzano and Rome, IT; Freiburg im Breisgau and Giessen, DE; Maastricht, NL)
- Long-term outcome following shock therapy with an implantable cardioverter defibrillator in MADIT-II trial.** P1650 (W)
 – I. Cygankiewicz, W. Zareba, H. Klein, J. Daubert, C. Jons, A.J. Moss, I. Goldenberg (Rochester Ny, US)
- Deaths and serious injuries associated with ICD and pacemaker lead extraction.** P1651
 – R.G. Hauser, W.T. Katsiyannis, L.M. Kallinen (Minneapolis, US)
- Implications of beta-blockers therapy dose on Antitachycardia Pacing effectiveness and shocks incidence among Monomorphic Ventricular Tachycardias occurred in ICD patients.** P1652
 – J. Jimenez-Candil, J. Morinigo, A. Martin, C. Ledesma, M. Ruiz, C. Martin-Luengo (Salamanca, ES)
- Mortality risk score in primary prevention implantable cardioverter defibrillator recipients with ischemic heart disease.** P1653
 – C.J.W. Borleffs, G.H. Van Welsenes, L. Van Erven, R.J. Van Bommel, E.T. Van Der Velde, E.E. Van Der Wall, J.G. Van Der Bom, F.R. Rosendaal, J.J. Bax, M.J. Schalij (Leiden, NL)
- Prediction of antitachycardia pacing effectiveness for monomorphic ventricular tachycardias based on the analysis of far-field electrograms morphology.** P1654
 – J. Jimenez-Candil, J. Hernandez, A. Martin, M. Ruiz Olgado, J. Morinigo, C. Ledesma, C. Martin Luengo (Salamanca, ES)
- Increasing risk of sprint fidelis implantable defibrillator lead failure.** P1655
 – R.G. Hauser, D.L. Hayes, L.M. Kallinen, M. Rott (Minneapolis and Rochester, US)
- Efficacy of calendar based ICD checks: conventional follow up compared to remote monitoring in the TRUST trial.** P1656
 – N. Varma, A. Epstein, A. Irmpen, L. Gibson, C. Love (Cleveland, Birmingham, New Orleans, Lake Oswego and Columbus, US)
- Comparison of single-lead ICD system capable of atrial sensing (A+ ICD) and a DDD-ICD system in patients without antibradycardia pacing indications.** P1657
 – C. Sticherling, M. Niehaus, M. Zabel (Basel, CH; Hannover and Gottingen, DE)
- Changes in impedance are associated with changes in ventricular volume in patients receiving defibrillators for resynchronization therapy.** P1658
 – M. Landolina, M. Maines, M. Lunati, G. Zanotto, A. Proclemer, M. Santini, M. Vimercati, A. Varbaro (Pavia, Rovereto, Milan, Verona, Udine and Rome, IT)
- Beta-2 Gln27Glu adrenergic receptor gene polymorphism and appropriate ICD shocks among the patients with heart failure.** P1659
 – N. Pezzali, M. Metra, L. Covolo, A. Curnis, U. Gelatti, F. Donato, L. Dei Cas (Brescia, IT)
- Antiarrhythmic effects of n-3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI-HF trial.** P1660
 – A. Finzi, S. Barlera, D.M. Serra, M.G. Rossi, A. Ruggeri, A. Mezzani, M.G. Franzosi, R. Marchioli, F. Bianchini, L. Tavazzi (Milan, Reggio Calabria, Veruno, Santa Maria Imbaro, Florence and Cotignola, IT; Lugano, CH)
- Bleeding complications after device implantation in patients receiving dual antiplatelet therapy- the results of the prospective, two-centre registry.** P1661
 – W. Kwasniewski, A. Przybylski, D. Urbanczyk-Swic, P. Derejko, A. Filipecki, J. Zakrzewska, W. Orszulak, M. Orczykowski, M. Trusz-Gluza, F. Walczak (Katowice and Warsaw, PL)
- Biventricular pacing prevents progression to heart failure in patients with ICD indication and left bundle branch block.** P1662
 – J. Brugada, I. Fernandez-Lozano, R. Ruiz, A. Berruezo, J.M. Porres, J. Alzueta, J. Zamora, J.G. Martinez, L. Mont (Barcelona, Madrid, Valencia, Donostia, Malaga and Alicante, ES)

- Fast atrial fibrillation as dominant cause of inappropriate discharges in adult ICD recipients.** P1663
 – E. Simeonidou, A. Papandreou, G. Tsigas, C. Michalakeas, C. Tsitlakidis, D. Alexopoulos, J. Lekakis, D. Kremastinos (Athens and Patras, GR)
- ICD therapy in Brugada syndrome - a single center experience.** P1664
 – C. Veltmann, R. Schimpf, J. Kuschyk, F. Streitner, N. Schoene, A. Krey, B. Staller, M. Borggrefe, C. Wolpert (Mannheim, DE)
- Lead extraction versus additional lead implantation: impact of different strategies for the treatment of first ICD lead defect on the perioperative complication rates of the following lead revision.** P1665
 – T. Kleemann, T. Becker, M. Strauss, U. Weisse, W. Saggau, K. Seidl (Ludwigshafen am Rhein, DE)
- Changes in intrathoracic impedance predicting heart failure decompenation episodes.** P1666
 – V. Castro, V.M.P. Monivas, E.P.P. Perez, V.M.M. Mariona, J.T.R. Toquero, E.S.S. Sufate, L.N.F. Nombela, J.E.V. Escudier, C.G.L. Gutierrez, I.F.L. Fernandez Lozano (Madrid, ES)
- Interrogation of ICD at time of death in MADIT II patients; Risk factors for arrhythmic vs non-arrhythmic death.** P1667
 – C. Jons, A.J. Moss, W. Zareba, I. Goldenberg (Rochester, US)
- Electrical Storm (ES) in patients with Implantable Cardioverter Defibrillator (ICD) - Long term follow-up.** P1668
 – K. Gepner, A. Maciag, P. Syska, D. Zajac, M. Lewandowski, M. Sterlinski, H. Szwed (Warsaw, PL)
- Clinical characteristics and ventricular tachyarrhythmia events in patients with an implantable cardioverter defibrillator and atrial fibrillation.** P1669
 – S. Ammar, F. Streitner, N. Schoene, C. Veltmann, R. Schimpf, C. Wolpert, M. Borggrefe, J. Kuschyk (Mannheim, DE)
- Incidence of mortality and appropriate shocks in patients with ischemic and non-ischemic cardiomyopathy after receiving implantable cardioverter defibrillators.** P1670
 – K. Gandhi, W. Aronow, H. Desai, H. Amin, H. Lai, W. Frishman, M. Cohen, C. Sorbera (Valhalla, US)
- METABOLIC AND BASIC ASPECTS OF HEART FAILURE**
- Archaeal gene-encoded organelles in association with asymptomatic form of Chronic Chagas disease.** P1671
 – M.L. Higuchi, J. Kawakami, M.M. Reis, J.M. Silvestre, E.A. Bocchi, N. Stolf (Sao Paulo, BR)
- Electrophysiological and electroanatomical mapping of the right atrium in patients with dilated cardiomyopathy: relation to the collagen turnover and to increased propensity for atrial fibrillation.** P1672
 – E.M. Kanoupakis, H.E. Mavrakis, C.A. Goudis, N.E. Malliaraki, M. Milathianaki, K. Stokkos, E.G. Manios, P.E. Vardas (Heraklion, GR)
- Intermittent fasting reduces mortality and attenuates post-infarction ventricular remodeling in rats.** P1673
 – K. Okoshi, M.A.M. Polin, J.R. Paladino Junior, P.F. Martinez, L.L. Rodrigues, C.M. Rosa, C. Bonomo, L.A. Zornoff, L.S. Matsubara, M.P. Okoshi (Botucatu, BR)
- Increased production of CXCL16 in experimental and clinical heart failure; a possible role in extracellular matrix remodeling.** P1674
 – C.P. Dahl, C. Husberg, L. Gullestad, A. Waehre, A.V. Finsen, B. Halvorsen, P. Aukrust, E. Oie, A. Yndestad, G. Christensen (Oslo, NO)
- Adaptive servoventilation improves respiratory stability and exercise capacity in patients with congestive heart failure and Cheyne-Stokes respiration.** P1675
 – R. Lehmann, T. Bitter, S. Korte, A. Schmidt, C. Prinz, C. Langer, D. Horstkotte, O. Oldenburg (Bad Oeynhausen, DE)
- Mitochondrial protection by post-conditioning during hindlimb ischemia-reperfusion is associated with reduced oxidative stress.** P1676
 – A.S. Guilbert, A.L. Lang, J. Zoll, J. Bouitbir, Z. Mansour, A.P. Di Marco, S. Talha, F. Piquard, B. Geny (Strasbourg, FR)

- Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model.** P1677
 – K. Lenk, V. Adams, A. Linke, R. Schur, S. Erbs, G. Schuler (Leipzig, DE)
- Combined hydrotherapy/endurance training compared to endurance training alone in elderly patients with chronic heart failure. Clinical and hemodynamic effects.** P1678
 – G. Caminiti, M. Volterrani, G. Marazzi, A. Cerrito, R. Massaro, S. Bovone, A. Franchini, M. Beato, A. Carluccio, G. Rosano (Rome, IT)
- Impaired energy metabolism in skeletal muscle and fat tissue of patients with chronic heart failure - interstitial metabolites assessed by microdialysis technique.** P1679
 – T. Szabo, M. Boschmann, E. Postrach, A. Maehler, S.D. Anker, W. Doehner (Berlin, DE)
- Low Triiodothyronine predicts impaired functional capacity in systolic heart failure patients.** P1680
 – M. Fontana, M. Emdin, R. Poletti, L.E. Pastormerlo, G. Vergaro, A. Valleggi, A. Giannoni, C. Passino (Pisa, IT)
- Attenuated expression of skeletal muscle IGF-1 splice variants in heart failure patients after high resistance exercise.** P1681
 – H.K. Rasmusen, J.F. Hansen, S.D.R. Harridge, V. Backer, B. Larsson, M. Kjaer (Copenhagen, DK; London, GB)
- Associations between the severity of left ventricular impairment and circulating levels of resistin, adiponectin and leptin in patients with heart failure.** P1682
 – A.S. Antonopoulos, C. Antoniadis, D. Tousoulis, A. Drolias, N. Koumallos, K. Marinou, C. Bakogiannis, C. Psaros, A. Trikas, C. Stefanadis (Athens, GR)
- Cardiotrophin-1 induces Interleukin-1b in human peripheral mononuclear cells via nuclear factor kappa B activation.** P1683
 – M. Fritzenwanger, K. Meusel, C. Jung, M. Franz, Z. Wang, M. Foerster, H.R. Figulla (Jena, DE; Fujian, CN)
- Ventricular tachyarrhythmias in advanced CHF are linked to recent weight loss and reduced body fat concent.** P1684
 – M. Kotrc, I. Nemcova, L. Necasova, D. Hackajlo, I. Malek, J. Kautzner, V. Melenovsky (Prague, CZ)
- Prediction of short-term course of heart failure in clinically stable heart transplant candidates with dilated cardiomyopathy.** P1685
 – M. Dandel, R. Jasaityte, H.B. Lehmkuhl, C. Knosalla, R. Hetzer (Berlin, DE)
- ASPECTS OF HEART FAILURE**
- Induction of mitogen activated protein kinases in response to pressure overload: a novel possible biomarker for uncontrolled human hypertension.** P1686
 – A. Franzone, G. Esposito, G. Capretti, G. Schiattarella, A. Cannavo, G. Pironti, L. Di Serafino, C. Perrino, M. Chiariello (Naples, IT)
- Peptidomic profiles of plasma from post myocardial infarction rats using affinity capture Matrix Assisted Laser Desorption Ionisation Time of Flight (MALDI-ToF) mass spectrometry.** P1687
 – B. Wang, S. Reisman, M. Ayhan, A. Kompa, H. Krum, G. Rice (Melbourne, AU)
- Genetic polymorphisms of beta-adrenergic and RAA systems in chronic heart failure: relation with remodeling and LV systolic function.** P1688
 – C. Bergamini, M. Ciccoira, A. Rossi, M. Rigolli, F. Vassanelli, D. Cassater, L. Zanolla, C. Vassanelli (Verona, IT)
- Recirculating delivery of AAV-BARKct for the treatment of heart failure in a large animal model.** P1689
 – M. Byrne, R. Idrizi, G. Akita, R. Kelly, J. Power, D.M. Kaye (Melbourne, AU; Boston, US)
- Evidence for contractile dysfunction and heart failure in pressure-overloaded wild-type mice - does the PGC-1alpha story hold true?** P1690
 – G. Faerber, H.F. Barreto-Pereira, R. Gilsbach, M. Schoepe, M. Schwarzer, L. Hein, T. Doenst (Leipzig and Freiburg im Breisgau, DE)
- Regulation of cAMP-release by adenylylcyclase in the unloaded terminal failing human heart.** P1691
 – A. Kassner, K. Toischer, M. Morshuis, D. Roefe, A. El-Banayosy, H. Milting (Bad Oeynhausen and Göttingen, DE; Hershey, US)

- Recombinant periostin peptide improves myocardial function in a preclinical infarct model.** P1692
 – D. Ladage, Y. Kawase, S. Shapiro, M. Garcia, R. Hajjar, B. Kuhn (New York and Boston, US)
- Mild hypothermia: An experimental proof for an increase of left ventricular end-diastolic pressure by slowed left ventricular relaxation.** P1693
 – H. Post, J.D. Schmitto, J. Christoph, R. Holland, P. Steendijk, F.A. Schoendube, B. Pieske (Graz, AT; Göttingen, DE; Leiden, NL)
- Incidence of left ventricular dysfunction after anthracycline chemotherapy in an elderly population.** P1694
 – C. Lestuzzi, E. Viel, L. Tartuferi, D. Crivellari, D. Lombardi, G.M. Miolo, L. Fratino, N. Meneguzzo (Aviano, IT)
- Cardiotoxicity of imatinib mesylate: a rare adverse effect?** P1695
 – M.S. Marcolino, N.C.D. Clementino, H.N.S. Bittencourt, M.M. Barbosa, M.C.P. Nunes, M.H.C.R. Silva, A.L.P. Ribeiro (Belo Horizonte, BR)
- The effects of early aldosterone blockade on myocardial fibrosis and contractility in rats with ascending aortic stenosis.** P1696
 – M.P. Okoshi, D.H.S. Campos, P.F. Martinez, A.R.R. Lima, M.D.M. Cezar, L.S. Matsubara, L.C.O. Costa, A.A. Guimaraes, A.C. Cicogna, K. Okoshi (Botucatu, BR)
- Urocortin 2 treatment reduces genes involved in cardiac remodelling in an ovine model of heart failure.** P1697
 – L. Ellmers, E. Carter, N.J.A. Scott, A.M. Richards, V.A. Cameron, M.T. Rademaker (Christchurch, NZ)
- Clinical profile of patients affected by dominant desmosomal arrhythmogenic right ventricular cardiomyopathy.** P1698
 – A. Tsatsopoulou, L. Antoniadis, A. Anastasakis, P. Syrris, A. Asimaki, G. Daniel, A. Vouliotis, C. Stefanadis, N. Protonotarios (Naxos and Athens, GR; Nicosia, CY; London, GB)
- The role of chemokine in enterovirus positive myocarditis- possible mechanism for the determination of inflammatory acuity.** P1699
 – F. Escher, U. Kuehl, D. Lassner, D. Westermann, H.P. Schultheiss, C. Tschoepe (Berlin, DE)
- Prevalence of viral genomes and coinfection in the myocardium of adults with idiopathic left ventricular dysfunction.** P1700
 – A. Gkouziouta, G. Karavolias, G. Saroglou, S. Adamopoulos, V. Voudris (Athens, GR)
- Cellular mechanisms of cardioprotective exercise training in heart failure.** P1701
 – A. Schmidt, K. Wagner, B. Pieske (Graz, AT)
- Chronic heart failure induces atrophy and myogenin downregulation in rat skeletal muscle.** P1702
 – P.F. Martinez, K. Okoshi, L.A.M. Zornoff, R.F. Carvalho, S.A. Oliveira Junior, D.H.S. Campos, A.R.R. Lima, C.R. Nogueira, M. Dal Pai-Silva, M.P. Okoshi (Botucatu, BR)
- ECHOCARDIOGRAPHY AND HEART FAILURE EPIDEMIOLOGY**
- Ultrasound Lung Comets for serial assessment of pulmonary congestion in heart failure.** P1703
 – L. Gargani, M.C. Scali, M. Agrusta, P. Tesorio, E. Poggianti, F. Frassi, R. Sicari, M. Mottola, E. Picano (Pisa and Mercogliano, IT)
- Echocardiography signs of early myocardial impairment in patients with breast cancer and Trastuzumab therapy.** P1704
 – S.A. Lange, B. Ebner, A. Wess, T. Hitschold, J. Jung (Worms and Dresden, DE)
- Subepicardial and subendocardial left ventricle rotational mechanics in heart failure patients: relation to left ventricular dimensions and mechanical activation.** P1705
 – M. Bertini, N. Ajmone Marsan, V. Delgado, G. Nucifora, R.J. Van Bommel, C.J.W. Borleffs, G. Boriani, M. Biffi, M.J. Schalij, J.J. Bax (Leiden, NL; Bologna, IT)
- Prognostic value of heart failure screening with echocardiography in patients with chronic obstructive pulmonary disease undergoing major vascular surgery.** P1706
 – W.J. Flu, Y.R.B.M. Van Gestel, J.P. Van Kuijk, S.E. Hoeks, R. Kuijper, O. Schouten, T.A. Winkler, D. Goei, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL)

- Assessment of right ventricular strain in patients with and without pulmonary hypertension.** P1707
 – A. Meris, C. Conca, C. Klersy, A. Evangelista, J. Klimusina, M. Averaimo, A. Auricchio, F. Faletra (Lugano, CH; Pavia, IT)
- Echocardiographic detection of congestive heart failure in postinfarction rats.** P1708
 – P.F. Martinez, K. Okoshi, L.A.M. Zornoff, S.A. Oliveira Junior, D.H.S. Campos, A.R.R. Lima, R.L. Damatto, C.R. Padovani, A.C. Cicogna, M.P. Okoshi (Botucatu, BR)
- Evaluation of systolic long-axis left ventricle function in patients with heart failure with normal ejection fraction diagnosed by the new criteria of European Society of Cardiology Guidelines.** P1709
 – A.J. Lagoeiro Jorge, E.T. Mesquita, M.L.G. Rosa, L.C.M. Fernandes, M.L. Ribeiro, F.V. Licio (Niteroi and Rio de Janeiro, BR)
- Mitral annular motion as a surrogate for left ventricular function: correlation with brain natriuretic peptide levels.** P1710
 – M.F. Elnamany, A. Kilany (Shebeen Elkom Menoufyia, EG)
- Pressure-volume relationship during stress echo predicts exercise tolerance in patients with congestive heart failure.** P1711
 – Q. Ciampi, L. Pratali, T. Bombardini, M. Della Porta, B. Villari, E. Picano, R. Sicari (Benevento and Pisa, IT)
- Operator-independent force-frequency relation monitoring with a new transcutaneous cardiac force sensor in pacing induced heart failure.** P1712
 – V. Gemignani, E. Bianchini, F. Faita, M. Campan, V. Lionetti, F. Recchia, E. Picano, T. Bombardini (Pisa, IT)
- Prognostic implications of indexed left ventricular end-diastolic diameter by echocardiography to outpatients with chronic systolic heart failure: application of ASE/ESC guidelines.** P1713
 – F. Bursi, A. Barbieri, C. Leuzzi, L. Reggianini, C. Manicardi, S. Copelli, M.G. Modena (Modena, IT)
- Reduced left atrial function and normal ejection fraction in hypertensive patients with dyspnoea.** P1714
 – Y.T. Tan, F. Wenzelburger, E. Lee, G. Heatlie, F. Leyva, M. Frenneaux, J.E. Sanderson (Birmingham and Stoke-On-Trent, GB)
- Investigation of left atrial function by strain imaging: comparative study in controls and coronary patients.** P1715
 – P.M.J. Claessens, C.W.F. Claessens, M.M.M. Claessens, J.E.J. Claessens, M.C.F. Claessens (Antwerp, Turnhout, Roeselare and Essen, BE)
- Prevalence of echocardiographic criteria of noncompaction in a non selected population.** P1716
 – J.-C. Eicher, F. Schaad, G. Habib, O. Barthez, J.-E. Wolf (Dijon and Marseille, FR)
- Presence of radial discoordination during ejection phase is a major determinant for reverse remodeling after cardiac resynchronization therapy.** P1717
 – T. Arita, K. Ando, Y. Soga, M. Goya, M. Iwabuchi, M. Nobuyoshi (Kitakyushu, JP)
- Specific features of heart failure in elderly patients. Results from the DEVENIR study.** P1718
 – M. Guenoun, P. Assyag, C. Contre, I. Leurs, P. Poncelet, P.L. Prost, J.F. Thebaut, A. Cohen-Solal (Plan De Cuques, Paris, Rungis, Henin Beaumont and Sarcelles, FR)
- Prevalence of heart failure in the community: preliminary results of an epidemiological survey in the elderly population in Italy. The PREDICTOR Study.** P1719
 – G.F. Mureddu, V. Rizzello, N. Agabiti, G. Cacciatore, G. Cesaroni, F. Forastiere, R. Latini, S. Masson, C.A. Perucci, A. Boccanelli (Rome and Milan, IT)
- Characteristics of male and female patients at the time of first data entry into the canadian heart failure network longitudinal database 1999 to 2008.** P1720
 – M. Arnold, A. Ignaszewski, H. Haddad, J. Howlett, M.-H. Leblanc, P. Staples, E. Azevedo, R. Gutierrez, S. Roth, G. Marchiori (London, Vancouver, Ottawa, Halifax, Quebec, Kingston, Toronto, Edmonton and Scarborough, CA)
- Analysis of a population with MADIT II-like criteria in a multidisciplinary Heart Failure Unit.** P1721
 – R. Villuendas, C. Pajuelo, C. Bosch, F. Pons, J. Perez-Rodon, X. Carrillo, B. Gonzalez, A. Urrutia, J. Lupon, V. Valle (Badalona, ES)

- U-shaped relationship between left ventricular ejection duration and mortality in patients undergoing coronary angiography.** P1722
 – T. Weber, M. Ammer, M. Rammer, E. Lassnig, B. Eber (Wels, AT)

CARDIOVASCULAR PHARMACOLOGY

- Both levosimendan and dobutamine are equally effective in improving LV systolic functions in heart failure patients receiving beta blocker therapy: a radionuclide ventriculographic study.** P1723
 – Y. Cavusoglu, A. Beyaztas, E. Entok, M. Tek, I. Uslu, C. Demirustu, A. Birdane, A. Unalir, B. Gorenek, N. Ata (Eskisehir, TR)

- Hypertension-related hypoalgesia: a retrospective cohort study in a hypertensive population under pharmacologic treatment.** P1724
 – E. Koch, T. Romero, D. Sandoval, C. Romero, M. Bravo, I. Segovia, O. Henriquez, L. Urrutia (Santiago, CL; San Diego, US)

- Experimental orthostasis elicits hypertension which can be prevented by antihypertensive drugs.** P1725
 – -. Cseko, -. Raffai, -. Monos (Budapest, HU)

- Efficacy of combination therapy using nebivolol and trimetazidine in patients with isolated systolic hypertension and stable effort angina.** P1726
 – S. Vatinian, S. Gurgenyanyan, K. Nikoghosyan (Yerevan, AM)

- Increased thromboxane production in preeclampsia, influence of aspirin treatment.** P1727
 – C. Perneby, K.B. Bremme Katarina, M.V. Marie Vahter, M.D. Maud Daleskog, P.H. Paul Hjemdahl (Stockholm, SE)

- The benefit of RAS inhibition in vascular disease without heart failure is strongly correlated to the cardiovascular risk.** P1728
 – P.J. Sousa, J. Ferreira, C.T. Aguiar, J.A. Silva (Lisbon, PT)

- Five years two center retrospective analysis of patients with digoxin toxicity.** P1729
 – R. Kockova, J. Skvaril, M. Cernohous, M. Zavoral, V. Kocka, T. Palecek, A. Praveckova, A. Linhart (Prague, CZ)

- Protective effects of chrysoeriol against doxorubicin-induced cardiotoxicity in vitro.** P1730
 – Z. Liu, X.D. Song, Y. Xin, X.J. Wang, H. Yu, Y.Y. Bai, J.H. Liu, C.N. Zhang, R.T. Hui (Beijing, CN)

- Single-dose rosuvastatin prevents endothelial dysfunction induced by ischemia and reperfusion via a COX-2 dependent mechanism, an effect that is independent of lipid lowering: a human in vivo study.** P1731
 – A. Liuni, M. Luca, T. Gori, J.D. Parker (Toronto, CA; Mainz, DE)

- TNF-alpha antagonists improve arterial stiffness in patients with inflammatory arthropathies: Results from a controlled study.** P1732
 – K. Angel, S.A. Provan, T.K. Kvien, D. Atar (Oslo, NO)

- Lipid-altering efficacy and tolerability of ER niacin/laropirant in type 2 diabetes mellitus patients.** P1733
 – A. Maclean, J. Mckenney, R. Scott, E. Brinton, H. Bays, H. Giezek, R. Ruck, K. Gibson, C. Mcrcrary Sisk, D. Maccubbin (Rahway, Richmond, Salt Lake City and Louisville, US; Canterbury, NZ)

- Achievement of LDL target level with three different drug strategies after failure of simvastatin 40mg.** P1734
 – P.J. Robinson, M.D. Blagden, R.A. Chipperfield, R.M.C. Gaunt, P.R. Harvey, T. McCormack, C. Mellon (Hoddesdon, Chesterfield, Welwyn Garden City, Chippenham, Addlestone and Whitby, GB)

- Serial assessments of coronary remodeling from the approach trial (assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history).** P1735
 – H.M. Garcia-Garcia, P.W. Serruys, H.C. Gerstein, C.P. Cannon, G.A. Van Es, N.S. Kolatkar, B.G. Kravitz, D.M. Miller, C. Huang, R.W. Nesto (Rotterdam, NL; Hamilton, CA; Boston, Philadelphia and Burlington, US)

- High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy.** P1736
 – G. Marenzi, H. Trivedi, S. Daram, A. Szabo, A.L. Bartorelli (Milan, IT; Milwaukee, US)

- Fibrinolysis and Insulin Sensitivity in Imidapril and Candesartan recipient (FISIC).** P1737
 – R. Fogari, I. Ferrari, T. Santoro, S. Salvadeo, A. Zoppi, P. Lazzari, G. Derosa (Pavia, IT)
- Healthcare costs and resource utilization of patients receiving combination treatments of angiotensin receptor blocker with chlorthalidone or with hydrochlorothiazide.** P1738
 – S. Sun, A. Yu, K. Chen, M. Mattson, Y. Xu, O. Dabbous (Deerfield and Boston, US)
- Pharmacogenetically determined treatment's influence on lipids profile and insulin resistance (IR) in relation to polymorphisms of ACE, AGTR1, eNOS, PPAR-g2, ADRB1 genes in hypertensive (EAH) patients.** P1739
 – L. Sydorochuk, K.M. Amosova, R.I. Sydorochuk, I.I. Sydorochuk (Chernivtsi and Kyiv, UA)
- High efficacy and metabolic safety of carvedilol in the treatment of hypertension in common clinical out-patient practice. Results of phase 4 clinical trial.** P1740
 – M. Gajdos (Bratislava, SK)
- Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction.** P1741
 – E. Omerovic, T. Ramunddal, P. Albertsson, L. Grip, G. Matejka (Gothenburg, SE)
- The effect of darapladib, a direct inhibitor of lp-pla2, on necrotic core volume by ldlc level: a subgroup analysis of the integrated biomarker and imaging study-2 (ibis-2).** P1742
 – P.W. Serruys, H.M. Garcia-Garcia, E.A. Tarka, T.M. Trivedi, R. Davies (Rotterdam, NL; Philadelphia, US)



TREATING DYSLIPIDEMIA. HOW AGGRESSIVE SHOULD WE BE?

Chairperson(s): V. Conraads (Edegem, BE)

Meet the Experts



18:15	Case 1. – U. Landmesser (Zurich, CH)	1743
18:25	Panel discussion. – U. Landmesser, J.E. Deanfield, I.M. Graham (Zurich, CH; London, GB; Dublin, IE)	1744
18:40	Case 2. – J.E. Deanfield (London, GB)	1745
18:50	Panel discussion. – U. Landmesser, J.E. Deanfield, I.M. Graham (Zurich, CH; London, GB; Dublin, IE)	1746
19:05	What do the Guidelines say? – I.M. Graham (Dublin, IE)	1747

**CARDIAC RESYNCHRONISATION
THERAPY: HOW TO SELECT THE
RIGHT CANDIDATES**

Read with the Experts

Chairperson(s): G.R. Sutherland (London, GB); G.A. Derumeaux (Bron, FR)

- | | | |
|-------|--|-------------|
| 18:15 | Cardiac resynchronisation therapy: a multi-parametric approach to optimal patient selection. | 1748 |
| | – O.A. Breithardt (Erlangen, DE) | |
| 18:25 | Panel discussion. | 1749 |
| | – G.R. Sutherland, G.A. Derumeaux (London, GB; Bron, FR) | |
| 18:40 | Cardiac resynchronisation therapy in failing ventricles: the role of stress echo. | 1750 |
| | – L. Anderson (London, GB) | |
| 18:50 | Panel discussion. | 1751 |
| | – G.R. Sutherland, G.A. Derumeaux, L. Anderson, O.A. Breithardt (London, GB; Bron, FR; Erlangen, DE) | |
| 19:05 | Conclusion. | 1752 |
| | – G.R. Sutherland, G.A. Derumeaux (London, GB; Bron, FR) | |



MITRAL REGURGITATION: WHEN THE TIME COMES, WHAT TO DO? **Meet the Experts**

Chairperson(s): O. Alfieri (Milan, IT)

- 18:15 **Mitral regurgitation and no symptoms: young asymptomatic woman with Barlow's disease and severe mitral regurgitation.** 1753
– O. Alfieri (Milan, IT)
- 18:25 **Panel discussion.** 1754
– L.A. Piérard, R. Rosenhek, J. Schofer (Liège, BE; Vienna, AT; Hamburg, DE)
- 18:40 **Heart failure and mitral regurgitation: old patient with dilated cardiomyopathy and severe mitral regurgitation.** 1755
– O. Alfieri (Milan, IT)
- 18:50 **Panel discussion.** 1756
– L.A. Piérard, R. Rosenhek, J. Schofer (Liège, BE; Vienna, AT; Hamburg, DE)
- 19:05 **What do the Guidelines say?** 1757
– O. Alfieri (Milan, IT)

**MYOCARDITIS –
STATE-OF-THE-ART WORK-UP**

Read with the Experts

Chairperson(s): D.J. Pennell (London, GB); J. Schwitter (Lausanne, CH)

18:15	Case 1. – M.G. Friedrich (Calgary, CA)	1758
18:25	Input. – U. Eriksson (Zurich, CH)	1759
18:30	Panel discussion. – M.G. Friedrich, H. Mahrholdt, U. Eriksson (Calgary, CA; Stuttgart, DE; Zurich, CH)	1760
18:45	Case 2. – H. Mahrholdt (Stuttgart, DE)	1761
18:55	Input. – U. Eriksson (Zurich, CH)	1762
19:00	Panel discussion. – M.G. Friedrich, H. Mahrholdt, U. Eriksson (Calgary, CA; Stuttgart, DE; Zurich, CH)	1763

**NON-INVASIVE CORONARY
ANGIOGRAPHY: HOW AND WHEN
TO DO IT**

Read with the Experts

Chairperson(s): J.J. Bax (Leiden, NL); M.A. Garcia Fernandez (Madrid, ES)

- | | | |
|-------|---|-------------|
| 18:15 | Computed tomography angiography.
– P.J. De Feyter (Rotterdam, NL) | 1764 |
| 18:25 | Panel discussion.
– P.J. De Feyter, M. Desai (Rotterdam, NL; Cleveland, US) | 1765 |
| 18:40 | Magnetic resonance angiography.
– M. Desai (Cleveland, US) | 1766 |
| 18:50 | Panel discussion.
– P.J. De Feyter, M. Desai (Rotterdam, NL; Cleveland, US) | 1767 |
| 19:05 | Conclusion.
– J.J. Bax, M.A. Garcia Fernandez (Leiden, NL; Madrid, ES) | 1768 |



**PULMONARY HYPERTENSION: THE
GUIDELINES
AND THE REAL WORLD**

Meet the Experts



Chairperson(s): N. Galie (Bologna, IT); I.M. Lang (Vienna, AT)

- | | | |
|-------|---|------|
| 18:15 | A deteriorating patient despite appropriate initial treatment choices. | 1769 |
| | – J.L. Vachiery (Brussels, BE) | |
| 18:25 | Panel discussion. | 1770 |
| | – J.L. Vachiery, O. Sitbon, A. Torbicki (Brussels, BE; Clamart, FR; Warsaw, PL) | |
| 18:40 | A young lady who is improving but not enough. | 1771 |
| | – N. Galie (Bologna, IT) | |
| 18:50 | Panel discussion. | 1772 |
| | – J.L. Vachiery, O. Sitbon, A. Torbicki (Brussels, BE; Clamart, FR; Warsaw, PL) | |
| 19:05 | What do the Guidelines say? | 1773 |
| | – N. Galie (Bologna, IT) | |

ANTICOAGULATION IN CONGENITAL HEART DISEASES Symposium

Chairperson(s): A. Bozio (Lyon, FR); P. Trigo Trindade (Zurich, CH)

The European Society of Cardiology and the Association for European Paediatric Cardiology

- | | | |
|-------|--|------|
| 18:15 | Anticoagulation in Fontan circulation. | 1774 |
| | – D. De Wolf (Ghent, BE) | |
| 18:37 | Anticoagulation and pregnancy. | 1775 |
| | – F. Walker (London, GB) | |
| 18:59 | Anticoagulation and non-cardiac surgery in grown-up congenital heart disease. | 1776 |
| | – C. Medrano Lopez (Madrid, ES) | |
| 19:21 | What is new in anticoagulation and antiplatelet therapy? | 1777 |
| | – F. Andreotti (Rome, IT) | |